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1. EARLIER EVALUATION 
In the early 1990s the Science and Technology Policy Council in Finland encour-
aged the Ministries to evaluate research institutions in their jurisdiction. In accordance 
to this policy, the Medical Research Council of the Academy of Finland carried out an 
evaluation of the research activities of the Finnish National Public Health Institute 
(KTL) in 1994-1995, in response to a proposal put forward by KTL and the Ministry of 
Social Affairs and Health (STM). The objective of this evaluation was to provide infor-
mation on the public health functions, strategic importance, scientific merit and value 
for money of the scientific work undertaken and to make proposals for future work. 
The international Evaluation Panel, chaired by Dr David Evered of the UK Medical 
Research Council, prepared an Evaluation Report to the Academy in October 1995. For 
the evaluation, KTL prepared a report describing the work in the Institute. The Evalua-
tion Panel worked via internal meetings, discussions with important stakeholders of 
KTL, and through site visits to the three divisions of KTL. On the basis of their evalua-
tion, the Panel made 35 major recommendations for further development of the organi-
zation, management and work of the Institute. 
Over the past 10 years, most of the recommendations made by the Panel have been 
implemented: the organization of KTL has been changed, several areas of research and 
public health work have been directed towards new priorities, and more emphasis has 
been put on the public health impact of the work of KTL. In addition, a renewed strat-
egy was prepared for the Institute in 2001 during a thorough process involving the 
whole organization. At the end of 2003, a new Director General was appointed to KTL. 
Based on these developments, and on changes in the environment, the time is ripe 
for a new evaluation of KTL. The purpose of such a task would be to evaluate the effec-
tiveness of the work and assess the scientific and public health impact of the Institute. 
2. KTL IN BRIEF 
2.1.Strategy and functions 
 
The mission of KTL is to protect and promote the health of the Finnish people. As a 
research and expert institute belonging to the Ministry of Social Affairs and Health, 
KTL is responsible for providing decision-makers, professionals and citizens with the 
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best possible health-related information for their choices. A general strategy for the In-
stitute was prepared in 2001, while detailed objectives for the work are agreed upon 
annually with the Ministry. 
The three main areas of work in KTL have traditionally been: 1) infectious diseases 
and immunizations, 2) chronic diseases and health promotion, and 3) environmental 
health. In all these areas, both research and public health functions are carried out. Ac-
tivities of the Institute include basic research, ranging from the detailed analysis of the 
molecular mechanisms of pathogenesis to large-scale epidemiological and preventive 
studies and research into factors influencing health. 
KTL monitors public health, diseases and their determinants through surveys and 
registers. Research and expert information is transferred into action by developing 
health-promoting and preventive measures and by advising and collaborating with vari-
ous stakeholders. National vaccine service, many centralized laboratory functions and 
forensic medicine investigations are some of KTL's service functions. 
Several of KTL's functions are based on laws, such as surveillance of infectious 
diseases and protection from communicable diseases by vaccinations. In the prevention 
of chronic diseases KTL works in close collaboration with various non-governmental 
organizations. In promoting healthy environment and preventing diseases KTL collabo-
rates with environmental authorities and municipalities. A strong presence in the media 
is a way to reach the people. The ultimate goal is to reduce the human suffering and 
economic cost caused by illness and to help people enhance their quality of life. 
2.2.Organization, personnel and budget 
 
KTL's main facilities are located in Helsinki and three other facilities in Kuopio, Oulu 
and Turku. The Institute has 11 departments, each of which is built of various laborato-
ries and units. 
Ultimate responsibility for leading and managing the whole Institute rests on the 
Director General of KTL. He is assisted by the Deputy Director General, the Adminis-
trative Director and the Steering Group, consisting of the Directors of Departments. The 
Director General is also advised by a Scientific Council of KTL, where representatives 
of the most important stakeholders are present. 
At the end of 2005, KTL had a staff of 887 persons, of whom 367 were scientists or 
experts. Women make up 73% of the staff. In addition to the permanent or temporary 
staff, KTL is also a working place for non-paid students or scientists who pursue their 
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studies and research together with the staff of KTL. Altogether, there were 158 PhD 
students working at KTL in 2005. 
The total expenditure of KTL was 63 million euros in 2005, and the operating ex-
penses were 54 million euros when the acquisition of vaccines is excluded. The majority 
(65%) of the operational funding comes from the national budget, 25% from external 
sources like the Academy of Finland, the European Union, the US National Institutes of 
Health, or various foundations supporting scientific research. The remaining 10% of 
KTL's budget is covered by income from chargeable services and from miscellaneous 
other funding. 
3. EVALUATION PROCESS 
3.1.Scope and purpose of evaluation 
 
The objective of the review is to provide an evaluation of the work of KTL for the Min-
istry of Social Affairs and Health. The evaluation should examine the functions, strate-
gic importance, scientific merits and value for money of the scientific and expert work 
undertaken, and to make proposals for future work. A special emphasis will be placed 
on the evaluation of the relevance and effectiveness of the work and of its impact on the 
health of the Finnish people. 
The evaluation and the Evaluation Report should address the following main issues: 
a.    National relevance and effectiveness of the activities 
b.    Appropriateness and adequacy of the research, expert functions and services 
c.    Output and quality of research activities 
d.    National and international co-operation 
e.    Resource allocation 
f.    Research fundraising 
g.   Development needs, especially regarding processes and organization 
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The main purpose of the evaluation is to guide the Ministry of Social Affairs and Health 
so that they can use it for the strategic management of KTL. The practical implementa-
tion of the results, based on the decisions made at the Ministry, is the responsibility of 
the Director General of KTL. 
3.2.Entities to be evaluated 
 
The first round of detailed evaluations consists of four separate, partly parallel evalua-
tions covering the main functional areas of KTL: 
1.  Environmental health 
2.  Chronic disease prevention and health promotion 
3.  Infectious diseases 
4.  Molecular medicine - the evaluation of this area will depend on whether the re-
sults of the planned evaluation conducted by the Ministry of Education will 
provide sufficient information for the purposes of the Ministry of Social Af-
fairs and Health. 
After the first round has been completed, the entire Institute will be evaluated. This 
evaluation will focus merely on the general strategy, function and management of the 
Institute, with less emphasis on the evaluation of individual research and expert functions. 
3.3.Information sources for the evaluation 
 
KTL will provide the Panels the following information: 
Published documents concerning the whole Institute 
1.  Annual Report 2006 
2.  Kansanterveyslaitoksen toimintakertomus ja tilinpäätöslaskelmat 2006 
(available only in Finnish) 
3.  Evaluation of the National Public Health Institute of Finland. Report of 
the Evaluation Panel 1995 
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A document prepared by the Director of each relevant Department involved in the 
evaluation will be provided for the evaluation. These documents describe 1) a report on 
progress in research over the 1996-2007 period and research plans for the 2007-2011 
period, 2) the arrangement for governance and management, and 3) allocation of staff 
and resources, and 4) his/her plans for the future development of the Department. 
Each Department involved in the evaluation will also provide the Panel a self-
evaluation of 1) the appropriateness of its work to the national public health needs, 2) its 
role in the dissemination of research results and knowledge and technology transfer, 3) a 
description of the interfaces between the Department and the key players in Finland and 
abroad. 
 
3.4. Evaluation of the Department of Mental Health and Alcohol Research 
 
Previous evaluation of the department was conducted in 1995 by the international 
panel reviewing the KTL. The panel recommended that: 
a. the programme should be focused further and directed primarily at de-
veloping the programmes in a) the genetics of mental disorders, b) the long 
term studies of the determinants of mental illness in adults and in childhood 
and adolescence, and c) on the psycho-social aspects of genetic screening; 
b. studies in health psychology should be more directly focused and form an 
integral component of the principal research themes of the Division and that 
other projects should be allowed to lapse in due course; 
c. the work on the possible viral origin of schizophrenia should not be un-
dertaken. 
Since 1996 the genetics of mental disorders has been one of the key research areas 
of the department. The long-term cohort studies from childhood and adolescence to 
adulthood and studies concerning development during adulthood have been strongly 
represented on our research agenda. Research on genetic screening was continued by 
the same team responsible for health psychology, but due to an organizational change, 
in the Department of Epidemiology. The laboratory-based studies on infectious etiology 
of schizophrenia were never started. However, register-based epidemiological studies 
on the association between schizophrenia and viral epidemics in Finland were success-
fully conducted in our research program as part of a more general approach to the etiol-
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ogy of schizophrenia. Finland and our Institute have internationally exceptionally good 
health statistics to conduct such studies. 
 
The Academy of Finland evaluated the psychiatric research in Finland in 1995 by 
using an international peer review (Marie Åsberg, John Cooper, Eugene Paykel and Per 
Vaglum: Psychiatric Research in Finland 1995. Publications of the Academy of Finland 
8/96). The psychiatric research conducted at the KTL was evaluated very positively. 
 
Department of Alcohol, Drugs and Traffic was also evaluated as a part of general 
evaluation of the KTL in 1995. The Panel recommended that: 
(1) a detailed and radical appraisal of opportunities for the future should be 
undertaken in the light of impending changes and transfer of research staff from the 
State Alcohol Monopoly to the KTL; 
(2) those small scale research activities which do not relate directly to the 
main research themes of the Department (ie the studies on mechanisms of addiction and 
those on the pharmacokinetics and safe use of drugs) should be accorded a low priority 
and discontinued. 
The functions and laboratories of the department joined the Department of Mental 
Health on May 1, 1996. The structure, functions and research program of the current 
Drug Research Unit has been totally renewed in the course of years. 
 
Research staff of the former State Alcohol Monopoly moved to the KTL on May 1, 
1996 as a separate department, but was merged with the Department of Mental Health 
from January 1997 on. Alcohol Research Unit has not been evaluated. However, two 
internationally famous alcohol researchers (professors Henri Begleiter and Harold 
Kalant) reviewed the research based on genetic animal models (mainly so-called AA- 
and ANA-rats) used by the unit, and supported the continuation of this activity and un-
derlined the scientific opportunities it would offer to basic alcohol research at the KTL. 
The raising of rat lines was moved away from the department and it is nowadays a spe-
cial supportive function run by a separate animal unit. 
 
7 
4.  DEPARTMENT OF MENTAL HEALTH  
AND ALCOHOL RESEARCH 
 
4.1. Background 
 
The department of Mental Health and Alcohol Research started as Mental Health 
Research Unit, responsible only for the National Suicide Prevention Project, in May 
1986. The functions extended in the course of the first five years. The Department of 
Mental Health was established as a part of the reorganization on the whole KTL in 
1992. The functions of the Drug Research Unit were merged with the department in 
May 1996. The Department of Mental Health and Alcohol Research started in its cur-
rent form in 1997 when biomedical alcohol research joined the department after being 
excluded from the state monopoly ALKO as a part of the national reorganization of the 
Finnish alcohol policy. The department has functioned in three separate locations rela-
tively apart from each other. In October 2007 two units on mental health and adminis-
trative functions will move to the main building area (Mannerheimintie 166, building C) 
close to drug research unit (Mannerheimintie 166, building F). Alcohol research will 
remain apart in its current location (Tukholmankatu 2).  
 
4.2. Objectives and organization 
 
        The primary task of the department is to study, monitor, promote and protect the 
mental health of the population. We aim to prevent and reduce problems caused by 
mental disorders and substance use. In order to achieve these goals our department (1) 
conducts high quality scientific research, (2) collaborates with both national and interna-
tional organizations and experts, 3) provides expertise to decision makers, health pro-
fessionals and the public, and (3) produces high quality laboratory services for screen-
ing and assessment of alcohol and drugs. 
                                 In 2006 there were five research units and a small administrative unit in the 
department. The scientific and expert work was mainly conducted in 13 different pro-
jects (research programs, Figure 1). Project teams consisted of KTL`s researchers, as-
sisting personnel and external experts participating in the project. Every researcher 
could be a member in one or several projects. 
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Figure 1. Organization of the Deparment 
 
 
 
Research projects: 
 
1 Alcohol and health 
2 Neurobiology of drug dependence 
3 Self-destructive behavior and suicide prevention 
4 Mental health development 
5 Mood disorder research 
6 Mood and behavior 
7 Severe Mental Disorders 
8 Drug research 
9 Drug dependence  
10 Drugs and Driving 
11 Paid Service Activity  
12 Mental health and psychiatric disorders in adolescence 
13 Finnish Twin Studies on Mental Health and Substance Use 
14 Addiction Prevention and Treatment  
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 Alcohol Research Unit (ATY) 
Currently and in the near future, substance abuse is the most serious threat to Fin-
nish public health. Presumably, the consumption of alcohol will increase, and illnesses 
and deaths related to alcohol will become more common. 
The objective of alcohol research is to provide Finnish society with scientific in-
formation about alcohol. 
The Alcohol Research Centre (ATY) studies the relationship between heavy alco-
hol use and general health, functional capacity and quality of life. 
 
Mental Health Research Unit (MTY) 
Mental health is influenced by a wide variety of factors. In order to understand 
them, we need information about the way mental health manifests itself in people’s lives 
and about the factors that protect from disorders or predispose to them. 
One in every five Finns has some mental disorder. According to the WHO, depres-
sion, schizophrenia, bipolar disorder and alcoholism all figure among the ten most injuri-
ous disorders. In order to improve the well-being of Finns, information about, among oth-
ers, the background, progress and treatment of these disorders is of crucial importance.                
The Mental Health Research Unit (MTY) works to study and promote mental 
health and the factors determining it. Additionally, the unit focuses on studying the oc-
currence, causes, prevention and treatment of mental disorders and symptoms. 
 
Drug Research Unit (HTY) 
With the increase of drug abuse, Finnish authorities have started to pay more atten-
tion to drug users and to preventing the development of addictions and developing drug 
addiction treatment units and methods. A cornerstone of a successful therapy is a thor-
ough understanding of the basic mechanisms of addiction. 
The objective of these studies is to produce information to promote particularly the 
health and functional capacity of adolescents. Also, it is our goal to contribute to the 
prevention and treatment of marginalisation and to keep substance abuse under control. 
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Drug research also develops alcohol and drug analysis and screening methods for the 
needs of health care, police, occupational  and other authorities.  
Drug Research Unit works to provide its customers with services related to drug 
analytics, such as alcohol, drug and medicine determination, to conduct drug research 
and to act as an expert in the field. 
 
Adolescent Mental Health Unit (NMY) 
Adolescence is a developmental phase during which several of the mental health 
disorders of adulthood appear. The monitoring studies conducted during this phase offer 
a good opportunity to gain a thorough understanding of the development of mental 
health and various mental disorders. The department uses additionally twin studies to 
study the mental health, drug and alcohol use and smoking of adolescents. The Adoles-
cent Mental Health Unit was founded in its present form in January 2005. 
 
Addiction Prevention and Treatment Unit (RHY) 
Addiction Prevention and Treatment Unit (RHY) was established in 2006 and is a 
continuation of the clinical team of Alcohol Research Center.  Our mandate is to pro-
tect, maintain and improve the health of the Finnish people and also to prevent addiction 
related health problems and to evaluate and implement new treatments on substance 
abuse. As a clinical research unit, RHY plays an important role in this process in the 
areas of alcoholism, drug dependence and mental health. The strength of RHY comes 
largely from the unique ability to take a new treatments all the way from its beginnings 
in theory, through animal testing, to world-class double-blind placebo-controlled clini-
cal trials, and then on to practical application.  
 
4.3. Staff and resources 
 
The Department has been functioning in its current form since 1997. The current 
functions and partially also the staff and basic resources of the Mental Health and Ado-
lescent Mental Health Units are based on the functions launched as new functions  5-10 
years earlier. The basic functions of the Substance Use Unit are from the 1970s and 
11 
early 1980s, from the period when the KTL produced mainly laboratory services. The 
basic staff and resources of the Alcohol Research Unit and the RHY come from the pe-
riod before 1996, when the unit was a part of the state alcohol monopoly, ALKO. In 
1996 staff with permanent service contract was 25. 3 of the total staff (n=48) had pro-
fessor positions, 4 were assistant professors or lecturers (docents), 16 had some other 
academic degree, and the rest were technical staff. At the end of 2006 altogether 102 
persons were employed by KTL. 8 had professor positions, 13 were assistant professors, 
50 had some other academic degree, and 31 were technical staff. 
About 40 % of the budget is direct funding by KTL, 20 % is based on income from 
laboratory services, and 40 % on external funding from outside the institute. 
Table 1. Personnel employed by KTL 31.12.1996 and 31.12.2006 
 
 
 
 
Table 2. KTL Research Budget for the year 2007 by units and projects 
 
UNIT PROJECT  
 Alcohol an Health 243 236 
 Neurobiology of Drug Depend-
ence 
353 536 
ATY  676 554 
 Self-destructive Behavior and 
Suicide Prevention 
37 725 
 Mental Health Development 76 603 
 Mood Disorder Research 42 605 
 Mood and Behavior 14 137 
 Severe Mental Disorders 139 556 
MTY  444 498 
 Drug Research 83 385 
 Drug Dependence 231 738 
 Drugs and Driving 45 299 
HTY  360 422 
 Mental Health and Psychiatric 
Disorders in Adolescence 
45 104 
 Finnish Twin Studies on Mental 
Health and Substance Use 
67 024 
NMY  122 188 
RHY Addiction Prevention and 
Treatment 
300 105 
MAO  2 160 00 
Year Staff Man-year Researchers Technical staff 
1996 48 – 22 26 
2006 102 85,66 50 52 
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4.4. Research areas 
 
The two main research areas of the department are mental health and substance use 
research.  
Mental health research has been focused on depression and suicide, severe mental 
disorders (psychoses), determinants and development of mental health, and mental 
health of adolescents.  
Within mental health our knowledge and competence has mainly been in epidemi-
ological population, cohort and intervention studies using Finnish health registers, clini-
cal assessments, questionnaire studies, brain imaging, neuropsychological testing, twin 
studies, molecular genetics and genetic epidemiology. 
Substance use studies has been focusing on mechanism of alcohol drinking and its 
pathological effects, alcohol´s effect on steroid hormones, neurobiology of alcohol 
depence, pharmacological and clinical studies on drug dependence, drugs and driving. 
The special advantages in substance use studies have been the opportunity to use 
special genetic AA and ANA rat lines which have been developing in Finland since the 
50ies for alcohol studies. Similarly we have had good opportunities to conduct drug de-
pendence studies in mice. We also have nationwide prospective data on alcohol and drugs 
in the traffic and persons driving under the influence of alcohol and psychoactive drugs.   
 
4.5. Scientific impact of research 
 
The scientific level of research has increased steadily if measured by the impact 
factors of the publications. Annually we are publishing more than 100 international sci-
entific reports, mostly in good international journals. Number of the publications cited 
more than 100 times is over 20. We are a leading scientific research center in Finland. 
We have a good international reputation and position in the field of mental health if 
measured by publications, international contacts, collaboration and funding. The impact 
of psychiatric and psychological research at our institute has been evaluated above that 
in the Karolinska Institut in Sweden and closes that at the University of Harvard (see 
Web of Science). 
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Table 3. Original articles and reviews of the department 1996-2006 
 
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
48 67 86 87 74 97 89 84 103 97 114 
         
0
20
40
60
80
100
120
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
 
 
4.6. Public health impact 
 
The expertise of the KTL concerning mental health and substance use issues is 
widely used by the the ministries (mainly by the Ministry of Social Affairs and Health, 
but also by Interior Affairs, Transportation, and Justice) in planning and law-drafting, 
occasionally directly also by the Government and the Parlament. In Finland the minis-
tries are relatively small and expert institutes and agencies under the ministries are rela-
tively large. This requires that The Department of Mental Health and Alcohol Research 
has to have expertise of the field quite broadly. We have participated in a number of 
committees and expert groups in various roles in developing national policies, pro-
grammes and guidelines. For example, we have had chairperson roles in national con-
census meetings of depression, panic disorder, drug dependence and psychotherapy. 
Similarly, we have chairpersons and leading experts in task groups delivering the na-
tional guidelines both for the treatment of alcohol problems, drug dependence and de-
pression. We have also participated as experts at the ministry of social affairs and health 
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in the planning and conducting the national alcohol and drug programs, working group 
for tsunami victims, treatment of drug dependence, national program for mental health 
and substance use problems. We have supported our ministry as experts of mental 
health and substance use issues in several international meetings as delegates of 
Finland, and participated in international collaboration as experts and consultants within 
WHO, European Union, Council of Europe and United Nations, and collaborated with 
Nordic and Baltic countries and with Russia. 
We have continuously and largely used the internet, KTL´s publications, domestic 
professional newspapers and the mass media to inform professionals, decision makers 
and the citizens about mental health and substance use, and to affect their health behav-
iour and healthy choices. We have had for several years close collaboration with mu-
nicipalities of Helsinki, Vantaa and Espoo and with Helsinki University Central Hospi-
tal and with some other regions for the development of mental health care system and 
services and delivering modern and updated treatments in the field of mental health. We 
have been editing the leading Finnish textbooks of psychiatry and substance use disor-
ders. Our senior members have several leading positions in professional associations, 
foundations, and associations representing “the third sector” of society. 
 
4.7. Proposal for future directions 
 
Our aim is to continue all the main research and public health areas we currently 
have. Our vision is to be a continuously changing leading expert and research center of 
mental health and substance use in Finland also in the future, providing all those ser-
vices and support functions expected by our owners and based on the KTL law, the pro-
gram of the government, the strategies of the Ministry of Social Affairs and Health and 
KTL, and annual action plans. The balance between public health work and scientific 
research is moving and will probably move in a direction which emphasizes even more 
the domestic needs of public health within mental health and substance use problems in 
Finland. To guarantee the knowledge base of our expertise and validity of public health 
work, our scientific work must stay at the high international level and be based on our 
national needs and special national opportunities. We have to develop our research pro-
grams more focused in every area to keep and enhance our current positions. We will 
need more external funding and yet keep stronger and more independent position as a 
partner in international collaboration. We need to strengthen the human resources di-
rected especially to mental health work and critically plan possible reallocation of the 
resources now connected with substance use area. The new research area we are possi-
bly launching in the future is widening the task of adolescent mental health to also in-
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clude the whole childhood from pregnancy through all phases of childhood to adoles-
cence and further to adulthood. In addition, we have plans to start to study pharma-
coepidemiology of the use of psychotropic drugs. We sincerely believe that our current 
staff is qualified enough to adapt to continual changes and attain these goals. 
The major challenges ahead are connected with very probable changes in the struc-
ture of current institutions under the Ministry of Social Affairs and Health. These 
changes expected to start from the year 2009 on will very probably concern also the 
area of mental health and substance use. So, we are prepared to integrate with the func-
tion from our sister organizations, even receive them as a part of our own functions. Our 
plan is that also in the future the mental health and alcohol and drug issues would be 
functioning well-integrated within the same department as they do in the WHO (Gen-
eve) and in most public services in Finland. 
In the near future, within next 3-10 years, we will have several changes in the sen-
ior staff of department due to the age-structure of the personnel.  
We will change the structure and functions of the department from January 2008 by 
increasing the autonomy of some research projects by stabilizing their functions by 
forming three new units. We will also allocate projects in a little bit new way and 
strengthen the roles of several expert teams (statistics and data management, epidemiol-
ogy, neuropsychology, imaging, and molecular genetics) in the matrix on the depart-
ment.  
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Figure 2. The Organization of the Department 2008- 
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5. ALCOHOL RESEARCH CENTRE 
 
5.1. Alcohol and health 
 
5.1.1. Research and public health significance of the area 
 
Our research has been divided into three main areas: mechanisms of alcohol drinking 
and its pathological effects; alcohol, steroid hormones and behavior; and epidemiology of 
alcohol and health. Mechanisms of alcohol drinking and its pathological effects have tra-
ditionally been subdivided into two aspects: the role of acetaldehyde in the actions of al-
cohol and animal models of alcoholic liver disease. The acetaldehyde aspect has involved 
the development of the appropriate analytical methods, establishing the in vivo acetalde-
hyde levels, characterizing the regulation of its metabolism, and settling its role in the 
etiology of alcohol addiction and related diseases. In conclusion, our research shows that 
acetaldehyde plays a crucial role in the biological regulation of alcohol drinking and in 
most types of tissue damage and in the development of alcohol-related cancers. 
The basic research on the alcohol-related liver disease in rats has involved the sepa-
ration and characterization of the different hepatic cell types, assessing the differential 
vulnerability regarding pathological development, determining the impact of the P450 
2E1 enzyme, settling the interrelations between the roles of endotoxin, CD14 receptors, 
complement, inflammation and cytokine factors. In conclusion, the perivenous cells in 
connection with active 2E1 are specifically vulnerable to the pathological develop-
ments. The interplay between endotoxin, CD14 receptors, complement, inflammation 
and cytokine factors is important in the development of alcoholic liver disease. 
The area of alcohol, steroid hormones and behavior has been subdivided into three 
aspects: effect of alcohol on steroid hormones; alcohol, steroid hormones, sexual and 
aggressive behavior; and steroid hormones and alcohol drinking. The effects of alcohol 
on testosterone have been investigated in rats, in vivo and in vitro experiments, as well 
as in human intervention studies. In conclusion, the overall result of the effects by alco-
hol is depending on the subtle balance between inhibition of testosterone biosynthesis 
and breakdown. Especially in situations involving acute stress, testosterone elevation 
seems to be the prominent response to alcohol. 
The effect of testosterone on sexual and aggressive behaviors has been studied in 
both men and women. In conclusion, testosterone associates with physical and violent 
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behavior. Estradiol reduces the physical but promotes the psychological aggression. 
High testosterone does not seem to initiate sexual or aggressive actions, but rather pro-
vides the force by which these actions are exerted. 
Alcohol-derived testosterone elevation as a potential reinforcer, which could be an 
important factor in the etiology of alcohol addiction, has become a prime research target 
in our group. In conclusion, we propose the theory that alcohol-induced testosterone 
elevations could, through an increasing effect on the feedback regulation of testosterone 
biosynthesis, elevate the concentrations of hypothalamic -endorphin and thus promote 
alcohol drinking. In addition, we suggest that stress could be a further promoting factor 
for the testosterone-mediated reinforcement of alcohol drinking. 
 
Our epidemiological research is focused on hypothesis-derived approaches, in 
which we have tested in population studies some of our hypotheses derived from basic 
research. So far, we have been able to verify the role of the CD14 receptor in the etiol-
ogy of alcoholic cirrhosis, the role of acetaldehyde metabolism in alcohol addiction and 
the role of testosterone in adolescent alcohol drinking. 
The aim, purpose and significance of our basic research is to generate and pass out 
relevant knowledge, the larger information and evaluation of which would be helpful 
and beneficial for our society in reducing alcohol consumption, its harmful health ef-
fects and the amount of alcohol-related violence, as well as in developing new treat-
ments for alcoholism. 
In addition, our group members within the limit of their expertise and ability are 
encouraged to personally take active part in the alcohol-policy decision making at all 
relevant levels. 
 
5.1.2. The main scientific achievements 
 
Mechanisms of alcohol drinking and its pathological effects 
 
Role of acetaldehyde in the actions of alcohol 
The development of methods for the determination of acetaldehyde in blood and 
tissues of rats and mice by headspace gas chromatography. The discovery and elimina-
tion of ethanol-derived artifact acetaldehyde formation during the analytical procedures. 
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Thiourea blocks artifact acetaldehyde formation from tissue extracts but correction pro-
cedures should be used for minimal artifact acetaldehyde formation in blood extracts. 
The assessment of acetaldehyde levels in blood, liver and brain during alcohol in-
toxication in rats and mice. In the brain, no detectable acetaldehyde levels can be found 
during normal alcohol intoxication. Most of the acetaldehyde in rat blood is bound to 
the hemoglobin. 
The characterization of the hepatic acetaldehyde metabolism in rats. Novel data 
displayed that ethanol-derived acetaldehyde is mainly oxidized in the mitochondria and 
that this reaction is regulated by the aldehyde dehydrogenase activity and the reoxida-
tion of NADH. 
The development of the novel perchloric acid/saline method for the human blood 
acetaldehyde determination by headspace gas chromatography. The discovery and 
elimination of ethanol-derived artifact acetaldehyde formation during the analytical pro-
cedures. Correction procedures should be used for minimal artifact acetaldehyde forma-
tion in blood extracts. In spite of a number of early reports of human blood acetaldehyde 
levels our conclusion still holds, according to which no detectable (<0.5 µM), ade-
quately determined "free and/or loosely bound" acetaldehyde has not yet been found in 
venous blood during normal alcohol oxidation in men. However, we have detected low 
acetaldehyde levels (1-3 µM on average) in women at high estradiol conditions. 
The assessment of breath and salivary acetaldehyde in humans. Breath acetalde-
hyde seems to reflect more accurately systemic concentrations compared with the sa-
liva, the acetaldehyde of which almost exclusively is of microbial origin. 
The role of acetaldehyde metabolism in the regulation of alcohol drinking. Elevated 
acetaldehyde levels as the consequence of decreased aldehyde dehydrogenase activity 
and or increase rate of alcohol metabolism was found to decrease voluntary alcohol 
consumption in rats (an animal model for Asian populations with elevated acetaldehyde 
levels during alcohol drinking). 
Recognition of the dual effect of acetaldehyde on alcohol drinking in experimental 
animals as well as in humans. Peripherally elevated acetaldehyde levels protects against 
alcohol drinking, but centrally produced acetaldehyde promotes drinking. 
The development of animal model for genetic manipulation to reduce alcohol 
drinking: demonstrated by transplanting aldehyde dehydrogenase deficient liver to rats 
selected for high alcohol preference and by a transgenic mouse model. 
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Animal models of alcoholic liver disease 
Digitonin-collagenase perfusion method for the separation and characterization of 
periportal and perivenous rat hepatocytes. The perivenous region is specifically suscep-
tible for the development of alcoholic liver disease (ALD). This seem to be explained 
by the ethanol-inducible cytochrome P450 2E1, which has potentially pro-oxidative and 
toxicological properties, and the expression of which is pronounced in the perivenous 
region of liver. The important events in the early development of ALD probably involve 
increased P450 2E1 expression, which subsequently leads to increased oxidative stress 
and the release of proinflammatory cytokines. 
Gut-derived endotoxins (lipopolysaccharide, LPS), which activate liver Kupffer 
cells via their CD14 receptor, promote alcohol-induced liver injury. 
Complement-mediated inflammation may promote the development of alcoholic 
liver disease. Ethanol-induced steatosis seen in normal (C3(/)) mice was absent in livers 
of C3-deficient (C3(/)) mice. Thus, these ethanol-induced alterations observed exclu-
sively in complement factor C3(/) mice contribute to protection against fatty infiltration 
and subsequent inflammatory processes in the liver of these mice. 
 
Alcohol, steroid hormones and behavior 
 
Effect of alcohol on steroid hormones 
Effect of alcohol on testosterone and corticosteroid metabolisms and levels in 
males. A high dose of alcohol generally elevates corticosteroid and lowers testosterone 
levels. The testosterone reduction was explained by inhibited testosterone synthesis in 
the testes. Recently we observed that a low dose of alcohol may, in fact, elevate testos-
terone levels in men. A landmark finding was that alcohol generally, regardless of dose, 
elevates testosterone levels in women. The testosterone elevation was due to inhibited 
breakdown of testosterone in the liver. The testosterone elevation explains the androge-
nization in women chronically drinking alcohol. 
 
Alcohol, steroid hormones, sexual and aggressive behavior 
Alcohol-derived testosterone elevations explain sustained activation of sexual be-
havior in women. Sex steroids play a role as cue factors in human pair mating. 
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Stress- and alcohol-mediated cortisol elevation is associated with increased aggres-
sive behavior. Alcohol-related male physical aggression is promoted by elevated testos-
terone levels and inhibited by elevated estradiol levels. On the other hand, elevated es-
tradiol levels enhance alcohol-related psychological aggression in men. 
 
Steroid hormones and alcohol drinking 
Stress and corticosterone promotes alcohol drinking in rats. High endogenous tes-
tosterone levels and alcohol-mediated testosterone elevation may promote alcohol 
drinking in rats and in humans. The alcohol-mediated testosterone elevation is pro-
nounced during stress, which may be channeled via endorphin-opiate mechanisms to 
reinforcement and to the etiology of alcohol addiction. 
 
Epidemiology of alcohol and health 
Promoter polymorphism of the CD14 endotoxin receptor gene displayed a risk fac-
tor for alcoholic liver disease. The results suggest that the T allele confers increased risk 
of alcoholic liver damage. In particular, TT homozygotes are at a high risk to develop 
cirrhosis. Thus, the importance of the endotoxin-CD14 receptor pathway in the devel-
opment of alcoholic liver disease is supported. 
In analyses of twins as individuals, higher testosterone levels characterized boys 
reporting ever drinking, more frequent intoxication, high density drinking, more alcohol 
symptoms, and diagnosed alcohol dependency on interview. Adjusting for pubertal de-
velopment, only associations with symptom count and diagnosis remained significant. 
CYP 2E1 and ALDH1 A1 polymorphisms demonstrate risk factors for the disposi-
tion to develop alcoholism. These findings support the importance of the brain alcohol 
and acetaldehyde metabolism in the etiology of alcoholism. 
 
5.1.3. The main public health achievements 
 
Updating the carcinogenic effects of alcohol and its metabolic product acetalde-
hyde at the WHO associated International Agency for Research on Cancer (IARC) in 
Lyon 5-14.2007 (published in Lancet Oncology 8: 293-293, 2007), represents the main 
international health achievement of our group so far. The chairmanship of the mechanis-
tic section, which was appointed to us based on our expertise on the role of acetalde-
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hyde in the actions of alcohol, made it possible for us together with other leading scien-
tist in the area to bring for the plenary sessions convincing new evidence for the car-
cinogenic effect of acetaldehyde. The inclusion of new WHO health directives regard-
ing the alcohol-derived acetaldehyde will be beneficial for about 40 % of the Asian 
population having an inherited disposition for ineffective acetaldehyde metabolism. 
Currently, every third individual of such a genotype will create cancer in the upper di-
gestive tract if they heavily consume alcohol. 
National public health achievements include expertise from our group, which 
has contributed correct and improve the law enforcement procedures regarding 
drunken driving. Another example is the active part in the alcohol policy decision-
making about the tax regulation of our alcoholic beverages. Here we have had an impact 
in enforcing actions to reduce the overall alcohol consumption in Finland. In general, 
our annual participation in the national alcohol policy discussion is including up to 100 
public advisory tasks, statements, interviews, etc. 
 
5.1.4. Funding for research and public health programs 
 
The project has been funded to the main part by The National Public Health Insti-
tute and to some extent by grants from Signe och Ane Gyllenberg, Ella och Georg Ehrn-
rooth and Yrjö Jahnsson foundations, Finska Läkaresällskapet, the Finnish Foundation 
for Alcohol Studies, and from the Academy of Finland. 
 
5.1.5. Personnel 
 
Peter Eriksson, PhD, Docent, Group leader 
Kai Lindros, PhD, Docent, Senior scientist (retirement 1.6.2007) 
Sirkku Saarikoski, PhD, Senior scientist 
Igor Bykov, MD, Scientist 
Tiina Etelälahti, MSc, Graduate student 
Sebastian Forsblom, Graduate student 
Tuomas Saarenmaa, Graduate student 
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Katri Pakarinen, Graduate student 
Maria Palmen, MSc, Research assistant 
Hilkka Salohalla, Research assistant 
Tuula Mäkelä, Research assistant 
 
5.1.6. Collaboration 
 
Carr, Lucinda, PhD, Professor, Department of Medicine, Indiana University 
Fahlke, Claudia, PhD, Professor, Department of Psychology, Göteborg university 
Henk Hendriks, PhD, Department of Nutritional Physiology, TNO Food and Nutri-
tion Research, The Netherlands 
Kaprio, Jaakko, MD, PhD, Professor, Department of Public Health, University of 
Helsinki, Helsinki 
Kauhanen, Jussi, MD, PhD, Professor, Department of Public Health and Clinical 
Nutrition, University of Kuopio 
Mäkisalo, Heikki, MD, PhD, Docent, Department of Transplantation and Liver 
Surgery, Helsinki University Hospital 
von der Pahlen, Bettina, PhD, Professor, Department of Psychology, University of 
Åbo Akademi 
Rose, Richard, PhD, Professor, Department of Psychological & Brain Sciences, 
Indiana university 
Sarkola, Taisto, MD, PhD, Hospital for Children and Adolescents, University of 
Helsinki 
Seppä, Kaija, MD, PhD, Professor, Department of General Practice, University of 
Tampere 
Wilhelmsen, Kirk, MD, PhD, Professor, Department of Genetics, University of 
North Carolina 
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5.1.7. Proposal for future work and expected benefits 
 
Mechanisms of alcohol drinking and its pathological effects 
The investigation on the role of acetaldehyde in the actions of alcohol goes on. We 
will test our hypothesis on the dual effect of acetaldehyde on alcohol drinking, as well 
as the mechanisms of the toxic and pathological effects of acetaldehyde. The data and 
knowledge obtained from the basic research on alcoholic liver disease will be consid-
ered in our future epidemiological studies. Our research aim is to develop biochemical 
methods to reduce the levels of alcohol-derived acetaldehyde. The expected benefits of 
our planned research would be to establish new biomarkers for alcohol drinking and its 
pathological effects, to develop methods of reducing the harmful health effects by alco-
hol, and finding new approaches for the treatment of alcoholism. 
 
Alcohol, steroid hormones and behavior 
Our future research on the steroid area will concern the mechanisms of the alcohol-
mediated testosterone elevations, and how these changes relate to the alcohol rein-
forcement and development of alcohol addiction. Emphasis will be put on the role of 
stress factors in these developments. Also other addictive drugs than alcohol will be 
investigated with a view to the steroid aspect. Our research aim is to evaluate our new 
hypothesis on the role of steroids in addiction. The eventual benefit would be to estab-
lish new markers for the disposition to addiction and to find new approaches for the 
treatment of addiction. 
 
The genetics and epidemiology of alcohol and health 
The future basic research on the genetics of alcohol drinking will concern our alco-
hol-preferring AA and alcohol-nonpreferring ANA rat lines. Here we continue from ear-
lier results on candidate gene regions for the regulation of alcohol preference obtained in 
studies using whole-genome scan and which have been verified in F2 intercrosses of the 
AA and ANA lines. The aim is to further narrow down the relevant genomic areas by 
using more dense sets of microsatellite markers. The eventual benefit would be to find the 
relevant genes, and subsequently the mechanisms, of alcohol addiction. 
Our planned collaborative epidemiological research program represents a multidis-
ciplinary investigation of the socio-biological etiology of alcoholism in Finnish popula-
tions. The basic design is molecular-epidemiological population study (both case-
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control and cross-sectional) involving both male and female control and alcoholic popu-
lations. The molecular aspect includes candidate genes and genome scanning, especially 
in the vicinity of known candidate polymorphisms. Other epidemiological parameters 
include the determination of blood steroids and state markers for excessive alcohol con-
sumption, and a number of other more exogenous phenotypes of psycho-social nature. 
An important feature of the present investigation is the hypothesis-derived ap-
proach. Thus we will put emphasis on our previously derived new hypotheses about the 
etiology of alcohol addiction and its harmful health consequences. These new mecha-
nisms involve, on one hand, the metabolism of alcohol and acetaldehyde in the brain. 
On the other hand, we also propose that a stress-related testosterone elevation, which 
subsequently causes increased hypothalamic beta-endorphin affecting opiate receptors, 
will also increase the reinforcement and the probability to develop addiction. Thus, the 
primary biological trait markers to be determined in the present study will be the basal 
sex-steroid levels and gene polymorphisms involved in the regulation of brain alcohol 
and acetaldehyde metabolism and sex-steroid homeostasis. 
In addition to the pathways for reinforcement we also will focus attention on the 
protective mechanisms against alcohol drinking. Such mechanisms relate to the alcohol 
and acetaldehyde metabolism outside the brain. 
The overall aim of our future research program is to realize the first comprehensive 
multidisciplinary investigation of the socio-biological etiology of alcoholism and its 
harmful health effects in the Finnish population. 
 
5.1.8. Main publications 
 
Mechanisms of alcohol drinking and its pathological effects 
Eriksson CJP, Koivisto T, Srivatanawongsa V, Martelius T, Mäkisalo H, Höckerstedt K: Manipula-
tion of alcohol drinking by liver transplantation. Alcohol Clin Exp Res 21: 763-765, 1997 
Alcohol-preferring AA and alcohol-avoiding ANA rat lines differ in their acetaldehyde metabolism 
and this has been suggested to be one reason for their different ethanol drinking behavior. To study 
whether acetaldehyde accumulation is indeed associated with alcohol drinking behavior and to evaluate 
which enzymatic differences previously observed in these rat lines are of importance in this regard, we 
produced an F2 generation from them. ADH and ALDH activities, and ALDH patterns were then as-
sessed from these hybrids and correlated with their voluntary ethanol drinking and blood acetaldehyde 
concentrations measured during ethanol metabolism. A significant negative correlation between voluntary 
ethanol intake and blood acetaldehyde concentration was observed in F2 females drinking less than 17% 
of the total fluid as ethanol. In F2 males, hepatic microsomal high Km ALDH activities correlated nega-
tively with blood acetaldehyde concentrations, indicating that low activity of this isoenzyme in ANA rats 
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could be at least in part responsible for the accumulation of acetaldehyde in their blood. Finally, F2 rats 
that possessed the cytosolic ALDH isoenzyme pattern most frequently found in the AA rat line drank 
significantly more ethanol than the animals with typical ANA pattern, suggesting that this polymorphism 
might also be relevant in the regulation of voluntary ethanol drinking although it is probably not associ-
ated with acetaldehyde metabolism. 
 
Järveläinen HA, Fang C, Ingelman-Sundberg M, Lindros KO: Effect of chronic coadministration of 
endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines. 
Hepatology 29: 1503-1510, 1999 
To better understand how gut-derived endotoxins influence alcohol-induced liver injury and the ex-
pression of inflammatory cytokines a new animal model was developed. After 2 weeks on a modified 
ethanol-containing liquid diet, some rats also were infused with endotoxin via osmotic minipumps for 4 
additional weeks. Ethanol diet alone increased plasma endotoxin threefold to 9.3 pg/mL. Endotoxin infu-
sion increased the levels to 388 and 513 pg/mL in controls and ethanol-fed animals, respectively. 
Panlobular macrovesicular and microvesicular steatosis and inflammatory foci were observed in livers 
from both ethanol- and ethanol-endotoxin-treated animals, but there was no significant potentiation by 
endotoxin. Only minor changes, mainly polymorphonuclear infiltration, were seen in animals treated with 
endotoxin alone although the messenger RNA (mRNA) expression of both proinflammatory cytokines 
tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta) and anti-inflammatory cytokines 
IL-4 and IL-10 were markedly increased, as shown by competitive polymerase chain reaction (PCR) 
analysis using cyclophilin as standard. The effect of endotoxin infusion on cytokine mRNA expression in 
ethanol-fed animals was not significantly different. Expression of transforming growth factor beta1 (TGF-
beta1) mRNA was increased twofold by ethanol, eightfold by endotoxin, but only threefold by ethanol-
endotoxin treatment. The mRNA expression of lipopolysaccharide binding protein (LBP) and CD14 en-
dotoxin receptor was not significantly increased by chronic endotoxin treatment, contrasting with the 
marked elevation observed after acute endotoxin challenge. These results suggest that the tolerance ob-
served despite sustained hepatic expression of proinflammatory cytokines is counteracted by the anti-
inflammatory cytokines and by down-regulation of CD14 and LBP. Furthermore, a similar adaptation 
may occur in alcoholics with continuous endotoxemia. 
 
Eriksson CJP: The role of acetaldehyde in the actions of alcohol (Update 2000). Alcohol Clin Exp 
Res 25: 15S-32S, 2001 
BACKGROUND: Recent advances in the field of acetaldehyde (AcH) research have raised the need 
for a comprehensive review on the role of AcH in the actions of alcohol. This update is an attempt to 
summarize the available AcH research. METHODS: The descriptive part of this article covers not only 
recent research but also the development of the field. Special emphasis is placed on mechanistic analyses, 
new hypotheses, and conclusions. RESULTS: Elevated AcH during alcohol intoxication causes alcohol 
sensitivity, which involves vasodilation associated with increased skin temperature, subjective feelings of 
hotness and facial flushing, increased heart and respiration rate, lowered blood pressure, sensation of dry 
mouth or throat associated with bronchoconstriction and allergy reactions, nausea and headache, and also 
reinforcing reactions like euphoria. These effects seem to involve catecholamine, opiate peptide, pros-
taglandin, histamine, and/or kinin mechanisms. The contribution of AcH to the pathological consequences 
of chronic alcohol intake is well established for different forms of cancer in the digestive tract and the 
upper airways. AcH seems to play a role in the etiology of liver cirrhosis. AcH may have a role in other 
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pathological developments, which include brain damage, cardiomyopathy, pancreatitis, and fetal alcohol 
syndrome. AcH creates both unpleasant aversive reactions that protect against excessive alcohol drinking 
and euphoric sensations that may reinforce alcohol drinking. The protective effect of AcH may be used in 
future treatments that involve gene therapy with or without liver transplantation. CONCLUSIONS: AcH 
plays a role in most of the actions of alcohol. The individual variability in these AcH-mediated actions 
will depend on the genetic polymorphism, not only for the alcohol and AcH-metabolizing enzymes but 
also for the target sites for AcH actions. The subtle balance between aversive and reinforcing, protecting 
and promoting factors will determine the overall behavioral and pathological developments. 
 
Bykov IL, Väkevä A, Järveläinen HA, Meri S, Lindros KO: Protective function of complement 
against alcohol-induced rat liver damage. Int Immunopharmacol 4: 1445-1454, 2004 
The complement system can promote tissue damage or play a homeostatic role in the clearance and 
disposal of damaged tissue. We assessed the role of the terminal complement pathway in alcohol-induced 
liver damage in complement C6 (C6-/) genetically deficient rats. C6/- and corresponding C6+/+ rats were 
continuously exposed to ethanol by feeding ethanol-supplemented liquid diet for six weeks. Liver sam-
ples were analyzed for histopathology and complement component deposition by immunofluorescence 
microscopy. Prostaglandin E receptors and cytokine mRNA levels were analyzed by RT-PCR and plasma 
cytokines by ELISA. Deposition of complement components C1, C3, C8 and C9 was observed in C6+/+ 
rats, but not in C6-/- animals. The histopathological changes, the liver weight increase and the elevation 
of the plasma pro-/anti-inflammatory TNF-alpha/IL-10 ratio were, on the other hand, more marked in C6-
/- rats. Furthermore, ethanol enhanced the hepatic mRNA expression of the prostaglandin E receptors 
EP2R and EP4R exclusively in the C6-/- rats. Our results indicate that a deficient terminal complement 
pathway predisposes to tissue injury and promotes a pro-inflammatory cytokine response. This suggests 
that an intact complement system has a protective function in the development of alcoholic liver damage. 
 
Bykov I, Jauhiainen M, Olkkonen VM, Saarikoski ST, Ehnholm C, Junnikkala S, Väkevä A, Lin-
dros KO, Meri S: Hepatic gene expression and lipid parameters in complement C3(/) mice that do not 
develop ethanol-induced steatosis. J Hepatol 46: 907-914, 2007 
The complement system can provoke but also participate in the repair of liver injury. Here we inves-
tigated by microarray analysis the effect of chronic ethanol consumption on hepatic mRNA expression of 
complement components and acute-phase proteins in complement C3-deficient (C3(/)) and wild-type 
(C3(/)) mice. Up-regulation by ethanol of factor B, C1qA-chain and clusterin but down-regulation of 
factor H, Masp-2, factor D and the terminal components C6, C8alpha and C9 was seen in both strains. 
Ethanol up-regulated C2 and down-regulated C4bp only in C3(/) mice, while in C3(/) mice up-regulation 
of C1qB-chain and vitronectin was observed. The expression of factor B, C6, C1qB and factor I was 
lower but that of factor D higher in C3(/) than in C3(/) mice. Ethanol induced mRNA synthesis of many 
acute-phase proteins including SPARC and lipocalin-2, but reduced the expression of SAP. The induction 
of early classical and alternative pathway components and suppression of terminal pathway components 
and soluble regulators may thus contribute to alcohol-induced liver injury. Lipocalin-2 and SPARC 
emerge as new candidate markers for early detection of liver damage. 
 
Eriksson CJP, Saarenmaa TP, Bykov IL, Heino PU: Acceleration of ethanol and acetaldehyde oxi-
dation by d-glycerate in rats. Metabolism 56: 895-898, 2007 
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The aim of the present study was to investigate whether d-glycerate (glycerate) could accelerate 
ethanol and acetaldehyde (AcH) oxidation in vivo in rats by circumventing the rate-limiting step, that is, 
the reoxidation of the reduced form of nicotinamide adenine dinucleotide. Male rats belonging to the 
ANA (Alko, nonalcohol) and AA (Alko, alcohol) rat lines were challenged with 1.2 g ethanol per kilo-
gram with or without glycerate administration (0.1-1.0 g/kg). Blood ethanol, blood AcH, and liver free 
glycerol concentrations were determined during ethanol intoxication. Glycerate treatment, regardless of 
the dose, accelerated ethanol elimination by approximately 25% (P < .001) in the ANA animals. Glycer-
ate also accelerated the AcH oxidation, but perhaps not as much as the ethanol oxidation, as indicated by 
a trend toward elevated AcH levels. In the experiments with the AA rats, glycerate treatment elevated 
hepatic free glycerol levels by about 50% (P < .05) during alcohol intoxication. The acceleration of etha-
nol and AcH oxidation in conjunction with elevated glycerol levels by the treatment with glycerate sup-
ports the hypothesis that the aldehyde dehydrogenase-mediated AcH oxidation can be coupled with the 
reduction of glycerate to d-glyceraldehyde catalyzed by the same enzyme. Such a coupling should in-
crease the availability of the oxidized form of nicotinamide adenine dinucleotide and thus accelerate both 
ethanol and AcH oxidation. Further studies are needed to investigate how the AcH could be even more 
efficiently oxidized to reduce the harmful effects of ethanol-derived AcH. 
 
Alcohol, steroid hormones and behaviour 
Sarkola T, Adlercreutz H, Heinonen S, von der Pahlen B, Eriksson CJP: The role of the liver in the 
acute effect of alcohol on androgens in women. J Clin Endocrinol Metab 86: 1981-1985, 2001 
The hypothalamic-pituitary-gonadal and -adrenal axes are regarded as the main sites of the actions of 
alcohol on steroids. In the present study the effect of alcohol (0.4-0.5 g/kg, orally) on venous plasma and 
urinary androgens was investigated in 21 premenopausal women using oral contraceptives as well as in 10 
premenopausal nonusers. After intake of alcohol, an acute elevation in plasma testosterone, a decline in 
androstenedione levels, and an elevation in the ratio of testosterone to androstenedione were observed in 
both groups. The effects lasted throughout the period of ethanol elimination and were abolished during pre-
treatment with 4-methylpyrazole (10-15 mg/kg, orally). The acute effects were higher in the group using 
oral contraceptives than in the nonusers. The testosterone effect in plasma was reflected in the free testoster-
one fraction. A decline in urinary androsterone and etiocholanolone levels, the principal catabolic products 
of androgens, was observed during alcohol intoxication. In conclusion, the present acute effects on plasma 
and urinary steroid hormones seem to be explained by an inhibited catabolism mediated by the alcohol-
induced change in the redox state in the liver. Our results suggests that the liver should be included as a 
major site in the acute endocrinological effects of alcohol on steroid hormones in women. 
 
von der Pahlen B, Sarkola T, Seppä K, Eriksson CJP: Testosterone, 5?-dihydrotestosterone and cor-
tisol in men with and without alcohol-related aggression. J Stud Alcohol 63: 518-526, 2002 
OBJECTIVE: The present investigation was designed to study steroid hormones, alcohol and ag-
gression interactions in men with a history of alcohol-related aggression (AGG+) and in a cross-sectional 
control population (AGG-). METHOD: AGG+ (n = 40) and AGG- (n = 44) male volunteers completed 
the Buss-Perry Aggression Questionnaire and the revised Michigan Alcoholism Screening Test (MAST), 
after which plasma-free and total testosterone, 5alpha-dihydrotestosterone (DHT) and cortisol were de-
termined. RESULTS: The AGG+ men displayed significantly (p < .05) higher aggression and MAST 
measures compared with the AGG- men; however, no significant group differences were observed re-
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garding the hormone values. Independently of the steroid hormones, MAST correlated positively with the 
hostility subscale in both AGG- and AGG+ groups. Free and total testosterone correlated positively with 
anger and DHT correlated positively with verbal aggression and anger, whereas cortisol correlated nega-
tively with physical aggression and anger in the AGG- group. No significant correlations between steroid 
hormones and aggression parameters were observed in the AGG+ group. The age factor explained part of 
the MAST and steroid hormone correlations with aggression. A hormone and MAST independent mod-
eration effect of age upon aggression was also found. CONCLUSIONS: The present study demonstrates 
an association between alcohol drinking and self-reported sober-state aggression, which implies that the 
etiology of alcohol misuse and aggressive behavior may involve common biological and/or social factors. 
These mechanisms, as well as age, androgens and cortisol, all represent factors that, in combination, regu-
late human aggression. 
 
Apter SJ, Eriksson CJP: The effect of alcohol on testosterone concentrations in alcohol preferring 
and non preferring rat lines. Alcohol Clin Exp Res 27:1190 1193, 2003 
BACKGROUND: Previous studies have reported associations between human alcohol drinking and 
testosterone levels. METHODS: In this study we investigated serum testosterone concentrations without and 
under the influence of alcohol in alcohol-preferring (AA) and nonpreferring (ANA) rat lines. Animals were 
tested in both mornings and afternoons and the alcohol doses were 0.75 and 1.50 g/kg. RESULTS: Higher 
basal serum testosterone levels were detected in the AA rats compared with the ANA rats in both mornings 
(152%, p = 0.028) and afternoons (75%, p = 0.035). The high alcohol dose decreased the testosterone con-
centrations of both the AA and the ANA rats (p = 0.001-0.01). The low dose, however, decreased testoster-
one concentrations only in the ANA line (line difference in the morning: p = 0.027; in the afternoon p = 
0.000). CONCLUSION: The present results support previous indications of a positive association between 
testosterone and alcohol drinking. Furthermore, the present results, together with earlier reports on the AA 
and ANA rats, introduce the possibility of a connection between this association and the hypothalamic opi-
ate system, which is also involved in the feedback regulation of testosterone synthesis. 
 
Sarkola T, Eriksson CJP: Testosterone increases in men after a low dose of alcohol. Alcohol Clin 
Exp Res 27: 682-685, 2003 
BACKGROUND: Heavy acute alcohol drinking decreases blood testosterone in men due to an ef-
fect on the testicular level. An acute increase in blood testosterone levels after a low alcohol dose has, 
however, recently been reported in women. The objective of this investigation was to study the effect of a 
low alcohol dose on testosterone in men and further elucidate the mechanism behind the effect by using 
4-methylpyrazole, an inhibitor of alcohol metabolism. METHODS: A double-blind placebo-controlled 
interventional crossover trial in random order (n = 13). RESULTS: After intake of alcohol (0.5 g/kg, 10% 
w/v), an acute increase in plasma testosterone (from 13.5 +/- 1.2 nmol/liter to 16.0 +/- 1.6 nmol/liter, 
mean +/- SEM; p < 0.05), a decrease in androstenedione (from 5.1 +/- 0.4 nmol/liter to 4.0 +/- 0.3 
nmol/liter; p < 0.05), and an increase in the testosterone:androstenedione ratio (from 2.8 +/- 0.3 to 4.2 +/- 
0.4; p < 0.01) were observed. The effects were not observed during pretreatment with 4-methylpyrazole 
(10-15 mg/kg orally), which inhibited the ethanol elimination rate by 37 +/- 3%. CONCLUSIONS: Alco-
hol intake affects the androgen balance in men through an effect mediated by the alcohol-induced change 
in the redox state in the liver. 
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Eriksson CJP, von der Pahlen B, Sarkola T, Seppä K: Oestradiol and human male alcohol- related 
aggression. Alcohol Alcohol 38: 589-596, 2003 
AIMS: In comparison to androgens, almost nothing is known about the role of endogenous oestrogens 
in human aggressive behaviour. This new aspect was studied in the present investigation involving men with 
a history of alcohol-related aggression (AGG+) and in an age-matched male control population (AGG-). 
METHODS: Male AGG+ volunteers were recruited through advertisements and the controls were drawn 
from the Finnish Population Register. Alcohol misuse and interpersonal partner violence were estimated by 
questionnaires. Endogenous hormone levels were measured from morning plasma samples. RESULTS: A 
positive association emerged between plasma oestradiol and emotional negotiation during interpersonal 
conflict situations. Furthermore, a negative association was observed between oestradiol and testosterone-
related physical, violent, aggression in the AGG+ men. In addition, oestradiol, rather than testosterone, was 
positively associated with psychological aggression in both groups of men. CONCLUSION: It is suggested 
that endogenous female sex hormones may be related to empathic behaviour and could, thus, represent a 
counter-balancing factor in alcohol-related male aggressive behaviour. Altogether, oestrogen may represent 
a multifactor ingredient in the complex interactions of partner conflicts. 
 
Apter S, Eriksson CJP: The role of social isolation in the effects of alcohol on corticosterone and 
testosterone levels in alcohol-preferring and non-preferring rats. Alcohol Alcohol 41: 33-38, 2006 
AIMS: Alcohol has been reported to affect the hypothalamic-pituitary-gonadal axis (HPG-axis) and 
hypothalamic-pituitary-adrenal axis (HPA-axis) as expressed by increased or decreased corticosterone 
and testosterone levels. Both hormones have also been related to the aetiology of alcohol drinking and the 
development of alcoholism. Our aim has been to study these interrelations in animal models of alcohol 
drinking by using social isolation as a model of anxiety. METHODS: The effects of alcohol on serum 
testosterone and corticosterone concentrations were investigated in alcohol-preferring (AA) and alcohol 
non-preferring (ANA) rat lines. Animals were tested in mornings and afternoons with 0.75 and 1.5 g 
alcohol/kg. Half of the animals were kept in single cages, while the control animals were housed in 
groups of four individuals. RESULTS: The group-caged ANA rats displayed higher control corticoster-
one levels than the corresponding AA rats during morning sessions (P = 0.007). The AA rats displayed 
elevated corticosterone levels (AM: P = 0.047) and the ANA rats displayed reduced control corticosterone 
levels (PM: P = 0.016) in the single cage situation compared with the group-cage situation. Corticoster-
one concentrations were not affected by low doses and increased (P < 0.05) by high doses of alcohol in all 
test groups except for isolated AA rats during afternoon sessions. In general, more significant reductions 
in testosterone levels following alcohol administration were found in the ANA line. In group-caged AA 
rats, alcohol reduced testosterone levels, while no such effect was observed in isolated AA rats. 
CONCLUSIONS: We suggest that social isolation, representing stress, may constitute a situation in 
which the HPA and HPG axes are connected together in promoting alcohol drinking. 
 
Epidemiology of alcohol drinking and related diseases 
Järveläinen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO: Promoter poly-
morphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 33: 
1148-1153, 2001 
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Twin concordance studies indicate that genetic factors influence the individual susceptibility for alco-
holic liver disease (ALD). Both clinical and experimental data suggest that Kupffer cell activation by gut-
derived endotoxins and other bacterial products is an important pathogenic factor. Activated Kupffer cells 
release proinflammatory cytokines, a process that is regulated by the CD14 endotoxin receptor (CD14). 
Recently, a C-->T (-159) polymorphism in the promoter region of the CD14 gene was detected and found to 
confer increased CD14 expression. In the present study, the association of CD14 promoter polymorphism 
with different forms of ALD was examined in 3 separate autopsy series. Among 442 men with valid alco-
hol-consumption data, 381 men had been moderate or heavy alcohol consumers. The allele frequency of the 
CD14 promoter genotype, determined by a modified cycle minisequencing technique, was 0.34 (CC), 0.51 
(CT), and 0.16 (TT). The T allele was found to be associated with advanced ALD, i.e., with alcoholic hepa-
titis (odds ratio OR: 2.48; P = .018), and especially with cirrhosis (OR: 3.45; P = .004), but not with fatty 
liver, periportal fibrosis, or bridging fibrosis. The overall age-adjusted risk for cirrhosis was 3.08 (P = .01) 
for the carriers of the CT genotype, and 4.17 (P = .005) for the homozygous TT genotype. These results 
suggest that in the relatively isolated Finnish population, the T allele confers increased risk of alcoholic liver 
damage. In particular, TT homozygotes are at a high risk to develop cirrhosis. 
 
Spence JP, Liang T, Eriksson CJP, Taylor RE, Wall TL, Ehlers CL, Carr LG: Evaluation of alde-
hyde dehydrogenase 1 promoter polymorphisms identified in human populations. Alcohol Clin Exp Res 
27: 1389 1394, 2003 
BACKGROUND: Cytosolic aldehyde dehydrogenase, or ALDH1A1, functions in ethanol detoxifica-
tion, metabolism of neurotransmitters, and synthesis of retinoic acid. Because the promoter region of a gene 
can influence gene expression, the ALDH1A1 promoter regions were studied to identify polymorphism, to 
assess their functional significance, and to determine whether they were associated with a risk for develop-
ing alcoholism. METHODS: Sequence analysis was performed in the promoter region by using Asian, Cau-
casian, and African American subjects. The resulting polymorphisms were assessed for frequency in Asian, 
Caucasian, Jewish, and African American populations and tested for associations with alcohol dependence 
in Asian and African American populations of alcoholics and controls. The functional significance of each 
polymorphism was determined through in vitro expression analysis by using HeLa and HepG2 cells. 
RESULTS: Two polymorphisms, a 17 base pair (bp) deletion (-416/-432) and a 3 bp insertion (-524), were 
discovered in the ALDH1A1 promoter region: ALDH1A1*2 and ALDH1A1*3, respectively. ALDH1A1*2 
was observed at frequencies of 0.035, 0.023, 0.023, and 0.012 in the Asian, Caucasian, Jewish, and African 
American populations, respectively. ALDH1A1*3 was observed only in the African American population, 
at a frequency of 0.029. By using HeLa and HepG2 cells for in vitro expression, the activity of the luciferase 
reporter gene was significantly decreased after transient transfection of ALDH1A1*3-luciferase compared 
with the wild-type construct ALDH1A1*1-luciferase. In an African American population, a trend for higher 
frequencies of the ALDH1A1*2 and ALDH1A1*3 alleles was observed in a population of alcoholics (p = 
0.03 and f = 0.12, respectively) compared with the control population. CONCLUSIONS: ALDH1A1*2 and 
ALDH1A1*3 may influence ALDH1A1 gene expression. Both ALDH1A1*2 and ALDH1A1*3 produce a 
trend in an African American population that may be indicative of an association with alcoholism; however, 
more samples are required to validate this observation. The underlying mechanisms contributing to these 
trends are still unknown. 
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Saarikoski ST, Suitiala T, Holmila R, Impivaara O, Järvisalo J, Hirvonen A, Husgafvel-Pursiainen 
K: Identification of genetic polymorphisms of CYP2S1 in a Finnish Caucasian population. Mutat Res 
554: 267-277, 2004 
CYP2S1 is a recently discovered member of the cytochrome P450 (CYP) gene superfamily. Inter-
estingly, even though the DNA sequence identifies it as the sole member of the new CYP2S family, 
CYP2S1 exhibits many features typical to CYP1 family members, e.g. dioxin-inducibility mediated by 
the aryl hydrocarbon receptor (AHR) and the aryl hydrocarbon receptor nuclear translocator (ARNT). In 
addition, CYP2S1 metabolises some aromatic hydrocarbons as well as cellular substances. These charac-
teristics, together with a wide extrahepatic tissue distribution, suggest that CYP2S1 may have an impor-
tant role in both exogenous and endogenous metabolism. This is the first study characterising CYP2S1 
alleles and naming them with the recommended CYP allele nomenclature. We used denaturing gradient 
gel electrophoresis (DGGE) and direct sequencing to investigate genetic variation of CYP2S1 in 100 
male Finnish Caucasians. Those exons in which variation was found were examined in subsequent 100 
subjects. The coding region of all of the nine exons, as well as a 449 bp fragment of the proximal pro-
moter region, was analysed. This systematic investigation revealed eight single nucleotide polymorphisms 
(SNPs), which comprise nine different variant alleles (haplotypes), in addition to the wild-type allele. 
Seven of the SNPs occurred in the protein-coding areas and one in the proximal 3' untranslated region 
(3'UTR). Two of these sequence variations (10347C > T and 13106C > T) result in non-conservative 
amino acid substitutions, i.e. Arg380Cys and Pro466Leu, respectively. The respective allelic variants, 
CYP2S1*2 ([10347C > T]) and CYP2S1*3 (13106C > T; 13255A > G]), occurred in our study popula-
tion at frequencies of 0.50 and 3.75%, respectively. The most common of the variant alleles was 
CYP2S1*1H (23.8%), harbouring a 13255A > G substitution located in the 3'UTR. 
 
Eriksson CJP, Kaprio J, Pulkkinen L, Rose RJ: Testosterone and alcohol use among adolescent male 
twins: Testing between family associations in within family comparisons. Behav Genet 35: 359 368, 2005 
We examined associations of testosterone (T) and alcohol use in adolescent twin brothers, conduct-
ing both between- and within-family analyses. The twins completed semi-structured interviews, provided 
two saliva samples to assay T, and reported their drinking patterns and pubertal development. We ad-
justed T levels for diurnal/seasonal effects and association with pubertal maturation. In analyses of twins 
as individuals, higher T levels characterized boys reporting ever drinking, more frequent intoxication, 
high density drinking, more alcohol symptoms, and diagnosed alcohol dependency on interview. Adjust-
ing for pubertal development, only associations with symptom count and diagnosis remained significant. 
The association with frequent intoxication replicated among drinking-discordant twin brothers, effectively 
ruling out between-family confounds, but that association was not significant after adjustment for puber-
tal development. The phenotypic correlation between T and pubertal maturation is largely genetic, invit-
ing study of the magnitude and meaning of linkages between testosterone and symptoms of alcoholism on 
follow-up in early adulthood. 
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5.2. Neurobiology of drug dependence 
 
5.2.1. Research and public health significance of the area 
  
The burden of disease attributable to alcohol-related health consequences in 
Finland is remarkable. Although intoxication is often an important mediator of harm, 
dependence can significantly exacerbate the hazards. Majority of the burden comes 
from heavy drinking and alcohol dependence, because heavy drinkers consume a sig-
nificant proportion of total alcohol consumption. It is also evident that alcohol depend-
ence predisposes to use of other drugs including nicotine. Treatments and other inter-
ventions for problem drinkers and alcoholics are potentially beneficial in the manage-
ment of alcohol-related problems. 
Alcohol addiction is characterized by compulsive, chronic and relapsing consump-
tion of alcohol. Moreover, the vulnerability to develop an addiction to alcohol is influ-
enced by a combination of environmental and genetic factors. The transition from rec-
reational alcohol use to alcohol abuse and addiction is not well understood. It probably 
involves a number of neural mechanisms, such as acute sensitivity of various neuronal 
systems to alcohol and neuroadaptations resulting from repeated and chronic exposure 
to alcohol. Understanding these mechanisms is of great importance in translating basic 
findings on the neural actions of alcohol into potential clinical applications. 
Development of effective pharmacotherapies, however, relies on our understanding 
of the mechanisms underlying addiction to alcohol. Animal models have proved useful 
particularly in exploring the neural basis of addiction to alcohol and other drugs of 
abuse. The purpose of the present project is to clarify the role of various neurochemical 
systems as well as the contribution of neurobehavioral sensitization to the development 
of addiction to alcohol using the animal model of alcohol-preferring AA and alcohol-
avoiding ANA lines of rats. 
 
Role of central opioidergic systems and neurobehavioral sensitization in addiction 
to alcohol 
Several strain-specific differences have been previously found in opioidergic 
mechanisms both on behavioral and neurochemical level between the AA and ANA 
rats. These differences may contribute to the higher sensitivity of AA rats to the effects 
of acute and repeated administration of opioids, and higher preference for oral etoni-
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tazene than ANA rats. The project addresses on neurochemical, behavioral and molecu-
lar levels the role of specific neuronal and neuroadaptive mechanisms in intake of etha-
nol, and development of addiction to it. Neurochemical aspects include neurobehavioral 
characterization of the rat lines by measuring opioid peptides in the nucleus accumbens, 
ventral tegmental area, and central amygdala, as well as GABA in the ventral pallidum 
of AA and ANA rats administered ethanol or morphine. Behavioral analyses include 
investigation of the role of ventral pallidum in ethanol intake, and testing AA and ANA 
rats for possible differences in the rewarding effects of morphine and nicotine, using 
conditioned place preference. Molecular studies will address the role of the expression 
of µ and ? opioid-receptors in ethanol self-administration using viral transfer of opioid 
receptor gene into the brain. Differences in deltaFosB and BDNF expression, as well as 
in the chromatin structure or DNA methylation pattern of BDNF and trkB genes be-
tween drug naïve and drug-treated AA and ANA rats will be studied. 
 
Long-term neurochemical and behavioral effects of exposure to drugs of abuse in 
an adolescent, genetic animal model 
Human adolescent studies suggest that during adolescence drugs of abuse may 
have distinctive effects making adolescents more vulnerable than adults to the long-term 
effects of exposure to alcohol or other drugs of abuse, and contributing to increased risk 
to develop drug dependence not only on the particular drug but also on other drugs, and 
that genetic factors may further increase vulnerability. 
The neurobehavioral and genetic mechanisms underlying increased risk for alcohol 
and drug dependence during adolescence are not well understood. The developing brain 
undergoes extensive maturation processes during adolescence. On the other hand, drugs 
of abuse induce adaptive changes in the brain that are hypothesized to contribute to de-
velopment of addiction and are manifested for instance as behavioural sensitisation. 
The overall goal of the study is to provide information for better understanding of 
the association between early onset substance abuse and the risk for alcohol or drug 
dependence later in life. The study will characterize the neurobehavioral and genetic 
mechanisms of enhanced vulnerability to substance abuse during adolescence by study-
ing the long-term neurobehavioral effects of drugs of abuse using selectively bred alco-
hol-preferring AA (Alko Alcohol) and alcohol non-preferring ANA (Alko Non-
Alcohol) rats, developed in this laboratory, which offer a model to study neurobehav-
ioral and genetic factors of enhanced vulnerability to drugs of abuse. Consequently, 
behavioral sensitization induced by repeated administration of four major drugs of 
abuse - alcohol, nicotine, morphine, or a cannabinoid drug - during adolescence or dur-
ing adulthood will be studied. The role of neuroadaptive changes (sensitization) in vul-
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nerability to drugs of abuse self-administration of alcohol will be assed by comparing 
adult AA- and ANA-rats that have been exposed to drug treatment during adolescence 
to those receiving the same regime of drug treatment during adulthood. 
Drug-induced release of monoamines and amino acids in the nucleus accumbens 
and ventral tegmental area, two structures of the reward pathway, using in vivo mi-
crodialysis will also be compared between differentially treated, adult AA- and ANA-
rats. The molecular studies will examine the putative differences in the expression of the 
key genes known to be involved in plasticity-related phenomena in the brain, as well as 
the genes for the primary molecular targets for each specific drug. 
 
Neural pathways and transmitter systems in relapse 
Drug and alcohol dependence are chronic relapsing disorders characterized by im-
paired ability to control drug taking, continued use at the expense of other behaviors and 
despite negative consequences, and craving.  Converging human and animal literature 
point to three important categories for initiating relapse: negative affect or stress, prim-
ing doses of drugs, and conditioned drug-associated stimuli. Insight into the neurobio-
logical mechanisms by which these factors induce relapse will contribute to develop-
ment of pharmacotherapies that could diminish the likelihood of relapse and improve 
other clinically relevant outcomes in dependent patients. 
Many aspects of drug and alcohol addiction, including relapse, can be successfully 
modeled and studied in laboratory animals.  In this study, we have developed animal 
models for examining the neural pathways modulating cue-induced relapse and for testing 
potential candidates for pharmacological relapse prevention. Because glutamate transmis-
sion has a central role in mediating associative learning, including the impact of environ-
mental cues on likelihood of relapse, our studies have investigated the involvement of 
various glutamate receptor subtypes in relapse. In addition, we have initiated studies on 
the pharmacological manipulation of the brain endocannabinoid system for controlling 
excessive alcohol drinking and relapse propensity. Future molecular studies will evaluate 
plastic synaptic processes involved in relapse, including participation of both down- and 
upstream components of the mitogen-activated protein kinase (MAPK) family. 
 
Gene expression profiling of rat lines selected for differential alcohol drinking 
Until recently, by far the most common strategy for probing the mechanisms be-
hind regulation of alcohol drinking has been the comparison of various central neuro-
transmitter systems in the selected lines. The multiplicity of the neurotransmitter sys-
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tems participating in mediation of alcohol reward and the complex interactions between 
them set limitations to this approach. However, advancement of functional genomic 
approaches based on microarrays has offered a novel approach for studying the neuro-
biology of the lines that is not limited by pre-existing hypotheses on the role of particu-
lar neuronal systems in alcohol drinking. Specifically, high-throughput functional ge-
nomics allows analysis of gene expression simultaneously and in a non-biased manner 
on a genomic scale, may yield new candidate targets for further verification, and shift 
research of neural basis of alcohol drinking to a more system-oriented view of neurobi-
ology. In this study, we compared the expression of several hundred genes in four brain 
regions of AA and ANA rats using the Affymetrix oligonucleotide microarray platform. 
 
5.2.2. The main scientific achievements 
 
Selectively bred as well as inbred rodent lines differing in ethanol-related phenotypes 
have been widely used to identify the neuronal mechanisms underlying drug and ethanol 
abuse. The alcohol-preferring AA (Alko Alcohol) and non-preferring ANA (Alko Non-
Alcohol) rat lines were among the earliest rodent lines produced by selection. This breed-
ing program based on bi-directional selection was initiated in Finland in the sixties, and 
the lines have been maintained beyond the 90th generation at the National Public Health 
Institute of Finland. AA and ANA rats represent two non-overlapping phenotypic distri-
butions of voluntary alcohol consumption, with an approximately ten-fold difference in 
the mean voluntary alcohol consumption between the lines. 
The utility of selected animals for unraveling the biological factors underlying pre-
disposition for high (or low) alcohol consumption, is based on the assumption that the 
animals produced by selectively breeding from a heterogeneous base population for a 
specific ethanol-related trait differ from each other only in the trait upon which selection 
has been applied, and in traits that are related to the selected trait either causally or 
through genetic linkage. Consequently, much effort has been put by us on the charac-
terization of these rat lines in search for the neurochemical correlates of differential al-
cohol drinking between AA and ANA rat lines. 
Dopaminergic neurons are probably not critically involved in the differential etha-
nol self-administration behavior of the AA and ANA rat lines. Measurements of the 
effect of ethanol on the levels of the metabolites of dopamine as well as data from mi-
crodialysis studies suggest that there are no consistent differences in ethanol- or drug-
induced changes in functioning of dopaminergic neurons between the lines have been 
37 
found. Moreover, injections of 6-hydroxydopamine into the nucleus accumbens of AA 
rats do not impair acquisition or maintenance of ethanol self-administration behavior. 
Neurochemical studies have revealed strain-specific differences in the opioidergic 
systems between the AA and ANA rat lines. AA rats showed lower spontaneous release 
of hypothalamic beta-endorphin release compared to ANA rats, although there is no 
difference in the ethanol stimulated release between the lines. AA rats also present a 
greater content of proopiomelanocortin mRNA in the arcuate nucleus of the hypothala-
mus compared to ANA animals. The content of proenkephalin mRNA in the prefrontal 
cortex and that of prodynorphin mRNA in the mediodorsal nucleus of the thalamus 
were also higher in the AA rats than in the ANA rats. Lower levels of pro-enkephalin-
derived peptides in the nucleus accumbens and pro-dynorphin peptides in the VTA of 
AA rats relative to those of ANA rats have also been reported, and that pro-enkephalin-
derived peptides were elevated to a greater extent in the NAC of AA than of ANA rats 
following exposure to ethanol. 
Studies comparing the distribution and density of the various classes of opioid recep-
tors between the lines indicate greater density of µ-opioid receptors in numerous brain 
parts, particularly in the shell of NAC and in the prefrontal cortex in AA rats compared to 
ANA rats, while a higher density of  binding sites is found in the ventromedial hypo-
thalamus of ANA rats. Such differences were not seen in receptor density.                
Behavioral studies present more evidence for the endogenous opioid system play-
ing a role in determining the differences in ethanol consumption between the AA and 
ANA rats. The AA rats have been found to consume more etoniatzene (a potent agonist 
of opiate receptors) solution than the ANA rats, and AA rats also learn to lever press for 
intravenous heroin more rapidly than ANA rats. The lines also differ in their sensitivity 
to the locomotor stimulatory effect of morphine AA rats showing higher sensitivity. In 
parallel with these findings, increased metabolism of dopamine in the caudate-putamen 
has been found. No differences between the lines in the effects of morphine on accum-
bal dopamine levels have been found either in postmortem or microdialysis studies. 
AA and ANA rats have also been shown to differ in their susceptibility to mor-
phine-induced behavioral and neurochemical sensitization. AA rats treated repeatedly 
with morphine were more susceptible than ANA rats to morphine-induced locomotor 
activity, rotational behavior and mesolimbic dopaminergic neurotransmission. Sensiti-
zation to the neurochemical effects of morphine was, however, transient. Consequently, 
increased susceptibility to morphine-induced sensitization in AA rats compared to ANA 
rats may be a reflection of functional differences in their opioidergic systems and may 
contribute to their differential ethanol self-administration behavior. The findings may 
also suggest that the behavioral sensitization to morphine may not involve sensitized 
dopaminergic mechanisms, or that the role of dopamine is transient. 
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Increased susceptibility to morphine-induced sensitization in AA rats compared to 
ANA rats might predict enhanced ethanol reinforcement in AA rats sensitized to mor-
phine. Sensitization of AA rats to the behavioral effects of morphine alone does not, 
however, seem to enhance the reinforcing properties of voluntarily consumed ethanol in 
AA rats. AA rats sensitized to the behavioral effects of morphine did not, show en-
hanced acquisition of ethanol intake when given continuous access to ethanol solution 
after discontinuation of repeated treatment with morphine. Neuroadaptations induced by 
repeated treatment with morphine, however, further enhance the reinforcement from 
ethanol when challenged with morphine. 
Glutamatergic neurotransmission plays an important role in the pathogenesis of alco-
hol and drug addiction. Prolonged drug use has been suggested to lead to alterations in 
glutamatergic neurotransmission that could predispose subjects to development of addic-
tion and increase the propensity to relapse. In agreement with this framework, we demon-
strated that systemic administration of AMPA/kainate antagonists, an NMDA/glycine 
antagonist, or an mGlu5 receptor antagonist attenuates cue-induced alcohol and cocaine 
seeking in rats. Particularly metabotropic glutamate receptors may offer interesting targets 
for pharmacological manipulation in humans with a good safety profile.      
In the first study comparing gene expression profiles between the AA and ANA 
rats using the Affymetrix oligonucleotide platform, we detected 48 differentially ex-
pressed genes between AA and ANA rats. The nucleus accumbens, a key component of 
brain reward systems, appeared to be the most divergent region and showed increased 
expression of a cluster of signal transduction genes in the AA line. These differences in 
mRNA levels seem to be associated with altered mitogen-activated protein kinases 
(MAPK) signaling. A robust downregulation of ß-arrestin was found in several brain 
regions of the AA rat. This finding provides a possible mechanism underlying the in-
creased responsiveness in opiate systems observed in this line. 
 
5.2.3. The main public health achievements 
 
The overall goal of the project is to provide information for better understanding of 
the association between early onset substance abuse and the risk for alcohol or drug 
dependence later in life, as well as better knowledge of these mechanisms will also help 
to understand genetically determined predisposition to develop alcohol dependence and 
liability co-use drugs of abuse. The information will be valuable for planning of preven-
tive measures, policies and treatments for related problems. 
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Conducting research on drug dependence will also provide the National Public 
Health Institute with the scientific expertise needed for health education in the preven-
tion of drug dependence and other drug-related health problems. 
 
5.2.4. Funding for research and public health programs 
 
The project is funded by the National Public Health Insitute (KTL) as well by 
grants from the Academy of Finland, the Finnish Foundation for Alcohol Studies, Yrjö 
Jahnsson Foundation, and Ella and Georg Ehrnrooth Foundation.     
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sity of Heidelberg, Central Institute of Mental Health, Mannheim, Germany 
 
5.2.8.  Key publications 
 
Koistinen, M., Tuomainen, P., Hyytiä, P., Kiianmaa, K.  Naltrexone suppresses ethanol intake in 6-
hydroxydopamine-treated rats. Alcohol.: Clin. Exp. Res. 25(11): 1605-1612, 2001 
 
BACKGROUND: The suppressive effect of opioid antagonists, such as naltrexone, on ethanol intake 
has been suggested to be based on the interference with ethanol-induced stimulation of dopamine release in 
the nucleus accumbens. The aim of this study was to determine whether reduction of dopamine innervation 
to the nucleus accumbens with the neurotoxin 6-hydroxydopamine (6-OHDA) alters naltrexone-induced 
suppression of ethanol consumption. Because the mesolimbic dopaminergic neurons have also been impli-
cated in ethanol reinforcement, the effects of 6-OHDA on the maintenance and acquisition of ethanol intake 
were also studied. METHODS: To damage accumbal terminals of the mesolimbic dopamine neurons, alco-
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hol-preferring Alko Alcohol (AA) rats were given bilateral injections of 6-OHDA or vehicle into the nucleus 
accumbens after pretreatment with desipramine and pargyline. The effect of the lesion on the acquisition or 
maintenance of ethanol self-administration was studied in animals having continual access to ethanol solu-
tion (10% v/v) and water. Subsequently the effect of naltrexone on ethanol consumption was determined. 
RESULTS: Naltrexone (0.03-3.0 mg/kg subcutaneously) suppressed ethanol consumption in a dose-
dependent manner both in 6-OHDA-treated and control animals given a daily 90-min access to ethanol 
solution. When the rats had continual access to ethanol, there was a clear day-to-day decline in ethanol in-
take during the first 5 days of the 7-day naltrexone treatment (10 mg/kg subcutaneously). 6-OHDA treat-
ment had no effect on either the acquisition or maintenance of ethanol self-administration. Postmortem 
analysis of the brain dopamine content revealed approximately 92% depletion of dopamine in the nucleus 
accumbens of the 6-OHDA-treated rats. CONCLUSIONS: The suppressive effect of naltrexone does not 
depend on naltrexone's interaction with dopaminergic terminals in the nucleus accumbens. Furthermore, the 
role of the mesolimbic dopamine pathway is probably not central either in the acquisition or maintenance of 
ethanol self-administration in alcohol-preferring AA rats. 
 
Ojanen S., Koistinen M., Bäckström P., Kankaanpää A., Tuomainen P. Hyytiä P., Kiianmaa K. Dif-
ferential behavioral sensitization to intermittent morphine treament in alcohol-preferring AA and alcohol-
avoiding ANA rats: role of mesolimbic dopamine. Eur J Neurosci 17: 1655-1663, 2003 
Alcohol-preferring AA (Alko Alcohol) and alcohol-avoiding ANA (Alko Non-Alcohol) rats have 
well-documented differences in their voluntary ethanol consumption and brain opioidergic systems. The 
aim of the present study was to investigate whether these rat lines differ in their susceptibility to mor-
phine-induced behavioural and neurochemical sensitization. The rats were given 15 injections of mor-
phine (10 mg/kg, s.c.) or saline every other day. Locomotor activity and release of dopamine in the nu-
cleus accumbens were monitored after a challenge with additional morphine injections (10 mg/kg) 1 and 
5 weeks after withdrawal from the repeated treatment. Morphine increased locomotion more in the previ-
ously morphine-treated rats than in the saline-treated controls. Furthermore, AA rats were more sensitive 
to this effect of morphine than ANA rats. Accumbal morphine-induced dopamine release was signifi-
cantly higher in the morphine-treated AA than ANA rats after the first challenge injection 1 week from 
withdrawal, but no differences were observed after the second challenge. The brain and plasma concen-
trations of morphine were similar among the lines suggesting that the differences in the effects of mor-
phine cannot be explained in terms of differential pharmacokinetics of morphine in these lines. These data 
show that AA rats are more susceptible to morphine-induced behavioural sensitization than ANA rats. 
Furthermore, it suggests that mesolimbic dopamine has at best only a transient role in the expression of 
opioid-induced behavioural sensitization. The relationship between the mechanisms underlying the differ-
ential sensitivity of these rat lines to the effects of repeated morphine and voluntary ethanol drinking 
remains to be determined. 
 
Arlinde C, Sommer W, Björk K, Reimers M, Hyytiä P, Kiianmaa K, Heilig M. A cluster of differ-
entially expressed signal transduction genes identified by microarray analysis in a rat genetic model of 
alcoholism. Pharmacogenomics J. 4(3):208-18, 2004         
Analyzing gene expression patterns in genetic models of alcoholism may uncover previously un-
known susceptibility genes, and point to novel targets for drug development. Here, we compared expres-
sion profiles in alcohol-preferring AA rats with the alcohol-avoiding counterpart ANA line, and unse-
lected Wistar rats. Cingulate cortex, Nc. accumbens, amygdala and hippocampus of each line were ana-
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lyzed using the Afymetrix RN U34 arrays and dChip 1.1 software. Analysis of line-specific expression 
revealed 48 differentially expressed genes between AA and ANA rats. Elevated hippocampal neuropep-
tide Y (NPY) was found in ANA rats in agreement with previous studies. A cluster of MAP-kinases indi-
cating altered signal transduction was upregulated within the Nc. Accumbens of the AA line, and is of 
particular functional interest. Within the amygdala, a more loosely inter-related cluster of cytoskeleton-
associated genes may point to structural abnormalities. The observed dysregulations may contribute to the 
alcohol-preferring phenotype. 
 
 Bäckström P, Bachteler D, Koch S, Hyytiä P, Spanagel R. mGluR5 antagonist MPEP reduces etha-
nol-seeking and relapse behavior. Neuropsychopharmacology29(5):921-8, 2004   
   The glutamatergic system plays an important role in mediating neurobehavioral effects of ethanol. 
Metabotropic glutamate receptors subtype 5 (mGluR5) are modulators of glutamatergic neurotransmis-
sion and are abundant in brain regions known to be involved in ethanol self-administration. Here, we 
studied the effects of 2-methyl-6-(phenylethynyl)-pyridine (MPEP), a highly potent, noncompetitive 
mGlu5 receptor antagonist, on voluntary ethanol consumption and relapse behavior. For this purpose, we 
used two models for the measurement of relapse behavior: (i) reinstatement of ethanol-seeking behavior 
by drug-associated cues and (ii) the alcohol deprivation effect in long-term ethanol-consuming rats. In the 
first set of experiments, rats were trained to lever press for ethanol in the presence of a distinct set of cues. 
After extinction, the animals were exposed to the respective cues that initiated reinstatement of respond-
ing. A response-contingent ethanol prime further enhanced responding compared to the conditioned cues 
alone. Under these conditions, MPEP (0, 1, 3, and 10 mg/kg) attenuated ethanol seeking significantly and 
in a dose-related manner. However, at the highest dose, MPEP also decreased the number of inactive 
lever responses. In the second set of experiments, rats with 1 year of ethanol experience and repeated 
deprivation phases were used. A subchronic treatment with MPEP (twice daily; 0, 3, and 10 mg/kg) re-
sulted in a significant and dose-dependent reduction of the alcohol deprivation effect (ADE). Although 
the same MPEP treatment regimen decreased baseline drinking, this effect was not as pronounced as on 
the ADE. These results show in two commonly used models of relapse to ethanol that pharmacological 
targeting of mGlu5 receptors may be a promising approach for the treatment of alcoholism.    
 
Ojanen, S.; Hyytiä, P.; Kiianmaa, K. Behavioural sensitisation and voluntary ethanol drinking in al-
cohol-preferring AA rats exposed to different regimens of morphine treatment. Pharmacol. Biochem. 
Behav. 80: 221-228, 2005. 
The purpose of the study was to investigate the effects of three different regimens of morphine 
treatment on subsequent voluntary ethanol drinking in alcohol-preferring AA (Alko Alcohol) rats. The 
rats were given morphine subcutaneously either intermittently on alternating days (15 x 10 mg/kg or 5 x 
5-20 mg/kg in escalating doses) or subchronically on four consecutive days (3-20 mg/kg/d). Horizontal 
locomotor activity was monitored after challenges with additional morphine injections (3 mg/kg) ten days 
and six weeks after termination of the pretreatment to test if behavioral sensitization was induced by re-
peated morphine administration. Both intermittent pretreatments induced sensitized locomotor response 
after the first challenge, whereas subchronic injections did not. After the challenge the rats were given a 
free choice between tap water and 10% (v/v) ethanol solution for four weeks. The rats pretreated and 
challenged with morphine did not differ significantly in the acquisition of ethanol drinking from the sa-
line-treated controls. In contrast, ethanol drinking was impaired during the first week of ethanol access in 
the saline-treated rats given a single morphine injection. The second morphine challenge given after the 
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ethanol-drinking phase did not reveal sensitization in any of the groups. The results suggest that pattern of 
morphine administration rather than the dose or number of exposures to the drug is the most important 
factor in induction of behavioral sensitization, and that exposure to ethanol may interfere with this proc-
ess. They also support earlier findings showing that acute morphine may suppress voluntary ethanol 
drinking, but failed to provide clear evidence for behavioral sensitization to morphine contributing to 
predilection towards ethanol in AA rats. 
Bäckström P, Hyytiä P. &nbsp;Ionotropic and metabotropic glutamate receptor antagonism attenu-
ates cue-induced cocaine seeking. Neuropsychopharmacology 31(4):778-86, 2006.   
      Neuroanatomical and pharmacological evidence implicates glutamate transmission in drug-
environment conditioning that partly controls drug seeking and relapse. Glutamate receptors could be 
targets for pharmacological attenuation of the motivational properties of drug-paired cues and for relapse 
prevention. The purpose of the present study was therefore to investigate the involvement of ionotropic 
and metabotropic glutamate receptor subtypes in cue-induced reinstatement of cocaine-seeking behavior. 
Rats were trained to self-administer cocaine using a second-order schedule of reinforcement 
(FR4(FR5:S)) under which a compound stimulus (light and tone) associated with cocaine infusions was 
presented contingently. Following extinction, the effects of the competitive NMDA receptor antagonist 
CGP 39551 (0, 2.5, 5, 10 mg/kg intraperitoneally (i.p.)), two competitive AMPA/kainate antagonists, 
CNQX (0, 0.75, 1.5, 3 mg/kg i.p.) and NBQX (0, 1.25, 2.5, 5 mg/kg i.p.), the NMDA/glycine site antago-
nist L-701,324 (0, 0.63, 1.25, 2.5 mg/kg i.p.), and the mGluR5 antagonist MPEP (0, 1.25, 2.5, 5 mg/kg 
i.p.) on cue-induced reinstatement of cocaine seeking were examined. The AMPA/kainate receptor an-
tagonists CNQX and NBQX, the NMDA/glycine site antagonist L-701,324, and the mGluR5 antagonist 
MPEP attenuated significantly cue-induced reinstatement. The NMDA antagonist CGP 39551 failed to 
affect reinstatement. Additional control experiments indicated that attenuation of cue-induced reinstate-
ment by CNQX, NBQX, L-701,324, and MPEP was not accompanied by significant suppression of spon-
taneous locomotor activity. These results suggest that conditioned influences on cocaine seeking depend 
on glutamate transmission. Accordingly, drugs with antagonist properties at various glutamate receptor 
subtypes could be useful in prevention of relapse induced by conditioned stimuli. 
 
Ojanen, S.; Hyytiä, P.; Kiianmaa, K. Enhanced morphine-induced ethanol drinking in alcohol-
preferring aa rats sensitized to morphine. Alcohol.: Clin. Exp. Res_._30(4): 621-629, 2006. 
BACKGROUND: Alcohol-preferring alko alcohol (AA) rats are more susceptible to morphine-
induced behavioral and neurochemical sensitization than alcohol nonpreferring alko nonalcohol (ANA) 
rats. Alko alcohol rats sensitized to morphine, however, do not show enhanced acquisition of ethanol 
drinking. The purpose of the present study was to clarify further interactions between morphine-induced 
behavioral sensitization and voluntary ethanol drinking in the AA rats. METHODS: Alko alcohol rats 
drinking ethanol in a limited 6-hour access paradigm were sensitized to morphine with repeated injections 
of morphine (5-15 mg/kg). Injection days alternated with days of ethanol access. Controls had access only 
to water and/or were given injections of saline. After a 5-day washout period from ethanol and morphine, 
the rats were challenged with morphine or saline and subsequent ethanol drinking or locomotor activity 
was recorded. RESULTS: Ethanol intake was suppressed during the repeated treatment with morphine, 
and the morphine-treated rats did not differ in ethanol intake from the controls when given access to etha-
nol after the washout. Intake of ethanol was, however, increased when the rats were challenged with mor-
phine [1 or 10 mg/kg, subcutaneously (s.c.)], while in the controls an increase in ethanol intake was seen 
only after 1 mg/kg morphine. Sensitization to the locomotor stimulating effects of morphine was revealed 
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in the morphine-treated rats after a challenge with morphine (3 or 10 mg/kg, s.c.). The controls that had 
been drinking ethanol also showed a sensitized response after morphine (3 mg/kg). CONCLUSIONS: 
Ethanol did not interfere with the development of sensitization to morphine. Furthermore, the neuroadap-
tations induced by repeated exposure to ethanol were sufficient to cause behavioral cross-sensitization to 
morphine. Sensitization to the behavioral effects of morphine alone, however, neither enhances the rein-
forcing properties of voluntarily consumed ethanol nor contributes to increase in its intake. The increase 
in ethanol intake found after an acute dose of morphine was augmented in rats withdrawn from repeated 
treatment with morphine. The data suggest that the neuronal mechanisms underlying behavioral sensitiza-
tion to morphine probably are distinct from those mediating reinforcement from ethanol and that the mor-
phine-induced neuroadaptations contribute to the enhancement of increase in ethanol intake by morphine.  
Bäckström P, Hyytiä P. Involvement of AMPA/kainate, NMDA, and mGlu5 receptors in the nu-
cleus accumbens core in cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology 
192(4):571-80, 2007         
   RATIONALE: Nucleus accumbens glutamate transmission has been implicated in drug-seeking 
behavior, but the involvement of glutamate receptor subtypes in drug seeking maintained by drug-
associated cues has not been fully investigated. OBJECTIVE: This study examined the effects of alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate, N-methyl-D-aspartate (NMDA) 
and mGlu5 receptor blockade in the nucleus accumbens core on cue-induced reinstatement of cocaine 
seeking. METHOD: Wistar rats were trained to self-administer cocaine and associate a compound stimu-
lus (light and tone) with the drug under an FR4(FR5:S) second-order schedule of reinforcement. After 
extinction, during which neither cocaine nor the compound stimulus was available, responding was rein-
stated by contingent presentations of the compound stimulus. The effects of the intra-accumbal 
AMPA/kainate receptor antagonist 6-cyano-7-nitro-quinoxaline-2, 3-dione (CNQX; 0, 0.01, and 0.03 
microg/side), the NMDA antagonist D-2-amino-5-phosphonopentanoate (D-AP5; 0, 1, and 2 mi-
crog/side), and the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP; 0, 0.5, and 1 mi-
crog/side) on reinstatement were examined in a within-subjects design. RESULTS: CNQX and D-AP5 
attenuated cue-induced reinstatement of cocaine seeking dose-dependently. MPEP, however, decreased 
cocaine seeking only relative to baseline because also the saline vehicle included in the within-subjects 
series of injections decreased responding, possibly reflecting conditioned anhedonic effects of MPEP. In 
additional experiments, none of the antagonists attenuated locomotor activity or responding for sucrose 
pellets. CONCLUSIONS: The results suggest that cue-induced reinstatement of cocaine seeking after a 
period of withdrawal from cocaine is sensitive to AMPA/kainate and NMDA receptor antagonism in the 
nucleus accumbens core and give further evidence for the role of the accumbal glutamate transmission in 
modulation of drug-seeking behavior.    
  Hansson AC, Bermúdez-Silva FJ, Malinen H, Hyytiä P, Sanchez-Vera I, Rimondini R, Rodriguez 
de Fonseca F, Kunos G, Sommer W, Heilig H. Genetic impairment of frontocortical endocannabinoid 
degradation and high alcohol preference. Neuropsychopharmacology 32(1):117-26, 2007.  
 Endocannabinoid signaling has recently been implicated in ethanol-seeking behavior. We analyzed 
the expression of endocannabinoid-related genes in key brain regions of reward and dependence, and 
compared them between the alcohol-preferring AA (Alko Alcohol) and nonpreferring ANA (Alko Non-
Alcohol) rat lines. A decreased expression of fatty acid amidohydrolase (FAAH), the main endocannabi-
noid-degrading enzyme, was found in prefrontal cortex (PFC) of AA rats, and was accompanied by de-
creased enzyme activity in this region. Binding of the endocannabinoid-cannabinoid 1 (CB1) receptor 
ligand (3)\[H\]SR141716A, and \[35S\]GTPgammaS incorporation stimulated by the CB1 agonist WIN 
55,212-2 were downregulated in the same area. Together, this suggests an overactive endocannabinoid 
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transmission in the PFC of AA animals, and a compensatory downregulation of CB1 signaling. The func-
tional role of impaired FAAH function for alcohol self-administration was validated in two independent 
ways. The CB1 antagonist SR141716A potently and dose-dependently suppressed self-administration in 
AA rats when given systemically, or locally into the PFC, but not in the striatum. Conversely, intra-PFC 
injections of the competitive FAAH inhibitor URB597 increased ethanol self-administration in non-
selected Wistar rats. These results show for the first time that impaired FAAH function may confer a 
phenotype of high voluntary alcohol intake, and point to a FAAH both as a potential susceptibility factor 
and a therapeutic target. 
 
6. MENTAL HEALTH RESEARCH UNIT 
 
6.1. Self-destructive behavior and suicide prevention 
 
6.1.1. Research and public health significance of the area 
 
There has been increasing awareness of the extent and burden of suicidal behaviour 
and suicide not only in Finland but also globally. WHO estimates that about 1 million 
people die by suicide. In Finland suicide mortality has increased steadily after the Sec-
ond World War reaching the highest rate ever in 1990 (30/100.000), 1500 suicides in 
total. The increasing suicide rate was the main reason to start the National Suicide Pre-
vention Project. The aim was to stop the increasing trend and decrease suicide mortality 
by 20% by the year 1995. This project, led by professor Jouko Lönnqvist, was the rea-
son behind establishing a separate new unit for mental health in the National Public 
Health Institute in 1986. Suicide research was a starting point to the development of the 
Department of Mental Health in 1992. As the first country in the world, Finland pub-
lished a national strategy of suicide prevention and an action plan for implementation in 
1991. Suicide rate has decreased steadily during the last 15 years and was 18/100.000 in 
2005. The annual amount of suicides has declined below 1000. Finland is not among the 
top ten countries in the world having a very high suicide rate any more. On the contrary, 
Finland is now internationally known as a model country for suicide prevention. How-
ever, Finland still has a relatively high suicide rate compared with other western EU 
countries. Suicide is a leading cause of death in Finland among those under the age of 
35 years. Suicide also means a major loss of expected active life years and a huge stress 
and long-term burden to all survivors. Suicidal ideation, plans and suicide attempts are 
common symptoms associating tightly with psychological, social and physical problems 
in the general population. Attempted suicides are nowadays main causes for costly visits 
46 
into emergency rooms of general hospitals. During the last 15 years, National Public 
Health Institute has been one of the leading centers in the world in the field of suicidol-
ogy. In 2004 Jouko Lönnqvist reveived the Annual Research Award of American Foun-
dation for Suicide Research. We have already educated “the third generation” of inter-
nationally well-known experts in suicide research and prevention. Suicide is a global 
phenomen of human society but it also has strong local, social, societal and cultural 
roots. We still need a strong research unit to study and prevent suicide in Finland, and to 
collaborate internationally.  
 
6.1.2. The main scientific achievements 
 
During the last ten years we have published about 100 scientific reports on suicidal 
behavior in international journals. Since 1996 twelve persons have published their doc-
toral thesis on suicidology based on our materials and supervised by our senior staff 
members. We have had the largest nation-wide psychological autopsy study conducted 
ever in the world. We have been successful in showing specificically how suicidal be-
havior and suicide especially is connected with mental disorders and comorbidity, and 
with several biological and circadian risk factors. We were among the first ones to show 
the lack of treatment among suicide victims before suicide as well as among suicide 
attempters, even after the suicide attempt. We also succeeded for first time ever in 
showing direct connection between the continuous use of antidepressants and decreased 
risk of suicide among depressive suicide attempters. We could also show that treatment 
adherence among schizophrenic patients prevents suicide. We were also able to show, 
against common beliefs, that dehospitalization has not increased suicide risk among 
schizophrenic patients in Finland.          
 
6.1.3. The main public health achievements 
 
Public awareness of the magnitude and character of suicide and suicidal behaviour 
and knowledge about this problem has been increasing. Suicide is not the taboo it used 
to be any more. The health care system is able to recognize and treat depression, at-
tempted suicides, substance use disorders and psychoses in a more proper way than pre-
viously based on the models of good practice which we have been developing as core 
experts in Finland. We believe that many activities we have been promoting explain the 
decreasing trend of suicide mortality in Finland. We have assessed that during the last 
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15 years the expected loss of active life years saved from suicide has been about 
100.000 person-years. 
We have actively participated in international suicide prevention activities as experts 
within WHO and EU for years. We also have been a part of a global expert group which 
has published a meta-analysis on suicide prevention. We have arranged national and in-
ternational meetings on suicide and suicide prevention, published textbooks and preven-
tion material both internationally and in Finland. We also continuously receive interna-
tional visitors, especially from Asia, to learn from our experience on suicide prevention. 
 
6.1.4. Funding for research and public health pograms 
 
Since 1996, we have not received any extra funding from the state or KTL budget 
for suicide research. All resources have been allocated from our basic annual budget, or 
largely received from several private Finnish funds. However, during the last six years, 
we have received 30.000 euros from the health promotion budget of Ministry of Social 
Affairs and Health annually to develop guidelines for prevention activities among ado-
lescents, mainly at schools. In addition, this year we received  20.000 euros  from the 
KTL budget to arrange an international symposium on suicide prevention in Helsinki 
together with WHO (Geneva) and Suicide Prevention International Inc (USA).
  
6.1.5. Personnel 
 
The project promotes and coordinates suicide research in the KTL. However, sui-
cide research is also conducted in several other projects of the department. In 2006-2007 
we published 15 articles and two doctoral theses on suicide and suicide related topics. In 
total, 10 of our researchers participated in these studies and total amount of work was 
about three person years.   
 
6.1.6. Collaboration 
 
In suicide research we have collaborated with Jorvi, Peijas and Helsinki hospital 
districts and with Helsinki university Central Hospital to get clinical samples. In addi-
tion, in register studies we have had excellent co-operation with Kuopio University (Jari 
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Tiihonen), and with The Social Insurance Institution of Finland (KELA) and Research 
and Development Centre for Welfare and Health (Stakes). We have participated in the 
WHO (Euro) parasuicide study for years as well as in the EU multicenter study on at-
tempted suicide in Europe (Armin Schmidtke, Wurzburg). We are actively planning, as 
one of eight European centers, a large EU evaluation study on suicide prevention (FP7, 
coordinated by Steven Platt, Edinburgh) starting possibly in 2008. Jouko Lönnqvist is 
the president of International Academy for Suicide Research, having about 100 most 
prominent suicide researchers in the world, in 2007-2009, and an expert member of the 
American Foundation for Suicide Prevention reviewing international applications (John 
Mann, Columbia University). We also have intensive co-operation with Karolinska In-
stitute in research, prevention and education (Danuta Wasserman).   
 
6.1.7. Proposal for future work and expected benefits 
 
We will monitor the suicide trends in Finland, and analyze the main factors ex-
plaining the continuous decline of the suicide rate. The main focus has been and still is 
in effects of maintenance treatments (antidepressants and antipsychotics) on suicide and 
total mortality. We are starting to analyze the biological and genetic background of sui-
cidal behaviour by using the Finnish twin cohort and our genetic cohorts of schizophre-
nia and bipolar disorder. In addition, we will participate in the EU- evaluation study on 
suicide prevention. Our aim is to also publish a total description and analysis of the na-
tional suicide prevention project since we now have a 20 years follow-up from the start 
of the project. We will also publish a 20 years follow-up study on survivors of suicide.
  
 
6.1.8. Main publications  
 
Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the 
risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. 
Department of Forensic Psychiatry, University of Kuopio and Niuvanniemi Hospital, Kuopio Uni-
versity Hospital, Kuopio, Finland. Jari.Tiihonen@niuva.fi 
BACKGROUND: It is unknown if antidepressant treatment is associated with either increased or de-
creased risk of suicide. OBJECTIVE: To estimate the risk of suicide, attempted suicide, and overall mortal-
ity during antidepressant treatments in a real-life setting with high statistical power. DESIGN AND 
SETTING: A cohort study in which all subjects without psychosis, hospitalized because of a suicide attempt 
from January 1, 1997, to December 31, 2003, in Finland, were followed up through a nationwide computer-
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ized database. PARTICIPANTS: A total of 15 390 patients with a mean follow-up of 3.4 years. MAIN 
OUTCOME MEASURES: The propensity score-adjusted relative risks (RRs) during monotherapy with the 
most frequently used antidepressants compared with no antidepressant treatment. RESULTS: In the entire 
cohort, fluoxetine use was associated with the lowest risk (RR, 0.52; 95% confidence interval [CI], 0.30-
0.93), and venlafaxine hydrochloride use with the highest risk (RR, 1.61; 95% CI, 1.01-2.57), of suicide. A 
substantially lower mortality was observed during selective serotonin reuptake inhibitor use (RR, 0.59; 95% 
CI, 0.49-0.71; P<.001), and this was attributable to a decrease in cardiovascular- and cerebrovascular-related 
deaths (RR, 0.42; 95% CI, 0.24-0.71; P=.001). Among subjects who had ever used any antidepressant, the 
current use of medication was associated with a markedly increased risk of attempted suicide (39%, 
P<.001), but also with a markedly decreased risk of completed suicide (-32%, P=.002) and mortality (-49%, 
P<.001), when compared with no current use of medication. The results for subjects aged 10 to 19 years 
were basically the same as those in the total population, except for an increased risk of death with paroxetine 
hydrochloride use (RR, 5.44; 95% CI, 2.15-13.70; P<.001). CONCLUSIONS: Among suicidal subjects who 
had ever used antidepressants, the current use of any antidepressant was associated with a markedly in-
creased risk of attempted suicide and, at the same time, with a markedly decreased risk of completed suicide 
and death. Lower mortality was attributable to a decrease in cardiovascular- and cerebrovascular-related 
deaths during selective serotonin reuptake inhibitor use. 
 
Tiihonen J, Walhbeck K, Lonnqvist J, Klaukka T, Ioannidis JP, Volavka J, Haukka J. Effectiveness 
of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation 
due to schizophrenia and schizoaffective disorder: observational follow-up study. 
Department of Forensic Psychiatry, University of Kuopio, Niuvanniemi Hospital, FIN-70240 Ku-
opio, Finland. jari.tiihonen@niuva.fi 
OBJECTIVE: To study the association between prescribed antipsychotic drugs and outcome in 
schizophrenia or schizoaffective disorder in the community. DESIGN: Prospective cohort study using 
national central registers. SETTING: Community care in Finland. PARTICIPANTS: Nationwide cohort 
of 2230 consecutive adults hospitalised in Finland for the first time because of schizophrenia or schizoaf-
fective disorder, January 1995 to December 2001. MAIN OUTCOME MEASURES: Rates of discon-
tinuation of drugs (all causes), rates of rehospitalisation, and mortality associated with monotherapy with 
the 10 most commonly used antipsychotic drugs. Multivariate models and propensity score methods were 
used to adjust estimates of effectiveness. RESULTS: Initial use of clozapine (adjusted relative risk 0.17, 
95% confidence interval 0.10 to 0.29), perphenazine depot (0.24, 0.13 to 0.47), and olanzapine (0.35, 0.18 
to 0.71) were associated with the lowest rates of discontinuation for any reason when compared with oral 
haloperidol. During an average follow-up of 3.6 years, 4640 cases of rehospitalisation were recorded. 
Current use of perphenazine depot (0.32, 0.22 to 0.49), olanzapine (0.54, 0.41 to 0.71), and clozapine 
(0.64, 0.48 to 0.85) were associated with the lowest risk of rehospitalisation. Use of haloperidol was asso-
ciated with a poor outcome among women. Mortality was markedly raised in patients not taking antipsy-
chotics (12.3, 6.0 to 24.1) and the risk of suicide was high (37.4, 5.1 to 276). CONCLUSIONS: The ef-
fectiveness of first and second generation antipsychotics varies greatly in the community. Patients treated 
with perphenazine depot, clozapine, or olanzapine have a substantially lower risk of rehospitalisation or 
discontinuation (for any reason) of their initial treatment than do patients treated with haloperidol. Excess 
mortality is seen mostly in patients not using antipsychotic drugs. 
 
50 
Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, Hegerl U, Lonnqvist J, Malone K, Ma-
rusic A, Mehlum L, Patton G, Phillips M, Rutz W, Rihmer Z, Schmidtke A, Shaffer D, Silverman M, Taka-
hashi Y, Varnik A, Wasserman D, Yip P, Hendin H. Suicide prevention strategies: a systematic review. 
New York State Psychiatric Institute, Division of Neuroscience, New York, NY 10032, USA. 
jjm@columbia.edu 
CONTEXT: In 2002, an estimated 877,000 lives were lost worldwide through suicide. Some devel-
oped nations have implemented national suicide prevention plans. Although these plans generally propose 
multiple interventions, their effectiveness is rarely evaluated. OBJECTIVES: To examine evidence for 
the effectiveness of specific suicide-preventive interventions and to make recommendations for future 
prevention programs and research. DATA SOURCES AND STUDY SELECTION: Relevant publications 
were identified via electronic searches of MEDLINE, the Cochrane Library, and PsychINFO databases 
using multiple search terms related to suicide prevention. Studies, published between 1966 and June 
2005, included those that evaluated preventative interventions in major domains; education and awareness 
for the general public and for professionals; screening tools for at-risk individuals; treatment of psychiat-
ric disorders; restricting access to lethal means; and responsible media reporting of suicide. DATA 
EXTRACTION: Data were extracted on primary outcomes of interest: suicidal behavior (completion, 
attempt, ideation), intermediary or secondary outcomes (treatment seeking, identification of at-risk indi-
viduals, antidepressant prescription/use rates, referrals), or both. Experts from 15 countries reviewed all 
studies. Included articles were those that reported on completed and attempted suicide and suicidal idea-
tion; or, where applicable, intermediate outcomes, including help-seeking behavior, identification of at-
risk individuals, entry into treatment, and antidepressant prescription rates. We included 3 major types of 
studies for which the research question was clearly defined: systematic reviews and meta-analyses (n = 
10); quantitative studies, either randomized controlled trials (n = 18) or cohort studies (n = 24); and eco-
logical, or population- based studies (n = 41). Heterogeneity of study populations and methodology did 
not permit formal meta-analysis; thus, a narrative synthesis is presented. DATA SYNTHESIS: Education 
of physicians and restricting access to lethal means were found to prevent suicide. Other methods includ-
ing public education, screening programs, and media education need more testing. CONCLUSIONS: 
Physician education in depression recognition and treatment and restricting access to lethal methods re-
duce suicide rates. Other interventions need more evidence of efficacy. Ascertaining which components 
of suicide prevention programs are effective in reducing rates of suicide and suicide attempt is essential in 
order to optimize use of limited resources. 
 
Heila H, Haukka J, Suvisaari J, Lonnqvist J. Mortality among patients with schizophrenia and re-
duced psychiatric hospital care. 
National Public Health Institute, Department of Mental Health and Alcohol Research, Manner-
heimintie, Helsinki, Finland. hannele.heila@ktl.fi 
BACKGROUND: There are suggestions that mortality, especially that due to suicide, increases 
among schizophrenia patients during a period of declining psychiatric beds. We investigated the mortality 
of schizophrenia patients in the general population of Finland during the reduction of psychiatric beds 
during 1980-1996. METHOD: Patients hospitalized for schizophrenia before 31 December 1996, and 
alive on 1 January 1980 (n = 58761) were identified via the National Hospital Discharge Register. Gen-
eral population data came from the National Population Register, and mortality data from the National 
Causes of Death Register. We calculated relative risks (RR) for total mortality, mortality due to natural 
causes (cancer, ischaemic heart disease, respiratory disease), unnatural causes (accident, homicide, sui-
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cide), and suicide. RESULTS: Patients with schizophrenia had an increased mortality both from natural 
causes (RR 2.59, 95% CI 2.55-2.63) and from suicide (RR 9.9, 95% CI 9.43-10.30). The RR for both 
natural and unnatural deaths was highest among patients with < 5 years since onset of schizophrenia. 
Among them all-cause mortality rose in the 1990s, but decreased among patients with > 10 years from 
onset. Otherwise no major changes or linear trends were found in mortality during deinstitutionalization. 
CONCLUSIONS: Reduction of psychiatric beds did not generally increase the mortality of patients with 
schizophrenia. However, patients in their early years of illness experienced increased mortality after the 
steepest bed reduction. Improved recognition and treatment of somatic illness would benefit patients with 
schizophrenia. 
 
Hakkarainen R, Partonen T, Haukka J, Virtamo J, Albanes D, Lonnqvist J. Is low dietary intake of 
omega-3 fatty acids associated with depression? 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, 
Finland. reeta.hakkarainen@ktl.fi 
OBJECTIVE: This study examined the association between the dietary intake of omega-3 fatty ac-
ids and low mood, major depression, and suicide. METHOD: A total of 29,133 men ages 50 to 69 years 
participated in a population-based trial in Finland. The intake of fatty acids and fish consumption were 
calculated from a diet history questionnaire. Self-reported depressed mood was recorded three times an-
nually, data on hospital treatments due to a major depressive disorder were derived from the National 
Hospital Discharge Register, and suicides were identified from death certificates. RESULTS: There were 
no associations between the dietary intake of omega-3 fatty acids or fish consumption and depressed 
mood, major depressive episodes, or suicide. CONCLUSIONS: Dietary intake of omega-3 fatty acids 
showed no association with low mood level. 
 
Suominen K, Isometsa E, Suokas J, Haukka J, Achte K, Lonnqvist J. Completed suicide after a sui-
cide attempt: a 37-year follow-up study. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, 
Finland. kirsi.suominen@ktl.fi 
OBJECTIVE: Attempted suicide is the strongest known predictor of completed suicide. However, 
suicide risk declines over time after an attempt, and it is unclear how long the risk persists. Risk estimates 
are almost exclusively based on studies of less than 10 years of follow-up. METHOD: The authors fol-
lowed a cohort of 100 consecutive self-poisoned patients in Helsinki in 1963, for whom forensically clas-
sified causes of death during the following 37 years were investigated. RESULTS: They found that sui-
cides continued to accumulate almost four decades after the index suicide attempt. CONCLUSIONS: A 
history of a suicide attempt by self-poisoning indicates suicide risk over the entire adult lifetime. 
 
 Suominen KH, Isometsa ET, Lonnqvist JK. Comorbid substance use reduces the health care con-
tacts of suicide attempters with schizophrenia spectrum or mood disorders. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, 
Finland. kirsi.suominen@ktl.fi 
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Utilization of health care services has been found to differ between psychiatric disorders. However, 
the pattern of health care contacts among suicide attempters with mental disorders is not known. This 
study systematically investigated the pattern of health care contacts among suicide attempters with 
schizophrenia spectrum versus mood disorders with or without comorbid substance use disorders both 
before and after attempted suicide. All consecutive medically treated suicide attempters in Helsinki from 
January 15, 1997, to January 14, 1998, were identified (n = 1,198). Data were gathered on all their health 
care contacts within the 12 months before and after the index attempt. Whereas the clear majority of all 
suicide attempters with schizophrenia spectrum or mood disorders had a treatment contact during the 30 
days following the attempt, half of those with pure substance use disorders were without any contact with 
health care. Comorbid substance use made treatment less likely after attempted suicide among both psy-
chiatric disorder groups; those with schizophrenia spectrum and comorbid substance use disorders were 
seven times more often left without aftercare recommendation than those without substance use comor-
bidity. Comorbid substance use disorders among suicide attempters with schizophrenia spectrum disor-
ders decrease the likelihood of active aftercare, despite high suicide risk. 
 
Suokas J, Suominen K, Isometsa E, Ostamo A, Lonnqvist J. Long-term risk factors for suicide mor-
tality after attempted suicide--findings of a 14-year follow-up study. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, 
Finland. 
OBJECTIVE: To determine the risk of suicide over a 14-year follow-up period, and to investigate 
the long-term risk factors for suicide using survival analysis. METHOD: Data were collected on all unse-
lected deliberate self-poisoning patients (n=1018) treated during 1983 in the emergency unit of Helsinki 
University Central Hospital. RESULTS: By the end of the 14 -year follow-up period 222 (21.7%) of these 
patients had died. Sixty-eight (6.7%) had committed suicide; 44 (9.2%) men and 24 (4.5%) women. The 
long-term risk factors for suicide were male sex, previous psychiatric treatment, previous suicide at-
tempts, somatic disease and a self-reported 'wish to die' motive for the index suicide attempt. 
CONCLUSION: The essential risk factors for suicide were being male and having previous suicide at-
tempts. In addition, history of earlier psychiatric treatment, presence of somatic disease and genuine in-
tent to die in the index suicide attempt suggest that the long-term risk has remained high for over a dec-
ade. The findings emphasize the need for long-term planning and treatment of suicide attempters met in 
the emergency room of general hospitals. 
 
Partonen T, Haukka J, Virtamo J, Taylor PR, Lonnqvist J. Association of low serum total choles-
terol with major depression and suicide. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, 
Finland. timo.partonen@ktl.fi 
BACKGROUND: It has been suggested that low serum total cholesterol is associated with an in-
creased risk of suicide. AIMS: To study the association between serum total cholesterol, depression and 
suicide using versatile, prospective data. METHOD: A total of 29,133 men aged 50-69 years were fol-
lowed up for 5-8 years. Baseline blood samples were analysed for serum total and high-density lipopro-
tein cholesterol concentrations. Self-reported depression was recorded, data on hospital treatments due to 
depressive disorders were derived from the National Hospital Discharge Register and deaths from suicide 
were identified from death certificates. RESULTS: Low serum total cholesterol was associated with low 
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mood and subsequently a heightened risk of hospital treatment due to major depressive disorder and of 
death from suicide. CONCLUSIONS: Our results suggest that low serum total cholesterol appears to be 
associated with low mood and thus to predict its serious consequences. 
 
   
Heila H, Heikkinen ME, Isometsa ET, Henriksson MM, Marttunen MJ, Lonnqvist JK. Life events 
and completed suicide in schizophrenia: a comparison of suicide victims with and without schizophrenia. 
National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, 
Finland. hannele.heila@ktl.fi 
Adverse life events are an established risk factor in completed suicide. However, few studies have 
examined life events and suicide in schizophrenia. We investigated and compared schizophrenia suicide 
victims and age- and sex-matched victims without schizophrenia as part of a psychological autopsy study 
of all suicides in Finland over a 12-month period. Recent life events were examined retrospectively by 
interviewing next of kin using a structured life event questionnaire. Overall, nearly half (46%) the schizo-
phrenia subjects had had adverse life events before suicide, significantly less than the nonschizophrenia 
subjects (83%). In both groups, however, suicide was preceded by life events independent of the victims' 
own behavior, such as death of a close person or illness in the family. Life events overall were more 
common among schizophrenia outpatients (52%) than inpatients (22%), and the association of life events 
with suicide was clearest among a subgroup of outpatients in residual phase who had used neuroleptic 
medication regularly. Overall, the prevalence of recent adverse life events varied between clinical sub-
groups of victims with schizophrenia, which may have implications for suicide prevention. 
 
Heilä H, Isometsä ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lönnqvist JK. Suicide vic-
tims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, 
Finland. Hannele.Heila@ktl.fi 
BACKGROUND: To investigate clinical characteristics and adequacy of antipsychotic treatment in 
different phases of illness and treatment among suicide victims with schizophrenia. METHOD: As part of 
the National Suicide Prevention Project, a nationwide psychological autopsy study in Finland, all DSM-
III-R schizophrenic suicide victims with a known treatment contact (N = 88) were classified according to 
the phase of illness (active/residual) and treatment (inpatient/recent discharge/other). Characteristics of 
victims in terms of known risk factors for suicide in schizophrenia, as well as adequacy of the neuroleptic 
treatment, were examined. RESULTS: Fifty-seven percent of suicide victims with active phase schizo-
phrenia were prescribed inadequate neuroleptic treatment or were non-compliant, and 23% were esti-
mated to be compliant nonresponders. Inpatient suicide victims had the highest proportion of negative or 
indifferent treatment attitudes (81%), whereas recently discharged suicide victims had the highest preva-
lence of comorbid alcoholism (36%), paranoid subtype (57%), and recent suicidal behavior or communi-
cation (74%), as well as the highest number of hospitalizations during their illness course and shortest last 
hospitalization. CONCLUSION: Suicide risk factors in different treatment phases of schizophrenia may 
differ. Substantial numbers of suicide victims with schizophrenia are receiving inadequate neuroleptic 
medication, are noncompliant, or do not respond to adequate typical antipsychotic medication. Adequacy 
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of psychopharmacologic treatment, particularly in the active illness phase, may be an important factor in 
suicide prevention among patients with schizophrenia. 
 
Isometsa ET, Lonnqvist JK. Suicide attempts preceding completed suicide. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, 
Finland. erkki.isometsa@ktl.fi 
BACKGROUND: This study investigated three questions with major implications for suicide pre-
vention: the sensitivity of the history of previous suicide attempt(s) as an indicator of suicide risk, the 
time interval from a preceding suicide attempt to the fatal one, and switching of suicide methods by those 
eventually completing suicide. METHOD: The lifetime history of suicide attempts and the methods the 
victims (n = 1397) used were examined in a nationwide psychological autopsy study comprising all sui-
cides in Finland within a 12-month research period in 1987-1988. RESULTS: Overall, 56% of suicide 
victims were found to have died at their first suicide attempt, more males (62%) than females (38%). In 
19% of males and 39% of females the victim had made a non-fatal attempt during the final year. Of the 
victims with previous attempts, 82% had used at least two different methods in their suicide attempts (the 
fatal included). CONCLUSIONS: Most male and a substantial proportion of female suicides die in their 
first suicide attempt, a fact that necessitates early recognition of suicide risk, particularly among males. 
Recognition of periods of high suicide risk on the grounds of recent non-fatal suicide attempts is likely to 
be important for suicide prevention among females. Subjects completing suicide commonly switch from 
one suicide method to another, a finding that weakens but does not negate the credibility of restrictions on 
the availability of lethal methods as a preventive measure. 
   
Heila H, Isometsa ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lonnqvist JK. Suicide and 
schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics 
of 92 suicide victims with schizophrenia. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, 
Finland. Heila@ktl.fi 
OBJECTIVE: The authors examined the clinical characteristics of suicide victims with schizophrenia 
in the general population of Finland. METHOD: As part of the nationwide National Suicide Prevention 
Project in Finland, all suicides over a 12-month period of persons with DSM-III-R schizophrenia were in-
vestigated by using the psychological autopsy method. Clinical characteristics and their variation with age, 
sex, and illness duration were examined. RESULTS: Among all suicide victims, 7% (N = 92) were identi-
fied as having suffered schizophrenia. Suicides occurred throughout the course of schizophrenia. Both active 
illness (78%) and depressive symptoms (64%) were highly prevalent immediately before suicide, and a 
history of suicide attempts (71%) was also common. Women were more likely than men to have committed 
suicide during an acute exacerbation of the illness. Marked variation in depressive symptoms, alcoholism, 
and suicide methods was found among sexes and age groups. Alcoholism was most common among middle-
aged men (45%), whereas middle-aged women had a high rate of depressive symptoms (88%). Younger 
male subjects most often used violent suicide methods. CONCLUSIONS: Suicide may occur at any point 
during the course of schizophrenia. The results indicate clinically important variation in depression, alcohol-
ism, and suicide methods among suicide victims with schizophrenia. This suggestion of age- and sex-
specific risk factors for suicide in schizophrenia needs further investigation. 
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6.2. Mental health development 
 
6.2.1. Research and public health significance of the area 
 
1. The project provides information on mental health development from childhood 
through adolescence and adulthood. The focus of this research line is to study processes 
and mechanisms that risk or promote mental health during development. 
2. The project contributes to epidemiological research on the occurrence and course 
of mental health problems and psychiatric disorders and their psychosocial etiology. 
3. The project co-ordinates and carries out research done in the department on so-
cioeconomic differences in mental health. 
 
6.2.2. The main scientific achievements 
 
National epidemiological studies 
The Finnish Health Care Study (FINHCS) was a population-based nationwide 
study designed to monitor the health of the general population and evaluate the use and 
need for services. Based on a one-stage cluster sample of 15-75 year old persons 
(N=5993) who were interviewed in 1996. It was the first nationwide study in Finland to 
investigate depression using structured diagnostic interviews (e.g. Lindeman et al. 
2000). A subsample of 15-24-olds was analyzed also separately to produce specific in-
formation on young adults (e.g. Haarasilta et al. 2001). 
 
Health 2000, carried out in 2000-2001, is a nationwide population-based compre-
hensive survey on health and functional capacity in Finland. Two-stage stratified cluster 
sampling was used to draw a representative sample of the adult population aged 30 
years and over (N=8028) (http://www.ktl.fi/terveys2000/julkaisut/baseline.pdf) and a 
sample of young adults aged 18-29 years (N=1894) (http://www.ktl.fi/attachments/ 
suomi/julkaisut/julkaisusarja_b/2005/2005b7.pdf). The survey consisted of a health in-
terview, self-reported questionnaires, and a thorough health examination (which in-
cluded the structured mental health interview CIDI) in age group 30 years and over. Our 
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department has been responsible for coordinating the planning and reporting the mental 
health part of this major study. The Health 2000 study has produced important informa-
tion on the prevalences and risk factors of the most common DSM-IV mental disorders 
(Pirkola et al. 2005a, 2005b). 
As a continuation of Health 2000, our department has launched two major psychiat-
ric studies of the same study samples, PIF (Psychoses in Finland) and MEAF (Mental 
health in early adulthood). In MEAF, a study using a two-phase study design, extensive 
data collection including semistructured diagnostic interviews of the study sample of 18–
29-year-olds was carried out to produce psychiatric diagnoses according to the DSM-IV-
TR criteria. The questionnaire of the screening phase of the MEAF was also planned to 
generate a design of a short-term follow-up survey of the young adult sample of Health 
2000. These studies build up unique data bases both for psychiatric epidemiological and 
other types of studies (e.g. those in molecular genetics and neuropsychology). 
 
Developmental studies 
The most important developmental study in the project is TAM (Stress, develop-
ment and mental health. A 16-year follow-up study of adolescents). It is a long-term 
prospective follow-up survey on stress, development and mental health from adoles-
cence to adulthood started in 1983. In the study one age cohort of adolescents in the 
town of Tampere (1967 birth cohort; N=2269) has been studied at ages 16, 22 and 32. 
During recent years the main results concerning depression include some interest-
ing gender differences and support the suggestion of different types of depression: In 
adolescent risk factors for depression in young adulthood externalizing factors were 
more typical for males and internalizing aspects for females. (Pelkonen et al. 2003). 
Midadolescent depressive symptoms predicted persistent but not episodic depression, 
and female sex increased the risk for episodic but not persistent depression (Pelkonen et 
al. 2007). At the age of 32 chronic illness associated with higher levels of depression 
among males only, and this marked gender difference was explained by the effects of 
psychosocial resource differences (Kiviruusu et al. 2007). 
Other important foci of research include risk factors and course of psychosomatic 
symptoms and alcohol misuse, and the role of family and socioeconomic factors for 
development and mental health. 
The main results on socioeconomic (SES) differences in mental health showed that 
these differences varied depending on the life stage, gender and health indicator (Huurre 
et al. 2003). Lower SES group subjects were also in adverse position with respect to 
social support and a greater effect of social support on depression was found among 
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subjects from lower social positions (Huurre et al .2007). The findings also highlighted 
the need of greater consideration of psychosomatic symptoms, particularly in adoles-
cence, for later socioeconomic outcomes (Huurre et al. 2005). 
 
SES differences in mental health (SES-project) 
SES differences in health have been one of the foci of research in KTL during re-
cent years. The project has been responsible for studying and coordinating research of 
socioeconomic differences in mental health in our department. In addition to research in 
TAM desribed earlier, this topic is studied in Health 2000 and other studies. There is a 
national register-based data set which is formed by linking hospital discharges and mor-
tality registers with sociodemographic background variables from population census, to 
analyze SES differences in psychiatric inpatient care and mortality. 
 
6.2.3. The main public health achievements 
 
Health 2000 and its psychiatric substudies provide the current view of the mental 
health in the Finnish population forming the knowledge base for the strategic planning 
of Ministry of Social Affairs and Health. Our developmental studies have contributed to 
the understanding on child development, especially on the role of family stress, socio-
economic factors and psychosocial resources for future mental health. The project has 
produced information on socioeconomic differences in mental health and participated in 
the planning of actions to promote the attainment of the objective of the Health 2015 
public health programme for reducing health inequalities. Joint report on inequalities in 
health in Finland including mental health will be published in 2007. 
 
6.2.4. Funding for research and public health programs 
 
The psychiatric studies of Health 2000 and SES-project have been mainly financed 
by KTL, supplemented by funding from Academy of Finland and foundations. The ma-
jority of the funding for TAM-project has come from external sources (Academy of 
Finland and Finnish foundations). 
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6.2.5. Personnel 
 
The current personnel consists of Hillevi Aro (50%) and Taina Huurre. Much of the 
work is done also by researchers from other projects. In addition, several PhD students 
with external funding work in the project. 
 
6.2.6. Collaboration 
 
The collaborative networking in the Health 2000 mental health research is wide-
spread in the Finnish research community. 
The research team of TAM-project is multidisciplinary including researchers in 
epidemiology, public health, psychiatry, psychology, education, social policy, and sta-
tistics. The main collaborators outside KTL come from the universities of Helsinki, 
Tampere, Umeå and Birmingham. 
The main collaborators in the SES-project come from National Research and De-
velopment Centre for Welfare and Health and University of Helsinki. 
 
6.2.7. Proposal for future work and expected benefits 
 
Monitoring and producing up-to-date information on the psychiatric morbidity and 
mental health development of Finnish people will be continued. The Health 2000 cohort 
will be followed up by registers, and the next large national health survey is planned to 
take place after 2010. In the TAM project the next follow-up survey will be carried out 
in 2009, when the persons will be 42 years old. 
 
 6.2.8. Main publications 
 
1. Pelkonen M, Marttunen M, Kaprio J, Huurre T, Aro H. Adolescent risk factors for episodic and 
persistent depression in adulthood. A 16-year prospective follow-up study of adolescents. J Affect Disord 
2007 (in press). 
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BACKGROUND: We examined mid-adolescent psychosocial problems as risk factors for subse-
quent depression up to adulthood proper, and differences in these for episodic and persistent depression. 
METHODS:In a 16-year follow-up of an urban Finnish community cohort (547 males and 714 females) 
from age 16 years risk factors for subsequent depression (S-BDI) were studied. Data were collected with 
a classroom questionnaire at 16 years and a postal questionnaire at 22 and 32 years. Differences in predic-
tors for episodic depression (only at age of 22 or 32 y) and persistent depression (both at 22 and 32 y) 
were studied using logistic and multinomial regression analyses. RESULTS: Mid-adolescent depressive 
symptoms predicted persistent and female sex episodic depression. Low self-esteem, dissatisfaction with 
academic achievement, problems with the law, having no dating experiences, and parental divorce all 
predicted both episodic and persistent depression. LIMITATIONS: We had two assessment points in 
adulthood, but no information about depression between these. CONCLUSIONS: The associations be-
tween mid-adolescent psychosocial problems and subsequent depression extended up to adulthood 
proper, somewhat differently for episodic and persistent depression. Preventive efforts should be focused 
towards young people at risk. 
2. Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S, Arpomaa A, Lönnqvist J. Impact of 
psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry 
2007;190:326-332. 
BACKGROUND: Measurement of health-related quality of life (HRQoL) with generic preference-
based instruments enables comparisons of severity across different conditions and treatments. This is 
necessary for rational public health policy. AIMS: To measure HRQoL decrement and loss of quality-
adjusted life-years (QALYs) associated with pure and comorbid forms of depressive and anxiety disor-
ders and alcohol dependence. METHOD: A general population survey was conducted of Finns aged 30 
years and over. Psychiatric disorders were diagnosed with the Composite International Diagnostic Inter-
view and HRQoL was measured with the 15D and EQ-5D questionnaires. RESULTS: Dysthymia, gener-
alised anxiety disorder and social phobia were associated with the largest loss of HRQoL on the individ-
ual level before and after adjusting for somatic and psychiatric comorbidity. On the population level, 
depressive disorders accounted for 55%, anxiety disorders 30%, and alcohol dependence for 15% of 
QALY loss identified in this study. CONCLUSIONS: Chronic anxiety disorders and dysthymia are asso-
ciated with poorer HRQoL than previously thought. 
3. Huurre T, Eerola M, Rahkonen O, Aro H. Does social support affect the relationship between 
socio-economic status and depression? A longitudinal study from adolescence to adulthood. J Affect 
Disord; 2007;100:55-64. 
BACKGROUND: The aim of this prospective longitudinal study of adolescents was to investigate 
socioeconomic differences in adult depression and in the domain of social support from adolescence to 
adulthood. We also studied the modifying effect of social support on the relationship between socioeco-
nomic status (SES) and depression. METHODS: All 16-year-old ninth-grade school pupils of one Finnish 
city completed questionnaires at school (n=2194). Subjects were followed up using postal questionnaires 
when aged 22 and 32 years. RESULTS: At 32 years of age there was a social gradient in depression, with 
a substantially higher prevalence among subjects with lower SES. Low parental SES during adolescence 
did not affect the risk of depression at 32 years of age, but the person's lower level of education at 22 
years did. Lower level of support among subjects with lower SES was found particularly in females. 
Some evidence indicated that low level of social support had a greater impact on depression among lower 
SES group subjects. However, this relationship varied depending on the domain of social support, life 
stage and gender. On the other hand, the results did not support the hypothesis that social support would 
substantially account for the variation in depression across SES groups. LIMITATIONS: The assessments 
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and classifications of social support were rather brief and crude, particularly in adolescence and early 
adulthood. CONCLUSIONS: It is important to pay attention to social support resources in preventive 
programs and also in the treatment settings, with a special focus on lower SES group persons. 
4. Kiviruusu O, Huurre T, Aro H. Psychosocial resources and depression among chronically ill 
young adults: Are males more vulnerable? Soc Sci Med 2007;65:173-186. 
This population-based study examined the association between chronic illness and depression and 
the role of psychosocial resources (coping styles, locus of control (LOC) and social support) in this asso-
ciation, among young Finnish adults aged 32. Gender differences in these phenomena were also investi-
gated. The study was based on questionnaire data from a Finnish cohort study. Participants with self-
reported chronic illness (e.g. diabetes, asthma, migraine) were grouped together (n=257) and compared to 
healthy controls (n=664). The results showed that the chronically ill males were more depressed than 
healthy control males. They also used more emotion-focused coping, had a more external LOC and were 
less often married or cohabiting than healthy males. The association between chronic illness and depres-
sion among males attenuated when the effects of emotion-focused coping disposition and LOC were 
taken into account, indicating a possible mediating role for these resources. Among females no differ-
ences were found in depression or psychosocial resources between the chronically ill and healthy control 
groups. Psychosocial resources, especially LOC, explained the gender difference in the association be-
tween chronic illness and depression. Only a few buffering effects of psychosocial resources emerged: an 
active problem-solving coping disposition among the chronically ill males and perceived social support 
among the chronically ill females seemed to act as buffers against depression. The results indicated a 
significant gender disparity in the association between chronic illness and depression among young adults 
and emphasised the role of psychosocial resources in this context. With regard to prevention we suggest 
that, chronically ill young adult males should be recognised as a risk group for depression that would 
probably benefit from guidance in learning more active coping skills and maintaining a sense of personal 
control in facing chronic physical illness. 
5. Huurre T, Junkkari H, Aro H. Long-term psychosocial effects of parental divorce. A follow-up 
study from adolescence to adulthood. Eur Arch Psych Clin Neurosci 2006;256:256-263. 
OBJECTIVE: The purpose of this 16-year follow-up study was to investigate whether 32-year-old 
adults who had experienced parental divorce before 16 years of age (n = 317) differed in psychosocial well-
being or life trajectories from those from non-divorced two-parent families (n = 1069).METHOD: The data 
were obtained from a follow-up survey of a Finnish urban age cohort from the age of 16 till 32 years (n = 
1471). The long-term impact of parental divorce on a variety of outcomes in adulthood, including psycho-
logical well-being, life situation, health behaviour, social networks and support, negative life events and 
interpersonal problems, was assessed.RESULTS: Females from divorced compared to non-divorced fami-
lies reported more psychological problems (higher scores in the Beck Depression Inventory, General Health 
Questionnaire and Psychosomatic Symptoms Score) and more problems in their interpersonal relationships. 
These differences were not found among males. Shorter education,unemployment, divorce, negative life 
events and more risky health behaviour were more common among subjects of both genders with a back-
ground of parental divorce.CONCLUSIONS: The study revealed that parental divorce is an indicator of 
sufficient stress in childhood for its influences to persist well into adulthood, possibly with wider scope 
among females. It is important to recognise specific needs of children in the divorce process in order to 
prevent or minimize negative consequences and chain reactions during their subsequent life. 
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6. Ahola K, Honkonen T, Isometsä E, Kalimo R, Nykyri E, Koskinen S, Aromaa A, Lönnqvist J. 
Burn-out in the general population. Results from the Finnish Health 2000 Study. Soc Psychiatry Psychiatr 
Epidemiol 2006;41:11-17. 
BACKGROUND: Burnout is a chronic stress syndrome which develops gradually as a consequence 
of prolonged stress situation. Socio-demographic factors related to job-related burnout have not been 
studied in the whole population. We investigated the relative differences in the level of burnout between 
groups based on various socio-demographic factors in the population-based Finnish sample. METHODS: 
The nationally representative sample comprised 3,424 employees aged 30-64 years. Burnout was assessed 
with the Maslach Burnout Inventory-General Survey. The socio-demographic factors of interest were 
gender, age, education, type of employment, work experience, socio-economic status (SES), working 
time, and marital status. RESULTS: Only small differences in burnout were found between the different 
population groups. As a three-dimensional syndrome, burnout was associated with age. In contrast to 
what has been consistently reported so far, mostly among human service work and in non-representative 
studies, burnout seemed to increase somewhat with age. Among women, burnout was also related to edu-
cation, SES, and work experience, and among men, to marital status. CONCLUSIONS: Burnout can 
evolve in all kinds of vocational groups. It seems that age does not generally protect against burnout. A 
low education level and low social status carry a possible risk of burnout for women, and being single, 
divorced, or widowed carry a possible risk of burnout for men. 
7. Huurre T, Rahkonen O, Komulainen E, Aro H. Socioeconomic status as a cause and consequence 
of psychosomatic symptoms from adolescence to adulthood. Soc Psychiatry Psychiatr Epidemiol 
2005;40:580-587. 
BACKGROUND: Few follow-up studies have investigated psychosomatic health and socioeco-
nomic status (SES) and associations between them at different life stages. The aim of this study was to 
investigate differences in psychosomatic symptoms by SES in adolescence, early adulthood and adult-
hood and to examine whether lower SES leads to higher levels of symptoms (social causation) or higher 
levels of symptoms to lower SES (health selection) or both. METHODS: All 16-year-old ninth-grade 
school pupils of one Finnish city completed questionnaires at school. Subjects were followed up using 
postal questionnaires when aged 22 and 32 years. RESULTS: Females reported significantly higher 
scores of psychosomatic symptoms than males at 16, 22 and 32 years of age. Higher rates of psychoso-
matic symptoms were found among females of manual class origin at 16 years. In addition, at 22 years, 
both females and males with only comprehensive school education and, at 32 years, those who worked in 
manual jobs had higher scores of symptoms. When low SES both as a cause and consequence of symp-
toms was investigated, the findings supported both these paths among females and more the health selec-
tion among males. In both genders, especially the path from psychosomatic symptoms in adolescence to 
lower education in early adulthood was strong. CONCLUSIONS: The results highlight the need of greater 
consideration of psychosomatic symptoms, particularly in adolescence, in later socioeconomic outcomes. 
8. Pirkola S, Isometsä E, Aro H, Kestilä L, Hämäläinen J, Veijola J, Kiviruusu O, Lönnqvist J. 
Childhood adversities as risk factors for adult mental disorders. Results from the Health 2000 Study. Soc 
Psychiatry Psychiatr Epidemiol 2005a;40:769-777. 
BACKGROUND: The sex-specific role of stressful or traumatic childhood experiences and adverse 
circumstances in developing adulthood mental disorders is complex and still in need of comprehensive 
research. METHODS: Within the Health 2000 project in Finland, a representative sample of 4,076 sub-
jects aged 30-64 years were investigated to examine associations between a set of retrospectively self-
reported adverse environmental factors during childhood (0-16 years) and mental disorders diagnosed in 
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the past 12 months by the Munich Composite International Diagnostic Interview. RESULTS: Of the 60% 
of adults reporting at least one childhood adversity, 17% had a current (past 12 months) mental disorder, 
compared to 10% of the non-reporters. A moderate dose-response relationship between the total number 
of adversities and current disorders was observed. Paternal mental health problems associated particularly 
strongly with male depressive disorders (OR 4.46), and maternal mental health problems with female 
depressive disorders (OR 3.20). Although seldom reported, maternal alcohol problems associated with 
alcohol use disorders in both sexes. Being bullied at school and childhood family discord predicted a 
variety of adulthood disorders in both sexes. All these four adversity items were more typical for depres-
sive disorders with an earlier onset. Among females, more adversities were associated with mental disor-
ders and their statistical significance was greater than among males. CONCLUSIONS: There are marked 
sex differences and several diagnosis-related patterns in the associations between reported childhood 
experiences and environmental circumstances and adulthood mental disorders. The impact of adversities 
is probably composed of a wide range of factors from direct causal associations to complex, interacting 
environmental effects. Variations in the reported associations reflect the differing genetic and environ-
mental transmission mechanisms of mental disorders. 
9. Pirkola S, Isometsä E, Suvisaari J, Aro H, Joukamaa M, Poikolainen K, Koskinen S, Aromaa A, 
Lönnqvist J. DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish 
general population. Results from the Health 2000 Study. Soc Psychiatry Psychiatr Epidemiol 2005b;40:1-
10. 
BACKGROUND: Information on prevalence, accumulation and variation of common mental disor-
ders is essential for both etiological research and development of mental health service systems. 
METHODS: A representative sample (6005) of Finland's general adult (> or = 30 years) population was 
interviewed in the period 2000-2001 with the CIDI for presence of DSM-IV mental disorders during the 
last 12 months in the comprehensive, multidisciplinary Health 2000 project. RESULTS: Depressive-, 
alcohol use- and anxiety disorders were found in 6.5%, 4.5 % and 4.1% of the subjects, respectively. A 
comorbid disorder was present in 19% of those with any disorder. Males had more alcohol use disorders 
(7.3 % vs. 1.4 %) and females more depressive disorders (8.3 % vs. 4.6 %). Older age, marriage and em-
ployment predicted lower prevalence of mental disorders and their comorbidity. Prevalences of alcohol 
use- and comorbid disorders were higher in the Helsinki metropolitan area, and depressive disorders in 
northern Finland. CONCLUSIONS: Mental disorders and their comorbidities are distributed unevenly 
between sexes and age groups, are particularly associated with marital and employment status, and vary 
by region. There appears to be no single population subgroup at high risk for all mental disorders, but 
rather several different subgroups at risk for particular disorders or comorbidity patterns. 
10. Hämäläinen J, Isometsä E, Laukkala T, Kaprio J, Poikolainen K, Heikkinen M, Lindeman S, 
Aro H. Use of health services for Major Depressive Episode in Finland. J Aff Disord 2004;79:105-112. 
BACKGROUND: A universal finding in psychiatric epidemiology is that only a minority of cur-
rently depressed people seek or receive treatment. AIMS: To investigate the predictors of use of health 
care services for depression. METHODS: A representative random sample of 5993 non-institutionalised 
Finnish individuals aged 15-75 years was interviewed in 1996. Major depressive episode during the last 
12 months was assessed using the Short Form of the University of Michigan version of the Composite 
International Diagnostic Interview (the UM-CIDI Short Form). Characteristics and health service use of 
the 557 depressed individuals were assessed. RESULTS: The proportion of people classified as having a 
major depressive episode who used any health services for their depression during the past 12 months was 
only 31% for men and 25% for women. Use of services was not predicted by sociodemographic factors. 
Longer duration, and greater severity and perceived disability predicted overall health service use for 
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depression, but not significantly whether treatment was sought from primary or psychiatric care. 
CONCLUSIONS: The probability of use of health services for major depression increases with duration, 
severity and perceived disability related to depression. Only 59% of those suffering from even the most 
severe major depressive episodes use health services for depression. Use appears to be unrelated to socio-
demographic factors in Finland. 
11. Huurre T, Aro H, Rahkonen O. Well-being and health behaviour by parental socioeconomic 
status. A follow-up study of adolescents aged 16 until age 32 years. Soc Psychiatry Psychiatr Epidemiol 
2003; 38: 249-255. 
BACKGROUND: The aim of the study was to investigate the impact of parental socioeconomic 
status (SES) on subjects' well-being and health behaviour in adolescence, early adulthood and adulthood, 
and whether these impacts remained after controlling for the person's own SES. METHODS: All 16-year-
old ninth-grade school pupils of one Finnish city completed questionnaires at school. Subjects were fol-
lowed up using postal questionnaires when aged 22 and 32 years. RESULTS: Females of manual class 
origin had lower self-esteem and more distress symptoms from adolescence to adulthood than those from 
a non-manual background. Lower self-esteem was found among males from manual class families in 
adolescence and early adulthood. In both genders, no significant class differences were found in depres-
sion, health status or prevalence of chronic illness. Unhealthier behaviours regarding smoking and physi-
cal activity were more prevalent among both genders of manual class origin, and females of this group 
had higher rates of overweight and higher body mass index scores. After controlling for the person's own 
SES, the effect of parental SES diminished but remained significant for smoking in both genders and for 
physical activity in males up to 22 years, and for self-esteem and BMI in females up to 32. 
CONCLUSIONS: This follow-up study contributes to the health inequality debate investigating parental 
SES differences in health behaviour and somatic health, and particularly in psychological health, which is 
relatively rarely investigated. The results indicate that parental SES has effects on early adult and adult 
well-being and health behaviour other than those mediated by current SES. 
12. Pelkonen M, Marttunen M, Aro H. Risk for depression: A six-year follow-up of Finnish adoles-
cents. J Aff Disord 2003;77:41-51 
BACKGROUND: Few longitudinal studies have attempted to identify risk factors in mid-
adolescence for subsequent depression in young adulthood. Mid-adolescence is a critical developmental 
phase for studying vulnerability to depression due to high incidence and prevalence of depression. 
METHODS: In a longitudinal study, following an urban Finnish community cohort (761 males and 887 
females) from age 16, mid-adolescent risk factors for depression at age 22 years were studied. Data were 
collected by a questionnaire at school at age 16, and by a postal questionnaire at age 22. RESULTS: Of 
the females 116 (13%) and of the males 69 (9%) had depression (S-BDI) in young adulthood. In multi-
variate analyses baseline depressive symptoms, low self-esteem, dissatisfaction with academic achieve-
ment, problems with the law, poor atmosphere at home and having no close friends predicted subsequent 
depression. Risk factors for males included more 'externalizing' aspects, for females more 'internalizing' 
factors. CONCLUSIONS: Mid-adolescence is an important age to study risk for depression, and self-
reported perceptions of psychosocial well-being have predictive value. Preventive efforts can be selec-
tively targeted at adolescents who have been exposed to identifiable risk factors. 
13. Haarasilta L, Marttunen M, Kaprio J, Aro H. The 12-month prevalence and characteristics of 
Major Depressive Episode in a representative nationwide sample of adolescents and young adults. Psy-
chol Med 2001; 31:1169-1180. 
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BACKGROUND: This study set out to estimate the 12-month prevalence of DSM-III-R major de-
pressive episode (MDE) and to analyse factors associating with psychosocial impairment, episode dura-
tion, phenomenology and symptom severity in a representative general population sample of adolescents 
(15-19-year-olds) and young adults (20-24-year-olds). METHOD: The Finnish Health Care Survey '96 
(FINHCS '96) was a cross-sectional nationwide epidemiological study. A random sample of 509 adoles-
cents and 433 young adults was interviewed in 1996. MDE was assessed by University of Michigan 
Composite Diagnostic Interview Short-Form. RESULTS: The 12-month prevalence of MDE was 5.3 % 
for adolescents (females 6.0%, males 4.4%) and 9.4% for young adults (females 10.7%, males 8.1%). 
When moderate psychosocial impairment was included in case definition, the prevalences were lowered 
by 20-25%. Increased impairment was associated with drunkenness at least twice a month, a higher mean 
number of depressive symptoms and impaired concentration. The median episode duration was 1 month. 
No factors associating with duration were found. With the exception of symptoms related to appetite 
being more common among females than males, the phenomenology of MDE was mainly independent of 
age and gender. CONCLUSIONS: Episodes of major depression among adolescents and young adults in 
the general population are short but often associated with psychosocial impairment, especially if frequent 
drunkenness coexists. 
14. Laukkala T, Isometsä E, Hämäläinen J, Heikkinen M, Lindeman S, Aro H. Antidepressant 
treatment of depression in the Finnish general population. Am J Psychiatry 2001;158:2077-2079. 
OBJECTIVE: Antidepressant use has increased in the last decade, but whether depression continues to 
be undertreated is unknown. The authors investigated the prevalence of antidepressant treatment and its 
predictors in a recent general population sample of depressed subjects. METHOD: As part of the Finnish 
Health Care Survey, in 1996 a representative sample of Finns (N=5,993) aged 15-75 years underwent a 
standardized face-to-face interview that used the DSM-III-R criteria for major depressive episode. 
RESULTS: Only 13% of subjects with a major depressive episode during the preceding 12 months (70 of 
557) reported current use of an antidepressant. In logistic regression models, use of psychiatric services for 
depression, regular use of any other medication, more than 1 month of sick leave, and smoking were associ-
ated with antidepressant treatment. CONCLUSIONS: Most depressed subjects in 1996 in Finland were not 
receiving antidepressant treatment despite the several-fold increase in antidepressant use in the 1990s. 
15. Lindeman S, Hämäläinen J, Isometsä E, Kaprio J, Poikolainen K, Heikkinen M, Aro H. The 12-
month prevalence and risk factors for major depressive episode. Representative sample of 5993 adults. 
Acta Psychiatr Scand 2000;102:178-184. 
OBJECTIVE: This study reports the 12-month prevalence of major depressive episode and its risk 
factors in a representative nationwide sample. METHOD: A random sample of non-institutionalized Fin-
nish individuals aged 15-75 years (N = 5993) was interviewed in 1996. Major depressive episode during 
the last 12 months was assessed using the Short Form of the University of Michigan version of the Com-
posite International Diagnostic Interview (the UM-CIDI Short Form). RESULTS: The population preva-
lence of major depressive episode was 9.3% [95% CI 8.5,10.0], and the age-adjusted prevalences for 
females and males were 10.9% [95% CI 9.7,12.0] and 7.2 [95% CI 6.2,8.2], respectively. In logistic re-
gression analyses the factors associated with major depressive episode after adjustment for age were ur-
ban residency, smoking, alcohol intoxication and chronic medical conditions. In addition, being single 
and obese were found to be risk factors for males. CONCLUSION: The female to male risk ratio for 
major depressive episode was smaller than in many previous studies. The sex-specific risk factor associa-
tions warrant further investigation into sex differences in depression.  
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6.3. Mood disorder research 
 
6.3.1. Research and public health significance of the area 
 
Depressive and bipolar disorders are major public health problems. According to 
the estimates of WHO's Global Burden of Disease Study, unipolar depression is the 
fourth and bipolar disorder 22nd most important illness in terms of disability-adjusted 
life years (DALYs). Furthermore, mood disorders are the most important single risk 
factor for suicidal behavior, including completed suicide, attempted suicide and suicidal 
ideation. The overall mortality of patients with mood disorders is approximately two-
fold as compared with the general population, due to not only suicides but also in-
creased mortality to e.g. cardiovascular disorders. In addition, mood disorders are 
among the most frequent causes for disability pensions or sick leaves, causing remark-
able costs to both the individual and the society. 
Research presented here involves several major research projects focusing on vari-
ous aspect of mood disorders, in particular their clinical epidemiology, focusing in par-
ticular to a) outcome in terms of chronicity, relapses and recurrences; b) suicidal behav-
ior (completed and attempted suicide, suicidal ideation), c) disability (overall level of 
functioning, social adjustment, sick leaves and disability pensions), and d) quality and 
continuity of treatment provided in health care. Besides clinical studies, several projects 
are involved in investigating associated functional (magnetoencephalography) and 
structural (MRI, diffusion tensor imaging) brain abnormalities, neuropsychological dys-
functions and putative candidate genes for mood disorders. 
The main projects include (but are not limited to) the Vantaa Depression Study 
(VDS), the Vantaa Primary Care Depression Study (PC-VDS), the Jorvi Bipolar Study, 
and the Molecular Genetics, Psychobiology and Neuropsychology of Mood Disorders 
(MMPN, acronym from the Finnish initials). The VDS (N=269), PC-VDS (N=137) and 
JoBS (N=191) are relatively large clinical, longitudinal cohort studies using life chart 
methodology, all based on screening for depression or bipolar I and II disorders; very 
careful and comprehensive diagnostic evaluation with structured interviews and excel-
lent reliabity (kappas 0.86-1.0), each effectively representing all psychiatric (VDS, 
JoBS) or primary care (PC-VDS) patients with mood disorders of city of Vantaa (VDS, 
PC-VDS) or the three neighbouring cities Espoo, Kirkkonummi and Kauniainen (JoBS). 
For most of the brain imaging, neuropsychological and molecular genetic studies, pa-
tients are recruited from these clinical cohorts. Besides these projects, other projects 
such as a magnetoencephalography (MEG) research project of depression, plus register-
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based studies general population surveys of patients and subjects with mood disorders 
or symptoms have been conducted. 
 
 6.3.2. The main scientific achievements 
 
The clinical studies have illuminated the clinical epidemiology of mood disorders 
in many ways:  
(a) The VDS has been the first major clinical cohort study that has comprehensively 
investigated psychiatric axis I and II comorbidity in patients with major depressive 
disorder (MDD), finding comorbidity the rule rather than an exception, and a factor 
that markedly influences the outcome and treatment of the patients. Nevertheless, 
the long-term (five-year) outcome of the VDS cohort is more variable, and not as 
consistently chronic as most of the current psychiatric literature suggests (typically 
based on unrepresentative, mostly inpatient, tertiary level patient samples). 
(b)  The PC-VDS has documented presence of psychiatric comorbidity also in pri-
mary care settings, and suggested that the perceived mostly subthreshold nature of 
depression in primary care is largely an artefact caused by exclusively cross-
sectional evaluation. In fact, most primary care patients with mild depressive 
symptoms suffer from MDD in lifetime perspective. The idea of mostly mild, self-
limited and subthreshold disorders in primary care is not tenable. 
(c) The JoBS has documented poor rate of recognition of particularly bipolar II disorder 
even in psychiatric settings, high prevalence of depressive mixed states (mixed de-
pression) in particular bipolar II but also bipolar I patients, and very high level of sui-
cidal behaviour in both types of the illness, largely explicable in terms of time spent in 
high-risk illness states (depressive and mixed illness phases) during follow-up. 
 
 6.3.3. The main public health achievements 
 
 The clinical studies have illuminated the clinical epidemiology of mood disorders 
in ways that have major implications for developing health care services for patients 
with these disorders: 
 
The PC-VDS documented major problems in recognition of depression in primary care, 
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raising the needs for education, screening and collaborative care models in primary care. 
The presence of psychiatric and somatopsychiatric comorbidity in both the VDS and the 
PC-VDS has major impact on planning treatments and services, as comorbidity usually 
complicates all treatment, and undermines generalizability of findings from clinical 
treatment trials into clinical practice. Finding that depressive patients in primary health 
care usually suffer from major depressive disorder suggest, that not only psychosocial 
interventions, but also antidepressant pharmacotherapy is usually warranted. 
As mood disorders are usually recurrent, continuity of acute and maintenance phase 
treatments is essential to prevent relapses and recurrences. However, the VDS has 
documented poor continuity of acute treatment for depression in psychiatric care. More-
over, maintenance antidepressant therapy is a cornerstone for prevention of recurrent 
depressive episodes, but the VDS found less than half (42%) of patients with a clear 
indication for maintenance antidepressant therapy to receive it all, and only for 18% of 
the months indicated, during the long-term follow-up. Thus, although treatments for 
depression are increasingly available, poor continuity of treatment remarkably compro-
mises the public health benefits of these interventions. 
 
        The JoBS documented poor rate of recognition of particularly bipolar II disorder 
even in psychiatric settings, and largely as a consequence, major inadequacies in clinical 
treatment of patients with bipolar disorder. As these patients represent a highly suicidal 
group of patients in psychiatric care, measures to improve quality of care are urgently 
needed. They include screening for bipolar disorder, psychoeducation, and more sys-
tematic use of mood diaries and life charts in follow-up. 
The three clinical cohort studies have provided a necessary epidemiological background 
for developing national evidence-based clinical care guidelines for depression (profes-
sor Isometsä chaired the task force) and bipolar disorder (chaired by associate professor 
Kirsi Suominen, a member of the JoBS research group). 
 
6.3.4. Funding for research and public health programs 
 
The mood disorders research has received large EVO (state subsidiary) grants from 
the Helsinki and Uusimaa Health Care District (151.000 € for the years 1998-2000; total 
180.000 € for 2005-2008), plus funding from the Academy of Finland (126.000 FIM for 
2001-2003; 150.000 € for 2005-2007). In addition, the projects and individual research-
ers have received numerous smaller grants. The molecular genetic aspect of the MMPN 
have been separately funded by the Academy of Finland. 
68 
 
6.3.5. Personnel 
 
At present, research professor Erkki Isometsä has a part-time (20%) position at the 
National Public Health Institute, his main affiliation being with the University of Hel-
sinki. The research described above involves a large and complex multidisciplinary 
network of researchers (about 30) including clinical psychiatrists, psychologists, epide-
miologists and statisticians, neuroradiologists and physicists, most affiliated with the 
Department of Mental Health and Alcohol Research or Department of Molecular Medi-
cine of the National Public Health Institute in Helsinki, or the Departments of Psychia-
try or Radiology at the Helsinki University Central Hospital. None of the researchers are 
in permanent research position, all work part-time or intermittently. However, the avail-
able funding has allowed sufficient time allocated for this research typically in periods 
of few months per year by the collaborators. Much of the clinical research has been un-
dertaken as Ph.D. theses (six accomplished, twelve under preparation). 
 
6.3.6. Collaboration 
 
The nature of this research is multidisciplinary and involves mainly collaboration be-
tween the Department of Mental Health and Alcohol Research and Department of Mo-
lecular Medicine of the National Public Health Institute in Helsinki, and the Departments 
of Psychiatry and Department of Radiology at the Helsinki University Central Hospital. 
Although many of the researchers have close contact with the international networks of 
researchers of their own field, this research per se has been conducted as collaborative 
projects between these nationally leading institutions. Much of the clinical research has 
been undertaken as Ph.D. theses (six accomplished, twelve under preparation). 
 
6.3.7. Proposal for future work and expected benefits 
 
The clinical cohort studies VDS, PC-VDS and JoBS are all now focusing on me-
dium (18 months) and long-term (five years) outcomes. These studies are based on life 
charts, and will illuminate the clinical course of illness in representative, unselected 
cohorts of patients. The studies will also be informative regarding the outcome of suici-
dal behaviour and level of functioning and work disability in the long-term. 
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A new cohort study of borderline personality disorder will be started during the fall 
2007. The aim is to collect a regionally representative cohort of carefully diagnosed 
psychiatric patients with borderline personality disorder (BPD), to characterize their 
clinical picture and investigate their clinical outcome. As with the patients in the mood 
disorder cohorts, patient from this cohort will be recruited into molecular genetic, 
neuropsychological and structural brain imaging (MRI, including diffusion tensor imag-
ing) studies as a part of the MMPN. 
The ongoing diffusion tensor imaging (DTI) studies of the MMPN (now starting with a 
new 3T scanner at the HUCH) are beginning to provide detailed information on the ab-
normalities in brain white matter among patients with mood disorders. The ongoing 
MMPN molecular genetic association studies will provide information on genetic risk 
factors (candidate genes) for mood disorders, their possible influence on the phenotype 
and long-term outcome, and interactions with life events (G x E interactions) when influ-
encing outcome. Furthermore, the possible impact of the putative candidate genes on 
brain structure will be investigated as a part of the MMPN project. This information can 
also be combined with data on neuropsychological abnormalities among these patients. 
Finally, a pilot study of actigraphy in mood disorders will be started during the fall 2007. 
The aim is to explore the potential usefulness of objective measurement of physical activ-
ity in measuring variations in mood state and sleep-wake-cycle. This kind of technology 
may prove to be a useful tool for differential diagnostic purposes in mood disorders, or 
indicator of escalating mood episodes. If the pilot study confirms the utility of actigraphy 
for these purposes, this line of research will proceed into more large-scale experiments. 
 
6.3.8. Key publications in 2004-2007 
 
1. Melartin T, Rytsälä H, Leskelä U, Lestelä-Mielonen, Sokero P, Isometsä E. Severity and comorbidity 
predict episode duration and recurrence of DSM-IV major depressive disorder. Journal of Clinical Psy-
chiatry 2004;65:810-819 
2. Mantere O, Suominen K, Leppämäki S, Valtonen H, Arvilommi P, Isometsä E. The clinical character-
istics of DSM-IV bipolar I and II disorders: baseline findings from the Jorvi Bipolar Study (JoBS). Bipo-
lar Disorders 2004;6:395-405. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
OBJECTIVE: To obtain a comprehensive view of the clinical epidemiology of bipolar I and II disorder in 
secondary-level psychiatric settings. METHODS: In the Jorvi Bipolar Study (JoBS), 1630 non-
schizophrenic psychiatric in- and outpatients in three Finnish cities were screened for bipolar I and II disor-
ders with the Mood Disorder Questionnaire. Diagnoses were made using semistructured SCID-I and -II 
interviews. Information collected included clinical history, current episode, symptom status, and other char-
acteristics. RESULTS: A total of 191 patients with bipolar disorder (90 bipolar I and 101 bipolar II) were 
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included in the JoBS. The majority of bipolar II (50.5%) and many bipolar I (25.6%) patients were previ-
ously undiagnosed; the remainder had a median 7.8 years delay from first episode to diagnosis. Despite 
several lifetime episodes, 26 and 58% of bipolar I and II patients, respectively, had never been hospitalized. 
A polyphasic episode was current in 51.3%, rapid cycling in 32.5%, and psychotic symptoms in 16.2% of 
patients. Mixed episodes occurred in 16.7% of bipolar I, and depressive mixed states in 25.7% of bipolar II 
patients. CONCLUSION: Even in psychiatric settings, bipolar disorders usually go undetected, or recog-
nized only after a long delay. A significant proportion of not only bipolar II, but also bipolar I patients are 
never hospitalized. Polyphasic episodes and rapid cycling are prevalent in both types. Depressive mixed 
states are at least as common among bipolar II patients as mixed episodes among bipolar I. 
3. Melartin TK, Rytsälä HJ, Leskelä US, Lestelä-Mielonen PS, Sokero TP, Isometsä ET. Continuity is the 
main challenge in treating major depressive disorder in psychiatric care. Journal of Clinical Psychiatry 
2005;66:220-227. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
OBJECTIVE: Several evidence-based treatment guidelines for major depressive disorder (MDD) have been 
published. However, little is known about how recommendations for treatment are adhered to by patients in 
current usual psychiatric practice. METHOD: The Vantaa Depression Study is a prospective, naturalistic 
cohort study of 269 psychiatric patients with a new episode of DSM-IV MDD who were interviewed with 
the Schedules for Clinical Assessment in Neuropsychiatry and Structured Clinical Interview for DSM-III-R 
Personality Disorders between February 1, 1997, and May 31, 1998, and again at 6 and 18 months. Treat-
ments provided, as well as adherence to and attitudes toward both antidepressants and psychotherapeutic 
support/psychotherapy, were investigated among the 198 unipolar patients followed for 18 months. 
RESULTS: Most depression patients (88%) received antidepressants in the early acute phase, but about half 
(49%) terminated treatment prematurely. This premature termination was associated with worse outcome of 
major depressive episodes, and with negative attitudes, mainly explained by fear of dependence on or side 
effects of antidepressants. Nearly all patients (98%) received some psychosocial treatment in the acute 
phase; about one fifth (16%) had weekly psychotherapy during the follow-up. About a quarter of patients 
admitted nonadherence to ongoing treatments. CONCLUSION: Problems of psychiatric care seem most 
related to continuity of treatment. While adequate treatments are provided in the early acute phase, antide-
pressants are terminated too soon in about half of patients, often following their autonomous decisions. 
From a secondary and tertiary preventive point of view, improving continuity of treatment would appear a 
crucial task for improving the outcome of psychiatric patients with MDD. 
4. Vuorilehto M, Melartin T, Isometsä E. Depressive disorders in primary care: Recurrent, chronic and 
comorbid. Psychological Medicine 2005; 35: 673-68. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
BACKGROUND: Preceding longitudinal course and current somatic and psychiatric co-morbidity of 
depression have been little investigated in primary care. METHOD: Consecutive patients (n = 1111) in 
primary care in the city of Vantaa, Finland, were screened for depression with the PRIME-MD, and posi-
tive cases interviewed by telephone. Cases with current depressive symptoms were diagnosed face-to-face 
with the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I/P). A cohort of 137 patients 
with unipolar depressive disorders, comprising all patients with at least two depressive symptoms and 
clinically significant distress or disability, was recruited. The Structured Clinical Interview for DSM-IV 
Axis II Disorders (SCID-II), medical records, rating scales, and a retrospective life-chart were used to 
obtain comprehensive cross-sectional and longitudinal information. RESULTS: Current major depressive 
disorder (MDD) was the most prevalent depressive disorder (66%); it was usually mild to moderate but 
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recurrent. A quarter of cases (23%) had MDD in partial remission or prodromal phase, and only 10% had 
true minor depression. Axis I co-morbidity was present in 59%, Axis II in 52%, and chronic Axis III 
disorders in 47%; only 12% had no co-morbidity. One third of patients presented with a psychological 
complaint, predicted by higher depression severity and younger age. CONCLUSION: From a lifetime 
perspective, the majority of primary-care patients with depressive disorders suffer from recurrent MDD, 
although they are currently often in prodromal or residual phase. Psychiatric and somatic co-morbidity are 
highly prevalent. Treatment of depression in primary care should not rely on an assumption of short-lived, 
uncomplicated mild disorders. 
5. Sokero TP, Melartin TK, Rytsälä HJ, Leskelä US, Lestelä-Mielonen PS, Isometsä ET. A prospective 
study of risk factors for attempted suicide among psychiatric patients with DSM-IV major depressive 
disorder. British Journal of Psychiatry 2005;186:314-8. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
BACKGROUND: There are few prospective studies on risk factors for attempted suicide among psychi-
atric out- and in-patients with major depressive disorder. AIMS: To investigate risk factors for attempted 
suicide among psychiatric out- and in-patients with major depressive disorder in the city of Vantaa, 
Finland. METHOD: The Vantaa Depression Study included 269 patients with DSM-IV major depressive 
disorder diagnosed using semistructured interviews and followed up at 6- and 18-month interviews with a 
life chart. RESULTS: During the 18-month followup, 8% of the patients attempted suicide. The relative 
risk of an attempt was 2.50 during partial remission and 7.54 during a major depressive episode, com-
pared with full remission (P 0.001). Numerous factors were associated with this risk, but lacking a part-
ner, previous suicide attempts and total time spent in major depressive episodes were the most robust 
predictors. CONCLUSIONS: Suicide attempts among patients with major depressive disorder are 
strongly associated with the presence and severity of depressive symptoms and predicted by lack of part-
ner, previous suicide attempts and time spent in depression. Reducing the time spent depressed is a credi-
ble preventive measure. 
6. Valtonen H, Suominen K, Mantere O, Leppämäki S, Arvilommi P, Isometsä ET. Suicidal Ideation and 
Attempts in Bipolar I and II Disorders. Journal of Clinical Psychiatry 2005;66;1456-1462. 
Department of Mental Health and Alcohol Research, National Public Health Institute, 00300 Helsinki, Finland. 
OBJECTIVE: Few studies have investigated the prevalence of and risk factors for suicidal ideation and 
attempts among representative samples of psychiatric patients with bipolar I and II disorders. METHOD: 
In the Jorvi Bipolar Study (JoBS), psychiatric inpatients and outpatients were screened for bipolar disor-
ders with the Mood Disorder Questionnaire from January 1, 2002, to February 28, 2003. According to 
Structured Clinical Interviews for DSM-IV Axis I and II Disorders, 191 patients were diagnosed with 
bipolar disorders (bipolar I, N = 90; bipolar II, N = 101). Suicidal ideation was measured using the Scale 
for Suicidal Ideation. Prevalence of and risk factors for ideation and attempts were investigated. 
RESULTS: During the current episode, 39 (20%) of the patients had attempted suicide and 116 (61%) 
had suicidal ideation; all attempters also reported ideation. During their lifetime, 80% of patients (N = 
152) had had suicidal behavior and 51% (N = 98) had attempted suicide. In nominal regression models, 
severity of depressive episode and hopelessness were independent risk factors for suicidal ideation, and 
hopelessness, comorbid personality disorder, and previous suicide attempt were independent risk factors 
for suicide attempts. There were no differences in prevalence of suicidal behavior between bipolar I and II 
disorder; the risk factors were overlapping but not identical. CONCLUSION: Over their lifetime, the vast 
majority (80%) of psychiatric patients with bipolar disorders have either suicidal ideation or ideation plus 
suicide attempts. Depression and hopelessness, comorbidity, and preceding suicidal behavior are key 
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indicators of risk. The prevalence of suicidal behavior in bipolar I and II disorders is similar, but the risk 
factors for it may differ somewhat between the two. 
7. Linkenkaer-Hansen K, Monto S, Rytsälä H, Suominen K, Isometsä E, Kähkönen S. Breakdown of 
long-range temporal correlations in theta oscillations in major depressive disorder. Journal of Neurosci-
ence 2005:25:10131-10137. 
BioMag Laboratory, Engineering Centre, Helsinki University Central Hospital, FIN-00029 HUS, Finland. 
klaus.linkenkaer@cncr.vu.nl 
Neuroimaging has revealed robust large-scale patterns of high neuronal activity in the human brain in the 
classical eyes-closed wakeful rest condition, pointing to the presence of a baseline of sustained endoge-
nous processing in the absence of stimulus-driven neuronal activity. This baseline state has been shown to 
differ in major depressive disorder. More recently, several studies have documented that despite having a 
complex temporal structure, baseline oscillatory activity is characterized by persistent autocorrelations for 
tens of seconds that are highly replicable within and across subjects. The functional significance of these 
long-range temporal correlations has remained unknown. We recorded neuromagnetic activity in patients 
with a major depressive disorder and in healthy control subjects during eyes-closed wakeful rest and 
quantified the long-range temporal correlations in the amplitude fluctuations of different frequency bands. 
We found that temporal correlations in the theta-frequency band (3-7 Hz) were almost absent in the 5-100 
s time range in the patients but prominent in the control subjects. The magnitude of temporal correlations 
over the left temporocentral region predicted the severity of depression in the patients. These data indicate 
that long-range temporal correlations in theta oscillations are a salient characteristic of the healthy human 
brain and may have diagnostic potential in psychiatric disorders. We propose a link between the abnormal 
temporal structure of theta oscillations in the depressive patients and the systems-level impairments of 
limbic-cortical networks that have been identified in recent anatomical and functional studies of patients 
with major depressive disorder. 
8. Mantere O, Suominen K, Melartin T, Valtonen H, Arvilommi P, Leppämäki S, Rytsälä H, Isometsä E. 
Differences in patterns of axis I and II comorbidity of bipolar I vs. II vs. major depressive disorders. Jour-
nal of Clinical Psychiatry 2006;67:584-593. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
OBJECTIVE: To obtain a comprehensive view of differences in current comorbidity between bipolar I 
and II disorders (BD) and (unipolar) major depressive disorder (MDD), and Axis I and II comorbidity in 
BD in secondary-care psychiatric settings. METHOD: The psychiatric comorbidity of 90 bipolar I and 
101 bipolar II patients from the Jorvi Bipolar Study and 269 MDD patients from the Vantaa Depression 
Study were compared. We used DSM-IV criteria assessed by semistructured interviews. Patients were 
inpatients and outpatients from secondary-care psychiatric units. Comparable information was collected 
on clinical history, index episode, symptom status, and patient characteristics. RESULTS: Bipolar disor-
der and MDD differed in prevalences of current comorbid disorders, MDD patients having significantly 
more Axis I comorbidity (69.1% vs. 57.1%), specifically anxiety disorders (56.5% vs. 44.5%) and cluster 
A (19.0% vs. 9.9%) and C (31.6% vs. 23.0%) personality disorders. In contrast, BD had more single 
cluster B personality disorders (30.9% vs. 24.6%). Bipolar I and bipolar II were similar in current overall 
comorbidity, but the prevalence of comorbidity was strongly associated with the current illness phase. 
CONCLUSIONS: Major depressive disorder and BD have somewhat different patterns in the prevalences 
of comorbid disorders at the time of an illness episode, with differences particularly in the prevalences of 
anxiety and personality disorders. Current illness phase explains differences in psychiatric comorbidity of 
BD patients better than type of disorder. 
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9. Vuorilehto M, Melartin T, Isometsa E. Suicidal behaviour among primary care patients with depressive 
disorders. Psychological Medicine 2006:36:203-210. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
BACKGROUND: Most national suicide prevention strategies set improved detection and management of 
depression in primary health care into a central position. However, suicidal behaviour among primary-
care patients with depressive disorders has been seldom investigated. METHOD: In the Vantaa Primary 
Care Depression Study, a total of 1119 primary-care patients in the City of Vantaa, Finland, aged 20 to 69 
years, were screened for depression with the Primary Care Evaluation of Mental Disorders (PRIME-MD) 
questionnaire. Depressive disorders were diagnosed with the Structured Clinical Interview for DSM-IV 
Axis I Disorders (SCID-I), and the 137 patients with depressive disorder were included in the study. Sui-
cidal behaviour was investigated cross-sectionally and retrospectively in three time-frames: current, cur-
rent depressive episode, and lifetime. Current suicidal ideation was measured with the Scale for Suicidal 
Ideation (SSI), and previous ideation and suicide attempts were evaluated based on interviews plus medi-
cal and psychiatric records. RESULTS: Within their lifetimes, 37% (51/137) of the patients had seriously 
considered suicide and 17% (23/137) attempted it. Lifetime suicidal behaviour was independently and 
strongly predicted by psychiatric treatment history and co-morbid personality disorder, and suicidal be-
haviour within the current episode was predicted most effectively by severity of depression. 
CONCLUSIONS: Based on these findings and their convergence with studies of completed suicides, 
prevention of suicidal behaviour in primary care should probably focus more on high-risk subgroups of 
depressed patients, including those with moderate to severe major depressive disorder, personality disor-
der or a history of psychiatric care. Recognition of suicidal behaviour should be improved. The complex 
psychopathology of these patients in primary care needs to be considered in targeting preventive efforts. 
10. Leskelä U, Rytsälä H, Melartin T, Komulainen E, Sokero P, Lestelä-Mielonen P, Isometsä E. Is the 
influence of psychosocial factors on the outcome of major depressive disorder equal for all current levels 
of depressive symptoms? Psychological Medicine 2006; 36:779-788. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
BACKGROUND: Adverse life events and social support may influence the outcome of major depressive 
disorder (MDD). We hypothesized that outcome would depend on the level of depressive symptoms pre-
sent at the outset, with those in partial remission being particularly vulnerable. METHOD: In the Vantaa 
Depression Study (VDS), patients with DSM-IV MDD were interviewed at baseline, and at 6 and 18 
months. Life events were investigated with the Interview for Recent Life Events (IRLE) and social sup-
port with the Interview Measure of Social Relationships (IMSR) and the Perceived Social Support Scale - 
Revised (PSSS-R). The patients were divided into three subgroups at 6 months, those in full remission (n 
= 68), partial remission (n = 75) or major depressive episode (MDE) (n = 50). The influence of social 
support and negative life events during the next 12 months on the level of depressive symptoms, meas-
ured by the Hamilton Rating Scale for Depression (HAMD), was investigated at endpoint. RESULTS: 
The severity of life events and perceived social support influenced the outcome of depression overall, 
even after adjusting for baseline level of depression and neuroticism. In the full remission subgroup, both 
severity of life events and subjective social support significantly predicted outcome. However, in the 
partial remission group, only the severity of events, and in the MDE group, the level of social support 
were significant predictors. CONCLUSIONS: Adverse life events and/or poor perceived social support 
influence the medium-term outcome of all psychiatric patients with MDD. These factors appear to have 
the strongest predictive value in the subgroup of patients currently in full remission. 
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11. Valtonen H, Suominen K, Mantere O, Leppämäki S, Arvilommi P, Isometsä E. Prospective study of 
risk factors for attempted suicide among bipolar disorder patients. Bipolar Disorders 2006:8:576-585. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
OBJECTIVE: There are few prospective studies on risk factors for attempted suicide among representa-
tive samples of psychiatric patients with bipolar I and II disorders. We conducted a prospective study to 
investigate risk for suicide attempts among a secondary-level sample of psychiatric in- and outpatients 
with bipolar disorder (BD). METHODS: In the Jorvi Bipolar Study (JoBS), 1,630 psychiatric in- and 
outpatients from three Finnish cities were screened for BDs with the Mood Disorder Questionnaire 
(MDQ). Using the Structured Clinical Interview for DSM-IV Disorders (SCID)-I and -II, 191 patients 
were diagnosed with BDs (90 bipolar I and 101 bipolar II). Information on suicide attempts during the 
follow-up was obtained for 176 patients (92%) at the 6-month follow-up and for 160 patients (84%) at the 
18-month follow-up. RESULTS: During the 18-month follow-up 20% of patients (35/176) attempted 
suicide. In a Cox regression model, baseline previous suicide attempts (OR 3.8, 95% CI 1.7-8.8; p = 
0.001), hopelessness (OR 1.2, 95% CI 1.1-1.3; p < 0.001), depressive phase at index episode (OR 2.4, 
95% CI 1.1-5.3; p = 0.03) and younger age at intake (OR 0.94, 95% CI 0.91-0.97; p < 0.001) were inde-
pendent risk factors for suicide attempts during follow-up, whereas factors such as bipolar I or II, or co-
morbidity did not reach statistical significance. CONCLUSIONS: During a medium-term follow-up, as 
many as one-fifth of random psychiatric patients with BD attempted suicide, which highlights the public 
health importance of suicidal behavior in BD. Previous suicide attempts, hopelessness and depressive 
phase were the key indicators of risk. 
12. Arvilommi P, Suominen K, Mantere O, Leppämäki S, Valtonen H, Isometsä ET. Adequacy of treat-
ment received by diagnosed and undiagnosed patients with bipolar I and II disorder. Journal of Clinical 
Psychiatry 2007;68:102-110. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
OBJECTIVE: To investigate the adequacy of pharmacotherapy received by psychiatric inpatients and 
outpatients with a research diagnosis of bipolar I or II disorder, including patients both with and without a 
clinical diagnosis of bipolar disorder. METHOD: In the Jorvi Bipolar Study (JoBS), 1630 psychiatric 
inpatients and outpatients in 3 Finnish cities were systematically screened between January 1, 2002, and 
February 28, 2003, for bipolar I and II disorders using the Mood Disorder Questionnaire. By using SCID-
I and -II interviews, 191 patients were diagnosed with bipolar disorder (90 bipolar I and 101 bipolar II). 
Information was collected on clinical history, diagnosis, and treatment. The adequacy of treatment re-
ceived was evaluated. RESULTS: Of the 162 patients with previous bipolar disorder episodes, only 34 
(20.9%) of all and 30 (55.5%) of those with a clinical diagnosis of bipolar disorder were using a mood 
stabilizer at onset of the index episode. Only 81 (42.4%) of all 191 patients and 76 (65.0%) of those diag-
nosed with bipolar disorder received adequate treatment for the acute index phase. The factor most 
strongly independently associated with adequate treatment was clinical diagnosis of bipolar disorder (OR 
= 25.34). In addition, rapid cycling (OR = 2.45), polyphasic index episode (OR = 2.41), or depressive 
index phase (OR = 3.36) independently predicted inadequate treatment. Outpatients received adequate 
treatment markedly less often than inpatients. CONCLUSIONS: Clinical diagnosis of bipolar disorder is 
by far the most important prerequisite for adequate treatment. Problems in treatment are associated mostly 
with outpatient settings, where adequacy of treatment of bipolar depression is a major concern. Lack of 
attention to the longitudinal course of illness is another major problem area. 
13. Mantere O, Suominen K, Valtonen H, Leppämäki S, Arvilommi P, Melartin T, Isometsä E. Differ-
ences in outcome of DSM-IV bipolar I and II disorders. Bipolar Disorders 2007:(in press). 
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6.4. Mood and behavior 
 
6.4.1. Research and public health significance of the area 
 
The key areas of interest include the seasonal changes in mood and behavior, feel-
ings of anxiety, symptoms of depression and insomnia at the general population level. 
On the other hand, anxiety, mood and sleep disorders are a focus of interest concerning 
clinical populations. The project aims at analyzing the genetic effect on the phenotypes 
by analyzing the behaviors of sleep, dietary intake and physical exercise and the pa-
rameters of electroencephalographic and hormone assessments. 
The main goals of research are targeted by using a range of methods from data statis-
tics and bioinformatics via interviews and interventions to systems biology and experi-
ments in vitro. Data are derived from the nationwide register-based and individualized 
data on the reimbursed prescriptions (The Social Insurance Institution of Finland), hospi-
tal treatments (National Research and Development Centre for Welfare and Health), and 
causes of death (Statistics Finland). Using the unique personal identity code for each citi-
zen (The Social Insurance Institution of Finland), the personal data on family relations 
(Population Register Centre) and the register-based population censuses (Statistics 
Finland), the samples of individuals, siblings including twins, nuclear families, pedigrees 
or reference populations can be identified and analyzed in subsequent studies. 
Data are also collected as part of the general population surveys including Health 
2000 Study and a series of the National FINRISK Studies (National Public Health Insti-
tute), and with the use of interventions on community-based and clinical populations for 
the project in particular. For the implementation of interventions with light therapy and 
physical exercise, the project when needed collaborates with the Lighting Laboratory at 
Helsinki University of Technology, and UKK Institute, respectively. 
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6.4.2. The main scientific achievements 
 
Since the start the etiology of major depressive and bipolar disorders with the sea-
sonal pattern, or seasonal affective disorder, have been a major focus of interest [1]. 
Interventions with light therapy and fitness training, together with measurements in the 
isolation unit or field conditions, have been applied for elucidation of the mechanisms 
of action underlying the pathogenesis. For the project, seasonal affective disorder has 
been taken as a representative of mood disorders in general. Moreover, seasonal 
changes in mood and behavior have been regarded as a proxy of abnormalities in the 
circadian clockwork which are responsive to interventions with the scheduled light ex-
posure or physical exercise. 
So far, the project has discovered the association of a mis-sense variant in the 
Npas2 gene, showing a recessive effect of the leucine allele on disease susceptibility 
[2], and the association of a polymorphism in each of the three circadian clock genes, 
which form a functional unit, with the disease [3]. In an analysis of the combined effect 
of these three genes, the project demonstrated additive effects and identified a genetic 
risk profile for the disorder. Carriers of the risk genotype combination have a four-fold 
risk of having the disorder as compared with the remaining genotypes, and a ten-fold 
risk as compared with those carrying the protective genotype combination. These risk 
and protective genotype combinations need to be verified first and thereafter character-
ized further in terms of the phenotype. Having this goal in mind, we have started the 
analysis of a sample of approximately 6000 individuals being representative of the Fin-
nish population aged over 30. 
For the project, there is a hypothesis that abnormalities in the circadian clockwork 
are a key to the pathogenesis of seasonal affective disorder in particular and mood disor-
ders in general. A rationale for the hypothesis is provided by two findings. First, earlier 
findings from the project showing that seasonal affective disorder was not associated with 
polymorphisms of functional relevance to the metabolism or transmission of serotonin 
gave support to the hypothesis. Second, transcriptional networks which include the cir-
cadian clock and have control of downstream pathways including the sleep-wake and 
seasonal cycles implicate further the potential impact of the circadian clock on the patho-
genesis of seasonal affective disorder in particular or mood disorders in general. 
Parallel to the recurrent major depressive disorder, bipolar disorder has been on the 
focus of interest. The project has demonstrated the high heritability of bipolar I disorder, 
with the estimate of .93, in a nationwide population-based twin sample [4] as well as the 
low lifetime prevalence for bipolar I disorder, with the estimate of .24, in a nationwide 
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random sample representative of the general population [5]. To elucidate the pathogene-
sis more in detail, the project has demonstrated that the left hemisphere white matter 
volumes link to the genetic factors predisposing to the disease [6], and carried out a 
population-based sample of families with bipolar I disorder yielding the high heritability 
estimates for psychomotor processing speed and executive functioning [7]. These cogni-
tive test performances may be valid traits for subsequent genetic studies of bipolar I 
disorder, for instance those studies which have applied for a genome-wide scan and fine 
mapping strategies [8] and those which will use a genome-wide single-nucleotide poly-
morphism association and lymphocyte or cell line based expression arrays. 
At the general population level, the project has found the association of sleep dura-
tion with health implications [9] and demonstrated the efficacy of dawn simulation for 
improvement in the quality of sleep in a community-based random sample [10]. The 
combination of light exposure with physical exercise was demonstrated to be of sub-
stantial benefit to those having marked seasonal changes in mood and behavior [11]. 
Because 38.9% of the general population aged 30 or over have seasonal changes in 
mood and behavior of a similar extent to winter blues, these interventions may be of 
benefit to as many as 1,266,531 citizens. 
 
In a population-based trial on 29,133 men aged 50 to 69 years, the project has 
demonstrated that there is no association of low dietary intake of fatty acids and fish 
consumption [12], in contrast to low baseline serum total cholesterol concentration [13], 
with subsequent self-reports of depressed mood and a risk of hospital treatment due to a 
major depressive episode and of death from suicide during follow-up. 
A population-based nationwide analysis of all the individuals who committed sui-
cide demonstrated that suicide mortality does vary by season and needs attention to be 
applied for suicide prevention [14]. For the preventive measures, it is essential to focus 
on the high-risk group of individuals with a prior suicide attempt. Contacts with the 
health care system due to suicide attempts do occur most often in the late evening and 
around midnight. The finding challenges the adequacy of staff numbers for psychiatric 
consultations and of time to plan aftercare [15]. 
 
6.4.3. The main public health achievements 
 
The project has been participating in dissemination of its research findings and ex-
pertise via media, including television, radio, newspapers, magazines, and Internet, to 
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the public in order to increase the awareness of health promotion against mood and 
sleep disorders. The project has been acting as a scientific expert for the Light Aware-
ness Day in February, the Brain Awareness Week in March, the Vigilance Awareness 
Week in March, and the Sleep Awareness Week in October. The project has been the 
first one in Finland to provide light therapy, and to analyze its efficacy and effectiveness 
in a series of trials starting from 1988. 
As part of these tasks, the project leader has acted as the supervisor for the EU-
funded Enough Sleep consortium (of the FP6 STREP scheme) and taken actions in Fin-
nish Medical Society Duodecim (Current Care guideline for the treatment of insomnia), 
both of which produce information to the laypersons as well. The project leader has in 
addition written three popular science books about mental health and participated in the 
editorial board of the textbook of psychiatry which has been used in the university level 
education. 
The project leader has acted as a member of the Communication Unit at National 
Public Health Institute, and contributed to the Information Journal of National Public 
Health Institute, having a circulation of 8700 with a good coverage of policymakers, 
and to the Internet portal of the Finnish Government which is dedicated to the health 
affairs and targeted to the laypersons. 
 
6.4.4. Funding for research and public health programs 
 
Grants have been awarded to Timo Partonen from the Finnish Medical Foundation 
66,000 EUR for Seasonal affective disorder: predisposing and protecting factors during 
2002-2003, and from the Academy of Finland 150,000 EUR for Genetic etiology of 
bipolar disorder during 2003-2006 and 275,000 EUR for Molecular mechanisms of bi-
polar and recurrent depressive disorders with the seasonal pattern during 2004-2009. 
In addition to these primary sources of funding, additional grants have been 
awarded from Finnish foundations to research associates working for the project. 
 
6.4.5. Personnel 
 
Timo Partonen, MD, is academy research fellow (Academy of Finland) and is cur-
rently working as the full-time project leader at the National Public Health Institute to-
gether with a number of research associates. Their current number is 22 of whom 5 are 
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post-doctoral scientists and 17 (5 biologists, 4 medical doctors, 4 graduate engineers, 2 
psychologists, 2 masters of science) are PhD students. 
 
6.4.6. Collaboration 
 
The project will continue collaboration with National Public Health Institute, De-
partment of Molecular Medicine (professor Leena Peltonen-Palotie), in Helsinki. The 
project is also part of a network of laboratories including Karolinska Institutet, Depart-
ment of Molecular Medicine and Surgery (professor Martin Schalling), in Stockholm; 
King's College, Institute of Psychiatry, Section of Addiction Biology (professor Gunter 
Schumann), in London; and University of Helsinki, Department of Physiology (Dr Piia 
Aarnisalo) and Department of Medical Genetics (Dr Iiris Hovatta), in Helsinki. In these 
studies the project will focus on the molecular genetics and systems biology of the cir-
cadian clock and their contribution to common and complex diseases, such as mood 
disorders, anxiety disorders, alcohol use disorders, metabolic syndrome, and non-insulin 
dependent diabetes mellitus. In addition, the regulation of the circadian clock genes will 
be analyzed in vitro and subsequently in vivo models. 
The project links to University of Helsinki, Department of Psychiatry; Helsinki Uni-
versity of Technology, Lighting Laboratory (www.lightinglab.fi); Finnish Meteorological 
Institute; Finnish Cancer Registry; Finnish Institute of Occupational Health, Human Fac-
tors at Work. These joint projects will elucidate the mechanisms of action of light expo-
sure using monochromatic spectra (Helsinki University of Technology), the spring peak 
in suicide mortality (Finnish Meteorological Institute), the risks of night-time shift work 
(Finnish Cancer Registry, and Finnish Institute of Occupational Health) and of jet lag for 
health, and the benefits and hazards of prescriptions for mental disorders. 
The project links to National Research and Development Centre for Welfare and 
Health, Health Services Research; and The Social Insurance Institution of Finland, 
Health Research. These joint projects will analyze the impact of antidepressant medica-
tion on mortality including deaths from suicide or cardiovascular disease in a popula-
tion-based cohort based on individualized prescriptions, and the effect of lithium medi-
cation, being specific to bipolar disorder and known to slow down the pace of the cir-
cadian clock in the suprachiasmatic nuclei of the anterior hypothalamus in the brain, on 
the incidence of dementia and diabetes. 
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6.4.7. Proposal for future work and expected benefits 
 
Since the circadian clock genes are involved in the cell division cycle, metabolic 
cycles and reproductive actions in addition to their roles in the generation of the cir-
cadian rhythms and sleep-wake cycles, the strategy applying molecular systems biology 
for studies of common and complex diseases will be of interest in a range of fields in 
medicine. 
The assessment of individual body time using the method of molecular timetable is 
relevant for mood disorders such as major depression, metabolic diseases such as meta-
bolic syndrome, and malignant processes sensitive to the circadian clockwork abnor-
malities such as non-Hodgkin lymphoma or breast cancer. Such methods might be used 
later as a routine assessment in a range of patient populations. 
Light exposure, physical exercise and sleep habits each are known to have influ-
ence and feed back on the circadian clock. Timed light exposure is taken a method to 
analyze the function and regulation of the circadian clock in specific. Applications of 
designed light exposures at home or working place conditions will be tested in collabo-
ration with the Lighting Laboratory at Helsinki University of Technology. 
Physical risk factors which contribute to the peak in suicide mortality during spring 
will be identified and the underlying mechanisms of action elucidated in collaborations 
with Finnish Meteorological Institute and the Department of Physiology at University of 
Helsinki, respectively. 
For the future, in order to elucidate the circadian clockwork by applying for the 
principles of molecular systems chronobiology and to have a system-level understand-
ing of transcriptional circuits underlying circadian clocks, the project will identify 
clock-controlled elements, including E/E' boxes, D boxes, RREs and NBREs, on clock 
and clock-controlled genes by using in silico analysis of mechanisms of action, real-
time monitoring of circadian transcriptional dynamics, and in vitro circadian phenotype 
assay. Conditional and tissue-specific methods for animal models will be available to 
verify findings of interest in vivo. The project has made a move towards and negotiated 
about joint projects together with University of California Irvine, Department of Phar-
macology (professor Paolo Sassone-Corsi) and of Psychiatry (professor William E. 
Bunney), in Irvine; University of Texas Southwestern Medical Center, Department of 
Biochemistry (professor Steven L. McKnight), in Dallas; University of Texas Health 
Science Center, Department of Biochemistry and Molecular Biology (professor Chen 
Chi Lee), in Houston; University of Lausanne, Center for Integrative Genomics (profes-
sor Mehdi Tafti), in Lausanne; University of Geneva, Department of Molecular Biology 
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(professor Ueli Schibler), in Geneva; and University of Tokyo, Department of Pharma-
cology (professor Hiroki R. Ueda), in Tokyo. 
Ultimate goals for the project are to have answers to the following questions: What 
are the mechanisms of action by which the metabolic, circadian and sleep-wake cycles 
link and contribute to mood? To what extent does the interaction between light-dark and 
warm-cold transitions contribute to the spring peak in suicide mortality? 
Subsequent aims on the basis of these data are to create measures for health promo-
tion and suicide prevention. 
 
6.4.8. Publications 
 
[1] Partonen T, Lönnqvist J. Seasonal affective disorder. Lancet 1998; 352: 1369-74 
 
Seasonal affective disorder (SAD) is a form of recurrent depressive or bipolar disorder, with episodes that 
vary in severity. Seasonal patterns of depressive episodes are common, but SAD seems to be less com-
mon than such patterns suggest. SAD was at first believed to be related to abnormal melatonin metabo-
lism, but later findings did not support this hypothesis. Studies of brain serotonin function support the 
hypothesis of disturbed activity. The short-allele polymorphism for serotonin transporter is more common 
in patients with SAD than in healthy people. Atypical depressive symptoms commonly precede impaired 
functioning, and somatic symptoms are frequently the presenting complaint at visits to family physicians. 
The best treatment regimens include 2500 Ix of artificial light exposure in the morning. When patients 
seem to have no response or to prefer another treatment, antidepressants should be considered. 
 
[2] Johansson C, Willeit M, Smedh C, Ekholm J, Paunio T, Kieseppä T, Lichtermann D, Praschak-Rieder 
N, Neumeister A, Nilsson LG, Kasper S, Peltonen L, Adolfsson R, Schalling M, Partonen T. Circadian 
clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. 
Neuropsychopharmacology 2003; 28: 734-9 
 
Disturbed circadian rhythms have been observed in seasonal affective disorder (SAD). The aim of this 
study was to further investigate this connection, and to test for potential association between polymor-
phisms in circadian clock-related genes and SAD, seasonality (seasonal variations in mood and behavior), 
or diurnal preference (morningness-eveningness tendencies). A total of 159 European SAD patients and 
159 matched controls were included in the genetic analysis, and subsets were screened for seasonality 
(n=177) and diurnal preference (n=92). We found that diurnal preference was associated with both SAD 
and seasonality, supporting the hypothesis of a link between circadian rhythms and seasonal depression. 
The complete case-control material was genotyped for polymorphisms in the CLOCK, Period2, Period3, 
and NPAS2 genes. A significant difference between patients and controls was found for NPAS2 471 
Leu/Ser (chi(2)=9.90, Bonferroni corrected P=0.035), indicating a recessive effect of the leucine allele on 
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disease susceptibility (chi(2)=6.61, Bonferroni corrected P=0.050). Period3 647 Val/Gly was associated with 
self-reported morningness-eveningness scores (n=92, one-way ANOVA: F=4.99, Bonferroni corrected 
P=0.044), with higher scores found in individuals with at least one glycine allele (t=3.1, Bonferroni cor-
rected P=0.013). A second, population-based sample of individuals selected for high (n=127) or low (n=98) 
degrees of seasonality, was also genotyped for NPAS2 471 Leu/Ser. There was no significant difference 
between these seasonality extreme groups, and none of the polymorphisms studied were associated with 
seasonality in the SAD case-control material (n=177). In conclusion, our results suggest involvement of 
circadian clock-related polymorphisms both in susceptibility to SAD and diurnal preference. 
 
[3] Partonen T, Treutlein J, Alpman A, Frank J, Johansson C, Depner M, Aron L, Rietschel M, Wellek S, 
Soronen P, Paunio T, Koch A, Chen P, Lathrop M, Adolfsson R, Persson ML, Kasper S, Schalling M, 
Peltonen L, Schumann G. Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter de-
pression. Ann Med 2007; 39: 229-38 
 
BACKGROUND: Multiple lines of evidence suggest that the circadian clock contributes to the patho-
genesis of winter depression or seasonal affective disorder (SAD). We hypothesized that sequence varia-
tions in three genes, including Per2, Arntl, and Npas2, which form a functional unit at the core of the 
circadian clock, predispose to winter depression. METHODS: In silico analysis of the biological effects 
of allelic differences suggested the target single-nucleotide polymorphisms (SNPs) to be analyzed in a 
sample of 189 patients and 189 matched controls. The most relevant SNP in each gene was identified for 
the interaction analysis and included in the multivariate assessment of the combined effects of all three 
SNPs on the disease risk. RESULTS: SAD was associated with variations in each of the three genes in 
gene-wise logistic regression analysis. In combination analysis of variations of Per2, Arntl, and Npas2, 
we found additive effects and identified a genetic risk profile for the disorder. Carriers of the risk geno-
type combination had the odds ratio of 4.43 of developing SAD as compared with the remaining geno-
types, and of 10.67 as compared with the most protective genotype combination. CONCLUSION: Varia-
tions in the three circadian clock genes Per2, Arntl, and Npas2 are associated with the disease, supporting 
the hypothesis that the circadian clock mechanisms contribute to winter depression. 
 
[4] Kieseppä T, Partonen T, Haukka J, Kaprio J, Lönnqvist J. High concordance of bipolar I disorder in a 
nationwide sample of twins. Am J Psychiatry 2004; 161: 1814-21 
 
OBJECTIVE: The few studies of bipolar I disorder in twins have consistently emphasized the genetic 
contribution to disease liability. The authors report what appears to be the first twin study of bipolar I 
disorder involving a population-based twin sample, in which the diagnoses were made by using struc-
tured, personal interviews. METHOD: All Finnish same-sex twins (N=19,124) born from 1940 to 1957 
were screened for a diagnosis of bipolar I disorder as recorded in the National Hospital Discharge Regis-
ter between 1969 and 1991 or self-reported in surveys of the Finnish Twin Cohort in 1975, 1981, and 
1990. Thirty-eight pairs were thereby identified and invited to participate in the study; the participation 
rate was 68%. Lifetime diagnoses were made by using the Structured Clinical Interview for DSM-IV. The 
authors calculated probandwise and pairwise concordances and correlations in liability and applied bio-
metrical model fitting. RESULTS: The probandwise concordance rates were 0.43 (95% CI=0.10 to 0.82) 
for monozygotic twins and 0.06 (95% CI=0.00 to 0.27) for dizygotic twins. The correlations in liability 
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were 0.85 and 0.41, respectively. The model with no familial transmission was rejected. The best-fitting 
model was the one in which genetic and specific environmental factors explained the variance in liability, 
with a heritability estimate of 0.93 (95% CI=0.69 to 1.00). CONCLUSIONS: The high heritability of 
bipolar disorder was demonstrated in a nationwide population-based twin sample assessed with structured 
personal interviews. 
 
[5] Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, Partonen T, Tuulio-Henriksson 
A, Hintikka J, Kieseppä T, Härkänen T, Koskinen S, Lönnqvist J. Lifetime prevalence of psychotic and 
bipolar I disorders in a general population. Arch Gen Psychiatry 2007; 64: 19-28 
 
CONTEXT: Recent general population surveys of psychotic disorders have found low lifetime preva-
lences. However, this may be owing to methodological problems. Few studies have reported the preva-
lences of all specific psychotic disorders. OBJECTIVE: To provide reliable estimates of the lifetime 
prevalences of specific psychotic disorders. DESIGN: General population survey. SETTING AND 
PARTICIPANTS: A nationally representative sample of 8028 persons 30 years or older was screened for 
psychotic and bipolar I disorders using the Composite International Diagnostic Interview, self-reported 
diagnoses, medical examination, and national registers. Those selected by the screens were then re-
interviewed with the Structured Clinical Interview for DSM-IV. Best-estimate DSM-IV diagnoses were 
formed by combining the interview and case note data. Register diagnoses were used to estimate the ef-
fect of the nonresponders. MAIN OUTCOME MEASURES: Diagnosis of any psychotic or bipolar I 
disorder according to the DSM-IV criteria. RESULTS: The lifetime prevalence of all psychotic disorders 
was 3.06% and rose to 3.48% when register diagnoses of the nonresponder group were included. Lifetime 
prevalences were as follows: 0.87% for schizophrenia, 0.32% for schizoaffective disorder, 0.07% for 
schizophreniform disorder, 0.18% for delusional disorder, 0.24% for bipolar I disorder, 0.35% for major 
depressive disorder with psychotic features, 0.42% for substance-induced psychotic disorders, and 0.21% 
for psychotic disorders due to a general medical condition. The National Hospital Discharge Register was 
the most reliable of the screens (kappa = 0.80). Case notes supplementing the interviews were essential 
for specific diagnoses of psychotic disorders. CONCLUSIONS: Multiple sources of information are es-
sential for accurate estimation of lifetime prevalences of psychotic disorders. The use of comprehensive 
methods reveals that their lifetime prevalence exceeds 3%. 
 
[6] Kieseppä T, van Erp TG, Haukka J, Partonen T, Cannon TD, Poutanen VP, Kaprio J, Lönnqvist J. Reduced 
left hemispheric white matter volume in twins with bipolar I disorder. Biol Psychiatry 2003; 54: 896-905 
 
BACKGROUND: Although the heritability of bipolar I disorder (BPI) is high, few magnetic resonance 
imaging (MRI) studies of siblings of bipolar patients exist. We performed MRI brain scans on a nation-
wide sample of twins with BPI, as well as on their co-twins and a demographically balanced sample of 
control twin subjects, to detect any structural alterations related to the disorder and to the increased ge-
netic risk. METHODS: The National Hospital Discharge Register, National Population Register, and 
Finnish Twin Cohorts were used to identify bipolar twins. Structured diagnostic interviews and MRI 
scans were obtained for 24 twins with BPI, 15 healthy co-twins, and 27 control twin subjects. RESULTS: 
Patients and co-twins showed a significant decrease in left hemispheric white matter volume. The dispar-
ity in patients was -16.1 cm(3) (95% confidence interval [CI] -26.6, -5.6) and in co-twins -11.3 cm(3) 
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(95% CI -22.1, -0.4) compared with control twin subjects. No gray matter decrease was seen in patients or 
co-twins. CONCLUSIONS: The results of this first large-scale MRI study of twins with BPI, their co-
twins, and appropriate control twin subjects, suggest that alterations of the left hemisphere white matter in 
BPI may reflect genetic factors predisposing to the disorder. 
 
[7] Antila M, Tuulio-Henriksson A, Kieseppä T, Soronen P, Palo OM, Paunio T, Haukka J, Partonen T, 
Lönnqvist J. Heritability of cognitive functions in families with bipolar disorder. Am J Med Genet (pub-
lished online 23 Apr 2007; doi: 10.1002/ajmg.b.30538) 
 
Bipolar disorder is highly heritable. Cognitive dysfunctions often observed in bipolar patients and their 
unaffected relatives implicate that these impairments may be associated with genetic predisposition to 
bipolar disorder and thus fulfill the criteria of a valid endophenotype for the disorder. However, the most 
fundamental criterion, their heritability, has not been directly studied in any bipolar population. This 
population-based study estimated the heritability of cognitive functions in bipolar disorder. A comprehen-
sive neuropsychological test battery and the Structured Clinical Interview for DSM-IV were administered 
to a population-based sample of 110 individuals from 52 families with bipolar disorder. Heritability of 
cognitive functions as assessed with neuropsychological test scores were estimated using the Solar pack-
age. Significant additive heritabilities were found in verbal ability, executive functioning, and psychomo-
tor processing speed. Genetic contribution was low to verbal learning functions. High heritability, in 
executive functioning and psychomotor processing speed suggest that these may be valid endophenotypic 
traits for genetic studies of bipolar disorder. 
 
[8] Ekholm JM, Kieseppä T, Hiekkalinna T, Partonen T, Paunio T, Perola M, Ekelund J, Lönnqvist J, 
Pekkarinen-Ijäs P, Peltonen L. Evidence of susceptibility loci on 4q32 and 16p12 for bipolar disorder. 
Hum Mol Genet 2003; 12: 1907-15 
 
We performed a genome-wide scan for susceptibility loci in bipolar disorder in a study sample colleted 
from the isolated Finnish population, consisting of 41 families with at least two affected siblings. We 
identified one distinct locus on 16p12 providing significant evidence for linkage in two-point analysis 
(Z(max)=3.4). Furthermore, three loci with a two-point LOD score >2.0 were observed with markers on 
4q32, 12q23 and Xq25, the latter locus having been earlier identified in one extended Finnish pedigree. In 
the second stage we fine mapped these chromosomal regions and also genotyped additional family mem-
bers. In the fine mapping stage, 4q32 provided significant evidence of linkage for the three-point analyses 
(Z(max)=3.6) and 16p12 produced a three-point LOD score of 2.7. Since the identified chromosomal 
regions replicate earlier linkage findings in either bipolar disorder or other mental disorders, they should 
be considered good targets for further genetic analyses. 
 
[9] Fogelholm M, Kronholm E, Kukkonen-Harjula K, Partonen T, Partinen M, Härmä M. Sleep-related 
disturbances and physical inactivity are independently associated with obesity in adults. Int J Obesity 
(advance online publication 19 Jun 2007; doi: 10.1038/sj.ijo.0803663) 
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Objective: To study relationships between obesity, physical inactivity and sleep-related disturbances 
(obstructive sleep apnea (OSA), sleep duration, sleep disturbances concomitant with daytime tiredness) in 
adults (>/=30 years). Design: Cross-sectional study with a random population sample. Participants: A 
total of 3377 men (mean age 52.3, s.d. 14.8, years) and 4264 women (56.4, s.d. 17.2, years).Main out-
come measures: Dependent variables, measured: Waist circumference (WC) and body mass index (BMI). 
Independent variables, from a detailed interview/questionnaire: probable OSA, other sleep-related distur-
bances, sleep duration, type and frequency of leisure physical activity. Age, mental health, smoking and 
education were included in analyses as potential confounders. Results: In men, OSA and physical inactiv-
ity increased likelihood for abdominal obesity (WC >/=102 cm). Physical inactivity also increased, but 
long (>/=9 h/day) sleep decreased likelihood for abdominal overweight (WC: 94-101 cm) in men. In 
women, abdominal obesity (WC >/=88 cm) was associated positively with OSA, moderate sleep-related 
disturbances, and physical inactivity. Education modulated the influence of age on abdominal obesity in 
both genders. Using BMI as the dependent variable did not change the general information obtained by 
the model. In addition, abdominal obesity was found to be an independent risk factor also in multivariable 
models predicting categories of a combined sleep duration and sleep disturbances. Conclusions: Sleep 
duration and sleep-related disturbances are associated with obesity, even after controlling for OSA and 
physical inactivity. The results support the hypothesis of vicious circle between sleep and obesity. 
 
[10] Leppämäki S, Meesters Y, Haukka J, Lönnqvist J, Partonen T. Effect of simulated dawn on quality 
of sleep - a community-based trial. BMC Psychiatry 2003; 3: 14 
 
BACKGROUND: Morning light exposure administered as simulated dawn looks a promising method to 
treat Seasonal Affective Disorder, but it may moreover help with resetting the inaccurate organisation of 
body clock functions relative to sleep occurring in winter among people in general. Disturbances in sleep 
patterns are common and may compromise wellbeing even in the short term. Our hypothesis was that 
simulated dawn could improve the subjective quality of sleep during winter. METHODS: A community-
based trial with 100 volunteer subjects provided with dawn simulators. Study period lasted for eight 
weeks, and subjects used the dawn simulators for two weeks at a time, each subject acting as his own 
control (ABAB-design). Main outcome measure was subjective quality of sleep recorded each morning 
with Groningen Sleep Quality Scale. RESULTS: 77 subjects completed the trial. Quality of sleep im-
proved while subjects were using dawn simulator-devices (p = 0.001). The treatment became beneficial 
after six days' use of dawn simulator, but the effect did not last after the use was ceased. CONCLUSION: 
Dawn simulation may help to improve the subjective quality of sleep, but the benefits are modest. Further 
research is needed to verify these findings and to elucidate the mechanism by which dawn simulation acts 
on the sleep-wake pattern. 
 
[11] Leppämäki SJ, Partonen TT, Hurme J, Haukka JK, Lönnqvist JK. Randomized trial of the efficacy of 
bright-light exposure and aerobic exercise on depressive symptoms and serum lipids. J Clin Psychiatry 
2002; 63: 316-21 
 
BACKGROUND: Season-related subsyndromal depressive symptoms during winter are common among 
populations at high latitudes. Both physical exercise and exposure to bright light can relieve the fatigue 
and downturn of mood associated with the shortening length of day. Serum cholesterol level may be re-
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lated to changes in mood, but the evidence is contradictory. Our objective was to compare the effect of 
aerobic exercise with or without bright-light exposure on health-related quality of life, mood, and serum 
lipids in a sample of relatively healthy adult subjects. METHOD: A randomized controlled trial was con-
ducted with subjects allocated to group aerobics training in a gym with bright light (2500-4000 lux) (N = 
40) or normal illumination (N = 42) or to relaxation/stretching sessions in bright light as a control group 
(N = 42) twice a week for a period of 8 weeks. Changes in mood were recorded using questionnaires at 
the beginning of the study, at weeks 4 and 8. and at follow-up 4 months after the study. A blood sample 
was drawn before and after the 8-week intervention to measure the concentrations of serum lipids. 
RESULTS: Ninety-eight subjects completed the 8-week study. Both exercise and bright light effectively 
relieved depressive symptoms. Bright light reduced atypical depressive symptoms more than exercise (p 
= .03), based on the atypical symptoms subscore of the Structured Interview Guide for the Hamilton De-
pression Rating Scale-Seasonal Affective Disorders Version Self-Rating Format. There were no signifi-
cant differences between the study groups in the changes in serum lipid levels. CONCLUSION: Bright 
light administered twice a week, alone or combined with physical exercise, seems to be a useful interven-
tion for relieving seasonal mood slumps. 
 
[12] Hakkarainen R, Partonen T, Haukka J, Virtamo J, Albanes D, Lönnqvist J. Is low dietary intake of 
omega-3 fatty acids associated with depression? Am J Psychiatry 2004; 161: 567-9 
 
OBJECTIVE: This study examined the association between the dietary intake of omega-3 fatty acids and 
low mood, major depression, and suicide. METHOD: A total of 29,133 men ages 50 to 69 years partici-
pated in a population-based trial in Finland. The intake of fatty acids and fish consumption were calcu-
lated from a diet history questionnaire. Self-reported depressed mood was recorded three times annually, 
data on hospital treatments due to a major depressive disorder were derived from the National Hospital 
Discharge Register, and suicides were identified from death certificates. RESULTS: There were no asso-
ciations between the dietary intake of omega-3 fatty acids or fish consumption and depressed mood, ma-
jor depressive episodes, or suicide. CONCLUSIONS: Dietary intake of omega-3 fatty acids showed no 
association with low mood level. 
 
[13] Partonen T, Haukka J, Virtamo J, Taylor PR, Lönnqvist J. Association of low serum total cholesterol 
with major depression and suicide. Br J Psychiatry 1999; 175: 259-62 
 
BACKGROUND: It has been suggested that low serum total cholesterol is associated with an increased 
risk of suicide. AIMS: To study the association between serum total cholesterol, depression and suicide 
using versatile, prospective data. METHOD: A total of 29,133 men aged 50-69 years were followed up 
for 5-8 years. Baseline blood samples were analysed for serum total and high-density lipoprotein choles-
terol concentrations. Self-reported depression was recorded, data on hospital treatments due to depressive 
disorders were derived from the National Hospital Discharge Register and deaths from suicide were iden-
tified from death certificates. RESULTS: Low serum total cholesterol was associated with low mood and 
subsequently a heightened risk of hospital treatment due to major depressive disorder and of death from 
suicide. CONCLUSIONS: Our results suggest that low serum total cholesterol appears to be associated 
with low mood and thus to predict its serious consequences. 
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[14] Partonen T, Haukka J, Nevanlinna H, Lönnqvist J. Analysis of the seasonal pattern in suicide. J Af-
fect Disord 2004; 81: 133-9 
 
BACKGROUND: Suicide has been attributed to social and psychological factors but also to geophysical 
effects. Of the latter, changes in solar radiation and geomagnetic activities may contribute to the fre-
quency and the seasonal pattern of suicides. METHODS: We studied with a population-based, nationwide 
analysis all the individuals who committed suicide (n=27,469) in Finlandduring the period of 1979 to 
1999. The daily data on the number of suicides, and the mean and maximum levels of geomagnetic activ-
ity were compiled and modelled with Poisson regression using the number of inhabitants in each province 
as the denominator. Time series analysis of monthly numbers of suicides was carried out using a sea-
sonal-trend decomposition procedure. RESULTS: There was a strong seasonal effect on suicide occur-
rence (P<0.00001), the risk of suicide being greatest in spring. The seasonal effect was most pronounced 
when the number of suicides was relatively low. High levels of solar radiation activity were associated 
with the increased risk of suicide (P=0.00001), but the effect of geomagnetic activity was weak. 
LIMITATIONS: No individual data on alcohol consumption or mental disorders were available. 
CONCLUSIONS: Suicide occurrence varies markedly by season and needs attention where prevention is 
concerned. 
 
[15] Valtonen H, Suominen K, Partonen T, Ostamo A, Lönnqvist J. Time patterns of attempted suicide. J 
Affect Disord 2006; 90: 201-7 
 
BACKGROUND: The association of mental disorders with time patterns of attempted suicide is poorly 
understood. METHODS: The study material consisted of all consecutive suicide attempts admitted to 
health care in Helsinki during a one-year period from 15 January 1997 to 14 January 1998. Clinical diag-
nosis was made according to ICD-10. RESULTS: Overall, the rate of suicide attempts varied markedly 
during the study period, peaking in autumn and being lowest during winter. Substance use disorders best 
explained suicide attempts occurring at weekends. There was considerable temporal variation among 
patients with mood disorders, compared to only slight variation among patients with schizophrenia spec-
trum disorders. Study subjects tended to contact health services in the late evening and around midnight. 
Those contacting health services outside normal hours received psychiatric consultation less frequently 
than others and were referred to aftercare less often. LIMITATIONS: Structured Clinical Interviews for 
DSM-IV Axis I and II Disorders were not used. CONCLUSIONS: There were marked time patterns of 
attempted suicide, especially among patients with mood disorders and substance use disorders. This con-
trasted with the limited fluctuation among patients with schizophrenia spectrum disorders. Contacts with 
the health care system occurred most often in the late evening and around midnight. The findings question 
the adequacy of staff numbers for psychiatric consultations and of time to plan aftercare. 
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6.5. Severe Mental Disorders 
 
6.5.1. Research and public health significance of the area 
 
Psychotic disorders are among the most severe and impairing medical diseases: ac-
tive psychosis was ranked the most disabling condition after quadriplegia and dementia 
in a WHO study (Üstun et al 1999). They are also more common than has been as-
sumed: the lifetime prevalence of all psychotic disorders in Finland is 3.48 per cent 
(Perälä et al, 2007). Thus, these disorders are a major public health concern. 
The aetiology of psychotic disorders is multifactorial. Several genes of small effect 
combine with environmental effects to determine the outcome, although rare chromo-
somal abnormalities with major effect are also known (Blackwood et al 2001, Murphy 
et al 2001). The heritability of schizophrenia (Cannon et al 1998, Sullivan et al 2003) 
and bipolar I disorder (Kieseppä et al 2004) exceeds 80 per cent. Environmental factors 
probably account more of the liability than the remaining 20 per cent, since gene-
environment interactions are typically attributed to genetic factors only in heritability 
calculations. Nevertheless, the high heritability of schizophrenia in Western countries 
suggests that genetic factors are currently more important than environmental factors in 
determining who develops schizophrenia or bipolar I disorder. 
The Research Project on Severe Mental Disorders comprises a set of studies focus-
ing on psychotic and other severe mental disorders. Our current scope is broad: we are 
investigating environmental and genetic risk factors and developmental precursors of 
psychotic disorders, prodromal phase of psychosis, epidemiology, comorbidity, and 
treatment of psychotic disorders, and neuropsychological impairments and brain struc-
tural and functional abnormalities related to psychotic disorders and liability to psycho-
sis. The individual studies of the project are briefly described in the following. 
 
The Genetic Epidemiology and Molecular Genetics of Schizophrenia 
The research on the etiology and epidemiology of schizophrenia and other psy-
chotic disorders was initiated at the Department of Mental Health and Alcohol Research 
at the end of 1980s, when the Genetic Epidemiology and Molecular Genetics of Severe 
Mental Disorders -study was started. In the 1990s, we formed, using nationwide health 
care registers, a representative cohort of 33731 persons with schizophrenia born in 
Finland from 1940 to 1976. The first-degree relatives of these individuals were identi-
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fied from the Population Register Center, and information on relatives was linked back 
to the health care registers to obtain information on their treatments and diagnoses. 
Two samples were collected for this population-based genetic study of schizophre-
nia. The first sample consisted of families with at least two siblings with schizophrenia 
from the whole geographical area of Finland. The second sample comprised patients 
and their parents and siblings from families with at least one member with schizophre-
nia from an isolated region in the northern part of the country with an exceptionally 
high lifetime risk (3.2%, Hovatta et al 1997) of schizophrenia. 
About 3400 subjects from one thousand families have participated in the ongoing 
study and have given blood samples for DNA analysis. Approximately one third of 
them have been interviewed using the Structured Clinical Interview for DSM-IV 
(SCID), and administered a neuropsychological test battery. From the remaining af-
fected individuals, we have obtained all case notes from psychiatric treatments, based 
on which we have rediagnosed the persons according to DSM-IV criteria and filled the 
OPCRIT checklist (McGuffin et al 1991). 
 
The Psychoses in Finland -study 
The Psychoses in Finland -study is a comprehensive study on the epidemiology of 
psychotic disorders based on the Health 2000 study, a health survey of a nationally rep-
resentative two-stage cluster sample of 8028 persons aged 30 or over. We used both 
self-report data and information from nationwide health care registers to screen persons 
with possible psychotic disorder. All screen positives and a random sample of screen 
negatives were invited to participate in a reassessment that included the SCID-I inter-
view and a neuropsychological test battery, and 543 participated in the interview. We 
obtained hospital and outpatient case notes from psychiatric and primary care units, 
except for the 6% who refused from the baseline Health 2000 survey. Final diagnostic 
assessment of psychotic disorders was based on DSM-IV-TR criteria and utilized both 
interview and case note data. In addition, comprehensive information on health and 
functional capacity is available from the health examination and interview of the Health 
2000 study, and from several nationwide registers. We identified 249 persons with a 
lifetime diagnosis of psychotic disorder. 
 
The Schizophrenia Twin Study 
A representative sample of monozygotic and dizygotic twin pairs concordant and 
discordant for schizophrenia and demographically similar control pairs from Finnish 
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twins born 1940 through 1990 has been collected as a large collaborative project be-
tween National Public Health Institute and the University of California, Los Angeles. 
The twins have been evaluated using structured psychiatric interviews (SCID I-II, 
SANS, SAPS), neuropsychological testing, and magnetic resonance imaging (MRI), and 
blood samples have been collected for genetic analyses and for determining the zygos-
ity. In addition, positron emission tomography (PET), functional MRI, magnetoen-
cephalography (MEG), and electroencephalography (EEG) have been conducted for a 
number of twin pairs. Approximately 200 twin pairs have been evaluated, and the study 
is still ongoing. 
 
The Helsinki High-Risk Study 
The Helsinki High-Risk Study (HHR) is a follow-up study of offspring born to 
mothers with psychotic disorders, and its aim is to identify developmental precursors of 
psychotic disorders, and to investigate the outcome of children of mothers with psy-
chotic disorder. Mothers (n=161) were identified from all female patients born between 
1916 and 1948 who had been treated because of schizophrenia spectrum psychotic dis-
orders in any of the mental hospitals of the city of Helsinki before 1975. The original 
study sample was limited to offspring born in Helsinki between 1960 and 1964, but we 
have now extended the study to all offspring of these mothers (n=337). Controls are 
previous same-sex births from the same maternity hospitals. Based on the National 
Hospital Discharge Register information, case notes from psychiatric hospital and out-
patient treatments were collected for both parents and offspring and all were rediag-
nosed according to DSM-IV-TR criteria. We filled the OPCRIT checklist (McGuffin et 
al 1991) and the Major Symptoms of Schizophrenia Scale (MSSS) (Kendler et al 1993), 
and collected additional information on the onset, course, and outcome of psychiatric 
disorders. Obstetric records, childhood developmental and school records, and criminal 
records were collected for both HR and control offspring. Information on those parents 
and offspring who had died and their causes of death have been obtained from the Sta-
tistics Finland. 
 
The Prodromal Symptoms of Psychotic Disorders in Adolescent Psychiatric Pa-
tients -study 
The ongoing Prodromal Symptoms of Psychotic Disorders in Adolescent Psychiat-
ric Patients -study was started in 2003, and its objective is to find criteria for identifying 
young people with an emerging psychotic disorder that could be used outside prodromal 
clinics in adolescent psychiatric treatment settings. We screened all patients aged 15 to 
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18 years who sought treatment in adolescent psychiatric units in the Helsinki area using 
the Prodromal Questionnaire (Loewy et al 2005). After that, the screen positive and a 
random sample of screen negative adolescents were interviewed using the Structured 
Interview for Prodromal Symptoms (SIPS) and administered a neuropsychological test 
battery. A 12-month follow-up was made using the same methods. We have permission 
from the adolescents to follow up their inpatient and outpatient treatments for 10 years. 
Brain functional magnetic resonance imaging (fMRI) was conducted to 30 subjects with 
the most severe prodromal symptoms. Thus far, over 400 adolescent patients have been 
screened, and more than 100 have been selected for the interview and neuropsychological 
assessment. In addition, all the instruments have been tested in a pilot study of 80 adoles-
cents in 2002. One branch of the prodromal study investigates predictors of psychotic 
disorders and other adverse outcomes in adolescents (n=53) residing in a reform school. 
 
The Helsinki 1951-1960 Cohort Study 
The Helsinki 1951-1960 cohort study is a cohort study of persons with schizophre-
nia born in Helsinki from 1951 to 1960 that analyses developmental factors that predict 
future development of schizophrenia (Cannon et al 1999), and the onset, course and 
outcome of schizophrenia as well as violent (Cannon et al 2002a) and suicidal behavior. 
The study population consists of all individuals who were born in Helsinki, Finland, 
between January 1, 1951 and December 31, 1960. Individuals with a diagnosis of core 
schizophrenia spectrum disorder (schizophrenia, schizoaffective disorder and schizo-
phreniform disorder, ICD-8 and ICD-9 diagnostic code 295) born during this 10-year 
period were ascertained from three health care registers. Based on hospital case notes, 
we have collected detailed information on symptoms, including the OPCRIT, from all 
subjects from the cohort (n=806) who had been treated because of schizophrenia spec-
trum psychosis (Pihlajamaa et al, in press). 
 
The Finnish Conscript Study on Psychotic Disorders 
The Finnish Conscript Study on Psychotic Disorders is based on a cohort of appar-
ently healthy males conscripted into the Finnish Defense Forces since 1982. Linkage 
with the Finnish Hospital Discharge Register identified conscripts later diagnosed with 
bipolar disorder, schizophrenia, or other psychoses. We have published results on pre-
morbid intellectual functioning in schizophrenia, bipolar disorder and other psychoses 
(Tiihonen et al 2005), and are currently investigating whether personality features, as 
measured by the MMPI, predict these disorders. We are extending the sample to include 
information on kinship (father, uncle, brother) in order to analyse whether genetic or 
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family-related factors modify the association between cognitive performance, personal-
ity features, and psychiatric disorders. 
 
The Peijas Schizophrenia Study 
Our study is a collaboration between the Peijas Outpatient Rehabilitation Unit, the 
Kellokoski Hospital, and the National Public Health Institute. We are creating a longitu-
dinal, cumulative data set of patients with schizophrenia and other psychotic disorders 
that would be used both in clinical work and in research. The idea is similar to the Cumu-
lative Needs for Care Register operating in South Limburg, the Netherlands (van os et al 
2006, Bak et al 2007). We will have a comprehensive baseline assessment, including 
neuropsychological examination, while follow-ups would be done using a smaller set of 
instruments. The data will be incorporated into the electronic hospital record system, and 
will be used to aid clinical work and in outcome studies. The project will also include 
validation of several rating scales and measures in Finnish. If successful, the method will 
be applied more widely at least within the Hospital District of Helsinki and Uusimaa. 
We are currently choosing the assessment methods that will be used in the study. 
The brief Psychiatric Rating Scale (BPRS) and the Health of the Nation Outcomes Scale 
(HoNOS) have been piloted in the Peijas outpatient clinic since February. Both nurses 
and psychiatrists have found the instruments useful and are motivated to use them. We 
are currently selecting the neuropsychological test battery. Our aim is to start data col-
lection in January 2008. 
 
Other studies of the Severe Mental Disorders -project 
The Mental Health in Early Adulthood -study (MEAF) is a follow-up study of the 
young adult sample of the Health 2000 study (N=1894). The study complements the PIF 
study; the two together provide reliable and comprehensive picture on the epidemiology 
of psychotic disorders in Finland. MEAF also provides interesting information on 
schizotypy in the general population. 
Investigation on suicides and mortality in schizophrenia is one of the oldest re-
search branches in the program; studies have been based on the National Suicide Pre-
vention Project study sample (Heilä et al 1997, 1998, 1999a, and 1999b) and on nation-
wide registers (Heilä et al 2005). 
The Viral Infections in the Aetiology of Severe Mental Disorders-study investi-
gates whether viral infections, particularly CNS infections, predispose to later develop-
ment of severe mental disorders. The study utilizes information on clinical samples 
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from 9,836 individuals analysed at the Department of Viral Diseases and Immunology 
during the 1960s and 1970s. Their data have been linked with information from the 
Hospital Discharge Register to identify persons treated for psychotic disorders. 
In addition to these projects, the senior researchers from this project are collabora-
tors in several projects conducted together with the University of Helsinki, the Univer-
sity of Kuopio, the National Research and Development Centre for Welfare and Health 
(Stakes), and the University of Southern California, Los Angeles. 
 
6.5.2. The main scientific achievements 
 
The Genetic Epidemiology and Molecular Genetics of Schizophrenia 
We have been pioneers in using quantitative traits derived from neuropsychological 
tests as vulnerability markers (endophenotypes) in genetic studies. We have investigated 
neuropsychological functions and their heritability in patients and their family members 
(Tuulio-Henriksson et al 2002, Tuulio-Henriksson et al 2003, Tuulio-Henriksson et al 
2004, Kuha et al 2007), and their clustering in families (Hoti et al 2004) and in indi-
viduals (Wessman et al, submitted). Using cognitive domains as quantitative phenotypes 
in a genomewide QTL analysis, the linkage signal enhanced in some previously identi-
fied chromosomal areas (Paunio et al 2004). Our findings related to DISC1 and reelin 
and cognitive functions further demonstrate the usefulness of the endophenotype ap-
proach (Hennah et al 2003, Hennah et al 2005, Wedenoja et al 2007). We have also in-
vestigated the prevalence and characterized the clinical phenotype of schizophrenia in 
the northeastern isolate (Arajärvi et al 2004, Arajärvi et al 2005), and studied growth 
patterns and risk of schizophrenia (Haukka et al, in press). 
We have utilized the register-based cohort of persons with schizophrenia born in 
Finland from 1940 to 1969 in several studies. We have shown that the heritability of 
schizophrenia in Finland in over 80 per cent (Cannon et al 1998), but family-related 
environmental factors also contribute to the risk of schizophrenia (Haukka et al 2004). 
We found that the age at onset is lower and outcome poorer in highly familial than in 
sporadic schizophrenia (Suvisaari et al 1998). We found that fertility is lower in persons 
with schizophrenia, which is not compensated by higher fertility in their siblings 
(Haukka et al 2003). 
Investigating the same cohort, we observed that the incidence of schizophrenia had 
declined in cohorts born in the 1960s, compared with cohorts born in the 1950s (Su-
visaari et al 1999). We have also investigated regional variation in the incidence of 
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schizophrenia, finding strong regional variation but much less urban-rural differences in 
the incidence (Haukka et al 2001). In a set of studies investigating seasonal variation of 
births in schizophrenia (Suvisaari et al 2000, Suvisaari et al 2001, Suvisaari et al 2004) 
and its possible link to polioepidemics (Suvisaari et al 1999a), we found that seasonal 
variation of births in schizophrenia is diminishing, is partly explained by procreational 
habits of the parents, and is not related to genetic risk. We also investigated comorbidity 
between schizophrenia and type 1 diabetes, and found that the risk of schizophrenia is 
considerably lower in persons with type 1 diabetes than in the general population (Ju-
vonen et al in press). 
At the Department of Molecular Medicine, genomewide scans have been con-
ducted at various phases of the study (Hovatta et al 1999, Ekelund et al 2000, Ekelund 
et al 2001, Paunio et al 2001, Ekelund et al 2004, Paunio et al 2004), and six areas of 
particular interest have been identified. Our most promising genetic findings thus far 
have been related to Disrupted in Schizophrenia Gene 1 (DISC1) (Blackwood et al 
2001). We have found (Ekelund et al 2001) and replicated (Ekelund et al 2004) linkage 
to the DISC1 area in Finnish schizophrenia families, and identified an allelic haplotype 
(HEP3) that is associated with increased risk of schizophrenia and visual working mem-
ory function deficits, particularly among males (Hennah et al 2003, Hennah et al 2005). 
We reanalyzed our genome-wide data conditioning on the DISC1 HEP3 haplotype and 
identified a DISC1 interacting protein, NDE1, that also associates with schizophrenia 
and visual working memory functions (Hennah et al 2007). We are currently investigat-
ing the genes of the binding proteins of the DISC1 further, and also the cellular expres-
sion of the DISC1. Another chromosomal area of particular interest is 7q22 (Ekelund et 
al 2000). Within this area, we have observed an allelic variant in the reelin gene that is 
associated with lower function in tests measuring working memory, memory, and ex-
ecutive functioning (Wedenoja et al, in press). 
Recently, a whole-genome association study was performed on 200 persons with 
schizophrenia, and 200 controls from our general population studies, revealing a novel 
genetic deletion associated with schizophrenia in the isolate families. The most promis-
ing findings from this study are currently being investigated in a larger association study 
sample. 
 
The Psychosis in Finland study 
The Psychosis in Finland study was the first study to report prevalences of all 
DSM-IV psychotic disorders from one country. The lifetime prevalence of psychotic 
disorders in the PIF study sample, 3.48%, is substantially higher than in other recent 
population surveys, possibly because we were able to use register data for case ascer-
95 
tainment and had access to case notes. However, the lifetime prevalence of schizophre-
nia (1.0%) and non-affective psychotic disorders (2.29%) is so high that it may be these 
disorders genuinely are more prevalent in Finland than in most other countries. (Perälä 
et al 2007) 
Investigating results from neuropsychological measurement, we found that persons 
with schizophrenia had a generalized cognitive impairment, persons with other non-
affective psychoses showed memory and processing speed deficits, persons with major 
depressive disorders were impaired in processing speed, while persons with bipolar dis-
orders showed no dysfunction as compared with a control group derived from the same 
study sample. (Tuulio-Henriksson et al, submitted) 
The prevalence of type 2 diabetes in persons with schizophrenia (22.0%) and other 
nonaffective psychotic disorders (ONAP) (13.4%) was considerably higher than in the 
general population (6.1%) (Suvisaari, Perälä et al in press). Also the prevalence of 
metabolic syndrome was high in these groups (36.2% and 41.4% vs. 30.1% in the gen-
eral population) (Suvisaari, Saarni et al in press), and persons with schizophrenia had 
high prevalence of coronary heart disease as well (14.8% vs. 10.8% in the general popu-
lation). In contrast, persons with affective psychoses did not have increased prevalence 
of these disorders. Medical comorbidity in persons with schizophrenia and in some 
variables also in persons with other nonaffective psychotic disorder was even more 
striking when continuous variables rather than dichotomized diagnoses were examined. 
Compared with persons without any psychotic disorder, persons with schizophrenia had 
significantly higher fasting plasma glucose, insulin, and triglyceride levels, lower HDL 
cholesterol level, larger waist circumference and lower bone ultrasound attunement 
value, suggesting lower bone mineral density. Persons with ONAP had larger waist cir-
cumference and higher body mass index, while persons with affective psychoses had 
larger waist circumference but also lower systolic blood pressure. When detailed body 
composition was investigated by bioimpedance, schizophrenia and other nonaffective 
psychotic disorders were associated with high fat percentage, and schizophrenia also 
with low fat free mass. Schizophrenia was strongly associated with abdominal obesity 
even after controlling for body mass index, suggesting a particular vulnerability to ab-
dominal obesity in persons with schizophrenia. 
Another important area in the Psychoses in Finland -study is the examination of 
functional disability. We found that after adjusting for age and sex, schizophrenia was 
associated with 5-fold odds of having visual impairment for distance, and 6-fold for 
impaired near vision, while other psychotic disorders were not (Viertiö et al, submitted). 
Schizophrenia is also associated with poor physical condition, and problems with mo-
bility and activities of daily living. 
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The Schizophrenia Twin Study 
We have investigated the inheritance of neuropsychological dysfunction in twins 
discordant for schizophrenia (Cannon et al 2000), the effect of genetic liability and ill-
ness on regional cortical gray-matter deficits (Cannon et al 2002), and more specifically, 
on hippocampus (van Erp et al 2004). We have also investigated how brain structure is 
influenced by individual genetic differences in general (Thompson et al 2001). We have 
shown that genetic liability to schizophrenia is associated with caudate D2 upregulation 
(Hirvonen et al 2005) and P50 and N100 decrease (Ahveninen et al 2006). When com-
paring cognitive functions in bipolar and schizophrenia twin, deficits in spatial working 
memory were related to genetic liability for schizophrenia but not bipolar I disorder, 
suggesting that they are specific to genetic liability to schizophrenia (Pirkola et al 2005). 
We also found in our schizophrenia twin sample two haplotypes within the DISC1 gene 
that were significantly overrepresented among individuals with schizophrenia and were 
associated with impairments in several memory functions and reduced gray matter den-
sity in the prefrontal cortex (Cannon et al 2005). 
 
The Helsinki high-risk study 
From the original sample consisting of 179 offspring, we have reported the cumula-
tive incidences of mental disorders, relationship of maternal symptoms to offspring's 
risk of developing psychotic disorders, and childhood developmental factors that predict 
the development of psychotic disorders in the offspring (Niemi et al 2004a, Niemi et al 
2004b, Niemi et al 2005a, Niemi et al 2005b). Among the HR offspring, social adjust-
ment problems at pre-school age and severe neurological symptoms predicted future 
schizophrenia spectrum disorder, while school-age behavioral and emotional problems 
predict the development of non-psychotic disorders (Niemi et al 2005a). Within HR 
children, the combination of being in the lowest tertile for ponderal index at birth but 
having BMI in the highest tertile at seven years predicted future schizophrenia spectrum 
disorder (Niemi et al 2005). Of maternal symptoms, only positive symptoms predicted 
offspring's risk for schizophrenia spectrum disorders, being inversely related to off-
spring's risk (Niemi et al 2004b). More recently, we have investigated whether school 
achievement predicts later development of mental disorders. 
From the extended sample, we have investigated findings on offspring's mortality, 
which was over two-fold higher in the high-risk offspring than in the general popula-
tion. Within the high-risk group, having been diagnosed with a psychotic disorder was 
associated with higher mortality from unnatural causes, and maternal suicide attempts 
strongly predicted offspring's suicide. (Suvisaari et al, submitted) 
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The Helsinki 1951-1960 Cohort Study 
In this cohort, poor performance in non-academic subjects at ages 7-10 years pre-
dicted later development of schizophrenia (Cannon et al 1999). Poor educational at-
tainment, poor grades for attention at school, higher birth weight and larger head cir-
cumference were significantly associated with the risk of criminal offending in adult-
hood in persons with schizophrenia (Cannon M et al 2002). The validity of register-
based schizophrenia spectrum diagnosis compared with case note -based OPCRIT diag-
nosis was found to be good in the largest validation study of hospital discharge register 
schizophrenia diagnosis ever conducted (Pihlajamaa et al, in press). 
 
The Finnish Conscript Study on Psychotic Disorders 
We found that poor performance on test assessing visuospatial reasoning was asso-
ciated with increased risk of schizophrenia, other psychotic disorders, and bipolar I dis-
order. In contrast, good performance in the test measuring arithmetic reasoning pre-
dicted higher risk of bipolar I disorder. (Tiihonen et al 2005) 
 
Other studies of the project 
Hannele Heilä has investigated clinical characteristics and antecedents of suicide in 
persons with schizophrenia (Heilä et al 1997, 1998, 1999a, 1999b). She found that sui-
cide was usually committed during an active phase of the illness, patients often had de-
pressive symptoms, one-third of patients were receiving inpatient care, and over half of 
patients were not prescribed antipsychotic medication or they were not using it. Suicide 
risk is highest during the first five years after the onset of the illness (Heilä et al 2005). 
In a previous study using a subset of the Viral Infections in the Aetiology of Severe 
Mental Disorders-study sample, we found no association between childhood viral CNS 
infection and later development of schizophrenia (Suvisaari et al 2003). In the future, 
we will be able to investigate the effect of different causative agents separately. 
 
6.5.3. The main public health achievements 
 
Our collaboration with clinicians in the Peijas area to develop systematic assess-
ment and longitudinal follow-up of patients with schizophrenic psychoses has involved 
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training and supervision of clinicians. The project will involve validation of several 
psychiatric rating scales and measures in Finnish for clinical use. It may in the future be 
linked to a wider project aiming at specifying a core set of psychiatric instruments for 
clinical use throughout the country, and developing an internet-based training instru-
ment for them. 
Our prodromal study has introduced the prodromal concept and its assessment 
methods to adolescent psychiatric treatment settings in Helsinki. The clinicians have 
found both the assessment of prodromal features and neuropsychological testing very 
useful. Our researchers have taught and supervised clinical psychologists and psychia-
trists in their use. The collaboration has benefited both parties. 
The senior researchers of the project are active lecturers in universities and hospi-
tals throughout Finland, and supervise doctoral theses in several Finnish universities. 
Jaana Suvisaari also organizes training concerning psychotic disorders of residents in 
psychiatry at the University of Helsinki. 
 
6.5.4. Funding for research and public health programs 
 
Jaana Suvisaari and Annamari Tuulio-Henriksson have positions from the Acad-
emy of Finland that include funding for their research projects as well. Three studies, 
The Genetic Epidemiology and Molecular Genetics of Schizophrenia, The Prodromal 
Symptoms of Psychotic Disorders in Adolescent Psychiatric Patients, and the Mental 
Health in Early Adolescence, receive currently funding from the Academy of Finland. 
The Academy has also funded the Psychoses in Finland -study from 2003 to 2006. The 
tiwn study is funded by the National Institute of Health. In addition, our PhD students 
have funding from several Finnish foundations. 
 
6.5.5. Personnel 
 
Docent Jaana Suvisaari, MD, PhD, psychiatrist, is the leader of the project and is 
involved in most of the individual studies, being the principal investigator of the PIF 
and MEAF studies. Other key senior scientists in several studies are docent Annamari 
Tuulio-Henriksson, PhD, psychologist, docent Jari Haukka, PhD, epidemiologist and 
statistician, and professor Jouko Lönnqvist, MD, PhD. Annamari Tuulio-Henriksson is 
the senior researcher leading and supervising neuropsychological investigations in most 
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of the studies in the Severe Mental Disorders -project and in other research projects 
conducted at the Department of Mental Health and Alcohol Research as well as the re-
search on quantitative traits at the Department of Molecular Medicine. Jari Haukka su-
pervises or conducts statistical analyses in many of these studies, besides leading a reg-
ister-based epidemiological research branch at the department. Professor Jouko 
Lönnqvist launched the Genetic Epidemiology and Molecular Genetics of Schizophre-
nia -study and is its principal investigator. He is involved in all studies of the project, 
and is also the principal investigator of the twin study in Finland. Other senior scientists 
in the project are Laura Häkkinen (former Niemi), who is the principal investigator of the 
Helsinki High-Risk Study, and Matti Huttunen, who works as a senior scientist in the twin 
study, and is the principal investigator of the prodromal study. Other senior scientists of 
the department, particularly docent Timo Partonen, MD, PhD, docent Kimmo Kuop-
pasalmi, MD, PhD, docent Sami Pirkola, MD, PhD, Dr. Hannele Heilä, MD, PhD, and 
professor Erkki Isometsä, MD, PhD, collaborate with us in some of the studies. 
Kirsi Niinistö, BA, is our research assistant, Tuula Mononen works in the Genetic 
Epidemiology and Molecular Genetics of Schizophrenia -study as research nurse, and 
Ulla Mustonen, BA, works as a clinical coordinator in the twin and prodromal studies. 
 
PhD students 
The Genetic Epidemiology and Molecular Genetics of Schizophrenia 
Annamaria Kuha, MPsych, and Minna Torniainen, MPsych, are preparing their PhD 
theses on cognitive functioning in persons with schizophrenia and their unaffected rela-
tives, and on the relationship between cognitive functions and other phenotypic features. 
 
The Psychoses in Finland -study 
There are five PhD students in the Psychoses in Finland -study: Jonna Perälä, MD, 
whose thesis focuses on the prevalence and comorbidity of different psychotic disorders 
and their regional and sociodemographic variation, Samuli Saarni, MD, MSocSc, whose 
thesis relates to health-related quality of life and its determinants, Annakaija Helén, 
MD, who investigates neuropsychological deficits and their role in determining the 
functional outcome of psychotic disorders, Satu Viertiö, MSc (Health), who investigates 
functional capacity among persons with psychotic disorders, and Krista Partti, BMed, 
who studies medical comorbidity in psychotic disorders. 
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The Helsinki High-Risk Study 
Yrjö Lähteenlahti, MD, is preparing his thesis on the association between maternal 
and offspring's symptoms and on criminal behavior and its predictors in the offspring. 
 
The Prodromal Symptoms of Psychotic Disorders in Adolescent Psychiatric Pa-
tients -study 
Sebastian Therman, MPsych, is doing his PhD on the relationship between neuro-
psychological performance and prepsychotic symptoms, and their value in predicting 
who will develop psychosis in the follow-up, and on the structure of psychosis prone-
ness. Marko Manninen, MPsych, is preparing his thesis based on the reform school 
study sample, investigating psychiatric morbidity and symptoms and neuropsychologi-
cal functioning in reform school adolescents, and their association with outcome. 
 
The Cohort Study of Persons with Schizophrenia Born in Helsinki During 1951-1960 
Johanna Pihlajamaa is preparing her PhD thesis on total and suicide mortality and 
its predictors in schizophrenia spectrum psychoses. 
 
Other studies of the project 
Anu Castaneda, MPsych, is doing her PhD on the relationship between neuropsy-
chological performance and anxiety and depressive disorders, and Antti Latvala, 
MPsych, on predictors and consequences cannabis use based on the Mental Health in 
Early Adulthood study sample. Sini Lähteenmäki, BMed, is preparing her PhD on eat-
ing disorders and disordered eating behavior based on the same study sample. Although 
these studies are focused on non-psychotic disorders, the senior researchers of the pro-
ject (Suvisaari or Tuulio-Henriksson) supervise these theses. 
 
6.5.6. Collaboration 
 
We have ongoing collaboration with the departments of Molecular Medicine (prof. 
Leena Peltonen-Palotie and her group), Health and Functional Capacity (prof. Antti 
Reunanen, docent Seppo Koskinen, docent Markku Heliövaara and their groups), and 
Viral Diseases and Immunology in our institute (prof. Tapani Hovi), with professor Ja-
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akko Kaprio and his twin study group at the Department of Public Health at the Univer-
sity of Helsinki, with other Finnish universities, particularly with prof. Jari Tiihonen 
from the University of Kuopio and with prof. Jarmo Hietala and his group from the 
University of Turku, with prof. Tyrone Cannon and prof. Arthur Toga and their groups 
at the UCLA, and with Dr. Mary Cannon at the University of Dublin. Professor Leena 
Peltonen-Palotie is the other principal investigator of the Genetic Epidemiology and 
Molecular Genetics of Schizophrenia -study, and professor Tyrone Cannon is the prin-
cipal investigator of the twin study. 
 
6.5.7. Proposal for future work and expected benefits 
 
Proposal for future work 
In the Genetic Epidemiology and Molecular Genetics of Schizophrenia, we con-
tinue analysing our previously identified candidate genetic areas and the identified can-
didate genes and their association with clinical phenotypes and quantitative traits. Our 
particular interest is presently on the deletion detected in the genomewide association 
study. We will continue collecting families, focusing on families with identified risk 
alleles or chromosomal abnormalities. We are currently interviewing and testing a ran-
dom control sample from the isolate. We continue investigating neuropsychological 
functioning in these families, and the association between cognitive and clinical fea-
tures. We also investigate how psychotropic medication affects cognitive functions. The 
aim is to identify those cognitive features that are most tightly linked to genetic risk of 
schizophrenia. 
In the PIF study, we will characterize the epidemiology and treatment of different 
psychotic disorders, e.g. delusional disorder and substance-induced psychotic disorders, 
further. We continue investigating medical comorbidity and functional disability in psy-
chotic disorders. We will investigate mortality and its predictors in psychotic disorders. 
We will further examine the associations between cognitive functions and clinical 
symptomatology, functional disability, and comorbidity. We will also investigate psy-
chotic-like symptoms and their correlates in the Health 2000 study sample. The sample 
will be used in genetic studies to investigate some candidate genes of psychotic disor-
ders and also of the most comorbid medical conditions. We will participate in future 
follow-ups of the Health 2000 study sample, the first of which will be conducted in 
2008-2009. 
In the twin study, we will continue analysing candidate genes of interest in relation 
to the CNS phenotypes obtained on the sample, and will also integrate gene expression 
102 
data into this research. In addition, the proteomic and metabolomic profile of the twins 
will be analysed to search for relevant biomarkers for schizophrenia. 
Clinical assessments in the prodromal symptoms of psychotic disorders in adoles-
cent psychiatric patients -study will continue for 2.5 years. We aim to investigate 
whether prodromal criteria are able to identify adolescents at high risk for psychotic 
disorders, and if not, whether they could be modified to have better predictive value. 
We also investigate the significance of different neuropsychological deficits in predict-
ing the clinical outcome of treatment-seeking adolescents. 
In the Helsinki high-risk study, we will continue investigating predictors of adult 
psychiatric disorders, criminality, and mortality in offspring of mothers with psychotic 
disorder. Clinical and developmental predictors of suicide and other types of mortality 
is also the main focus currently in the Helsinki 1951-1960 cohort study. 
The Peijas Schizophrenia Study will be started in 2008. The aim is to have longitu-
dinal information on the course of schizophrenia and other psychotic disorders and fac-
tors affecting the outcome. Through this study in particular, the project will maintain its 
link to clinical work and to the development of treatment of psychotic disorders. 
 
Expected benefits 
Because of our large, epidemiologically representative, carefully assessed study 
samples, our studies may provide unique information on the etiology of psychotic dis-
orders. We also provide information on the quality of life, comorbidity, and functional 
disability that persons with psychotic disorder living in the community have, and the 
treatment they receive. Such information is essential for developing health care for per-
sons with psychotic disorders. Our results concerning premorbid developmental prob-
lems give information on which types of problems are particularly alarming in connec-
tion with genetic high-risk, which is useful when systems for supporting children who 
have parents with severe mental disorders are being developed. The prodromal study 
produces vital information on whether psychiatric symptoms and problems in neuro-
cognitive domains can predict future development of psychotic disorders in treatment-
seeking adolescents and thus enable the identification of ultra high-risk persons. In 
Finland, we provide information on the prevalence of psychotic disorders and the 
health, treatment, and needs of persons suffering from them. We educate clinical work-
ers by distributing results from evidence based studies, and participate in the develop-
ment of mental health care systems. 
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 6.5.8. The most important publications of the project in years 1997-2007 
Juvonen H, Reunanen A, Haukka J, Muhonen M, Suvisaari J, Arajärvi R, Partonen T, Lönnqvist J. Inci-
dence of schizophrenia in a nationwide cohort of patients with type 1 diabetes mellitus. Archives of Gen-
eral Psychiatry; in press 
Department of Mental Health and Alcohol Research, National Public Health Institute, Mannerheimintie 
166, 00300 Helsinki, Finland. hannu.juvonen@ktl.fi. 
CONTEXT: Patients with schizophrenia have an increased risk of type 2 diabetes mellitus. However, 
very few studies have dealt with the association of type 1 diabetes and schizophrenia. Preliminary evi-
dence points to a possible inverse association. OBJECTIVE: To investigate the incidence of schizophre-
nia in a nationwide cohort of patients with type 1 diabetes born in 1950 through 1959 in Finland. 
DESIGN: A cohort study of individuals born in 1950 through 1959 with a follow-up of 1969 through 
1991. SETTING: Finland. Patients All individuals born in 1950 through 1959 with type 1 diabetes were 
identified through nationwide registers. The incidence of schizophrenia until 1992 among the total 1950-
1959 cohort and in individuals with type 1 diabetes was calculated using information from 3 health care 
registers. Main Outcome Measure Incidence of schizophrenia. RESULTS: The incidence of schizophrenia 
was 0.21 per 10 000 person-years in the group with type 1 diabetes and 0.56 per 10 000 person-years in 
the group without type 1 diabetes (P < .001). CONCLUSION: The incidence of schizophrenia is de-
creased in patients with type 1 diabetes. 
Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, Partonen T, Tuulio-Henriksson A, 
Hintikka J, Kieseppä T, Härkänen T, Koskinen S, Lönnqvist J. Lifetime prevalence of psychotic and 
bipolar I disorders in a general population. Archives of General Psychiatry 2007;64:19-28. 
Department of Mental Health and Alcohol Research, National Public Health Institute, University of Hel-
sinki, Mannerheimintie 166, 0300 Helsinki, Finland. jonna.perala@ktl.fi 
CONTEXT: Recent general population surveys of psychotic disorders have found low lifetime preva-
lences. However, this may be owing to methodological problems. Few studies have reported the preva-
lences of all specific psychotic disorders. OBJECTIVE: To provide reliable estimates of the lifetime 
prevalences of specific psychotic disorders. DESIGN: General population survey. SETTING AND 
PARTICIPANTS: A nationally representative sample of 8028 persons 30 years or older was screened for 
psychotic and bipolar I disorders using the Composite International Diagnostic Interview, self-reported 
diagnoses, medical examination, and national registers. Those selected by the screens were then re-
interviewed with the Structured Clinical Interview for DSM-IV. Best-estimate DSM-IV diagnoses were 
formed by combining the interview and case note data. Register diagnoses were used to estimate the ef-
fect of the nonresponders. MAIN OUTCOME MEASURES: Diagnosis of any psychotic or bipolar I 
disorder according to the DSM-IV criteria. RESULTS: The lifetime prevalence of all psychotic disorders 
was 3.06% and rose to 3.48% when register diagnoses of the nonresponder group were included. Lifetime 
prevalences were as follows: 0.87% for schizophrenia, 0.32% for schizoaffective disorder, 0.07% for 
schizophreniform disorder, 0.18% for delusional disorder, 0.24% for bipolar I disorder, 0.35% for major 
depressive disorder with psychotic features, 0.42% for substance-induced psychotic disorders, and 0.21% 
for psychotic disorders due to a general medical condition. The National Hospital Discharge Register was 
the most reliable of the screens (kappa = 0.80). Case notes supplementing the interviews were essential 
for specific diagnoses of psychotic disorders. CONCLUSIONS: Multiple sources of information are es-
sential for accurate estimation of lifetime prevalences of psychotic disorders. The use of comprehensive 
methods reveals that their lifetime prevalence exceeds 3%. 
Cannon TD, Hennah W, van Erp TG, Thompson PM, Lonnqvist J, Huttunen M, Gasperoni T, Tuulio-
Henriksson A, Pirkola T, Toga AW, Kaprio J, Mazziotta J, Peltonen L. Association of DISC1/TRAX 
haplotypes with schizophrenia, reduced prefrontal gray 
matter, and impaired short- and long-term memory. Archives of General Psychiatry 2005;62:1205-13 
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Department of Psychology, 1285 Franz Hall, University of California-Los Angeles, Los Angeles, CA 
90095, USA. cannon@psych.ucla.edu 
CONTEXT: Chromosome 1q42 is among several genomic regions showing replicated evidence of link-
age with schizophrenia, but the specific susceptibility mechanisms underlying this relationship remain to 
be identified. OBJECTIVE: To examine a series of haplotype blocks of single-nucleotide polymorphic 
markers from a segment of 1q42 spanning the disrupted-in-schizophrenia 1 (DISC1) and translin-
associated factor X (TRAX) genes for association with schizophrenia and several endophenotypic traits 
thought to be involved in disease pathogenesis. DESIGN: Population-based twin cohort study. SETTING: 
Finland. PARTICIPANTS: Two hundred thirty-six subjects, consisting of 7 twin pairs concordant for 
schizophrenia (6 monozygotic [MZ] and 1 dizygotic [DZ]), 52 pairs discordant for schizophrenia (20 MZ 
and 32 DZ), and 59 demographically balanced normal pairs (28 MZ and 31 DZ), were drawn from a twin 
cohort consisting of all of the same-sex twins born in Finland from 1940 through 1957. MAIN 
OUTCOME MEASURES: Psychiatric diagnosis, performance on neurocognitive tests of short- and long-
term memory, and gray matter volume measurements taken from high-resolution magnetic resonance 
images. RESULTS: A common haplotype incorporating 3 single-nucleotide polymorphic markers near 
the translocation break point of DISC1 (odds ratio, 2.6 [P = .02]) and a rare haplotype incorporating 4 
markers from the DISC1 and TRAX genes (odds ratio, 13.0 [P = .001]) were significantly overrepre-
sented among individuals with schizophrenia. These haplotypes were also associated with several quanti-
tative endophenotypic traits previously observed to covary with schizophrenia and genetic liability to 
schizophrenia, including impairments in short- and long-term memory functioning and reduced gray 
matter density in the prefrontal cortex, as demonstrated using a population-based brain atlas method, with 
a trend toward association with reduced hippocampal volume. CONCLUSIONS: Specific alleles of the 
DISC1 and TRAX genes on 1q42 appear to contribute to genetic risk for schizophrenia through disruptive 
effects on the structure and function of the prefrontal cortex, medial temporal lobe, and other brain re-
gions. These effects are consistent with their production of proteins that play roles in neuritic outgrowth, 
neuronal migration, synaptogenesis, and glutamatergic neurotransmission. 
Hennah W, Tuulio-Henriksson A, Paunio T, Ekelund J, Varilo T, Partonen T, Cannon TD, Lönnqvist J, 
Peltonen L. A haplotype within the DISC1 gene is associated with visual memory functions in families 
with a high density of schizophrenia. Molecular Psychiatry 2005;10:1097-1103. 
Department of Molecular Medicine, National Public Health Institute, Helsinki, Finland. 
We have previously reported evidence of linkage and association between markers on 1q42 and schizo-
phrenia in a study sample of 498 multiply affected Finnish nuclear families, leading to the recent identifi-
cation of four significantly associated haplotypes that specifically implicate the Translin-Associated Fac-
tor X (TRAX) and Disrupted in Schizophrenia 1 and 2 (DISC1 and DISC2) genes in the genetic etiology 
of schizophrenia. Previously, the DISC genes were found to be disrupted by a balanced translocation 
(1;11)(q42.1;q14.3) that cosegregated with schizophrenia and related disorders in a large Scottish pedi-
gree. Interestingly, we also reported earlier suggestive linkage between endophenotypic quantitative traits 
of visual and verbal memory and microsatellite markers in close proximity to TRAX/DISC, on 1q41. 
Here, we tested if the identified allelic haplotypes of TRAX/DISC would be associated with visual and/or 
verbal memory function impairments that are known to aggregate with schizophrenia in families. One 
haplotype of DISC1, HEP3, displayed association with poorer performance on tests assessing short-term 
visual memory and attention. Analysis of affected and unaffected offspring separately revealed that both 
samples contribute to the observed association to visual working memory. These results provide genetic 
support to the view that the DISC1 gene contributes to sensitivity to schizophrenia and associated distur-
bances and affects short-term visual memory functions. This finding should stimulate studies aiming at 
the molecular characterization of how the specific alleles of DISC1 affect the visual memory functions 
and eventually participates in the development of schizophrenia. 
Niemi LT, Suvisaari JM, Haukka JK, Wrede G, Lönnqvist JK. Cumulative incidence of mental disorders 
among offspring of mothers with psychotic disorder: Results from the Helsinki High-Risk Study. British 
Journal of Psychiatry 2004; 185:11-17 
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Department of Mental Health and Alcohol Research, KTL, National Public Health Institute, Helsinki, 
Finland. laura.niemi@ktl.fi 
BACKGROUND: The Helsinki High-Risk Study follows up all women born between 1916 and 1948 and 
treated for schizophrenia-spectrum disorders in psychiatric hospitals in Helsinki, their offspring born 
between 1960 and 1964, and controls. AIMS: To determine the cumulative incidence of adulthood Axis I 
disorders among offspring. METHOD: Using all hospital and out-patient treatment records we rediag-
nosed parents and offspring according to DSM-IV-TR criteria. Offspring were grouped by mother's diag-
nosis (schizophrenia n=104, schizoaffective disorder n=20, other schizophrenia-spectrum disorder n=30, 
and affective disorder n=25) and compared with a control group (n=176). The cumulative incidences of 
Axis I disorders among offspring were calculated. RESULTS: The cumulative incidences of any psy-
chotic disorder were 13.5%, 10.0%, 10.0%, 4.0% and 1.1% among offspring of mothers with schizophre-
nia, schizo-affective disorder, other schizophrenia-spectrum disorders, affective disorders and controls, 
respectively. The corresponding figures for schizophrenia were 6.7%, 5.0%, 6.7%, 0% and 0.6%, and for 
any mental disorder 23.1%, 20.0%, 20.0%, 12.0% and 6.9%. CONCLUSIONS: Offspring of mothers 
with a psychotic disorder have heightened risk of developing a wide range of severe mental disorders. 
Paunio T, Tuulio-Henriksson A, Hiekkalinna T, Perola M, Varilo T, Partonen T, Cannon TD, Lonnqvist 
J, Peltonen L. Search for cognitive trait components of schizophrenia reveals a locus for verbal learning 
and memory on 4q and for visual working memory on 2q. Human Molecular Genetics 2004;13:1693-702. 
Department of Molecular Medicine, National Public Health Institute, Helsinki, Finland. ti-
ina.paunio@ktl.fi 
Research to identify predisposing genes for complex diseases relying solely on clinical diagnosis is probably 
not ideal. Here, we analyzed genome-wide data for 168 schizophrenia families using neuropsychological 
variables associated with disease susceptibility, with the aid of SOLAR, a program for variance-component 
analysis. The linkage signal was greatly accentuated by application of the quantitative traits compared with 
diagnosis. We found evidence for a locus for verbal learning and memory on 4q21 (Z=3.01, Z(mp)=3.84 
and empiric P=0.031 for delayed memory; Z=2.96, Z(mp)=3.4 and P=0.026 for verbal learning) and sugges-
tive evidence for visual working memory on 2q36 (Z=2.80, Z(mp)=2.08 and P=0.093). In addition, some 
evidence emerged for a locus for recognition memory on 10p13, visual attention on 15q22 and executive 
function on 9p22 in the complete sample, as well as for delayed memory on 8q12, semantic clustering and 
intrusions on 1q42 and visual attention on 3p25 in the genealogically distinctive sample subsets. Of the loci 
linked to schizophrenia in diverse populations, in addition to the earlier mentioned regions, some evidence 
of linkage was observed for 2q, 6q, 7q, 11q, 13q, 14q, 18q and 22q. Our results reveal initial information on 
the effect of the loci associated with schizophrenia in multiple studies, and emphasize the value of trait com-
ponents in the search for susceptibility loci for complex diseases. 
Haukka J, Suvisaari J, Lönnqvist J. Fertility of patients with schizophrenia, their siblings, and the general popu-
lation: a cohort study from 1950 to 1959 in Finland. American Journal of Psychiatry 2003;160:460-463. 
Kansanterveyslaitos, National Public Health Institute, Helsinki, Finland. jari.haukka@ktl.fi 
OBJECTIVE: Genetic factors are the most important risk factors for schizophrenia. However, despite the 
fact that patients with schizophrenia have significantly fewer offspring than the general population, 
schizophrenia persists. The authors investigated whether the siblings of patients with schizophrenia pro-
duce more offspring, thereby compensating for the low fertility of the affected individuals. METHOD: 
From all 870,093 individuals born in Finland from 1950 to 1959, the authors determined how many had 
schizophrenia or were siblings of schizophrenia patients and how many offspring they had. The popula-
tion data were obtained from the Population Register Center of Finland, and the National Hospital Dis-
charge Register was used to identify all persons who had been hospitalized because of schizophrenia. 
Appropriate regression models were used to model age at the birth of the first child, number of children, 
and proportion of males among offspring. RESULTS: Of the total population, 1.3% were patients with 
schizophrenia, and 2.8% were their siblings. The mean number of offspring among female siblings was 
slightly but significantly higher than among women in the general population (1.89 versus 1.83), while 
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the opposite was true for the male siblings (1.57 versus 1.65 among men in the general population). The 
mean number of offspring among patients with schizophrenia was 0.83 for women and 0.44 for men. 
CONCLUSIONS: Lower than average fertility among patients with schizophrenia is not compensated for 
by higher fertility among their siblings. Thus, the persistence of schizophrenia in the general population is 
not explained by this simple evolutionary mechanism. 
Suvisaari J, Mautemps N, Haukka J, Hovi T, Lönnqvist J. Childhood central nervous system viral infec-
tions and adult schizophrenia. American Journal of Psychiatry 2003;160:1183-1185. 
Department of Mental Health and Alcohol Research and the Deparment of Virology, National Puablic 
Health Institute, Helsinki, Finland. jaana.suvisaari@ktl.fi 
OBJECTIVE: An earlier Finnish cohort study suggested that childhood viral CNS infections are associated 
with a fivefold increased odds of developing schizophrenia in adulthood. The authors sought to replicate this 
finding. METHOD: From the archives of the Department of Virology of the National Public Health Institute 
in Finland, 320 individuals born between 1960 and 1976 who had suffered virologically confirmed CNS 
infections before their 15th birthdays were identified. Of the infections, 202 had been caused by enterovi-
ruses. The sample was followed up in the 1969-2000 records of the National Hospital Discharge Register of 
Finland to identify all cases of schizophrenia that emerged. RESULTS: The cumulative incidence of schizo-
phrenia was 0.94% in the whole sample and 0.99% among individuals who had suffered enteroviral infec-
tions. These rates are comparable to that found in the general population. CONCLUSIONS: Childhood viral 
CNS infections were not associated with increased risk of schizophrenia. 
Tuulio-Henriksson A, Arajarvi R, Partonen T, Haukka J, Varilo T, Schreck M, Cannon T, Lönnqvist J. 
Familial loading associates with impairment in visual span among healthy siblings of schizophrenia pa-
tients. Biological Psychiatry 2003;54:623-628. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
BACKGROUND: The effect of familial loading on neurocognitive deficits in relatives of schizophrenia 
patients has been detected in family and twin studies. The present study examined this effect among healthy 
siblings of schizophrenia patients in a Finnish isolate with high prevalence of schizophrenia. METHODS: 
We assessed performance in verbal and visual span tasks, in tests measuring intelligence, and in declarative 
verbal memory and learning tasks in 31 and 67 healthy siblings from families with one schizophrenia pa-
tient, or with two or more patients, respectively. The differences between the groups were tested using linear 
mixed effects models. RESULTS: An effect of familial loading was detected in the backward visual span 
task, measuring immediate visual memory with requirements from the visual domain of working memory. 
In this task, the healthy siblings from multiply affected families performed worse than those from the single-
ton families. CONCLUSIONS: The finding that the multiplex vs. singleton differences were selective to the 
backward visual span task, strengthens the view that the visual domain of working memory may provide a 
valuable endophenotypic marker for genetic schizophrenia studies. 
Thompson PM, Cannon TD, Narr KL, van Erp T, Poutanen V-P, Huttunen M, Lönnqvist J, 
Standertskjöld-Nordenstam C-G, Kaprio J, Khaledy M, Dail R, Zoumalan CI, Toga AW. Genetic influ-
ences on brain structure. Nature Neuroscience 2001;4:1253-1258. 
Laboratory of Neuro Imaging and Brain Mapping Division, Department of Neurology, UCLA School of 
Medicine, 710 Westwood Plaza, Los Angeles, California 90095-1769, USA. thompson@loni.ucla.edu 
Here we report on detailed three-dimensional maps revealing how brain structure is influenced by indi-
vidual genetic differences. A genetic continuum was detected in which brain structure was increasingly 
similar in subjects with increasing genetic affinity. Genetic factors significantly influenced cortical struc-
ture in Broca's and Wernicke's language areas, as well as frontal brain regions (r2(MZ) > 0.8, p < 0.05). 
Preliminary correlations were performed suggesting that frontal gray matter differences may be linked to 
Spearman's g, which measures successful test performance across multiple cognitive domains (p < 0.05). 
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These genetic brain maps reveal how genes determine individual differences, and may shed light on the 
heritability of cognitive and linguistic skills, as well as genetic liability for diseases that affect the human 
cortex. 
Cannon TD, Huttunen MO, Lonnqvist J, Tuulio-Henriksson A, Pirkola T, Glahn D, Finkelstein J, Hieta-
nen M, Kaprio J, Koskenvuo M. The inheritance of neuropsychological dysfunction in twins discordant 
for schizophrenia. American Journal of Human Genetics 2000;67:369-382. 
Department of Psychology, UCLA, 90095, USA. cannon@psych.ucla.edu 
While genetic influences in schizophrenia are substantial, the disorder's molecular genetic basis remains 
elusive. Progress has been hindered by lack of means to detect nonpenetrant carriers of the predisposing 
genes and by uncertainties concerning the extent of locus heterogeneity. One approach to solving this 
complexity is to examine the inheritance of pathophysiological processes mediating between genotype 
and disease phenotype. Here we evaluate whether deficits in neurocognitive functioning covary with 
degree of genetic relationship with a proband in the unaffected MZ and DZ co-twins of patients with 
schizophrenia. Twin pairs discordant for schizophrenia were recruited from a total population cohort and 
were compared with a demographically balanced sample of control twin pairs, on a comprehensive neuro-
psychological test battery. The following four neuropsychological functions contributed uniquely to the 
discrimination of degree of genetic loading for schizophrenia and, when combined, were more highly 
correlated within MZ pairs than within DZ pairs, in both discordant and control twins: spatial working 
memory (i.e., remembering a sequence of spatial locations over a brief delay), divided attention (i.e., 
simultaneous performance of a counting and visual-search task), intrusions during recall of a word list 
(i.e., "remembering" nonlist items), and choice reaction time to visual targets. Together with evidence 
from human and animal studies of mediation of these functions by partially distinct brain systems, our 
findings suggest that there are multiple independently inherited dimensions of neural deficit in schizo-
phrenia and encourage a search for genes contributing to quantitative variation in discrete aspects of dis-
ease liability. On tests of verbal and visual episodic memory, but not on the liability-related measures, 
patients were more impaired than their own MZ co-twins, suggesting a preferential impact of nongenetic 
influences on long-term memory systems. 
Suvisaari JM, Haukka JK, Tanskanen AJ, Lönnqvist JK. Decline in the incidence of schizophrenia in 
Finnish cohorts born from 1954 to 1965. Archives of General Psychiatry 1999;56:733-740. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
jaana.suvisaari@ktl.fi 
BACKGROUND: The declining incidence of schizophrenia observed in several countries is believed by 
many to merely reflect methodological problems in the studies performed. We report the first nationwide 
historical cohort study of changes in the incidence of schizophrenia, in which many of the previous meth-
odological problems were overcome. METHODS: We used the Finnish Population Register to identify 
everyone born in Finland from 1954 to 1965. These persons were followed up from their 16th to their 
26th birthdays, and all cases of schizophrenia (International Classification of Diseases, Eighth Revision 
and International Classification of Diseases, Ninth Revision code 295) that emerged were identified from 
the National Hospital Discharge Register, the Pension Register, and the Free Medicine Register. Persons 
for whom an age of onset could be defined were included in the analyses (n = 5645). We used the Poisson 
regression model to estimate the effects of age, sex, birth cohort, period of diagnosis, and season of birth 
on the incidence of schizophrenia. The relative importance of cohort and period were assessed using an 
age-period-cohort model. RESULTS: The incidence declined significantly in each successive cohort, 
from 0.79 to 0.53 per 1000 among males and from 0.58 to 0.41 per 1000 among females. The effects of 
cohort and period on the change were both significant. CONCLUSIONS: The incidence of schizophrenia 
has declined in Finland. This was partly caused by confounding factors, as reflected in the significant 
period effect. The significant birth cohort effect suggests that the intensity or frequency of one or more 
risk factors for schizophrenia has decreased. 
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Hovatta I, Varilo T, Suvisaari J, Terwilliger J, Ollikainen V, Arajärvi R, Juvonen H, Kokko-Sahin M-L, 
Väisänen L, Mannila H, Lönnqvist J, Peltonen L. A genomewide screen for schizophrenia genes in an 
isolated Finnish subpopulation, suggesting multiple susceptibility loci. American Journal of Human Ge-
netics 1999;65:1114-1124 
Department of Human Molecular Genetics, National Public Health Institute, Helsinki, Finland. 
Schizophrenia is a severe mental disorder affecting approximately 1% of the world's population. Here, we 
report the results from a three-stage genomewide screen performed in a study sample from an internal 
isolate of Finland. An effort was made to identify genes predisposing for schizophrenia that are poten-
tially enriched in this isolate, which has an exceptionally high lifetime risk for this trait. Ancestors of the 
local families with schizophrenia were traced back to the foundation of the population in the 17th century. 
This genealogical information was used as the basis for the study strategy, which involved screening for 
alleles shared among affected individuals originating from common ancestors. We found four chromoso-
mal regions with markers revealing pairwise LOD scores>1.0: 1q32.2-q41 (Z(max)=3.82, dominant af-
fecteds-only model), 4q31 (Z(max)=2. 74, dominant 90%-penetrance model), 9q21 (Z(max)=1.95, domi-
nant 90%-penetrance model), and Xp11.4-p11.3 (Z(max)=2.01, recessive 90%-penetrance model). This 
finding suggests that there are several putative loci predisposing to schizophrenia, even in this isolate. 
 
7. DRUG RESEARCH UNIT 
7.1. Drug research 
 
7.1.1. Research and public health significance of the area 
 
The project derives from the beginning of 1990s when the research topics included 
-Drug and alcohol effects in drivers suspected to drive under the influence of drugs and 
alcohol. 
-Clinical pharmacokinetic and -dynamic studies on opioids and other CNS active drugs 
in different patient groups, 
-Perinatal exposure to drugs and tobacco during pregnancy, 
-Development of assay methods for drugs of abuse, 
-Epidemiologic studies on the use of drugs in traffic, drug use among conscripts, in 
prisons and psychiatric hospital, 
-Health risks associated with the abuse of anabolic androgenic steroids and other ana-
bolic agents, and 
-Animal studies on addiction mechanisms. 
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Since then the research topics and resources have been restricted and include nowadays: 
-Estimation of the prevalence of drug abusers in Finland by capture-recapture method, 
and 
-Central pharmacology of addictive drugs in animals.  
 
Prevalence of amphetamine and opiate abuse in Finland 
Acknowledgment of the amount of drug abusers and the abuse pattern in the coun-
try is important to development of health and social affairs. Estimation of the prevalence 
of amphetamine and opiate abusers is made by capture-recapture method utilizing offi-
cial data sources such as The Hospital Patient Discharge Register (maintained by 
STAKES), Criminal Report Register (maintained by  the police), C-hepatitis Register 
and Register of Drivers Suspected to Drive Under the Influence of Drugs (maintained 
by KTL). The estimation is carried out regularly (repeated mostly every second year) 
and the results are utilized by national officials responsible for maintaining and devel-
opment of health and social affairs. 
 
Pharmacological modulation of addictive properties of psychomotor stimulants 
and morphine 
Drug addiction is a disease that is characterized by compulsive drug use, augmenta-
tion of the drug dose due to tolerance, difficulties in withdrawal, and weakening of 
physical and mental health. Typically psychomotor stimulant drugs produce psycho-
logical dependence but cessation of their abuse does not necessarily induce physical 
withdrawal signs and symptoms unlike withdrawal from opiates. In order to understand 
the characteristics of addictive behavior and to be able to provide novel pharmacologi-
cal treatment strategies for addiction diseases, it is essential to understand neurochemi-
cal mechanisms mediating the rewarding properties of drugs of abuse. Conditioning and 
sensitization are powerful modulators of addictive behavior. The involvement of brain 
dopaminergic system in the conditioning of the rewarding properties of drugs of abuse 
is generally recognized. Roles of other neuronal systems, however, are more incom-
pletely understood, and even less is known about the mechanisms mediating sensitiza-
tion of the rewarding properties of drugs of abuse. 
 
110 
Amphetamine-type designer drugs: Assessment of addiction potential 
The expanding market for synthetic amphetamine-type stimulant drugs (ATSs) is 
currently believed to be one of the worlds most severe drug problems.  In addition to 
traditional drugs of abuse that are classified in Schedule I of Controlled Substances or 
its equivalent, there is an increasing variety of so-called designer´s drugs in the illicit 
market. Designer drugs are compounds that often resemble traditional drugs in terms of 
efficacy and molecular structure. However, their distribution, possession, or use is often 
outside of existing legal controls. Since the advent of the Internet, designer drugs have 
been promoted world-wide in drug-culture related web sites. These commonly include 
presentations of both synthesis and use of these substances, together with users' descrip-
tions of their subjective effects. Unfortunately, the users often consider the new syn-
thetic drugs to be less harmful than traditional drugs, despite that the effects or health 
risks of their use are usually not known. 
ATSs are believed to exert their central effects by increasing the synaptic concen-
trations of dopamine and 5-hydroxytryptamine (5-HT), as well as norepinephrine. Mi-
nor modifications in molecular and/or spatial structure results in a series of compounds 
whose subjective effects extend from stimulatory to hallucinogenic. A large body of 
evidence suggests that their ability to increase a strong elevation of extracellular dopa-
mine levels in nucleus accumbens plays a crucial role in their stimulative and reinforc-
ing effects, while hallucinogenic properties are thought to be associated with 5-HTergic 
activity. Although these compounds are abused by humans, their neurochemical effects, 
including addiction potential, remain largely unknown. 
 
The abuse of anabolic steroids 
Abuse of anabolic androgenic steroids became fairly commonplace in the 1970s 
and 1980s, particularly in the power sports. The uncontrolled use of anabolic agents is 
no longer localized to competitive athletes as they are nowadays being used widely by 
amateur power athletes, and also by non-athletic groups. The abuse of anabolic agents 
has became an important public health issue. Supraphysiological doses of anabolic ster-
oids stimulate protein synthesis and increase muscle mass and power, especially when 
combined with weight training. However, this kind of abuse has many serious side ef-
fects, e.g. increasing athletes´ risk of cardiovascular diseases and sudden cardiac death. 
Relatively little attention has been paid to abuse of anabolic agents. 
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The central effects of anabolic steroids and their interactions with other substances 
of abuse  
Concomitant use of anabolic androgenic steroids (AASs) with more conventional 
drugs of abuse, such as amphetamine or cannabis, has increased among the young men. 
More than half of the population abusing anabolic steroids develops drug dependence 
that fulfills the criteria of ICD-10 classification. Anabolic steroids have been shown to 
induce aggressive and violent behavior and this is suggested to be enhanced by alcohol 
and other drugs of abuse. Understanding of the mechanisms behind harmful central ef-
fects of AASs is crucial for the development of preventive biochemical treatment meth-
ods for AAS and other type of drug abuse. Comparing underlying neurobiological 
changes caused by AAS and other type of addictive substances may open new insights 
to the addiction research and to develop treatment strategies towards AAS and other 
substance abuse. Addiction may reflect drug-induced adaptations in the central nervous 
system and common mechanisms behind different type of addiction may exist.    
 
7.1.2. The main scientific achievements 
 
Prevalence of amphetamine and opiate abuse in Finland 
The number of heavy amphetamine and opioid users has increased significantly in 
Finland between 1995 and 2005. It has been estimated that the amount of heavy am-
phetamine and opiate users in Finland varies between 16,000 - 21,000 subjects. Accord-
ing to latest survey the number of the users is no longer increasing in the district of Hel-
sinki but increases are still found in other parts of Finland. 
 
Pharmacological modulation of addictive properties of psychomotor stimulants 
and morphine 
The involvement of the GABA A and 5-HT3 receptor mediated neurotransmission 
and their role mediating dopaminergic and 5-HTergic (serotonergic) effects of cocaine, 
mazindol, amphetamine and methylphenidate in conditioning of the rewarding proper-
ties have been studied in several series of animal trials. 
 Both GABA A and 5-HT3 receptor mediated neurotransmission are involved in 
regulatory action over conditioning of psychomotor stimulant reward. The GABA A 
receptor agonist diazepam, unlike another GABA A receptor agonist zolpidem with a 
distinct binding profile from that of diazepam, was able to prevent place preference in-
112 
duced by cocaine and amphetamine. Hence, it appears that the GABA A receptor-
mediated inhibitory control may involve "zolpidem-insensitive" receptors. 5-HT3 recep-
tors are involved in cocaine- and mazindol-induced neurochemical and behavioral ef-
fects, in particular the acquisition of conditioned reward. Instead, blockade of the 5-HT3 
receptors failed to modify the effects of methylphenidate, the drug with no significant 
effect on 5-HTergic system, thereby suggesting that the ability of a drug to increase 5-
HTergic transmission would be a prerequisite for the drug to be susceptible to the 5-
HT3 antagonism. 
 Methylphenidate (MP) is a psychomotor stimulant drug widely used for the treat-
ment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Although the 
abuse of MP is considered rare in controlled use for the treatment of ADHD among 
children and adolescents, its illicit use has been recognized by several reports indicating 
that methylphenidate possesses abuse potential. We have found that methylphenidate-
induced place preference was enhanced by prior exposure to the drug, i.e. rewarding 
properties of methylphenidate appeared to be sensitized. This is not due to attenuation 
of withdrawal induced by prior exposure, or development of tolerance to methylpheni-
date's aversive properties. While dopamine DA 1 receptor antagonists unlike DA 2 re-
ceptor antagonists are able to directly prevent methylphenidate-induced place prefer-
ence, both type of antagonists, when co-administered with methylphenidate during the 
prior exposure, prevents the enhancement of place preference. Thus, both DA 1 and 
DA2, the latter possibly more specifically, are involved in the sensitization processed of 
methylphenidate reward. 
The role of potassium (K+) channel-related mechanisms in the conditioning of 
morphine's rewarding properties has been studied with two K+ channel blockers. Qui-
nine, but not 4-aminopyridine attenuates morphine-induced place preference, whereas 
morphine-induced secondary hyperactivity is attenuated by both drugs. Our results im-
ply that at least some K+ channel related effects of morphine are involved in condition-
ing of morphine induced reward. 
 
Amphetamine-type designer drugs: Assessment of addiction potential  
This series of studies have been carried out to assess the implication of changes in 
molecular structure on neurochemical and behavioral effects of design derivatives of 
amphetamine in the rat. 
 
The finding that the hallucinogenic 4-methyl-2,5-dimethoxyamphetamine (DOM, 
"STP") does not elevate 5-HT-levels indicates that it acts directly by receptor activation 
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and not via reuptake inhibition.  Similar to amphetamine, 3,4-methylenedioxy-
amphetamine (MDA) and its methyl derivative 3,4-methylenedioxymethamphetamine 
(MDMA, "Ecstasy") act via dopaminergic and 5-HTergic mechanisms involving the 
inhibition of transmitter reuptake. 
4-Methylaminorex is a stimulant drug of abuse that exists in four stereoisomers. 
Therefore it is an ideal compound for studying the impact of spatial structure on abuse 
potential and underlying neurochemical effects. The ability of the stereoisomers of 4-
methylaminorex to elevate extracellular 5-HT and dopamine levels, as well as to induce 
motor activation, is strongly associated with the S-configuration of the molecule. The 
differences in the potencies between the 4-methylaminorex isomers are pharmacody-
namic rather than pharmacokinetic in nature. 
1-benzylpiperazine is a psychoactive compound increasingly encountered on the 
clandestine market. It induces place preference in the rat, indicating that the compound 
possesses rewarding properties, and thus abuse potential.  Furthermore, as shown by 
experiments with dopamine and 5-HT receptor antagonists, both dopaminergic and 5-
HTergic neuronal systems are involved in its action. It appears advisable to consider 
placing 1-benzylpiperazine under statutory control. Indeed, The Council of the Euro-
pean Union and the European Monitoring Center of Drugs and Drug Abuse (EMCDDA) 
are commencing risk assessment of 1-benzylpiperazine. 
 
Abuse of anabolic steroids 
Male power athletes were followed up for months or years during their self-
regimen of substance abuse and during withdrawal periods. None of the volunteers were 
competitive sports athletes subject to doping regulations, and they abused the drugs, 
which they had obtained from the black market. Medical examinations were carried out 
in different hospitals and some comparisons were made to endurance athletes screened 
not to use any doping agents. 
Numerous adverse effects are associated with the abuse of anabolic agents. These 
include e.g. pathological remodelling of the myocardium, electrocardiographic changes 
such as severe QT dispersion, ventricular tachycardia, transient infertility, and athero-
genic changes in lipoprotein profile. Many adverse effects are dose-related. Concomi-
tant use of human growth hormone potentiates the effects of anabolic steroids on car-
diac hypertrophy. Regardless of anabolic steroid-induced hypogonadotrophic hypo-
gonadism, human chorion gonadotrophic hormone maintains spermatogenesis but se-
men quality remains impaired. 
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The mortality of competitive powerlifters suspected to have used anabolic agents 
was compared with the mortality of  population controls. The mortality during the 12-
year follow-up was 12.9 % for the powerlifters compared to 3.1 % in the control popu-
lation. Thus, the risk of death among the powerlifters was 4.6 times higher. These statis-
tically highly significant results give evidence of an association between anabolic ster-
oid abuse and premature death, and support the view that measures to decrease misuse 
of anabolic agents among both competitive and amateur athletes are justified. 
 
The central effects of anabolic steroids and their interactions with other substances 
of abuse 
The effects of the anabolic androgenic steroids, alone or with other substances of 
abuse, on dopaminergic and 5-HTergic activities in the brains of rat have been investi-
gated by microdialysis. 
Supraphysiological doses of anabolic-androgenic steroids lead to increased synthe-
sis of dopamine and 5-HT in the brain areas that regulate motivation, emotions, reward-
related associative learning as well as higher cognitive functions in rats. Sub-chronic 
treatment with high doses of nandrolone attenuates dose dependently the increase in 
extracellular dopamine concentration in nucleus accumbens evoked by amphetamine, 
cocaine or 3,4-methylenedioxymethamphetamine. 
 
7.1.3. The main public health achievements 
 
Knowledge of effects and risks of compounds which are suitable for abuse, and 
which are actively marketed on the Internet, is essential for educational and informa-
tional purposes and it is needed when considering their placing under statutory control. 
Results from our studies with abusers of anabolic agents have been utilized when 
so called doping law was enforced in Finland in 2002, and further, when the law was 
applied into practice. 
 
7.1.4. Funding for research and public health programs 
 
These subprojects are supported by National Public Health Institute, and in part by 
the Yrjö Jahnsson Foundation, Helsinki, Finland, Finnish Foundation for Alcohol Stud-
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ies, Helsinki, Finland, Ensio Hyvärinen Foundation, Helsinki, Finland, National Insti-
tute on Drug Abuse (NIDA), Bethesda, MD, USA, and medical companies. 
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Professor Klaus T. Olkkola, Department of Anesthesia, Turku University Central 
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7.1.7. Proposal for future work and expected benefits 
 
Because the recreational use of designer drugs, with changing variety of com-
pounds emerging in the illegal market, continues to be a problem in most western coun-
tries, both acute and long-term effects of these drugs need to be studied further. 
 
 7.1.8 Main publications 
 
Meririnne E, Kajos M, Kankaanpaa A,Seppala T:Rewarding properties of 1-benzylpiperazine, a new drug 
of abuse, in rats. Basic Clin Pharmacol Toxicol. (2006) Apr;98(4):346-50. 
Drug Research Unit, Department of Mental Health and Alcohol Research, National Public Health Insti-
tute, Mannerheimintie 166, FIN-00300 Helsinki 30, Finland. esa.meririnne@ktl.fi 
1-Benzylpiperazine (also known as 'Legal X', 'Legal E', or 'A2') is a psychoactive compound increasingly 
encountered on the clandestine market. Previous experimental data suggest that the compound possesses 
addictive properties. In the present study, we used the conditioned place preference method in the rat to 
test whether 1-benzylpiperazine possesses rewarding properties. Furthermore, the mechanisms of the 1-
benzylpiperazine reward were investigated using selected dopamine and serotonin receptor antagonists. 1-
Benzylpiperazine (1.25, 5, and 20 mg/kg) induced dose-dependently place preference. This place prefer-
ence was attenuated by the antagonists SCH23390 (0.2 mg/kg; dopamine D1-like receptors) and 
MDL72222 (1.0 mg/kg; serotonin3 receptors), but not by raclopride (0.8 mg/kg; dopamine D2-like recep-
tors) or ketanserin (2 mg/kg; preferentially serotonin2 receptors). Our results show that 1-
benzylpiperazine possesses rewarding properties in the rat, which suggests the compound to be suscepti-
ble to human abuse. The brain dopaminergic and serotonergic systems appear to be involved in the 1-
benzylpiperazine reward. 
Meririnne E, Kajos M, Kankaanpää A, Koistinen M, Kiianmaa K and Seppälä T  Rewarding properties of 
the stereoisomers of 4-methylaminorex: involvement of the dopamine system. Pharmacol Biochem Behav 
(2005) 81: 715-724. 
Drug Research Unit, National Public Health Institute, Mannerheimintie 166, FIN-00300 Helsinki 30, 
Finland. esa.meririnne@ktl.fi 
4-Methylaminorex is a potential psychostimulant drug of abuse that exists as four stereoisomers: cis-
4R,5S, cis-4S,5R, trans-4S,5S, and trans-4R,5R. The racemic mixture of the cis-isomers has been encoun-
tered in illicit samples, but previous animal studies suggest that also the trans-isomers could have similar 
stimulant-like properties. We tested whether the stereoisomers possess rewarding properties and com-
pared their potency using the conditioned place preference method in rats. Furthermore, the involvement 
of the brain dopaminergic system in the 4-methylaminorex reward was tested with the dopamine D1- and 
D2-receptor antagonists SCH 23390 and raclopride administered systemically, or with the neurotoxin 6-
hydroxydopamine injected into the nucleus accumbens. All the four isomers induced place preference, 
with no apparent differences in their potency. SCH 23990 and raclopride attenuated 4-methylaminorex-
induced increase in place preference, and 6-hydroxydopamine also tended to be efficacious. These find-
ings indicate that all the four stereoisomers of 4-methylaminorex possess rewarding properties and thus 
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abuse potential; the trans-isomers are at least as potent as the cis-isomers. Furthermore, the brain dopa-
minergic system appears to be involved in the 4-methylaminorex-reward. 
Kurling S, Kankaanpää A, Ellermaa S, Karila T, Seppälä T  The effect of sub-chronic nandrolone de-
canoate treatment on dopaminergic and serotonergic neuronal systems in the brains of rats. Brain Res 
(2005) 1044: 67-75. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Mannerheimintie 
166, FIN-00300 Helsinki, Finland. sanna.kurling@ktl.fi 
Anabolic-androgenic steroids (AASs) are widely abused by adolescents, although persistent AAS use can 
cause several adverse physical and mental effects, including drug dependence. The first aim of the present 
study was to study the action of nandrolone decanoate on dopaminergic and serotonergic activities in the 
brains of rats. In order to evaluate the anabolic or toxic effects of the dosing regimens used, selected pe-
ripheral effects were monitored as well. Male Wistar rats were treated for 2 weeks. Injections containing 
nandrolone (5 and 20 mg/kg, i.m.) or vehicle were given once daily, 5 days a week. The levels of dopa-
mine (DA), 5-hydroxytryptamine (5-HT) and their metabolites were assayed from dissected brain regions 
3 days after the last injection. Blood was collected for chemical assays before, after 1 week treatment and 
at decapitation. Both doses of nandrolone significantly increased the levels of 3,4-dihydroxyphenylacetic 
acid (DOPAC), a metabolite of DA in the cerebral cortex, and the higher dose of nandrolone increased the 
concentrations of 5-HT in the cerebral cortex compared with the vehicle. In addition, after nandrolone 
treatment, the levels of hemoglobin and erythrocytes increased, and reticulocyte levels decreased. The 
results suggest that nandrolone at supraphysiological doses, high enough to induce erythropoiesis, induces 
changes in the dopaminergic and serotonergic neuronal system in the brains of rats. These phenomena 
may account to some of the observed central stimulatory properties that have been reported following 
AAS abuse. 
Pokela M-L, Anttila E, Seppälä T, Olkkola K: Marked variation in oxycodone pharmacokinetics in in-
fants. Pediatric Anaesthesia (2005) 15: 560-565 
Department of Paediatrics, University of Oulu, Oulu, Finland. 
BACKGROUND: The pharmacokinetics of oxycodone (13-hydroxy-7,8-dihydrocodeinone) has been 
studied in adults and in children who are older than 6 months but there is no information on the disposi-
tion of oxycodone in neonates and young infants. The aim of this study was to study the pharmacokinetics 
of oxycodone in infants varying in age from 0 to 6 months. METHODS: Twenty-two infants undergoing 
surgery were given postoperatively an intravenous bolus of 0.1 mg.kg(-1) of oxycodone hydrochloride. 
Ten of the patients were younger than 1 week (group 1), six from 1 week to 2 months (group 2) and six 
from 2 to 6 months (group 3). Plasma samples were collected for the analysis of oxycodone concentra-
tions up to 24 h. Pharmacokinetics were characterized by noncompartmental methods. RESULTS: The 
median (range) values for the clearance (Cl) were 9.9 (2.3-17.2), 20.1 (3.7-40.4) and 15.4 (14.8-80.2) 
ml.min(-1).kg(-1) in the above three groups. The values for volume of distribution at steady-state were 
3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 
3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively. Both Cl (r = 0.46) and half-life (r = -0.46) were correlated 
to the age of the patient (P < 0.05). There were 13 patients who were on mechanical ventilation at the 
time of oxycodone administration. None of the spontaneously breathing infants had hypoventilation 
which required assistance during the study. CONCLUSIONS: The values for Cl and t(1/2) varied greatly 
between the subjects. This variability was most pronounced in the two youngest groups. Routine dosing 
of oxycodone in young infants may be dangerous. The dose of oxycodone must be titrated individually. 
Vekovischeva OY, Aitta-aho T, Echenko O, Kankaanpää A, Seppälä T, Honkanen A, Sprengel R, Korpi 
ER: Reduced aggression in AMPA-type glutamate receptor GluR-A subunit-deficient mice. Genes, Brain 
and Behavior (2004) 3: 253-265. 
Institute of Biomedicine/Pharmacology, Biomedicum Helsinki, University of Helsinki, Finland. 
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The importance of AMPA-type glutamate receptors has been demonstrated in neuronal plasticity and in 
adaptation to drugs of abuse. We studied the involvement of AMPA receptors in social interaction and 
anxiety and found that in several paradigms of agonistic behavior naïve male mice deficient for the GluR-
A subunit- containing AMPA receptors are less aggressive than wild-type littermates. GluR-A deficient 
mice and wild-type littermates exhibited similar basic behavior and reflexes as monitored by observa-
tional Irwin's test, but they tended to be less anxious in elevated plus-maze and light-dark tests. Maternal 
aggression or male-female encounters were not affected which suggests that male hormones are involved 
in the expression of suppressed aggressiveness. However, testosterone levels and brain monoamines can 
be excluded and found to be similar between GluR-A deficient and wild-type littermates. The reduced 
AMPA receptor levels caused by the lack of the GluR-A subunit, and measured by a 30% reduction in 
hippocampal [3H]-S-AMPA binding, seem to be the reason for suppressed male aggressiveness. When 
we analyzed mice with reduced number of functional AMPA receptors mediated by the genomic intro-
duced GluR-A(Q582R) channel mutation, we observed again male-specific suppressed aggression, pro-
viding additional evidence for GluR-A subunit-containing AMPA receptor involvement in aggression. 
Meririnne E, Ellermaa S, Kankaanpää A, Bardy A, Seppälä T (2004) Pharmacokinetics and tissue distri-
bution of the stereoisomers of 4-methylaminorex in the rat. J Pharmacol Exp Ther 309: 1198-1205. 
Drug Research Unit, Department of Mental Health and Alcohol Research, National Public Health Insti-
tute, Mannerheimintie 166, FIN-00300 Helsinki, Finland. esa.meririnne@ktl.fi 
4-Methylaminorex, a potential psychostimulant drug of abuse, exists as four stereoisomers: cis-4R,5S, 
cis-4S,5R, trans-4S,5S, and trans-4R,5R, which were shown previously to possess stereospecific effects. 
This study characterized their pharmacokinetic and tissue distribution profiles, and metabolic turnover to 
norephedrine and norpseudoephedrine, in male Wistar rats. The rats received each isomer intravenously, 
intraperitoneally, or orally, followed by blood sample collection via cannula (pharmacokinetic study), or 
tissue sample collection at predetermined time points (tissue distribution study). The samples were ana-
lyzed for cis- and trans-isomers, and when appropriate for norephedrine and norpseudoephedrine, with 
gas chromatography/mass spectrometry. Trans-4S,5S-, cis-4R,5S-, and cis-4S,5R-isomers behaved com-
parably kinetically (volume of distribution 1.7-2.3 l/kg, distribution half-life 3.8-7.0 min, elimination 
half-life 35-42 min, and bioavailability 32-57% intraperitoneally or 4-16% orally), whereas trans-4R,5R-
isomer differed from the others, with a longer elimination half-life (118-169 min) and higher bioavailabil-
ity (100% intraperitoneally or 83% orally). The highest isomer concentrations were observed in the kid-
ney followed most frequently by the liver, brain, muscle, and last by fat and blood. The elimination half-
lives of the stereoisomers from the tissues were generally similar to those in blood. No pharmacologically 
significant amounts of norephedrine or norpseudoephedrine were detected in blood or the brain. In con-
clusion, differences between the stereoisomers of 4-methylaminorex in the pharmacokinetics and tissue 
distribution are described. However, these differences are not compatible with, and thus may not account 
for, the distinct behavioral and neurochemical effects of the stereoisomers demonstrated previously. Fur-
thermore, metabolic turnover to norephedrine and norpseudoephedrine does not seem to contribute sig-
nificantly to 4-methylaminorex pharmacology. 
Karila TAM, Karjalainen JE, Mäntysaari MJ, ViitasaloMT, Seppälä TA: Anabolic androgenic steroids 
produce dose-dependent increase in left ventricular mass in power athletes, and this effect is potentiated 
by concomitant use of growth hormone. Int J Sport Med (2003) 24: 337-343 
Pärssinen M, Seppälä T: Steroid use and long-term health risks in former athletes. Sports Med (2002) 32 
(2) :83-94. 
aboratory of Substance Abuse, National Public Health Institute, Helsinki, Finland. miia.parssinen@ktl.fi 
This article focuses on anabolic steroid adverse effects on the cardiovascular system and mental health 
issues as well as the possible increase in the incidence of neoplasms in anabolic steroid users. On the 
basis of findings in the literature, the authors consider these three issues as the most significant concern-
ing morbidity and mortality among anabolic steroid users. A study by Pärssinen et al. (2000) has shown 
an increased incidence of premature mortality among power lifters. Anabolic steroids and other concomi-
119 
tantly used drugs are the probable cause of this increased mortality, as power training itself does not in-
crease health risks and all types of physical activity promote health. 
Kankaanpää A, Ellermaa S, Meririnne E, Hirsjärvi P, Seppälä T (2002) The acute neurochemical and 
behavioral effects of the stereoisomers of 4-methylaminorex in relation to brain drug concentrations. J 
Pharmacol Exp Ther 300: 450-459. 
Drug Research Unit, Department of Mental Health and Alcohol Research, National Public Health Insti-
tute, Helsinki, Finland. aino.kankaanpaa@ktl.fi 
4-Methylaminorex is a stimulant drug of abuse that exists as four stereoisomers: cis-4R,5S, cis-4S,5R, trans-
4S,5S, and trans-4R,5R. These isomers have previously been shown to differ markedly in various respects. 
In the present study we assessed the effects of the isomers of 4-methylaminorex (2.5, 5.0, and 10 mg/kg i.p.) 
on extracellular dopamine and 5-hydroxytryptamine (5-HT) levels in the nucleus accumbens, as well as 
behavior in the rats simultaneously. The relative concentrations of the isomers in the brain were also meas-
ured. The samples were collected by in vivo microdialysis and then analyzed for neurotransmitters with 
high-performance liquid chromatography/electrochemical detection and for cis- and trans-4-methylaminorex 
with gas chromatography/mass spectrometry. The behavioral effects of the isomers were assessed from 
videotapes recorded during the microdialysis experiments. All isomers elevated the extracellular levels of 
both dopamine and 5-HT, with the exception of trans-4R,5R. The rank order of potency for elevating dopa-
mine was trans-4S,5S > cis-4S,5R approximately cis-4R,5S > trans-4R,5R, and for elevating 5-HT cis-
4S,5R > trans-4S,5S approximately cis-4R,5S > trans-4R,5R. Analysis of the behavioral data, together with 
the neurochemical data, suggests that behavioral effects of the isomers of 4-methylaminorex are related to 
drug-induced dopamine release and, in the case of higher doses of the most efficacious isomers, to 5-HT as 
well. The brain concentrations of the isomers did not reflect their neurochemical efficacy, which implies that 
their differences are pharmacodynamic rather than pharmacokinetic. 
Meririnne E, Kankaanpää A, Seppälä T (2001) Rewarding properties of methylphenidate: sensitization by 
prior exposure to the drug and effects of dopamine D1- and dopamine D2-receptor antagonists. J Pharma-
col Exp Ther 298: 539-550. 
National Public Health Institute, Department of Mental Health and Alcohol Research, Drug Research 
Unit, Helsinki, Finland. esa.meririnne@ktl.fi 
In drug addiction, a sensitization phenomenon has been postulated to play a critical role. The aim of our 
study was to evaluate whether sensitization occurs to the rewarding properties of methylphenidate, a psy-
chostimulant drug known to possess abuse potential, as assessed with the biased conditioned place prefer-
ence method in rats. In addition, since the brain dopaminergic system is considered to be important in drug-
reward, the involvement of dopamine D1- and D2-receptors both in the rewarding properties of methyl-
phenidate and in sensitization to these properties was assessed. Conditioning with methylphenidate at doses 
of 1.25 to 20 mg/kg increased preference for the paired environment, whereas a dose of 0.31 mg/kg was 
ineffective. However, following the 7-day sensitization treatment with methylphenidate (0.62-20 mg/kg), 
conditioning with a dose of 0.31 mg/kg resulted in an increased preference for the paired environment, i.e., 
the rewarding properties of methylphenidate appeared to be sensitized. Control experiments indicated that 
the enhancement of preference was not due to attenuation of sensitization treatment-induced withdrawal nor 
to tolerance to aversive properties of methylphenidate. When conditioned with methylphenidate, D1-
antagonist SCH 23390 but not D2-antagonist raclopride prevented place preference. However, when coad-
ministered with methylphenidate during the sensitization treatment, both SCH 23390 and raclopride pre-
vented the development of sensitization. These data indicate that the rewarding properties of methylpheni-
date are sensitized by prior exposure to the drug and that both D1- and D2-receptors, the latter of which 
possibly more specifically, appear to be involved in the development of this sensitization. 
Kankaanpää A, Meririnne E, Ellermaa S, Ariniemi K, Seppälä T (2001) Detection and assay of the stereo-
isomers of 4-methylaminorex in urine, plasma and tissue samples. Forensic Sci Int 121: 57-64. 
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Research Unit on Substance Abuse, Department of Mental Health and Alcohol Research, National Public 
Health Institute, Mannerheimintie 166, FIN-00300 Helsinki, Finland. aino.kankaanpaa@ktl.fi 
The 4-methylaminorex (4-MAX) is an amphetamine-related psychostimulant drug that has appeared on 
the clandestine market with a street name of "U4Euh". This compound exists as four stereoisomers, trans-
4R,5R, trans-4S,5S, cis-4R,5S and cis-4S,5R, of which the cis forms have been classified as Schedule I 
substances in the US. The increasing variety of designer drugs has highlighted the importance of detec-
tion, identification, and quantitative measurement of these drugs, including 4-MAX, in biological sam-
ples. In the present study, the isomers of 4-MAX were detected in urine of rats treated with the drugs by 
some but not all of the on-site immunoassays tested, mainly as amphetamine or methamphetamine. To 
facilitate identification of 4-MAX by laboratories specialized in drug analysis, the electron-ionization 
mass spectrum and TLC data for underivatized 4-MAX using a routine laboratory drug-screening proce-
dure is provided. In addition, a GC/MS method is described for the quantitative determination of cis- and 
trans-4-MAX as tert-butyldimethylsilyl-derivatives in plasma, urine and tissue. 
Pärssinen M, Kujala U, Vartiainen E, Sarna S, Seppälä T: Increased premature mortality of competitive 
powerlifters suspected to have used anabolic agents. Int J Sports Med (2000);21:225-227 
National Public Health Institute, Laboratory of Substance Abuse, Helsinki, Finland. miia.parssinen@ktl.fi 
Misuse of supraphysiological doses of anabolic steroids is claimed to have serious side effects. The aim 
of the study was to determine the mortality, and the cause of premature deaths among a group of subjects 
who are strongly suspected to have used anabolic steroids for a non-medical purpose over several years. 
The mortality of 62 male powerlifters placed 1st-5th in weight series 82.5-125 kg in Finnish champion-
ships during 1977-1982 was compared with the mortality of population controls. The mortality during the 
12-year follow-up was 12.9% for the powerlifters compared to 3.1% in the control population. By 1993 
eight of 62 powerlifters and 34 of 1094 population controls had died, thus the risk of death among the 
powerlifters was 4.6 times higher (95% CI 2.04-10.45; p = 0.0002). The causes of premature death among 
the powerlifters were suicide (3), acute myocardial infarction (3), hepatic coma (1) and non-Hodgkin's 
lymphoma (1). These findings add to the growing amount of evidence of an association between anabolic 
steroid abuse and premature death, and support the view that measures to decrease AAS misuse among 
both competitive and amateur athletes are justified. 
Korte T, Pykäläinen J, Seppälä T: Drug abuse of Finnish male prisoners in 1995. For Sci Internat (1998) 
97: 171-183 
National Public Health Institute, Helsinki, Finland. 
The purpose of the present research was to estimate the extent and variety of abuse of illegal drugs, use 
and misuse of hypnotics and sedatives and anabolic steroids in the Finnish prison population. The study 
was undertaken during October-November 1995 at four prisons, three of which were closed institutions 
and one an open prison; one of the three closed institutions was a juvenile prison. There was a total of 707 
inmates in the prisons selected for the study. Questionnaires were given personally to all prisoners in the 
open prison and in the young prisoners' division in the juvenile prison, but in two large central prisons 
only some divisions were selected for the study. The questionnaires were completed by 354 prisoners; 75 
prisoners refused to respond. A total of 27.7% of subjects reported taking illegal drugs while in their 
current prison and 70.1% had sometimes used them. Of those who were drug-free before their first im-
prisonment, 21.7% began using drugs in prison. At present hypnotics and sedatives were reported as in 
use by 41.8% of subjects, one-third as prescribed drugs and about 10% illicitly. A total of 3.7% of sub-
jects reported taking anabolic steroids in the current prison. Cannabis and amphetamine were the most 
common illegal drugs reported. Intravenous drug use was reported by 19.2% of the respondents at some 
point in their lives, and 10.7% of prisoners had injected drugs in their current prison. Use of illegal drugs 
and misuse of drugs were significantly higher among young prisoners (< or = 25 years of age). 
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Tallgren M, Olkkola K T, Seppälä T, Höckersted, Lindgren L: Pharmacokinetics and ventilatory effects 
of oxycodone before and after liver transplantation. Clin Pharmacol Ther (1997) 61:655-661. 
Department of Anesthesia, Fourth Department of Surgery, Helsinki University Hospital, Finland. 
The pharmacokinetics and ventilatory effects of oxycodone were studied in six volunteer patients with 
end-stage liver cirrhosis before and after orthotopic liver transplantation. Plasma samples and urine were 
collected for 24 hours after intravenous administration of 0.05 mg/kg oxycodone hydrochloride. Concen-
trations of oxycodone and its metabolites, noroxycodone and oxymorphone, were measured in plasma and 
urine. THe median elimination half-life of oxycodone was 13.9 hours (range, 4.6 to 24.4 hours) in pa-
tients with cirrhosis before transplantation and 3.4 hours (range, 2.6 to 5.1 hours) after transplantation (p 
< 0.05). Correspondingly, oxycodone clearance increased from 0.26 L/min (range, 0.15 to 0.73 L/min) 
before transplantation to 1.13 L/min (range, 0.71 to 3.98 L/min) after transplantation (p < 0.05). Oxy-
codone depressed ventilation more strongly before transplantation than after transplantation (p < 0.05). 
Care should be exercised when oxycodone is used in patients with end-stage disease. 
Kaukonen O, Kinnunen A, Partanen P, Seppälä T, Simpura J, Virtanen A: Estimating the number of am-
phetamine and opiate users in the greater Helsinki area. European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA). Methodological pilot study of local level prevalence estimates. Lisbon: 
EMCDDA (1997): pp. 17-36 
 
7.2. Drug dependence 
 
7.2.1. Research and public health significance of the area 
 
The research project started at the beginning of 2005 and includes several subpro-
jects which are presented separately below. 
 
Harm reduction and treatment of amphetamine dependence  
 Illicit drug use is currently a major national health problem also in Nordic countries. 
It has been estimated that the amount of problem users in Finland varies between 16,100 - 
21,100 subjects. The most widely used illegal drug in Finland is cannabis. The use of hard 
drugs; e.g. amphetamine and opioids, has increased significantly between 1995 and 1999. 
Epidemiological studies have clarified the use of amphetamine, methamphetamine, and 
heroin in the district of Helsinki, and in the whole country. Compared with the situation 2 
years earlier (year 1997), illicit drug use had increased by nearly 50% and the latest sur-
vey has shown that the number of drug users is no longer increasing in the district of Hel-
sinki but increases are still found in other parts of Finland. Amphetamine use is a major 
health problem in Sweden, Australia and New Zealand as well. While methadone and 
buprenorphine have proven highly effective substitute medications for opioid dependence, 
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no pharmacological treatment has been found for amphetamine dependence. Partial do-
pamine agonists such as aripiprazole have been considered to be promising medications 
for addiction since they have been supposed to balance and restore normal function of the 
mesolimbic dopamine system. Some studies have suggested that oral dextroamphetamine 
may be used to replace illicit intravenous amphetamine use which proposes that oral 
methylphenidate might also be used to substitute for intravenous amphetamine use. Thus, 
the aim of the study was to compare the effectiveness of aripiprazole, methylphenidate 
and placebo in the treatment of amphetamine dependence using urinalysis as an objective 
measure of primary outcome. 
 
Detoxification of buprenorphine dependence  
Intravenous buprenorphine use in Finland is a major health problem. There have 
been reports of buprenorphine abuse in many other countries, such as Australia, Bang-
ladesh, France, India and New Zealand. Elsewhere in the European Union the number 
of buprenorphine misusers is much lower; in the Czech Republic, Denmark, Germany 
and Sweden buprenorphine misuse is referred to only in informal sources; in the other 
countries misuse is reported to be extremely rare (close to zero). Majority of all opioid 
dependent subjects in Finland use i.v. buprenorphine as a primary drug (e.g., in 2004, 
93% of opioid dependent patients seeking treatment in Helsinki Deaconess Institute 
used i.v. buprenorphine and only 6% i.v. heroin.) Although the advent of buprenor-
phine-naloxone combination (Suboxone) may have reduced this problem, it will not 
totally eradicate it, since buprenorphine is smuggled in large amounts from France and 
Baltic countries. The effectiveness of psychosocial treatments in opioid dependence has 
remained modest. Also pharmacological withdrawal or maintenance treatment of i.v. 
buprenorphine dependence is problematic, since there are no scientific data available on 
the efficacy or effectiveness of these treatments. Studies on heroin dependent patients 
indicate that buprenorphine (duration 1- 2 weeks) is superior to clonidine or methadone 
in the management of withdrawal, but it is not clear if longer treatment (lasting several 
weeks) is more efficient that the short one. The purpose of the 3-arm study is to com-
pare the effectiveness of short (9 days) buprenorphine vs. long (25 days) buprenorphine 
vs. lofexidine treatment (21 days) in the management of i.v. buprenorphine withdrawal. 
The study will start in August 2007. 
 
Comorbid drug use and other mental disorders 
The treatment of mental disorders including the substance use disorders has devel-
oped significantly during the recent years. In addition to the randomized clinical trials 
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there are nowadays practice guidelines (e.g. published by APA), which are based on the 
scientific literature. Guidelines have been published at least for bipolar disorder, major 
depressive disorder, panic disorder, schizophrenia, substance use disorders and for bor-
derline personality disorder.  In addition, there are publications which include compre-
hensive treatment approaches for patients with comorbid mental and substance use dis-
order, but these approaches are mainly based on clinical experience and expert consen-
sus, not so much on clinical efficacy and effectiveness trials. Therefore, there is urgent 
need to examine which treatments of mental disorders (e.g mood, anxiety and psychotic 
disorders) are still effective in patients with comorbid disorders in spite of the presence 
of substance use disorder. Thus, randomized controlled trials to compare the efficacy 
and effectiveness between treatments are needed. In spite of the fact that antidepressant 
drugs are effective for major depression, the results of them cannot be generalized for 
example to the patient group with comorbid depression and opioid or amphetamine 
abuse or dependence. Only doxepin and imipramine seem to be effective in this comor-
bid patients group but for example SSRI drugs seem not to be effective in the treatment 
of depression in opioid dependent patients. There are to our knowledge only a few stud-
ies on the efficacy of the use of antipsychotic drugs to treat comorbid psychosis and 
substance use disorder. The purpose of the present study, therefore, is to evaluate the 
effictiveness of different drug treatments of mental disorders in patient group with co-
morbid mental and substance use disorder. 
The prevalence of comorbid depression, anxiety disorders and psychosis in patients 
with substance use disorders is high. In addition, the prevalence of HIV in patients with 
intravenous substance use is increased. Therefore, potential harmful interaction between 
antidepressant, anxiolytics and antipsychotics with illicit drugs and HIV drugs are great.  
The aim is to study the pharmacokinetic and dynamic interactions of drugs to predict the 
possible harmful interaction between them. The first study has already been carried out 
(interaction between diazepam and efavirenz) and the manuscript is in progress. 
 
Modern analytical approaches for drug determination in clinical and forensic toxi-
cology 
Abuse of illicit drugs and other psychoactive substances is a global problem. It has 
been estimated that 5 per cent of the world population (age 15-64) use illicit drugs at 
least once a year (UNODC 2006). In most of the countries, also in many developing 
ones, toxicological laboratories are increasingly performing drug analyses for a wide 
range of purposes ranging from work place drug testing, and drugs and driving cases to 
clinical purposes, such as therapeutic drug monitoring, emergency toxicology and com-
pliance of patients for medication. Therefore, novel analytical techniques and applica-
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tions for drug determination are valuable tools for toxicological laboratories and prereq-
uisites for competent laboratory operation and performance. 
Toxicological drug analyses have conventionally been based on chromatographic 
separation and mass spectrometric detection techniques after appropriate sample prepa-
ration in laboratory. Novel analytical strategies for analyte determination, such as fast 
gas chromatography combined with non-laborious micro-scale volume sample prepara-
tion, significantly improves cost-efficiency and rapidity of routinely applicable toxico-
logical analyses. A lack of currently published research data and significant benefits 
from the fast techniques have opened a possibility to be on the frontline of research 
globals and improve not only our own laboratory performance, but of many other toxi-
cological laboratories confronting the same challenges. 
Another important trend emphasized at research focus, is the increasing role of so-
called alternative matrices, such as oral fluid, in toxicological analyses. For example, 
oral fluid offer easy, supervised and non-invasive sampling with minimal opportunity 
for sample adulteration or substitution by the person tested. This is beneficial in various 
areas of drug testing, such as in roadside or workplace drug testing and in many areas of 
the health care sector. 
 
Identification of club and designer drug use 
The expanding market for synthetic amphetamine-type stimulant drugs (ATSs), in-
cluding amphetamine, methamphetamine, and 3,4-methylenedioxyamphetamine 
(MDMA, "ecstasy") is currently believed to be one of the world’s most severe drug 
problems. A particular challenge to laboratories performing drug tests is the fact that the 
ATS market is also changing, partly in response to the efforts of drug control authorities 
and partly as a result of the dynamics of abuse patterns. This trend is evidenced, for ex-
ample, by the recent reports of fatalities related to the thus far less common ATSs such 
as 3,4-methylenedioxyethylamphetamine (MDEA), para-methoxyamphetamine (PMA) 
and 4-methylthioamphetamine (4-MTA). 
Gamma-hydroxybutyrate (GHB) is an increasingly popular drug of abuse that 
causes stimulation, euphoria, anxiolysis and hypnosis depending on the dose used. Low 
doses of the drug are used recreationally, and also implicated in drug facilitated sexual 
assaults (DFSA). Because of the unusually steep dose-response curve, accidental GHB 
overdosing, leading to coma, seizures or death can occurr. Being a controlled substance, 
GHB is often substituted with its non-scheduled precursors gamma-butyrolactone 
(GBL) and 1,4-butanediol (BD), which are rapidly metabolized into GHB in the body. 
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However, the presence of the precursors has also been demonstrated in urine and blood 
samples in cases of GBL and BD related deaths. 
Given that chemical identification of club and designer drugs in biological samples 
is needed in hospital emergencies, post-mortem examinations, investigations of DFSAs, 
as well as drugs and driving cases, validated methods for their analyses are essential in 
every forensic laboratory. 
 
Differentiation between therapeutic use of precursor drugs and abuse of amphetamines  
Amphetamine and methamphetamine are widely abused substances that exist in two 
enentiomers, D- and L-(meth)amphetamine. Determination of enantiomeric composition 
of positive amphetamine findings may be needed in situations, such as differentiation 
between the use of prescribed pharmaceutical preparations consisting of one enantiomer 
only (e.g. Dexedrine (R)), and the use of clandestinely manufactured racemic ampheta-
mine. In addition, there are drugs such as the anti-parkinsonian selegiline, which are me-
tabolized to one enantiomer of amphetamine or methamphetamine, but may lead to false 
positive drug of abuse finding unless enentiomeric determination is used.   
 
7.2.2. The main scientific achievements 
 
Harm reduction and treatment of amphetamine dependence 
 The result showed that methylphenidate treatment was associated with statistically 
significant reduction in intravenous amphetamine use when compared with placebo. It is 
first controlled evidence of an effective pharmacological treatment for amphetamine 
dependence. It is likely that methyphenidate should be dispensed mostly on a daily basis 
under supervision because of its abuse potential. On the contrary, aripiprazole, a partial 
dopamine agonist, was associated with a higher proportion of amphetamine-positive 
urine samples than placebo. However, no conclusion can be made on the potential effi-
cacy of aripiprazole in a relapse prevention among detoxified patients. 
 
Modern analytical approaches for drug determination in clinical and forensic toxicology 
Novel analytical strategies have been developed for screening, identification and 
quantification of wide-range of multiple illicit drugs (e.g. ?9-tetrahydrocannabinol, co-
caine, amphetamine-type stimulant drugs, opiates) and other psychoactive substances 
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(e.g. benzodiazepines, hypnotic agents, antidepressants, antipsychotics, antiepileptics) 
in biological specimens. The most recently published papers are based on unique ap-
proaches in toxicological analyses using fast capillary gas chromatography/mass spec-
trometry (GC/MS). The use of fast GC/MS decrease analyses costs and significantly 
improve sample throughput, speed and also in some cases reliability of analyses in a 
comparison to traditionally used conventional GC/MS, which has been considered a 
golden standard in toxicological analysis. 
Scientific papers (Gunnar et al.) based on the applied research work and method 
development have been published in top-rated publications in the field of biomedical 
and organoanalytical chemistry. Possibilities of fast chromatographic separation and 
several applications have also been presented in scientific conferences and a doctoral 
thesis is under preparation. The method developed for simultaneous quantitative deter-
mination of 30 drugs of abuse in oral fluid was awarded as the best young scientist pub-
licationin the field of forensic toxicology by the International Association of Forensic 
Toxicologists (TIAFT) in Seoul, South-Korea 2005. 
 
Identification of club and designer drug use 
In the field of applied analytical chemistry, the rapid pretreatment procedure with a 
single-step extraction-derivatization for analysis of ATSs by gas chromatography - mass 
spectrometry (GC-MS) is unique.  It enables this method to be used, besides of quantita-
tive determination of positive samples, also for preliminary screening of ATSs from a 
large number of whole blood, serum, oral fluid or urine samples. The use of GC-MS 
method for preliminary screening would markedly improve the qualitative accuracy of 
ATS screening by detecting a wider variety of substances and by complying better with 
the low cut-off values required for drug analyses in blood. The method has been pub-
lished in a peer reviewed scientific journal (Kankaanpää et al., 2004). 
The method developed for simultaneous, quantitative analysis of GHB, GBL and 
BD in blood and urine samples utilizes a salting-out approach, that has not been de-
scribed for these compounds. This method was presented in the 44th international meet-
ing of the International Association of Forensic Toxicologists (TIAFT) held in Ljubl-
jana, Slovenia. Manuscript describing the method will be published in a peer reviewed 
scientific journal (Kankaanpää et al., in press). 
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7.2.3. The main public health achievements 
 
Harm reduction and treatment of amphetamine dependence  
Effective treatment can reduce the medical and social problems related to intrave-
nous use of amphetamine.  
 
Modern analytical approaches for drug determination in clinical and forensic toxi-
cology 
The analytical strategies published for determination of various illicit drugs and 
other psychoactive substances in biological specimens offer more comprehensive, sensi-
tive, cost-efficient and faster analytical approaches for toxicological laboratories serving 
hospitals, rehabilitation clinics, law enforcement, and other research projects. 
 
Identification of club and designer drug use 
The method developed for analysis of ATSs, as well as the GHB and precursor as-
say, has widened the selection of club and designer drugs analyzed by the analytical 
service of the Drug Research Unit.  Since their accreditation, both methods have been 
used for routine analyses in the Drug Research Unit. Improved methods assure more 
versatile and reliable analysis services that both health care, including rehabilitation of 
drug addicts, and law enforcement benefit. 
 
Differentiation between therapeutic use of precursor drugs and abuse of ampheta-
mines 
Ability to determine the enantiomeric composition of positive amphetamine find-
ings has been essential in several forensic cases in which the patient has claimed to have 
used prescribed Dexedrine (R). After determination of enantiomeric composition of the 
positive amphetamine finding, the origin of the amphetamine causing the positive find-
ing can be tracked to medicament vs. clandestinely manufactured amphetamine. Given 
that amphetamine is one of the most common drugs of abuse in Finland, and also use of 
prescribed D-amphetamine in treatment of ADHD is increasing, the significance of en-
antiomeric amphetamine analysis is still increasing. 
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7.2.4. Funding for research and public health programs 
 
The subprojects Harm reduction and treatment of amphetamine dependence and de-
toxification of buprenoprhine dependence has received funding from the program called 
Addiktio of the Academy of Finland. The funding of the rest of the subprojects is carried 
out by National Public Health Insitute. 
 
7.2.5. Personnel 
 
Kimmo Kuoppasalmi, MD, PhD; Teemu Gunnar, MSc (Chem), BSc (Econ), Aino 
Kankaanpää, PhD (Pharm), Esa Meririnne, MD, PhD, Saija Turtiainen, MD, Jari 
Haukka, PhD  
 
7.2.6. Collaboration 
 
Professor jari Tiihonen, MD,PhD, Department of Forensic Psychiatry, University 
of Kuopio, Niuvanniemi Hospital 
Outi Kuikanmäki, MD,  Pekka Tuomola, MD, Jaana Föhr, MD, Substance Abuse, 
Welfare Work and Mental  Health Care, Helsinki Diaconess Institute 
Helena Vorma, MD,PhD, Heikki Katila MD, PhD, Department of Psychiatry, Insti-
tute of Clinical Medicine, Faculty of Medicine, University of Helsinki and Helsinki 
University Hospital, Department Of Psychiatry 
Matti Ristola, MD,PhD, Asko Järvinen, MD,PhD Department of Medicine, Divi-
sion of Infectious Diseases, Helsinki University Hospital 
Professor Erkki Vuori, MD,PhD, Department of Forensic Medicine, Faculty of 
Medicine, University of Helsinki 
Professor Aarno Palotie, MD, PhD, Biomedicum Helsinki, Research Program in 
Molecular Mdicine, University of Helsinki 
Professor Raimo Salokangas, MD,PhD, Antti Mikkonen, MD, Mika Kallio MD, 
Turku University Hospital, Departement of Psychiatry  
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7.2.7. Proposal for future work and expected benefits 
 
Harm reduction and treatment of amphetamine dependence  
The study needs to be continued as a comparison between methyphenidate and pla-
cebo to certify the effectiveness of methylphenidate in a larger patient population with 
higher statistical power. 
 
Comorbid drug use and mental disorders  
There is only scanty information on the treatment of comorbid depression and psy-
chosis. The study will give new information to treatments of comordid disorders. 
 
Modern analytical approaches for drug determination in clinical and forensic toxi-
cology 
Rapid, cost-efficient and reliable multianalyte procedures for drug determination 
are vital for various toxicological laboratories confronting increasing amount of analysis 
requests, need for resource optimization and rising number of drugs to be tested. These 
challenges can be tackled by developing innovative analytical methodologies and appli-
cations, which finally serve the customers of laboratory services, e.g., in health care and 
law enforcement. Alternative biological specimens and especially oral fluid, has the 
potential to replace/supplement conventionally matrices (whole blood and urine) and 
ease drug testing procedure in many areas of clinical and forensic toxicology. Expertise 
from drug analysis in biological specimens are planned to be utilized in highly sensitive 
analysis of drugs of abuse in wastewater collected from sewage treatment plant. This 
will allow, e.g., epidemiological studies and a long-term approach to study drug use in 
general population in unique and representative manner. 
 
Identification of club and designer drug use 
In order to continue to be able to provide versatile and reliable analysis services in 
the future, it is essential to continuously monitor the changing abuse patterns, and to 
develop methods that are able to identify a wide range of novel drugs of abuse. This 
work will benefit both law enforcement and health care authorities. 
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 7.2.8 Main publications 
 
Gunnar T, Engblom C, Ariniemi K, Pressure-adjusted continual flow heart-cutting for the high through-
put determination of amphetamine-type stimulant drugs in whole blood by fast multidimensional gas 
chromatography-mass spectrometry, J. Chromatogr. A; (2007), in press. 
National Public Health Institute, Drug Research Unit, Mannerheimintie 166, 00300 Helsinki, Finland. 
teemu.gunnar@ktl.fi      
Innovative features and technical improvements in modern bench-top quadrupole gas chromatograph-
mass spectrometer (GC-MS) have prepared the way for faster and more cost-effective applications while 
still maintaining sufficient chromatographic resolution, speed of MS data acquisition and reliability of 
analytical methodology. In this paper, a short wide-bore capillary column with low film thickness (5 m x 
0.32 mm{_}i.d._, 0.1 µm) was used a pre-fractionating column and only chosen heart-cuts were trans-
ferred to the second chromatographic dimension (15 m x 0.25 mm _i.d._, 0.25 µm) by means of a pres-
sure-adjusted continual flow type switching device for quantification of five common amphetamine-type 
stimulant drugs. The instrumental setting used, in combination with carefully optimized operational fast 
GC and MS parameters, markedly decreased the retention times of the targeted analytes, e.g. ampheta-
mine 0.891 min and methamphetamine 1.037 min, and the total chromatographic runtime (1.700 min), as 
well as reducing the need for continuous cleaning of the MS ion source and increasing column life com-
pared with conventional GC-MS approaches. The performance of the instrumental configuration and 
analytical method was evaluated in validation experiments and the method was also applied to authentic 
samples. The method demonstrates the potential of fast GC-MS in combination with a gas-phase micro-
fluidic Deans switch device for analysing of (semi)volatile compounds, such as amphetamine-type stimu-
lant (ATS) drugs. This should be particularly useful in modern laboratories aiming at cost-efficient analy-
sis as well as the optimum use of available laboratory capacity and instrumentation. 
Kankaanpää A, Liukkonen R, Ariniemi K (in press) Determination of gammahydroxybutyrate (GHB) and 
its precursors in blood and urine samples: a salting-out approach. Forensic Sci Int. 
Drug Research Unit, Department of Mental Health and Alcohol Research, National Public Health Insti-
tute, Mannerheimintie 166, Helsinki, Finland. aino.kankaanpaa@ktl.fi <aino.kankaanpaa@ktl.fi> 
Gamma-hydroxybutyrate (GHB) is an increasingly popular drug of abuse that causes stimulation, eupho-
ria, anxiolysis or hypnosis, depending on the dose used. Low doses of the drug are used recreationally, 
and also implicated in drug-facilitated sexual assaults. Because of the unusually steep dose-response 
curves, accidental GHB overdosing, leading to coma, seizures or death can occur. Being a controlled 
substance, GHB is often substituted with its non-scheduled precursors gamma-butyrolactone (GBL) and 
1,4-butanediol (BD), which are rapidly metabolized into GHB in the body. Here we describe an assay for 
GHB, GBL and BD in blood and/or urine samples. GHB and BD were extracted from diluted 200 microL 
aliquots of samples with t-butylmethylether (plus internal standard benzyl alcohol) in test tubes preloaded 
with NaCl. After acidification and centrifugation the solvent phase was transferred to a test tube pre-
loaded with Na(2)SO(4), incubated for 30 min, centrifuged again, and evaporated in vacuum. The residue 
was mixed with N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) in acetonitrile, and injected into 
a GC-MS. When analyzing GBL, the salting-out step was omitted, and analysis was performed with a 
GC-FID apparatus. As revealed by the validation data this procedure is suitable for quantitative determi-
nation of GHB and its precursors in blood and/or urine samples. 
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Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, Sokero P, Haukka J, Merir-
inne E : A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J 
Psychiatry 2007;164:160-2. 
Department of Forensic Psychiatry, University of Kuopio, and the Department of Psychiatry, Helsinki 
University Hospital, Finland. jari.tiihonen@niuva.fi 
OBJECTIVE: Problems related to illegal amphetamine use have become a major public health issue in 
many developed countries. To date, evidence on the effectiveness of psychosocial treatments has re-
mained modest, and no pharmacotherapy has proven effective for amphetamine dependence. METHOD: 
Individuals meeting DSM-IV criteria for intravenous amphetamine dependence (N=53) were randomly 
assigned to receive aripiprazole (15 mg/day), slow-release methylphenidate (54 mg/day), or placebo for 
20 weeks. The study was terminated prematurely due to unexpected results of interim analysis. An inten-
tion-to-treat analysis was used. The primary outcome measure was the proportion of amphetamine-
positive urine samples. RESULTS: Patients allocated to aripiprazole had significantly more ampheta-
mine-positive urine samples than patients in the placebo group (odds ratio=3.77, 95% CI=1.55-9.18), 
whereas patients who received methylphenidate had significantly fewer amphetamine-positive urine sam-
ples than patients who had received placebo (odds ratio=0.46, 95% CI=0.26-0.81). CONCLUSIONS: 
Methylphenidate is an effective treatment for reducing intravenous drug use in patients with severe am-
phetamine dependence. 
Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, Partonen T, Tuulio-Henrikkson A, 
Hintikka J, Kieseppä T, Harkanen T, Koskinen S, Lönnqvist J: Lifetime prevalence, of psychotic and 
bipolar I dosrder in a general population. Arch Gen Psychiatry 2007;64:19-28. 
Department of Mental Health and Alcohol Research, National Public Health Institute, University of Hel-
sinki, Mannerheimintie 166, 0300 Helsinki, Finland. jonna.perala@ktl.fi 
CONTEXT: Recent general population surveys of psychotic disorders have found low lifetime preva-
lences. However, this may be owing to methodological problems. Few studies have reported the preva-
lences of all specific psychotic disorders. OBJECTIVE: To provide reliable estimates of the lifetime 
prevalences of specific psychotic disorders. DESIGN: General population survey. SETTING AND 
PARTICIPANTS: A nationally representative sample of 8028 persons 30 years or older was screened for 
psychotic and bipolar I disorders using the Composite International Diagnostic Interview, self-reported 
diagnoses, medical examination, and national registers. Those selected by the screens were then re-
interviewed with the Structured Clinical Interview for DSM-IV. Best-estimate DSM-IV diagnoses were 
formed by combining the interview and case note data. Register diagnoses were used to estimate the ef-
fect of the nonresponders. MAIN OUTCOME MEASURES: Diagnosis of any psychotic or bipolar I 
disorder according to the DSM-IV criteria. RESULTS: The lifetime prevalence of all psychotic disorders 
was 3.06% and rose to 3.48% when register diagnoses of the nonresponder group were included. Lifetime 
prevalences were as follows: 0.87% for schizophrenia, 0.32% for schizoaffective disorder, 0.07% for 
schizophreniform disorder, 0.18% for delusional disorder, 0.24% for bipolar I disorder, 0.35% for major 
depressive disorder with psychotic features, 0.42% for substance-induced psychotic disorders, and 0.21% 
for psychotic disorders due to a general medical condition. The National Hospital Discharge Register was 
the most reliable of the screens (kappa = 0.80). Case notes supplementing the interviews were essential 
for specific diagnoses of psychotic disorders. CONCLUSIONS: Multiple sources of information are es-
sential for accurate estimation of lifetime prevalences of psychotic disorders. The use of comprehensive 
methods reveals that their lifetime prevalence exceeds 3%. 
Gunnar T, Ariniemi K, Lillsunde P, Fast gas chromatography-negative-ion chemical ionization mass 
spectrometry with micro-scale volume sample preparation for the determination of benzodiazepines and 
?-hydroxy metabolites, zaleplon and zopiclone in whole blood, J Mass Spectrom, 2006; 41: 741-754. 
National Public Health Institute, Drug Research Unit, Mannerheimintie 166, 00300 Helsinki, Finland. 
teemu.gunnar@ktl.fi 
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Fast gas chromatography/negative-ion chemical ionization mass spectrometric (GC/NICI-MS) assay 
combined with rapid and nonlaborious sample preparation is presented for the simultaneous determina-
tion of benzodiazepines and alpha-hydroxy metabolites, zaleplon and zopiclone in whole blood. The 
compounds were extracted from 100 microl of whole blood by simultaneous multitube, microscale liquid-
liquid extraction (LLE) and derivatized by N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide 
(MTBSTFA), without the need for the time-consuming concentration stage. In the analytical separation, 
various parameters of fast GC/NICI-MS were applied, e.g. the use of hydrogen as a GC carrier gas, a high 
carrier gas velocity, a small film thickness of the analytical column, fast MS data acquisition, fast tem-
perature ramping, and high initial and final temperatures of GC column. Sensitive identification, screen-
ing and quantitation of 18 compounds of interest were achieved in chromatographic separation in only 
4.40 min. Accurate and reproducible results were obtained by using five different and carefully selected 
deuterated analogues on the basis of the chemical properties of the target analytes. Nevertheless, for al-
pha-OH-midazolam, and for bromazepam and flunitrazepam at low concentrations, the results can be 
considered only semiquantitative on the basis of the validation data. The extraction efficiencies ranged 
from 74.3 to 105.7% and the limits of quantitation (LOQ) from 1 to 100 ng ml(-1). Rapid sample prepara-
tion and fast chromatographic separation allowed cost-efficient, reliable and high sample-throughput 
analyses with a low amount of manual work. The method was fully validated and accredited according to 
EN ISO/IEC 17025 standards and is applicable for sensitive, reliable and quantitative determination of 
benzodiazepines, zaleplon and zopiclone, e.g. in clinical and forensic toxicology. Copyright (c) 2006 John 
Wiley & Sons, Ltd. 
Gunnar T, Eskola T, Lillsunde P, Fast Gas Chromatography-Mass Spectrometric Determination of Metha-
done and the Primary Metabolite EDDP in Whole Blood, Rapid Commun Mass Sp, 2006; 20: 673-9. 
National Public Health Institute, Drug Research Unit, Mannerheimintie 166, 00300 Helsinki, Finland. 
teemu.gunnar@ktl.fi 
A toxicological analysis was developed and validated for simultaneous screening and quantification of 
methadone (METH) and its primary metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
(EDDP). The method employs microscale liquid-liquid extraction (microLLE) and direct injection of a 
separated aliquot of the organic layer into a gas chromatography/mass spectrometric (GC/MS) system 
without any other pre-treatment stages. A fast GC/MS runtime (total 5.8 min; METH, Rt = 3.55 min; 
EDDP, Rt = 3.40 min) combined with rapid sample preparation allowed cost-efficient and routinely ap-
plicable performance with a low amount of manual work. The validated parameters included: linearity 
(25-1000 ng mL(-1) both; R(METH)2 = 0.998 and R(EDDP)2 = 0.997), accuracy (Bias(METH): from -
0.05 to 11.3%, Bias(EDDP): from 1.11 to 4.37%); intra and inter-assay precision (RSD(METH): from 2.4 
to 3.9%, from 4.89 to 10.3%; RSD(EDDP): from 4.50 to 6.20%, from 4.57 to 15.2%), extraction effi-
ciency (METH = 95.5%; EDDP = 90.6%), LOQ(Meth,EDDP) = 25 ng mL(-1). Samples were stable for at 
least 25 h and no selectivity problems or baseline interference were observed. The method should be 
applicable for identifying and quantitative confirmation of possible misuse and/or illegal use of METH in 
toxicological cases. Copyright 2006 John Wiley & Sons, Ltd. 
Gunnar T,Ariniemi K, Lillsunde P, Validated toxicological determination of 30 drugs of abuse as opti-
mized derivatives in oral fluid by long column fast gas chromatography/electron impact mass spectrome-
try, J Mass Spectrom 2005; 40: 739-753. 
National Public Health Institute, Drug Research Unit, Mannerheimintie 166, 00300 Helsinki, Finland. 
teemu.gunnar@ktl.fi 
An analytical procedure was developed for the simultaneous sensitive identification, screening and quan-
titation of 30 drugs of abuse using 250 microl of human oral fluid. The method employs sequential 
mixed-mode solid-phase extraction (SPE), optimized derivative formation and long-column fast gas 
chromatography/electron impact mass spectrometry (GC/EI-MS). After sequential SPE elution, the most 
sensitive and stable derivatives were formed by taking careful account of the characteristics of the active 
functional groups and possible steric hindrances affecting derivatization chemistry. Amphetamine-type 
stimulant drugs were acylated with heptafluorobutyric anhydride, benzodiazepines and Delta(9)(tert-
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butyldimethylsilyl)trifluoroacetamide and benzoylecgonine, codeine, ethylmorphine, 6-
monoacetylmorphine, morphine, pholcodine, buprenorphine and norbuprenorphine with N-methyl-N-
(trimethylsilyl)trifluoroacetamide. In addition, the following analytes were included: methadone, cocaine, 
alprazolam, midazolam, fentanyl and zolpidem. In GC separation, fast temperature ramping and high 
carrier gas flow-rate combined with long 30 m columns of i.d. 0.32 mm offered a reduction in analysis 
time and sharp peak shapes while still maintaining sufficient resolution and high sample capacity. Vali-
dated parameters including selectivity, linearity, accuracy, intra- and inter-day precision, extraction effi-
ciency and limit of quantitation were all within required limits. In contrast to previously published meth-
ods, this single procedure is suitable for the simultaneous toxicological determination of the most com-
mon illicit drugs and benzodiazepines, and also zolpidem, in a small amount of oral fluid. 
Kankaanpää A, Gunnar T, Ariniemi K, Lillsunde P, Mykkänen S, Seppälä T: A single-step procedure for 
gas-chromatography-mass spectrometry screening and quantitative determination of amphetamine-type 
stimulants and related drugs in blood, serum, oral fluid and urine samples. J Chromatogr B 2004;810: 57-68. 
Drug Research Unit and Laboratory of Substance Abuse, Department of Mental Health and Alcohol Re-
search, National Public Health Institute, Mannerheimintie 166, FIN-00300 Helsinki, Finland. 
aino.kankaanpaa@ktl.fi 
We describe a rapid GC/MS assay for amphetamine-type stimulant drugs (ATSs) and structurally related 
common medicaments in blood, serum, oral fluid and urine samples. The drugs were extracted from their 
matrices and derivatized with heptafluorobutyric anhydride (HFBA) in a single step, using the following 
procedure: 100 microl (oral fluid) or 200 microl (blood, serum, urine) of the sample were mixed with 50 
microl of alkaline buffer and 500 microl of extraction-derivatization reagent (toluene + HFBA + internal 
standard), centrifuged, and injected into a GC/MS apparatus. As revealed by the validation data this pro-
cedure, with its limit of quantitation being set at 20 ng/ml for oral fluid, 25 ng/ml for blood or 200 ng/ml 
for urine, is suitable for screening, identification and quantitative determination of the ATSs and related 
drugs in all the matrices examined. Thus, time-consuming and expensive multiple analyses are not 
needed, unless specifically required.  
Vorma H, Naukkarinen H, Sarna S, Kuoppasalmi K: Long-term outcome after benzodizepine withdrawal 
treatment in subjects with complicated dependence. Drug Alcohol Depend 2003; 70:309-14. 
A-clinic Foundation, Helsinki, Finland. helena.vorma@hus.fi 
BACKGROUND: The study aimed to monitor subjects with benzodiazepine (BZ) dependence after with-
drawal treatment in order to evaluate long-term outcome and predictors of remaining BZ-free. Subjects 
with high-dose dependence or co-occurring alcohol problems were not excluded. METHOD: Seventy-six 
participants in an earlier, randomized, controlled trial of outpatient BZ discontinuation were interviewed, 
and documents from their treatment settings obtained, along with urine and serum samples for BZ use. 
Long-term outcomes for a cognitive-behavioral treatment group and a treatment-as-usual group were 
measured. RESULTS: BZ discontinuation treatment outcomes were maintained in both treatment groups. 
No between-group differences were found. At the end of the study 25% of the subjects were BZ-free, and 
the median dose decrease from pre-treatment levels was 16.1 mg in diazepam equivalents. Subjects with 
pre-treatment doses exceeding 40 mg were able to maintain their doses at therapeutic levels through the 
follow-up. Pre-treatment low BZ dose, no previous withdrawal attempts, and high life satisfaction pre-
dicted success in staying BZ-free. CONCLUSIONS: In subjects with complicated BZ dependence, the 
benefits of BZ discontinuation treatment may persist, but more studies are needed. 
Vorma H, Naukkarinen H, Sarna S, Kuoppasalmi K: Treatment of out-patients with complicated benzodi-
azepine dependence: comparison of two approaches. Addiction 2002;97:851-9. 
A-Clinic Foundation, Helsinki, Finland. helena.vorma@ktl.fi 
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AIMS: To evaluate whether gradual benzodiazepine taper combined with cognitive-behavioural treatment 
is more effective than standard treatment for patients with dependence in out-patient clinics. DESIGN: A 
randomized, controlled clinical trial, using standard questionnaires and serum and urine tests. 
SETTINGS: Four public-sector out-patient clinics for alcohol and drug abusers in Helsinki. 
PARTICIPANTS: Seventy-six patients with benzodiazepine dependence (DSM-III-R). Patients taking 
high doses of the drug or with alcohol use disorders were included to obtain a subject group representa-
tive of usual clinical practice. INTERVENTION: Subjects received gradual benzodiazepine taper com-
bined with cognitive-behavioural therapy (experimental group) or standard withdrawal treatment not 
scheduled by the researchers (control group). MEASUREMENTS: The outcome was measured in terms 
of attaining a state of abstinence or by a decrease in the dosage during the study period of up to 12 
months' duration. FINDINGS: No statistically significant differences in the outcomes were observed 
between the groups. A total of 13% of the experimental group and 27% of the control group were able to 
discontinue drug use. In addition 67% of the experimental group and 57% of the control group were able 
to decrease the dose. CONCLUSIONS: The search continues for improved methods of helping patients 
with complicated benzodiazepine dependence. 
Heikman P, Kalska H, katila H, sarna S, Tuunainen A, Kuoppasalmi K: Right unilateral and bifrontal 
electroconvulsive therapy in the treatment of depression: a preliminary study. J ECT 2002; 18:26-30. 
Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland. pertti.heikman@hus.fi 
The short-term outcome of electroconvulsive therapy (ECT) was studied in 24 patients with a current 
major depressive episode (DSM-IV). Patients were randomized to high dose (400% above the seizure 
threshold) right unilateral (RUL) ECT, to moderate dose (150% above seizure threshold) RUL ECT, and 
to low dose (just above seizure threshold) bifrontal (BF) ECT. Primary outcome measures included num-
ber of treatments, Hamilton Depression Rating Scale score, and Mini-Mental State Examination score. 
High dose RUL ECT was associated with a significantly faster response to treatment than low dose BF 
ECT. Moreover, there was a tendency to a higher response rate with high dose RUL ECT compared with 
either moderate dose RUL ECT or BF ECT. 
Heikman P, Katila H, Sarna S, Wahlbeck K, Kuoppasalmi K: Differential response to right unilateral 
ECT in depressed patients: impact of comorbidity and severity of illness. BMC Psychiatry 2002;2:2. 
Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland. pertti.heikman@hus.fi 
BACKGROUND: Recent electroconvulsive therapy (ECT) efficacy studies of right unilateral (RUL) ECT 
may not apply to real life clinics with a wide range of patients with major depressive episodes. 
METHODS: The study included two groups of patients. In addition to a homogeneous group of patients 
with major depression according to DSM-IV criteria with severity of the major depressive episode > 16 
scores on 17-item Hamilton Rating Scale for Depression (HDRS) (Group 1, n = 16), we included a het-
erogeneous group of patients with less severe major depressive episodes or with a variety of comorbid 
conditions (Group 2, n = 24). We randomly assigned the patients to an RUL ECT treatment dosed at 5 or 
2.5 times seizure threshold with an intent-to-treat design. The outcomes measured blindly were HDRS, 
number of treatments, and Mini-Mental State Examination (MMSE). The patients were considered to 
have responded to treatment if the improvement in HDRS score was at least 60% and they had a total 
score of less than ten. RESULTS: The Group 2 patients responded poorer (8% vs. 63%), and had more 
often simultaneous worsening in their MMSE scores than Group 1 patients. The differences in the out-
comes between the two different doses of RUL ECT treatment were not statistically significant. 
CONCLUSIONS: ECT effectiveness seems to be lower in real-life heterogeneous patient groups than in 
homogeneous patient samples used in experimental efficacy trials. 
Heikman P, Salmelin R, Mäkelä J, Hari R, Katila H, Kuoppasalmi K: Relation between frontal 3-7 Hz 
MEG activity and the efficacy of ECT in major depression. J ECT 2001;17:136-40. 
Department of Psychiatry, Helsinki University Central Hospital, Finland. pertti.heikman@hus.fi 
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The efficacy of electroconvulsive therapy (ECT) in major depression has been linked to the accentuation 
of postconvulsive prefrontal electroencephalography slow-wave activity. We investigated the change in 
slow-wave activity (0.5-7 Hz) using whole-scalp magnetoencephalographic (MEG) recordings. The 3-7 
Hz (theta) activity increased in the right frontal and occipital regions during the course of treatment. After 
four treatments, the increase of the theta activity in the left frontal cortex correlated with the efficacy of 
the ECT treatment. Moreover, the change of the ratio of left and right frontal theta activity to occipital 
theta activity had a positive correlation with the therapeutic effect. These findings suggest that an efficient 
ECT treatment increases MEG theta activity in the frontal cortex. 
Heinälä P, Alho H, kiianmaa K, Lönnqvist J, Kuoppasalmi k, Sinclair JD: Targeted use of naltrexone 
without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo 
controlled tirea. J Clin Psychopharmacol 2001;21:287-92. 
National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, Finland. 
Several studies have shown the opioid antagonist naltrexone to be effective when combined with psycho-
social therapies for the treatment of patients who are dependent on alcohol with fixed medication and 
time (12 weeks). In this study, 121 nonabstinent outpatients with alcohol dependence (DSM-IV) were 
treated with sessions of cognitive coping skills (N = 67) or supportive therapy (N = 54) and either naltrex-
one 50 mg/day (N = 63) or placebo (N = 58) daily for the first 12 weeks and thereafter for 20 weeks only 
when craving alcohol (i.e., targeted medication) in a prospective one-center, dual, double-blind, random-
ized clinical trial. The dropout rate for all subjects was 16.5% during the first 12-week period and ap-
proximately twice that level by the end of the study. There were no significant group differences in study 
completion and therapy participation rates. After the continuous medication (12 weeks), the cop-
ing/naltrexone group had the best outcome, and coping/placebo had the worst. This difference remained 
during the targeted medication period (the following 20 weeks). Naltrexone was not better than placebo in 
the supportive groups, but it had a significant effect in the coping groups: 27% of the coping/naltrexone 
patients had no relapses to heavy drinking throughout the 32 weeks, compared with only 3% of the cop-
ing/placebo patients. The authors' data confirm the original finding of the efficacy of naltrexone in con-
junction with coping skills therapy. In addition, their data show that detoxification is not required and that 
targeted medication taken only when craving occurs is effective in maintaining the reduction in heavy 
drinking. 
Heikman P, Tuunainen A, Kuoppasalmi K: Value of the initial stimulus dose in right unilateral and bi-
frontal electroconvulsive therapy. Psychol Med 1999;29:1417-23.  
Department of Psychiatry, Helsinki University Central Hospital and KTL, National Public Health Insti-
tute, Finland. 
BACKGROUND: The outcome of electroconvulsive therapy (ECT) is affected by the placement and dose 
of the stimulus. In general, the ECT dose can be selected either by the dose-titration method (on which 
the measured seizure threshold level is based), or the method of predetermined dose (e.g. the age-based 
dosing and the fixed high dose method). METHODS: Seizure thresholds were measured in 50 patients 
with right unilateral (RUL) and in 30 patients with experimental bifrontal (BF) ECT stimulus. The ECT 
dose (mC) of the age-based dosing was calculated by multiplying the age (years) by 5.0 (age method) or 
2.5 (half-age method). The fixed high dose was set to 378 mC. RESULTS: The seizure thresholds had 
only a moderate correlation with the age of the patients. The methods based on the predetermined dose 
would have led us to give patients with the lowest seizure thresholds in the RUL ECT group very high 
stimulus doses, up to 12 (age method) or 15 (fixed high dose method) times the individual seizure thresh-
old. In contrast, the RUL ECT patients with the highest seizure thresholds would have received low 
stimulus doses down to 1.5 times (half-age method) the initial seizure threshold. In the BF ECT group 
the-age based dose would have been similarly dependent on the initial seizure threshold level. 
CONCLUSION: The use of the dose-titration method is recommended, because it is the only method that 
allows for the individual selection of ECT stimulus dose relative to the seizure threshold. 
136 
 
7.3. Drugs and Driving 
 
Alcohol, Drugs and Driving 
The business idea of the Drugs and Driving Project is to study driving under the in-
fluence of alcohol and other psychoactive substances, to reinforce preventive work for 
reducing the number of traffic accidents, to develop testing methods for police use on 
the road and for the laboratory in order to recognize and identify drug use. Development 
of on-site methods and oral fluid testing may be useful e.g. in monitoring pain kill-
ers/opioid concentrations in cancer patients. Applicability of innovations will thus be 
tested in other areas, too. Former projects have benefited the Service Laboratory as well. 
Expertise has been given to the community e.g. in the mode of developing best practices 
in police work for recognizing external symptoms of drug use in order to take drug 
drivers off the roads (Training book: Huumeet ja Liikenne, 2003; instructions and or-
ders of Ministry of Interiors:"Breath and saliva Testing on the road", "Drug dependence 
and driving permission","Drug Use Control in road traffic / Field Sobriety Observa-
tion"), intervention practices for drunken drivers (Päihderiippuvuuden arviointi ja 
ajokelpoisuus, 1998, opas lääkäreille), legislation initiatives and work for law proposals 
for drugs and driving (Zero-tolerance law for illicit drugs and driving, 2003) (resulting 
Traffic Safety Award 2007) as well as best practices and work for legislation and decree 
for work place drug testing (Asetus huumausainetestien tekemisestä 218/2005; Huu-
mausainetestaus työelämässä, 2006). 
The Drugs and Driving project is lead by Dr. Pirjo Lillsunde. The project started in 
the beginning of 2007. The work leading to the start of this project is originating from a 
long and thorough expertise in the field as head of the former drug testing laboratory 
and as a ministerial expert in drug policy and in traffic policy. The objectives of the 
project are to provide information for drug- and traffic policy in order to prevent harm 
associated to drug and alcohol use, especially in road traffic. 
 
The four on-going studies of the project funded by external funds are an EU-project 
Driving under the Influence of Alcohol, Drugs and Medicines (DRUID), The life course 
of DUI offenders (RATTI /Finnish Academy), Monitoring of opioid levels in plasma 
and oral fluid in cancer patients (HUS) and a developing project for opioid on-site tests 
(VTT/TEKES).  The DRUID-project is a Integrated Project funded by the European 
Commission within the 6th framework programme. The DRUID- and (Life course of 
DUI offenders) Ratti-projects will last four years until 2010. The fifth important area is 
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work place drug testing, especially in establishing best practices in that area. Work 
Place testing practices (decree etc.) were prepared under Ministry of Social Affairs and 
Health and the Institute of collaboration 
 
7.3.1. Research and public health significance of the area 
 
One fourth of all fatal traffic accident victims were killed in drink driving accidents 
during the last few years in Finland. Driving under the influence of alcohol and/or drugs 
is often associated with alcohol, social, economical, medical, criminal and other prob-
lems.  Mortality from accidents, suicides and homicides was found to be significantly 
higher among drunken drivers than in the general population. There is evidence that 
drug users are more prone to high risk behaviour than the general population. The zero 
tolerance law for drugs and driving has sharply increased the number of prosecuted 
drugs and driving cases. Between 1972-1994, approximately half of the Finnish drunken 
drivers were problem drinkers and 2/3 were recidivists. 
Harmful effects of alcohol are one of the major health and social problems in 
Finland. They are intended to be reduced by means of different activities laid down in 
the Alcohol Program (Ministry of Social Affairs and Health 2004). One of the most 
efficient means in reducing harmful effects of alcohol is to prevent drunk driving. The 
traffic Safety Action Plan for the years 2006-2010 includes measures to be taken in or-
der to prevent DUI. Its proposals are reducing legal limit from 0.5 o/oo to 0.2 o/oo and 
the use of alcolock as prevention (Ministry of Traffic and Communication, 2005). In 
addition, the growth of social exclusion is considered to be a major social problem and 
the greatest challenge to improving internal security (Ministry of the Interior 2004). The 
number of people living on the margin of society may increase and cause serious per-
sonal, health, social, and economic problems. Still today, people slide into a criminal 
way of life mainly because they feel excluded from society. Supporting young people 
by early intervention and encouraging their integration into society are important means 
in prevention of social exclusion. Driving license ownership is a marked symbol of in-
dependent and integrated citizenship, which impaired driving will jeopardize. The 
knowledge of the factors that lead to DUI is poor. Moreover, little is known about the 
past, present and future life course of the DUI offenders. New knowledge is needed in 
decision making for health policy and traffic policy actions e.g. planning and imple-
menting prevention, intervention and treatment programs.  
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DRUID 
DRUID deals with the scourge of drink-and-drug-driving and is intended to find 
answers to questions concerning the use of drugs or medicines that affect people's abil-
ity to drive safely. It will bring together the most experienced organisations and re-
searchers throughout Europe, involving about 20 European countries. The aim is to gain 
new insights to the real degree of impairment caused by psychoactive drugs and their 
actual impact on road safety. All in all this Integrated Project will fill the gaps of knowl-
edge and provide a solid base to generate harmonised, EU-wide regulations for driving 
under the influence of alcohol, drugs and medicine.  
The main emphasis in KTL will be to assess the prevalence of alcohol and other 
psychoactive substances in drivers in general traffic and drivers involved in injury acci-
dents, to calculate the accident risk for drug impaired drivers and to identify characteris-
tics of drug impaired drivers. Equipment and skills to recognize drug users in traffic will 
be further developed. The work will serve as a basis to gain more knowledge in the field 
to aid the prevention and legislation actions. 
 
The life course of DUI offenders 
The main questions of this study are: 1) what are the factors that lead to driving 
under influence of alcohol and/or drugs? 2) what happens to the DUI offenders during 
their subsequent life span in terms of health and social position? 3) what kind of preven-
tive conclusions can be drawn? 
The study employs the register data of suspected driving under the influence of al-
cohol and/or drug cases. Data include all suspected DUI-drivers since 1988 in Finland, 
about 20.000 persons per year. The basic data will be complemented by linking data 
from other Finnish registers following privacy protection, data security and ethical 
rules. In this follow-up study the history of criminality, movement, employment peri-
ods, marital status, hospital inpatient treatment etc. before the indexed DUI can be in-
vestigated retrospectively, too. The site of the research is the Department of Mental 
Health and Alcohol Research in National Public Health Institute. 
The results will improve the scientific understanding of DUI behavior, the impact 
of changes in laws and different policies on DUI behavior, and, the association of DUI 
episodes to the process of social exclusion, and to inequalities in health and mortality. 
The new knowledge is needed in decision making for health policy and traffic pol-
icy actions e.g. planning and implementing prevention, intervention and treatment pro-
grams. This study will identify entry points for relevant policies and interventions. 
139 
The project is funded by the the Finnish Academy. Dr Aini Ostamo is the responsi-
ble researcher and she is supervising two Ph.D. students in this project.       
 
Monitoring of opioid levels in plasma and oral fluid 
This study consists of two sub projects. The aim of the collaboration study with the 
Helsinki University Hospital Pain Clinic is to survey opioid concentrations in cancer 
patients' plasma and oral fluid. Absorption and the usability of different administration 
routes can be evaluated according to the plasma drug concentrations and to plan the 
drug administration/dosages to correspond the needs of the patient. Opiod levels in oral 
fluid and plasma are compared. The aim is to find out whether oral fluid could be used 
for monitoring opioid concentrations in cancer patients. It would open the possibility for 
on-site testing by cancer patient at home. Therefore this project is connected to another 
project with VTT Reseach center. VTT has developed a specific on-site test for detect-
ing morphine (later other substances). The results of VTT on site test and laboratory 
GC/MS tests will be compared. 
Although this is not a traffic project, this subproject gives added value to the traffic 
projects because of the technology used. The knowledge gained and methods developed 
in this sub project can be used in traffic projects as well as in drug testing generally. 
 
Work Place Drug Testing 
A follow-up study on work place drug testing will be done in 2007-2008 in col-
laboration with Institute of Occupational Health and with the Ministry of Social Affairs 
and Health. The aim is to investigate experiences and the extent that work place drug is 
done in the Finnish Society. Also the effect of the new legislation is studied. 
 
7.3.2. The main scientific achievements 
 
Success in seeking external funds has resulted in establishing the 'Päihteet ja 
liikenne' /Alcohol, Drugs and Driving Project in January 2007. Pirjo Lillsunde now has 
possibilities to concentrate more on alcohol, drugs and driving research since 2006.  The 
project is at the very beginning. In addition to the earlier established international col-
laboration centers in EU-projects and good collaboration with the ministries (Traffic 
and Communication; Interior; Social Affairs and Health, Justice), new collaboration 
networks have been built with different KTL departments (Injury Prevention Unit etc), 
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with universities (Helsinki, Tampere and Turku), with Finnish Motor Investigation In-
surers' centre / Traffic Safety Investigation Teams and with the Polytechnic Police 
Academy. 
Drugs and driving research projects produced five publications in 2005-2007. Dur-
ing the previous Rosita project, laboratory methods were developed extensively and 
these methods were published and for example will be part of a doctoral thesis by 
Teemu Gunnar. One of those publications was awarded as a best young scientists' pub-
lication in 2005. Analyzing drugs in oral fluid opens new possibilities and oral fluid is 
used as important specimens also in the DRUID project. The analytical development 
work around the oral fluid is continuing. 
Work place drug testing development work produced six publications in 2006-2007. 
 
Publications in Drugs and Driving projects: 
Engblom C, Gunnar T, Rantanen A, Lillsunde P. Driving Under the Influence of Drugs-Amphetamine 
Concentrations in Oral Fluid and Whole Blood Samples. J Anal Toxicol. 2007 31:276-80. 
National Public Health Institute, Drug Research Unit, Mannerheimitie 166, FI-00300 Helsinki, Finland. 
charlotta.engblom 
This study investigated amphetamine concentrations in both oral fluid and whole blood samples of per-
sons suspected of driving under the influence of drugs. The data for the study were obtained from 153 
cases. The mean volume of oral fluid collected with the Intercept oral fluid collection device was 224 
microL. Because of the small sample volume of oral fluid, the results of the amphetamine concentrations 
in oral fluid were not used in the calculations for 39 cases. The total number of cases positive for am-
phetamine in oral fluid was 100 out of 114. In seven cases the oral fluid sample was positive (cutoff 25 
microg/L), even though the whole blood sample was negative (cutoff 20 microg/L). All of the cases found 
positive in whole blood (n = 93) were also positive in oral fluid. Oral fluid would therefore be well suited 
as a testing matrix for amphetamine when driving under the influence is suspected. The results neverthe-
less indicated that the cutoff used for amphetamine in oral fluid (i.e., 25 microg/L) could be higher to 
correspond to the window of detection given by the level of 20 microg/L in whole blood. 
Gunnar T, Ariniemi K, Lillsunde P. Validated toxicological determination of 30 drugs of abuse as opti-
mized derivatives in oral fluid by long column fast gas chromatography/electron impact mass spectrome-
try. J Mass Spectrom. 2005 40(6):739-53. 
National Public Health Institute, Drug Research Unit, Mannerheimintie 166, 00300 Helsinki, Finland. 
teemu.gunnar@ktl.fi 
An analytical procedure was developed for the simultaneous sensitive identification, screening and quan-
titation of 30 drugs of abuse using 250 microl of human oral fluid. The method employs sequential 
mixed-mode solid-phase extraction (SPE), optimized derivative formation and long-column fast gas 
chromatography/electron impact mass spectrometry (GC/EI-MS). After sequential SPE elution, the most 
sensitive and stable derivatives were formed by taking careful account of the characteristics of the active 
functional groups and possible steric hindrances affecting derivatization chemistry. Amphetamine-type 
stimulant drugs were acylated with heptafluorobutyric anhydride, benzodiazepines and Delta(9)-
tetrahydrocannabinol were silylated with N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide and 
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benzoylecgonine, codeine, ethylmorphine, 6-monoacetylmorphine, morphine, pholcodine, buprenorphine 
and norbuprenorphine with N-methyl-N-(trimethylsilyl)trifluoroacetamide. In addition, the following 
analytes were included: methadone, cocaine, alprazolam, midazolam, fentanyl and zolpidem. In GC sepa-
ration, fast temperature ramping and high carrier gas flow-rate combined with long 30 m columns of i.d. 
0.32 mm offered a reduction in analysis time and sharp peak shapes while still maintaining sufficient 
resolution and high sample capacity. Validated parameters including selectivity, linearity, accuracy, intra- 
and inter-day precision, extraction efficiency and limit of quantitation were all within required limits. In 
contrast to previously published methods, this single procedure is suitable for the simultaneous toxico-
logical determination of the most common illicit drugs and benzodiazepines, and also zolpidem, in a 
small amount of oral fluid. 
Gunnar T, Rantanen A, Engblom C, Seppä H, Lillsunde P. ROSITA 2 in Finland. Rosita-2 project, Final 
Report. 2006:55-95. 
Lillsunde P, Gunnar T. Drugs and driving: The Finnish perspective. Bulletin on Narcotics 2007 in press. 
Rantanen A, Gunnar T, Engblom C, Seppä H, Jama A, Lillsunde P. Roadside oral fluid testing : Compari-
son of the results of Drugwipe 5 and Drugwipe Benzodiazepines on-site tests with laboratory confirma-
tion results of oral fluid and blood. Forensic Sci Int. 2007 Jul 17 
National Public Health Institute, Drug Research Unit, Mannerheimintie 166, FI-00300 Helsinki, Finland. 
Drugged drivers pose a serious threat to other people in traffic as well as to themselves. Reliable oral fluid 
screening devices for on-site screening of drugged drivers would be both a useful and convenient means 
for traffic control. In this study we evaluated the appropriateness of Drugwipe 5 and Drugwipe Benzodi-
azepines oral fluid on-site tests for roadside drug screening. Drivers suspected of driving under the influ-
ence of drugs were screened with the Drugwipe tests. Oral fluid and whole blood samples were collected 
from the drivers and tested for amphetamine-type stimulant drugs, cannabis, opiates, cocaine and benzo-
diazepines by immunological methods, GC and GC-MS. The performance evaluations of the tests were 
made by comparing the results of the Drugwipe tests with laboratory GC-MS confirmation results of oral 
fluid or whole blood. In addition to the performance evaluations of the Drugwipe tests based on labora-
tory results, a questionnaire on the practical aspects of the tests was written for the police officers who 
performed the tests. The aim of the questionnaire was to obtain user comments on the practicality of the 
tests as well as the advantages and weak points of the tests. The results of the performance evaluations 
were: for oral fluid (sensitivity; specificity; accuracy) amphetamines (95.5%; 92.9%; 95.3%), cannabis 
(52.2%; 91.2%; 85.1%), cocaine (50.0%; 99.3%; 98.6%), opiates (100%; 95.8%; 95.9%), benzodiazepi-
nes (74.4%; 84.2%; 79.2%) and for whole blood accordingly, amphetamines (97.7%; 86.7%; 95.9%), 
cannabis (68.3%; 87.9%; 84.9%), cocaine (50.0%; 98.5%; 97.7%), opiates (87.5%; 96.9%; 96.6%) and 
benzodiazepines (66.7%; 87.0%; 74.4%). Although the Drugwipe 5 successfully detected amphetamine-
type stimulant drugs and the police officers were quite pleased with the current features of the Drugwipe 
tests, improvements must still be made regarding the detection of cannabis and benzodiazepines. 
 
Publications in work place drug testing subproject 
Lillsunde P, Haavanlammi K, Partinen R, Mukala K, Lamberg M. Finnish guidelines for workplace drug 
testing. Forensic Sci Int. 2007 May 11 
National Public Health Institute, Helsinki, Finland. 
The Finnish guidelines for workplace drug testing outlined here represent what is considered the best 
practice for workplace drug testing to be followed in Finland. The guidelines are based on the act on the 
protection of privacy in working life (759/2004), the occupational health care act (1383/2001) and the 
decree on workplace drug testing (218/2005). They start by defining situations in which workplace testing 
142 
is allowed and continue up to the point where the certificate is submitted to the employer. The role of the 
occupational health care system is crucial in the procedure. The guidelines include the best practice pro-
cedures to be followed by laboratories providing workplace drug testing services. The laboratory recom-
mendations are based on general principles established internationally. In the Finnish guidelines, accredi-
tation is an absolute prerequisite for a laboratory functioning as a workplace drug testing laboratory. The 
laboratory section of the guidelines includes specimen collection, laboratory organisation, analysis proce-
dure, quality assurance and quality control measures. These largely conform to the European laboratory 
guidelines for legally defensible workplace drug testing published by the European workplace drug test-
ing society (EWDTS), but there are differences. In addition to using urine as a specimen, the Finnish 
guidelines also encompass blood. 
Lillsunde P, Mukala K, Partinen R, Lamberg M. Role of occupational health services in workplace drug 
testing. Forensic Sci Int. 2007 Apr 26. 
National Public Health Institute, Helsinki, Finland. 
In Finland, workplace drug testing is mainly performed in accordance with the Act on the Protection of 
Privacy in Working Life (759/2004), (http://www.finlex.fi/en/laki/kaannokset/2004/20040759) [1], the 
Occupational Health Care Act (1383/2001), (http://www.finlex.fi/en/laki/kaannokset/2001/20011383) [2] 
and the Decree on Workplace Drug Testing (218/2005) [3]. The role of occupational health services is 
stated in the Occupational Health Care Act. All workplace drug tests are carried out by health services 
according to good occupational health care practice. A referral for a drug test is given by a physician or a 
nurse working in health care services. When giving the referral, the physician or nurse should inform the 
person to be tested of the purpose and content of the test, record any medication they may be using, and 
make sure they are aware that they can later dispute the result of the test. The identity of the person 
should be checked before taking a sample. The analysis laboratory sends the result of the drug test to the 
health care service unit that has given the referral. If the test result is positive, the laboratory gives a de-
tailed analysis of the test result. The health care service personnel provide the testee with the result. If it is 
negative, it may be given by a nurse. When the test result is positive, a Medical Review Officer (MRO) 
should interpret the answer and evaluate whether the positive result is due to medication, or another rea-
sonable explanation offered by the person tested. The MRO informs the person of the options of rehabili-
tation treatment available to drug abusers stated in the written drug testing policy/programme of the em-
ployer/company. The testee takes the test result report to his/her employer personally. 
Meririnne E, Henriksson M, Mykkänen S, Lillsunde P, Kuoppasalmi K, Lerssi R, Laksonen I, Lehtomäki 
K. Työpaikan huumetestaus puolustusvoimissa 2002-2005. Suomen Lääkärilehti 2007 14-15:1540-41b. 
 
Meririnne E, Mykkänen S, Henriksson M, Lillsunde P, Lehtomäki K. Workplace drug testing in a mili-
tary organization: results and experiences from the testing program in Finnish defence forces. Forensic 
Sci Int. 2007 Aug 6;170(2-3):171-4. Epub 2007 Jul 13. 
Centre for Military Medicine, The Finnish Defence Forces, Lahti, Finland. esa.meririnne@mil.fi 
<esa.meririnne@mil.fi> 
In the military environment drug abuse is a particular risk for occupational safety. In the Finnish Defence 
Forces a drug testing program was conducted in 2002-2005; soldiers, professional civilians, and military 
students were tested when applying for a work or right to study; furthermore, annually 5% of the person-
nel were subjected to random testing. In total, over 2000 urine samples were analyzed in an accredited 
laboratory for cannabis, opiates, amphetamines, or cocaine. In this article, the drug testing program as a 
part of the anti-drug strategy of the Finnish Defence Forces is described, and the findings including prac-
tical experiences and financial expenses are reported. Only one person applying for a civilian post tested 
positive for amphetamine and cannabis. In seven other samples codeine and morphine were detected; 
these were, however, due to prescribed medication, not drug abuse. In the execution of the program, no 
143 
particular difficulties were reported. In conclusion, it seems that the use of illicit drugs in the Finnish 
military is extremely rare, at least partly due to the successful anti-drug strategy. After an elaborate plan-
ning, even an extensive drug testing program can be executed without substantial setbacks. In the future, 
the effectiveness of drug testing programs as a means of improving occupational safety needs to be inves-
tigated in controlled studies using comparative design. 
Lamberg ME, Kangasperko R, Partinen R, Lillsunde P, Mukala K, Haavanlammi K. The Finnish legisla-
tion on workplace drug testing. Forensic Sci Int. 2007 May 9. 
Ministry of Social Affairs and Health, PB 33, FIN-00023 Government, Helsinki, Finland. 
In Finland, the Act on the Protection of Privacy in Working Life (759/2004) that entered into force in 
2004 incorporates provisions related to drug use testing, e.g. on the employers' right to process in certain 
situations information on job applicants' and employees' drug use. In the same context, provisions were 
added to the Occupational Health Care Act (1383/2001) on the employer's obligation to draw up, together 
with the staff, a written programme dealing with alcohol and drugs for the workplace. The programme 
defines the overall objectives for and the practices to be observed at the workplace in order to prevent 
substance abuse and to refer the problem users to treatment. The Occupational Health Care Act also in-
cludes provisions on drug tests and the drug test certificate as well as on reimbursement of the expenses 
of drug tests. Furthermore, the Act lays down a definition of drug tests. Every workplace shall have a 
plan/programme on drug-free workplace, where the jobs in which the workers have to present a drug test 
certificate to the employer must be defined. This plan/programme shall be discussed in cooperation on 
tripartite basis at the workplace. A Government decree on drug use testing (218/2005) has been issued in 
virtue of the Occupational Health Care Act. It lays down provisions on the practical performance of drug 
tests, i.e. taking and analysis of samples, and interpretation of the test results. The purpose of the Gov-
ernment decree is to ensure that workplace drug testing is carried out in a way presupposed by a good 
occupational health care practice and the laboratory quality standards, taking into account the integrity 
and protection of privacy of the persons tested as well as their other fundamental rights. 
Lamberg ME, Lillsunde P, Mukala K, Partinen R. Huumausainetestaus työelämässä. Sosiaali- ja terveys-
ministeriön julkaisuja 2006 2:54 s. 
 
Several congress presentations are to be given by the team members in 2007, in-
cluding two presentations as invited speakers: 1) Anna Pehrsson: Selection of Oral 
fFuid Collection Device for the DRUID-project ( ICADTS2007, Seattle) and 2)  Pirjo 
Lillsunde  Drug Testing in Oral Fluid (International Congress of Therapeutic Drug 
Monitoring & Clinical Toxicology, Nice, 2007). 
 
7.3.3. The main public health achievements 
 
The traffic safety award was given by the minister of traffic and communication in 
June 2007 because of the previous work for developing best practices (police training - 
recognizing drugs from external symptoms, road side drug tests; instructions, orders and 
legislation changes, especially during the two EU-ROSITA projects 1998-2005). It has 
resulted in better means for the police to pick out drivers that are under influence of 
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drugs. The results can be seen also in the Drug Research Unit / Service Laboratory, 
where the number of samples has increased four fold in ten years. Police suspected 1010 
drivers in 1996 for driving under influence of drugs and correspondingly 4025 drivers in 
2006. In particular the Rosita project has benefited the Service Laboratory through 
blood screening method developmentr which has prepared the Drug Research Unit's 
Service Laboratory for changes that were needed in analytical procedures for adjusting 
to the zero tolerance law. 
The main achievement in drug policy in 2007 was that the UN resolution proposal 
made by Pirjo Lillsunde during the Finnish EU Presicency was presented as common 
EU resolution proposal in United Nations Commission for Narcotic Drugs. The resolu-
tion was accepted by all Nations in UN in March 2007 (Resolution 50/4 Improving 
quality and performance of drug analysis laboratories). 
Work place testing practices were developed in collaboration with the Ministry of 
Social Affairs (Matti Lamberg and Riva Partonen) and Institute of Occupational Health 
(Kristiina Mukala) and a follow-up study in order to evaluate the legislative changes 
will start in 2007. As output a decree for workplace drug testing was accepted in 2005, 
the guide 'Best practices for work place drug testing' was published (Ministry of Social 
Affairs and Health) and three articles are in press in Forensic Science International. In 
work place drug testing research there was collaboration with the Finnish Defense 
Forces in the form of publications and congress presentations. 
 
7.3.4. Funding for research and public health programs 
 
 
Study Contributor Amount Duration 
DRUID 
European commis-
sion 
1 088 
130.40 
15.10.2006-
14.10.2010 
RATTI Academy of Finland 415 000 1.1.2007-31.12.2010 
Opioids Cancer Trust 7000 1.1.2007-31.12.2008 
Opioids VTT/TEKES 20 000 1.1.2007-31.12.2008 
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7.3.5. Personnel 
 
Regular personnel  
Head of Laboratory Pirjo Lillsunde, PhD docent (70 %) (30 % in the Service Labo-
ratory) 
RATTI 
Senior researcher Aini Ostamo, PhD (50 %) 
 
Project personnel 
DRUID 
Researcher Charlotta Engblom, M.Sc. (Tech). 
Researcher Anna Pehrsson (née Rantanen),  M.Sc. (Tech). 
Researcher Kaarina Langel (50 %, starting October 2007), M.Sc (Tech). 
Diploma work student Tom Blencowe, B.Sc. 
 
RATTI  
Senior researcher Aini Ostamo, PhD (50 %). 
Researcher Antti Impinen, M.Sc. (50 %-80%). 
Researcher Karoliina Ojaniemi, M.Sc. 
 
7.3.6. Collaboration 
 
DRUID  
KTL is a partner in the consortium consisting of 36 partners from 18 European 
countries. The research colleagues in this consortium consist of experts and young sci-
entists representing a multidisciplinary field.  
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The collaborators in Finland are: 
Ministry of Interior / Police Department / Heikki Ihalainen; Mobile Police/ Pasi 
Kemppainen, Jari Pajunen, Jussi Pohjonen ja Emmi Virret. 
Finnish Motor Insurers' Centre / Esa Räty  
Finnish Road Administration /Pekka Räty 
Helsinki University / prof. Erkki Vuori  
 
RATTI 
Jari Haukka, PhD, docent, senior researcher: National Public Health Institute 
(KTL), Department of Mental Health and Alcohol Research 
Aarne Kinnunen, M.Sc, Ministerial Adviser: Department of Mental Health and Al-
cohol Research 
Seppo Koskinen, MD, PhD, docent, chief physician:  Department of Health and 
Functional Capacity 
Tomi Lintonen, PhD, docent, senior researcher, Polytechnic Police Academy 
 
Jouko Lönnqvist, MD, PhD, professor: Head of the Department Department of 
Mental Health and Alcohol Research, University of Helsinki, Department of Psychiatry 
Tuija Martelin, PhD, senior researcher: Department of Health and Functional Ca-
pacity 
Pia Mäkelä, PhD, docent, senior researcher: STAKES, The National Research and 
Development Centre for Welfare and Health 
Mika Salminen, PhD, docent, Head of the Laboratory: KTL, Department of Infec-
tious Disease Epidemiology 
Heikki Seppä, Chief Superintendent: Ministry of the Interior 
Heikki Summala, PhD, professor: University of Helsinki, Department of Psychology 
Erkki Vuori, MD, PhD, professor: University of Helsinki, Department of Forensic 
Medicine 
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Monitoring of opioid levels in plasma and oral fluid 
The main partner in this project is HUS/Pain clinic (prof. Eija Kalso and MD Tarja 
Heiskanen), VTT /PhD Timo Pulli and Helsinki University/Forensic Medicine Depart-
ment, Forensic Medicine /Prof Erkki Vuori.  
 
7.3.7. Proposal for future work and expected benefits 
 
The project was just started in 2007. The aim is to strengthen and deepen this re-
search field in KTL in collaboration with other partners. Results will be used in decision 
making for health policy, traffic policy and drug policy actions e.g. planning and im-
plementing prevention, intervention and treatment programs. The aims are to reduce 
accidents caused by alcohol and drugs, reduce recidivism, prevent social exclusion and 
increase well being and health of the target groups and increase safety. 
 
7.4. Paid Service Activity 
 
7.4.1. Research and public health significance of the area 
 
Driving under the influence of alcohol or drugs is a serious national problem.  
Blood samples or breath samples are annually taken from about 25 000 drivers on the 
request of the police. Paid service activity includes the analysis of alcohol and drugs in 
blood, and urine of suspected  drinken and drugged drivers caught by police. In addi-
tion, drug analysis are also used for work place drug testing as well as drug testing in 
health care units, and in units of welfare for alcohol and drug abusers.  
 
7.4.2. The main scientific achievements 
 
Paid service activity has no scientific goals, but high level of customer-oriented 
services, customer satisfaction, quality assurance, fast response time and cost-
effectiveness of the processes to produce the analysis results are needed.  
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7.4.3. The main public health achievements 
 
 Paid service activity must produce competent answer for police as a part of the 
preliminary investigation before the court proceedings. In addition, a lot of development 
work in co-operation with police has been carried out during the past few years (see in 
details Päihderiippuvuus and Päihteet ja liikenne -projects). 
 
7.4.4. Funding for research and public health programs 
 
The funding of paid service activity is based on a price list which has been agreed 
upon with the customers. No other funding for the paid service activity is available.  
 
7.4.5. Personnel 
 
The personnel includes altogether 22 persons, 10 of them with an academic degree. 
The rest of the workers are laboratory technicians or office workers. The equipment 
includes nine bench-top GC-MS instruments (which some of them are very modernly 
equipped) and a few GCs. 
 
7.4.6. Collaboration 
 
The contract with the police is a strategic one and thus also includes development work.  
 
7.4.7. Proposal for future work and expected benefits 
 
Continuous development work is needed to keep the paid service activity as com-
petitive as possible.   
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8. ADOLESCENT MENTAL HEALTH UNIT 
 
8.1. Mental health and psychiatric disorders in adolescence 
 
8.1.1. Research and public health significance of the area 
 
Most major psychiatric disorders have their onset in adolescence and the incidence 
and prevalence of psychiatric disorders in adolescence are high, so research on adoles-
cent mental health and disorders may have a major public health impact. 
"The Mental health in adolescence" project at the Dpt of Mental Health and Alco-
hol Research at the KTL started in 1998. It focuses on adolescent mental health and 
major psychiatric disorders. The main research areas are prevalence, risk factors, course 
and its predictors, and treatment of adolescent psychiatric disorders, particularly depres-
sive disorders, and suicidal behaviour among youth. Health promotion and early identi-
fication of disorders among youth are other foci of the project. 
The main databases for research consist of adolescent psychiatric patient cohorts 
and general adolescent and young adult population cohorts. 
 
Adolescent psychiatric patient cohorts 
The Adolescent Depression Study (ADS) is a naturalistic clinical research and de-
velopment project on adolescent depressive disorders using a sample of 218 consecutive 
13-19-year-old adolescent psychiatric outpatients (referred in 1998 - 2001) and a 
school-based control group of 200 age- and sex-matched controls. At baseline, the pa-
tients were screened for depressive symptoms and diagnosed using the K-SADS-PL 
interview. Several observer and self report measures were used at the baseline and at 
12-month follow-up. Six-year follow-up interviews will be conducted in the autumn 
2007 and spring 2008. 
The follow-up study of youth with psychiatric disorders (FYPD) consists of over 
500 subjects from two cohorts: unselected 13-22 year-old outpatients treated in 1984-
1994 at a psychiatric outpatient secondary care clinic and 11 - 22-year old inpatients 
admitted to Kellokoski hospital in 1972-1975. Data were collected as part of routine 
clinical work and systematically coded in medical records using structured coding 
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sheets. Best estimate clinical diagnoses (DSM-III-R)] were assigned. A register follow-
up of accidents in 302 outpatients was conducted in 2006. 
The Kellokoski Adolescent Inpatient Follow-Up Study (KAIFUS) is a development 
and research project started in 2006. It aims at following up and finding clinical and 
biological predictors for outcome for 2 and 5 years in a patient cohort of 300 consecu-
tive adolescent psychiatric inpatients and a school-based sample of 200 controls. At the 
moment, data collection is under way. Clinical interview and register follow-ups are to 
be conducted. 
The Suicidality in Children and Adolescents (SCA) is a study aiming at developing 
the assessment and treatment of children and adolescents referred to the emergency de-
partment (ED) of the Hospital for Children and Adolescents of the HUCH. It consists of 
a retrospective pilot study and a prospective study. A retrospective hospital record pilot 
study sample of 100 children and adolescents referred due to intoxication at the ED of 
the Hospital for Children and Adolescents of the HUCH in 2003 has been collected and 
analyses are under way. Prospective structured data collection started in 2006 and is 
under way. The study aims at characterizing the intoxicated children and adolescents, at 
finding out what proportion of the intoxications are suicide attempts and at following up 
their outpatient treatment after discharge. Their outcome after two and five years after 
discharge will be studied in a register follow-up. 
 
Adolescent general population cohorts 
The Adolescent Mental Health Cohort Study (AMHC-Study) is an ongoing pro-
spective cohort study of 3 278 15-year old subjects conducted in two Finnish cities 
Tampere and Vantaa. Data collection at baseline was conducted during the school term 
2002 -2003 among ninth grade students of all the Finnish-speaking comprehensive 
schools in the two cities. The students completed a person-identifiable questionnaire 
during a school lesson. A two-year follow-up was conducted in 2004 - 2005 using 
postal questionnaires. The study examines epidemiology, comorbidity and risk and pro-
tective factors of non-psychotic disorders in adolescence. 
Mental Health in Young Adults (MHYA) is a study of originally 1493 high-school 
students from Helsinki and Jyväskylä, with a 5-year follow-up of 709 students who vol-
unteered for follow-up at the baseline. The study provides data on adolescent risk fac-
tors for major disorders in young adulthood, data on the epidemiology on current psy-
chiatric disorders, particularly depression in young adulthood as well as data on help 
seeking and use of health care services. 
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Health promotion 
In the health promotion projects several guides on early detection and depression, 
suicidal behavior, ADHD, conduct and substance use disorders for adolescents and their 
parents and professionals working with adolescents have been prepared and published 
in the internet (KTL homepage). The guides have been developed in a collaborative 
network of shool nurses, counselors, social workers, and professional in the fields of 
treatment of youthful substance users and adolescent psychiatry in the city of Vantaa. 
 
Other studies conducted in collaboration with the project 
POLKU study is an ongoing study in Mikkeli focusing on psychiatric morbidity, 
particularly depressive, conduct and substance use disorders among 87 students in three 
correctional schools. Study 70 is a study of over 400 inpatients aged 12 - 17 years ad-
mitted at the ward 70 of the University Hospital of Oulu in 2001-2005. The Kuopio 
Adolescent Inpatient Study is a study of 63 adolescent inpatients treated at the adoles-
cent psychiatric wards of the University Hospital of Kuopio in 1997-1999. The project 
collaborates also with the School Health Promotion Survey, conducted by STAKES and 
Tampere School of Public Health. 
 
8.1.2. The main scientific achievements 
 
Using the adolescent psychiatric patient cohorts, we have reported high rates of 
suicidality (42 - 49 %) among adolescent outpatients. Severe psychosocial impairment, 
psychiatric treatment history and mood disorders characterize suicidal adolescent pa-
tients in these cohorts. Particularly deliberate self-harm with no suicidal intent (mostly 
cutting) associated with anxiety symptoms. Our group is among the few reporting char-
acteristics of adolescents with adjustment disorders, and suicidal behaviour among 
them, a little studied disorder in youth. Common risk factors for suicidality, like previ-
ous psychiatric treatment, poor psychosocial functioning, exposure to suicide of signifi-
cant others, and depressed mood characterized suicidal patients with adjustment disor-
ders. Improvement in adolescent outpatients´ psychosocial functioning during treatment 
as usual was highly dependent on psychiatric diagnosis and comorbidity. Early dropping 
out from outpatient treatment associated with low parental socioeconomic status and 
substance abuse. Suicidal adolescent patients were as compliant as non-suicidal, a find-
ing differing from many previous studies. During a 6-year follow-up of adolescent out-
patients, total mortality (10.3 %) and suicide mortality (7.1 %) rates were high among 
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males. Severe impairment and suicidality associated with mortality. In a 20-year regis-
ter-based follow-up of former adolescent inpatients, half of the subjects had not been 
long-term pensioned and better psychosocial functioning and capability for work in 
young adulthood associated with better outcome in terms of working capacity. 
The rate of psychiatric comorbidity was high (78 %, particularly anxiety, substance 
use, eating and disruptive disorders) among adolescents with depressive disorders. Co-
morbidity with DSM-IV Axis II disorders was also high (41 %) which has not usually 
been elaborated in previous studies on adolescent depression. Only half of the depressed 
patients remitted during a 1-year follow-up, a considerably lower proportion than re-
ported in most previous reports consisting of adolescents recruited to treatment trials 
indicating the need of studies in "real life" settings. 
Our aims in analyzing the adolescent general population cohorts have been to re-
port on the epidemiology of common psychiatric problems, their correlates and predic-
tors, and use of services among adolescents and young adults. The prevalence of any 
psychiatric disorder among young adults was 24 %, the most prevalent being depressive 
(11 %), anxiety (7 %), substance use (6%) and personality disorders (6%). Current co-
morbidity was common (39%). Only one third of subjects with a current disorder, and 
less than half of those with depression reported a contact with psychiatric services indi-
cating severe under-treatment. Comorbidity was related to impairment, treatment need, 
and treatment contacts among depressed young adults. 
Depressive symptoms in adolescence predicted depressive disorders, but also co-
morbidity, psychosocial impairment, and problem drinking in early adulthood. Use of 
cannabis in young adulthood was related to male gender, absence of mother, frequent 
lack of interest and early age at first sexual intercourse. Relief smoking, relief drinking, 
and their interaction predicted higher average alcohol intake and heavy drinking in 
young adulthood. The level of somatic symptoms in early adulthood was predicted by 
the respective level in adolescence and by relief smoking among men. Among women, 
the level of somatic symptoms at follow-up was predicted by the respective level in ado-
lescence, self esteem, and the number of negative life events at baseline. High trait 
anxiety and somatic symptoms among adolescent females and immature defence style 
among males predicted mental distress in young adulthood. After validating the Social 
Phobia Inventory for use in Finnish adolescents, the prevalence and correlates of social 
phobia have been studied and found to be prevalent among Finnish adolescents. 
Using the School Health Promotion Survey database, we have reported an in-
creased prevalence of depression and severe suicidal ideation among both those who 
were bullied and those who were bullies. Depression was most common among those 
students who were both bullied by others and who were also bullies themselves. When 
symptoms of depression were controlled for, suicidal ideation occurred most often 
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among adolescents who were bullies indicating need for psychiatric intervention both 
for victims of bullying and for bullies. Analyses of the same database showed early pu-
berty to be associated with externalising symptoms among both genders, and also inter-
nalizing symptoms among girls. 
 
8.1.3. The main public health achievements 
 
The aims of all the clinical studies (ADS, KAIFUS, POLKU, SCA) are both to cre-
ate databases for scientific purposes and to develop treatment practices. They all include 
education of clinical staff on psychiatric issues, different treatment approaches, and de-
velopment of treatment and services for adolescents. The epidemiological and clinical 
data form a scientific basis for development. 
The guides in the health promotion projects have been developed in a collaborative 
network of school nurses, councelors, social workers, and professionals in the fields of 
treatment of youthful substance users and adolescent psychiatry in the city of Vantaa. 
The guides base on analyses of the existing databases at the KTL and literature reviews. 
The guides cover early detection of depression, suicidal behavior, ADHD, conduct and 
substance use disorders. A guide on substance use and violence in adolescence is under 
preparation. 
 
8.1.4. Funding for research and public health programs 
 
In addition to departmental funds, the studies have been and are funded by the HUS 
EVO-funding, by the Health Promotion funds of the Ministry of Social Affairs and 
Health, and different Finnish foundations. 
 
8.1.5. Personnel 
 
Personnel currently paid by the KTL include Mauri Marttunen (20 %), Mirjami 
Pelkonen (20 %), and Tiia Pirkola (35 %). Other personnel, (one researcher (100 %), 
research assistant (20 %), research secretary (30 %) is currently paid by a fund from the 
Sigrid Juselius Foundation. 
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In all, eight post doc researchers and ten researchers preparing their theses partici-
pate in the studies. 
 
8.1.6. Collaboration 
 
All the patient cohort studies are conducted in collaboration between the Helsinki 
University Central Hospital and the Department of Mental Health and Alcohol Research 
of the KTL. 
The AMHC-Study is carried out in collaboration between the cities of Tampere and 
Vantaa, the Tampere School of Public Health; Department of Mental Health, KTL, the 
Tampere University Hospital and the Helsinki University Central Hospital. The 
POLKU-study is a collaboration between KTL, University of Kuopio, two reform 
schools in Mikkeli, and with the Central Hospital of Mikkeli. The KAIFUS study is a 
collaboration between KTL and Kellokoski Hospital. The planned "Effectiveness of 
IPT-A in adolescent depression" study is to be conducted in collaboration with Laura 
Mufson at the Columbia University (USA), University of Tromso (Norway), and with 
4-5 university sites in Finland. 
 
8.1.7. Proposal for future work and expected benefits 
 
The ADS study is in a phase of active analyses and reporting. Analyses on antide-
pressant treatment and its association with changes in suicidality in adolescent mood 
disorders are ongoing. Analyses of treatment emergent suicidality among subjects with 
and without antidepressant treatment are to be conduced. These analyses will shed light 
in the ongoing debate on the "suicidogenic" effect of antidepressants in adolescent 
mood disorders. In the autumn 2007, six-year follow-up of the patient cohort is to be 
conducted. Besides clinical follow-up and structured diagnostic interviews, a register 
based follow-up will be conducted. For selected 80 patients (20 subjects with only the 
index depressive episode, 20 who have a chronic depression, 20 who have "switched" to 
bipolar disorder, and 20 healthy controls) assessments including MRI scans and a 
neuropsychological test battery will also be made in order to find out the possible struc-
tural brain abnormalities and their association with neuropsychological impairment in 
different early onset mood disorders. 
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The KAIFUS study will provide data on the short- and long term outcome and both 
clinical and biological predictors of outcome of adolescent inpatients. 
Further analyses of the AMHC database will be conducted in order to find out risk 
factors for the main outcomes (depression, conduct problems, aggression, alcohol and 
other substance abuse) during a 2-year follow-up. In the near future, 5-year follow-up of 
the subjects will be conducted. 
In the ongoing health promotion project, a guide on substance use and violence in 
adolescence is under preparation. 
Two trials are planned to start in 2007 / 2008. A study on the effectiveness of cog-
nitive behavioral "Coping with stress (CWS) course" in the prevention of adolescent 
depression will be started in the autumn 2007 in collaboration between the KTL and 
three Finnish cities (Vantaa, Turku, Kuopio). The intervention has been piloted in Van-
taa and found to be applicable. Subjects of the study will be 15-year-olds in schools 
with an R-BDI-score of 5-15 (300 students in intervention group and 200 students in 
comparison "treatment as usual" condition) followed up for 24 months. 
Another trial will be "Effectiveness of IPT-A in adolescent depression" -study con-
ducted in collaboration with Laura Mufson at the Columbia University, two university 
clinics in Norway, and 4 - 5 university clinics in Finland. It will be the firstr trial to test 
the effectiveness of IPT-A in Europe and it will consist of 180 13 - 18-year old de-
pressed patients in the intervention condition and 180 patients in the control condition 
(treatment as usual). 
8.1.8 The most important publications 
 
Aalto-Setälä T, Haarasilta L, Marttunen M, Tuulio-Henriksson A, Poikolainen K, Aro H. Major depres-
sive episode among young adults: CIDI-SF versus SCAN consensus diagnoses. Psychol Med 
2002;32:1309-1314. 
National Public Health Institute, Department of Mental Health and Alcohol Research, Mannerheimintie, 
Finland. 
BACKGROUND: We aimed to evaluate the diagnostic accuracy of a highly structured diagnostic inter-
view in relation to a semi-structured diagnostic procedure. We compared the World Health Organization 
Composite International Diagnostic Interview Short Form (CIDI-SF) in diagnosing major depressive 
episode (MDE) to consensus diagnoses based on the SCAN interview (Schedules for Clinical Assessment 
in Neuropsychiatry). METHOD: Subjects comprised a follow-up sample of 239 20-24-year-old former 
high-school students who were administered the SCAN and immediately thereafter the CIDI-SF. Concor-
dance was estimated for 12-month MDE, using different cut-points of the CIDI-SF and for any affective 
disorders. RESULTS: Correspondence between instruments was moderate for MDE (kappa = 0.43, sensi-
tivity 0.71, specificity 0.82), but better for any affective disorder (kappa = 0.60, sensitivity 0.70, specific-
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ity 0.90). Most false negatives suffered from their depression as much as those correctly identified by the 
CIDI-SF. False negativity was mainly due to not endorsing the stem questions of the CIDI-SF. Of the 
false positives almost half had an affective disorder other than MDE. CONCLUSIONS: The CIDI-SF 
seems to function best in identifying a broader category of affective disorders. It could be useful in large-
scale community surveys where more extensive psychiatric interviews are not feasible. 
Aalto-Setälä T, Marttunen M, Poikolainen K, Tuulio-Henriksson A, Lönnqvist J. One-month prevalence 
of depression and other DSM-IV disorders among young adults. Psychol Med 2001;31:791-801. 
National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki. 
BACKGROUND: We aimed to provide prevalence data on depression and other current mental disorders, 
impairment, need of psychiatric care and use of mental health services among young adults. METHODS: 
Based on a semi-structured clinical interview, current DSM-IV disorders, impairment, need of psychiatric 
care and use of mental health services were evaluated in a sample of 20-24-year-old young urban adults 
(N = 245), mean age 21.8, screened from a baseline population of 706. One-month prevalence estimates 
for disorders were calculated by the double sampling method, using various additional criteria to identify 
cases. RESULTS: One in four young adults (23.8%) suffered from a current mental disorder, the most 
prevalent being depressive (10.8%), anxiety (6.9%), substance use (6.2%) and personality disorders 
(6.0%). Prevalence estimates varied substantially according to the use of additional diagnostic criteria. 
Impairment (GAF < 61) together with DSM-IV symptom criteria produced an overall disorder prevalence 
of 10.3%, and 5.5% for depression. Prevalences were higher for females than males, except for alcohol 
abuse and personality disorders. Current co-morbidity was found in 39% of subjects with any disorder, 
and in more than half of those with depression. One-third of subjects with a current disorder reported an 
associated contact with psychiatric services and 16% had an ongoing contact. CONCLUSIONS: Our 
findings support the use of additional criteria to produce clinically relevant prevalence data. Co-morbidity 
should receive special attention due to its amplification of both need for psychiatric care and severity of 
impairment. Finally, our results show disturbed young adults to be severely undertreated. 
Aalto-Setälä T, Marttunen M, Tuulio-Henriksson A, Poikolainen K, Lönnqvist J. Psychiatric treatment 
seeking and psychosocial impairment among young adults with depression J Affect Disord 2002;70:35-
47. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Mannerheimintie 
166, FIN-00300 Helsinki, Finland. terhi.alto-setala@ktl.fi 
BACKGROUND: We report data on 1-year prevalence and comorbidity of depression, related impair-
ment, treatment need, and psychiatric treatment among young adults. METHODS: A sample of young 
urban adults (n=245) mean age 21.8 years was screened from a baseline population of 706 high-school 
students and given a semistructured clinical interview to evaluate 12-month prevalence of depression, 
psychosocial functioning according to DSM-IV GAF scale, need for psychiatric treatment, and use of 
mental health services. RESULTS: One in 10 young adults suffered from depression with associated 
psychosocial impairment, the female-to-male-ratio being approximately 2:1. Most depressive disorders 
were comorbid with other DSM-IV disorders, depression usually occurring secondary to other disorders. 
Comorbidity was related to impairment, treatment need, and treatment contacts. Less than half of the 
depressed young adults had ever contacted mental health services, and less than one-third reported treat-
ment contacts during the index episode. Males were less likely than females to report previous treatment 
contacts or intention to refer to mental health services for their problems, but treatment contacts during 
the index episode were reported equally often by both sexes. CONCLUSIONS: A minority of the se-
verely depressed young adults with associated impairment had sought treatment. Except for subjects with 
dysthymia, no gender difference emerged in treatment contact rates during the 12-month depression epi-
sode. Comorbidity showed important clinical implications by its relation to severity of depression and 
treatment contacts. 
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Aalto-Setälä T, Marttunen M, Tuulio-Henriksson A, Poikolainen K, Lönnqvist J. Depressive symptoms in 
adolescence predict early adulthood depressive disorders and maladjustment Am J Psychiatry 
2002;159:1235-1237. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Iirislahdenranta 30, 
FIN-02230 Espoo, Finland. 
OBJECTIVE: The authors examined the association between self-reported depressive symptoms in ado-
lescence and mental well-being in early adulthood. METHOD: A questionnaire assessing psychosocial 
well-being was given to a group of subjects (N=651) in their last 3 years of high school (mean age=16.8 
years) and again when these subjects reached early adulthood (mean age=21.8 years). Diagnostic inter-
view data were obtained from a subgroup of the young adults (N=245). Adolescents' depressive symp-
toms were analyzed in relation to their early adulthood mental health outcome data. RESULTS: Depres-
sive symptoms in adolescence predicted early adulthood depressive disorders (major depression and dyst-
hymia), comorbidity, psychosocial impairment, and problem drinking. CONCLUSIONS: Depressive 
symptoms in adolescence deserve attention as a potential risk for early adulthood mental disorders. 
Haapasalo-Pesu K-M, Vuola T, Lahdelma L, Marttunen M. Mirtazapine in the treatment of adolescents 
with major depression. An open-label, multicenter pilot study. J Child Adolesc Psychopharmacol 
2004;14:175-184. 
Adolescent Psychiatry Clinic, Hansakatu 5, FIN-28100 Pori, Finland. kirsi-maria.haapasalo-
pesu@satshp.fi 
This multicenter, open-label study with a duration of 85 days was performed to evaluate the antidepres-
sant efficacy and safety of mirtazapine (dose range, 30-45 mg) in 12-18-year-old adolescents diagnosed 
with major depression. Twenty-four (24) patients (15 female patients and 9 male patients) meeting the 
DSM-IV criteria for major depression and the Hamilton Rating Scale for Depression (HAM-D-17) score 
of 18 at baseline were enrolled in the study. The primary outcome measures were HAM-D-17, Beck De-
pression Inventory (BDI), and Clinical Global Impression (CGI) scales. Any changes in symptoms of 
anxiety were measured using the Hamilton Anxiety Rating Scale (HAM-A). The average age of the 23 
subjects, who were eligible for analysis, was 16.3 years (standard deviation (SD) 6.11, median 17.3). The 
mean daily dose of mirtazapine was 32.9 mg. Mirtazapine showed a marked efficacy on all rating scales 
and was well tolerated. Mirtazapine had a beneficial effect on sleep. A rapid onset of sleep and pattern of 
action was seen. No dropouts due to adverse events were recorded. The most common treatment-
emergent adverse events were tiredness, increased appetite, and dizziness. The results of this study sug-
gest that mirtazapine may be an effective treatment for major depression in adolescents. 
Holi MM, Eronen M, Toivonen K, Toivonen P, Marttunen M, Naukkarinen H. Left prefrontal rTNS in 
Schizophrenia. Schizophr Bull. 2004;30(2):429-34. 
Helsinki University Central Hospital, Department of Psychiatry, Helsinki, Finland. 
In a double-blind, controlled study, we examined the therapeutic effects of high-frequency left prefrontal 
repetitive transcranial magnetic stimulation (rTMS) on schizophrenia symptoms. A total of 22 chronic 
hospitalized schizophrenia patients were randomly assigned to 2 weeks (10 sessions) of real or sham 
rTMS. rTMS was given with the following parameters: 20 trains of 5-second 10-Hz stimulation at 100 
percent motor threshold, 30 seconds apart. Effects on positive and negative symptoms, self-reported 
symptoms, rough neuropsychological functioning, and hormones were assessed. Although there was a 
significant improvement in both groups in most of the symptom measures, no real differences were found 
between the groups. A decrease of more than 20 percent in the total PANSS score was found in 7 control 
subjects but only 1 subject from the real rTMS group. There was no change in hormone levels or neuro-
psychological functioning, measured by the MMSE, in either group. Left prefrontal rTMS (with the used 
parameters) seems to produce a significant nonspecific effect of the treatment procedure but no therapeu-
tic effect in the most chronic and severely ill schizophrenia patients. 
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Kaltiala-Heino R, Marttunen M, Rantanen P, Rimpelä M. Early puberty associates with mental health 
problems in middle adolescents. Soc Sci Med 2003;57:1055-1064. 
Tampere School of Public Health, 33014 University of Tampere, Box 607, 33101 Tampere, Finland. 
merihe@uta.fi 
This study set out to assess the relationship between pubertal timing and emotional and behavioural prob-
lems in middle adolescence. The study involved a school based survey of health, health behaviour and 
behaviour in school as well as questions about emotional and behavioural problems (the School Health 
Promotion Study). Secondary schools in four regions and 13 towns in Finland participated in the study in 
1998. The respondents were 36,549 adolescents aged 14-16. The study included questions on depression, 
bulimia nervosa, psychosomatic symptoms, anxiety, drinking, substance use, smoking, bullying and tru-
ancy. Among girls, both internalising and externalising symptoms were more common the earlier puberty 
occurred. Among boys, externalising symptoms only were associated with early puberty. It is concluded 
that early pubertal timing is associated with increased mental health problems. Professionals working 
with adolescents should consider the mental health needs of early maturing adolescents. 
Kaltiala-Heino R, Rimpelä M, Marttunen M, Rantanen P, Rimpelä A. Bullying, depressive symptoms and 
severe suicidal ideation. BMJ. 1999;319:348-351. 
University of Tampere, Tampere School of Public Health, Box 607, 33101 Tampere, Finland. 
merihe@uta.fi 
OBJECTIVE: To assess the relation between being bullied or being a bully at school, depression, and 
severe suicidal ideation. DESIGN: A school based survey of health, health behaviour, and behaviour in 
school which included questions about bullying and the Beck depression inventory, which includes items 
asking about suicidal ideation. SETTING: Secondary schools in two regions of Finland. 
PARTICIPANTS: 16 410 adolescents aged 14-16. RESULTS: There was an increased prevalence of 
depression and severe suicidal ideation among both those who were bullied and those who were bullies. 
Depression was equally likely to occur among those who were bullied and those who were bullies. It was 
most common among those students who were both bullied by others and who were also bullies them-
selves. When symptoms of depression were controlled for, suicidal ideation occurred most often among 
adolescents who were bullies. CONCLUSION: Adolescents who are being bullied and those who are 
bullies are at an increased risk of depression and suicide. The need for psychiatric intervention should be 
considered not only for victims of bullying but also for bullies. 
Karlsson L, Pelkonen M, Heilä H, Holi M, Kiviruusu O, Tuisku V Ruuttu T, Marttunen M. Differences in 
the clinical characteristics of adolescent depressive disorders. Depress Anxiety 2006 Oct 18; Epub ahead 
of print  
The National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, 
Finland. 
Our objective was to analyze differences in clinical characteristics and comorbidity between different 
types of adolescent depressive disorders. A sample of 218 consecutive adolescent (ages 13-19 years) 
psychiatric outpatients with depressive disorders was interviewed for DSM-IV Axis I and Axis II diagno-
ses. We obtained data by interviewing the adolescents themselves and collecting additional background 
information from the clinical records. Lifetime age of onset for depression, current episode duration, 
frequency of suicidal behavior, psychosocial impairment, and the number of current comorbid psychiatric 
disorders varied between adolescent depressive disorder categories. The type of co-occurring disorder 
was mainly consistent across depressive disorders. Minor depression and dysthymia (DY) presented as 
milder depressions, whereas bipolar depression (BPD) and double depression [DD; i.e., DY with super-
imposed major depressive disorder (MDD)] appeared as especially severe conditions. Only earlier life-
time onset distinguished recurrent MDD from first-episode MDD, and newly emergent MDD appeared to 
be as impairing as recurrent MDD. Adolescent depressive disorder categories differ in many clinically 
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relevant aspects, with most differences reflecting a continuum of depression severity. Identification of 
bipolarity and the subgroup with DD seems especially warranted. First episode MDD should be consid-
ered as severe a disorder as recurring MDD. Depression and Anxiety 0:1-12, 2006. (c) 2006 Wiley-Liss, 
Inc. 
Karlsson L, Pelkonen M, Ruuttu T, Kiviruusu O, Heilä H, Holi M, Kettunen K, Tuisku V, Tuulio-Henriksson 
A, Törrönen J, Marttunen M, Current comorbidity among consecutive adolescent psychiatric outpatients with 
DSM-IV mood disorders. Eur Child Adolesc Psychiatry 2006;15:220-31. Epub 2006 Feb 23. 
The National Public Health Institute, Dept. of Mental Health and Alcohol Research, , Helsinki, Finland. 
linnea.karlsson@utu.fi 
OBJECTIVE: To compare selected characteristics (age, sex, age of onset for depression, impairment, 
severity of depression, somatic comorbidity, and treatment status) of adolescents with currently comorbid 
and non-comorbid depression. METHOD: A sample of 218 consecutive adolescent (13-19 years) psychi-
atric outpatients with depressive disorders, and 200 age- and sex-matched school-attending controls were 
interviewed for DSM-IV Axis I and Axis II diagnoses. RESULTS: Current comorbidity, most commonly 
with anxiety disorders, was equally frequent (>70%) in outpatients and depressed controls. Younger age 
(OR 0.20; 95% CI 0.08, 0.51) and male gender (OR 0.02; 95% CI 0.09, 0.55) were associated with con-
current disruptive disorders. Current comorbidity with substance use disorders (SUD) was independent of 
age (OR 1.13; 95% CI 0.51, 2.49) and sex (OR 0.51; 95% CI 0.22, 1.17). Personality disorders associated 
with older age (OR 2.06; 95% CI 1.10, 3.86). In multivariable logistic regression analysis, impairment 
(GAF <or=60) was associated with current comorbidity (OR 3.13; 95% CI 1.53, 6.45), while severity of 
depression and lifetime age of onset for depression were not. CONCLUSIONS: Adolescent depression 
presents with age- and sex-dependent patterns of multiple co-occurring problem areas. While many clini-
cal characteristics of adolescent depression are not affected by comorbidity, comorbidity associates with 
increased impairment. 
Pelkonen M, Marttunen M, Henriksson M, Lönnqvist J. Adjustment disorders among adolescent outpa-
tients. Eur Psychiatry 2006, doi:10.1016/jeurpsy.2006.04.010. 
National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, Finland; 
Department of Social Psychiatry, University of Tampere, Tampere School of Public Health, Tampere, 
Finland. 
OBJECTIVE: Research on adolescent adjustment disorder (AD) is scarce. We characterized adolescent 
outpatients with AD in psychosocial background and treatment received compared with patients with 
other non-psychotic disorders (OND). Furthermore, we explored precipitant stressors, distress symptoms 
and behavioral problems among males and females with AD. METHOD: Data were collected prospec-
tively on 290 consecutive psychiatric outpatients, aged 12-22 yrs, at a secondary care clinic in Finland. 
DSM-III-R diagnoses were assigned, based on all available information, at the end of treatment. 
RESULTS: AD was the second most common diagnosis among non-psychotic patients (31% of 290). 
Compared to OND-patients, those with AD were predominantly female and had less severe psychosocial 
impairment. In multivariate comparisons school-related stressors, problems with law and restlessness 
characterized males, and parental illness and internalizing symptoms females with AD. Intensity and 
duration of treatment of AD-patients varied widely. CONCLUSIONS: Adjustment disorder comprised a 
common clinical entity among adolescent outpatients. Psychiatric assessment and treatment should be 
individually targeted by taking into account gender-specific stressors and distress symptoms among 
young people with AD. 
Pelkonen M, Marttunen M, Lönnqvist J, Laippala P. Factors associated with early drop out from adoles-
cent outpatient treatment. J Am Acad Child Adolesc Psychiatry 2000;39:329-336. 
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. 
Mirjami.Pelkonen@ktl.fi 
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OBJECTIVE: To examine background factors, psychopathology, and psychosocial impairment among 
adolescents complying with or dropping out early from outpatient psychiatric treatment. METHOD: Fam-
ily background, psychiatric history, and other data were collected prospectively on 143 male and 154 
female outpatients aged 12 to 22 years. DSM-II-R psychiatric diagnoses were assessed at the end of 
treatment. RESULTS: Fifty-three adolescents (17.8%) attended 1 or 2 treatment appointments, and 33 of 
them (11.1% of 297) then dropped out; 50.5% of the total attended 3 to 13, and 31.6% attended 14 or 
more appointments. Low parental socioeconomic status was more common among the early dropouts 
than the other patient groups (88%, 69%, 63%, respectively). The early dropouts had had more problems 
with the law than the adolescents attending 14 or more appointments (18%, 6%), but less suicidal behav-
ior (24%, 56%, respectively). Among the early dropouts, mood disorders were less common (21%, 49%), 
especially major depression (0%, 20%), and substance abuse was more common (9%, 0%) than among 
patients attending 14 or more appointments. CONCLUSIONS: Low parental socioeconomic status, not 
having mood disorder, not having psychotropic medication, and having substance abuse were associated 
with early dropout of adolescents from outpatient psychiatric treatment. 
Pelkonen M, Marttunen M, Pulkkinen E, Koivisto A-M, Laippala P, Aro H. Excess mortality among 
former adolescent male outpatients. Acta Psychiatr Scand 1996; 94:60-66. 
Tampere School of Public Health, University of Tampere, Finland. 
Mortality among 156 males and 122 females referred to an out-patient adolescent psychiatric clinic in a 
Finnish town between 1984 and 1989 was examined. During the follow-up (mean duration 6 years; range 
0-6.3 years for the deceased, 0.6-10.3 years for the survivors), 16 male subjects but no females had died. 
Among those who had died, the mode of death was suicide in 11 cases. The mortality for any cause for 
males was 10.3% and that for suicide was 7.1%. All male victims had similar high levels of individual 
and familial disturbances. Current suicidal ideation and suicide attempts, poor psychosocial functioning 
and a recommendation for psychiatric hospital treatment during the index treatment were associated with 
male mortality/suicidality. A high risk for mortality for several years after psychiatric treatment was 
found. It is concluded that, in clinical settings, perceived current suicidal tendencies should be assessed 
carefully. 
Pelkonen M, Marttunen M, Pulkkinen E, Laippala P, Lönnqvist J, Aro H. Disability pensions in severely 
disturbed in-patient adolescents. Twenty-year prospective study. Br J Psychiatry 1998;172:159-163. 
Tampere School of Public Health, University of Tampere, Finland. 
BACKGROUND: Knowledge of working capacity from adolescence until adulthood among severely 
disturbed in-patients is scarce. METHOD: In a follow-up study of 61 adolescent in-patients, we studied 
associations between being on a disability pension 20 years after hospitalisation, and the patients' psycho-
pathology and treatment-related factors during the hospitalisation and seven-year follow-up. RESULTS: 
Of the former in-patients, 27% had not been on a disability pension, 20% had short-term pension periods, 
and 53% were pensioned. Subjects whose overall psychosocial functioning had improved and who had 
not utilised in-patient services until the seven-year follow-up, had a better prognosis in terms of working 
capacity. Half of the subjects who had not been on pension during the follow-up had received a diagnosis 
of conduct disorder at discharge, and half of those pensioned had a psychotic disorder. CONCLUSIONS: 
The patients' level of psychosocial functioning and capability to work in young adulthood were associated 
with long-term prognosis in terms of working capacity. Adolescence seems to be the critical time for 
intensive psychiatric care combined with vocational rehabilitation programmes. 
Poikolainen K, Tuulio-Henriksson A, Aalto-Setälä T, Marttunen M, Anttila T, Lönnqvist J. Correlates of 
initiation to cannabis use: a 5-year follow-up of 15-19-year old adolescents. Drug Alcohol Depend 
2001;62:175-180. 
Järvenpää Addiction Hospital, FIN-04480, Haarajoki, Finland. kari.poikolainen@a-klinikka.fi 
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Initiation to cannabis is often the first step in the use of illicit drugs. We studied the correlates of initiation 
in a 5-year follow-up study. A total of 21.4% of the subjects reported using cannabis at some time. Of the 
139 users, 89.2% had tried cannabis not more than once or a few times. This initiation to cannabis was 
related to male gender, absence of mother, frequent lack of interest and early age at first sexual inter-
course in logistic regression analysis. These factors seem to be useful in predicting initiation to cannabis. 
Poikolainen K, Tuulio-Henriksson A, Aalto-Setälä T, Marttunen M, Lönnqvist J. Predictors of alcohol 
intake and frequent heavy drinking in early adulthood: a 5-year follow-up of 15-19-year old adolescents. 
Alcohol Alcohol 2001;36:85-88. 
Finnish Foundation for Alcohol Studies, P.O. Box 220, FIN-00531 Helsinki, Finland. 
Relative contributions of earlier drinking and smoking vs mental health risk factors in predicting alcohol 
intake and heavy drinking in young adulthood were assessed. Higher average alcohol intake and heavy 
drinking (13 or more drinks on one occasion) in 1995 were significantly related to male gender and earlier 
high scores in 1990 of relief smoking, relief drinking, and their interaction. Parental alcohol problems, 
social group, perceived degree of social support, trait anxiety, number of negative life events, self-esteem, 
grade-point average, somatic symptoms score, or immature, neurotic, or mature defence style measured in 
1990 did not predict alcohol intake or heavy drinking 5 years later. The findings suggest that alcohol 
intake and heavy drinking in young adulthood can be predicted by earlier self-reports on relief smoking 
and alcohol intake in adolescence. 
Ranta K, Kaltiala-Heino R, Koivisto A-M, Tuomisto M, Pelkonen M, Marttunen M. Age and gender 
differences in social anxiety symptoms during adolescence: the Social Phobia Inventory (SPIN) as a 
measure. Psychiatr Res (Accepted 12/2006) 
School of Public Health, University of Tampere, Tampere, Finland; Department of Adolescent Psychia-
try, Turku University Central Hospital, Turku, Finland. 
The aim of the present study was to examine age and gender differences in social anxiety symptoms dur-
ing adolescence, and to investigate the psychometrics of the Social Phobia Inventory (SPIN) among ado-
lescents. The SPIN was administered to a large general population sample (n=5252) of Finnish adoles-
cents aged 12-16 years. Age and gender trends in scores and internal consistency and factorial composi-
tion of the SPIN were examined in this sample. The test-retest reliability of the SPIN was examined in a 
smaller sample of adolescents (n=802). Results showed that girls scored higher than boys on the SPIN 
full scale and three subscales across the whole age range. Eighth graders (14- to 15-year-olds) scored 
higher than seventh and ninth graders on the full scale, for boys the differences were significant. Good 
test-retest reliability (r=0.81), and internal consistency (alpha=0.89) were found for the SPIN. An ex-
ploratory factor analysis (EFA) performed on a random half (n=2625) of the population sample yielded a 
one-factor model accounting for 38% of the variance between items. This one-factor model, plus an alter-
native three-factor model, were examined in the holdout half of the population sample (n=2627) by means 
of a confirmatory factor analysis (CFA). Some support was gained for both factor structures. Our results 
indicate that symptoms of social phobia may increase in mid-adolescence. The SPIN appears to be a reli-
able self-report instrument among adolescents. 
Tuisku V, Pelkonen M, Karlsson L, Holi M, Kiviruusu O, Ruuttu T, Punamäki R-L, Marttunen M. Suici-
dal Ideation, Deliberate Self-harm Behavior and Suicide Attempts among Adolescent Outpatients with 
Depressive Mood Disorders and Comorbid Axis I Disorders. Eur Child Adolesc Psychiatry 2006;15:199-
206. Epub 2006 Apr 8. 
Dept. of Mental Health and Alcohol Research, National Public Health Institute, Mannerheimintie 166, 
00300 Helsinki, Finland. Virpi.Tuisku@ktl.fi 
OBJECTIVE: We aimed to analyse and compare prevalence and associated clinical features of suicidal 
ideation, self-harm behaviour with no suicidal intent and suicide attempts among adolescent outpatients 
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with depressive mood disorders with or without comorbidity. METHOD: A sample of 218 consecutive 
adolescent outpatients aged 13-19 years with depressive mood disorders was interviewed using K-SADS-
PL for DSM-IV Axis I diagnoses. They filled out self-report questionnaires assessing depressive and 
anxiety symptoms. Suicidal behaviour was assessed by K-SADS-PL suicidality items. RESULTS: Half of 
the subjects reported suicidal ideation or behaviour. There was no difference in prevalence of suicidal 
behaviour between non-comorbid and comorbid mood disorder groups. Multivariate logistic regression 
analyses produced the following associations: (1) suicidal ideation with self-reported depressive symp-
toms and poor psychosocial functioning, (2) deliberate self-harm behaviour with younger age and poor 
psychosocial functioning, and (3) suicide attempts with self-reported depressive symptoms and poor psy-
chosocial functioning. CONCLUSIONS: Depressed mood disorders, whether comorbid or not, are asso-
ciated with suicidal ideation and suicide attempts. Diagnostic assessment should be supplemented by self-
report methods when assessing suicidal behaviour in depressed adolescents. 
 
8.2 Finnish Twin Studies on Mental Health and Substance Use 
 
8.2.1. Research and public health significance of the area 
 
Genetic epidemiology of substance use and psychiatric morbidity using twins and 
families 
 
8.2.2. The main scientific achievements 
 
1. During the past six years, we have sought to establish a resource to identify loci 
and genes associated with nicotine dependence and alcohol use & abuse. We completed 
the data collection of our nicotine dependence families in mid-2006 (762 families re-
cruited with 2412 family members). A joint analysis of this multicenter project of one 
quantitative phenotype, the maximum number of cigarettes ever smoked, was published 
in the American Journal of Human Genetics in May 2007, showing significant linkage 
to chromosome 22 in both Finnish and Australian families. A separate paper on only 
Finnish results for  nine binary phenotypes replicated previous linkage findings on 10q 
(max LOD 3.12) for a smoker phenotype, and on 7q and 11p (max LOD 2.50, and 2.25, 
respectively) for the ND phenotype, and revealed a number of promising findings to 
follow-up on (Loukola et al, The Pharmacogenomics Journal, 2007). Analyses in the 
Australian data set did not show strong linkage and have not been reported. Ongoing 
analyses on nicotine withdrawal also indicate a stronger signal from Finnish than Aus-
tralian families. Thus, for smoking, it is remarkable that the strongest linkage signals 
have come from the Finnish data set, despite the smaller number of families and lower 
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mean values of the phenotypes on average. This further indicates the value of relatively 
large but genetically isolated populations with homogeneous cultures and health care 
systems such as Finland and Iceland in searching for genes underlying complex traits. 
2. Our second major study aim is to characterize risk across development con-
nected to genes associated with substance dependence in adulthood. While some analy-
ses are in progress or have been reported on our longitudinal studies of younger twins 
(the FinnTwin12 and Finntwin16) studies, we have started in the spring of 2006 a major 
data collection on the Finntwin12 sample, with a now fourth wave of data collection. 
This entails travel to Helsinki for a one day session, which starts with blood samples for 
serum and DNA, anthropometric measures, taste and smell assessments, neuropsy-
chological tests and a structured psychiatric assessment of substance use, abuse and 
associated psychiatric conditions. The subjects are aged 22-24 years of age on assess-
ment and thus our follow-up is more than 10 years as it started at age 11-12. The first 
year of assessments completed data collection for 250 subjects, and our goal is study 
1000-1200 subjects by early 2009. This is a collaborative project with Professor Richard 
J Rose and co-workers, Department of psychology and cognitive science, Indiana Uni-
versity (joint NIH funding (AA-12502) for studies of alcohol-related behavior genetics 
in young Finnish twins); Finnish Funding comes from the Academy of Finland Centre 
of Excellence and other grants. 
3. Our third research arm focuses on gene-environment interaction, by characteriz-
ing how the risk associated with susceptibility genes may be moderated by the pres-
ence/absence of environmental factors. A number of papers reporting such results have 
been published are under review or are in preparation. These analyses are based primar-
ily on the FinnTwin12 and FinnTwin16 studies, and are done in close collaborations 
with Research Assistant Professor Danielle Dick, Washington University, St. Louis. 
Analysis of gene-environment interaction in the development of substance use, sup-
ported by NIH AA-15416. 
4. We have extended our current research area to include other substance use than 
alcohol and smoking. The use of cannabis has increased in particular among younger 
Finns, though even the majority of ever-users only experiments a few times. Nonethe-
less this was felt to be an area worth including. Dr. Anja Huizink (University of Rotter-
dam) has received Dutch funding for the study of cannabis use in our younger twins 
(starting 1.11.06), and Jaakko Kaprio has received funding from the program called 
Addiktio of the Academy of Finland (starting 1.1.07) for studies on causes and conse-
quences of alcohol and cannabis use, with collaboration of Academy researcher Jaana 
Suvisaari (KTL) and doc. Annamari Tuulio-Henriksson (KTL). As these are tightly as-
sociated with psychiatric morbidity, these tie into our broader research interests in neu-
ropsychiatric genetics. Thus, we will examine the neuropsychological and neurophysi-
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ological correlates of alcohol use in the presence and absence of cannabis use, based on 
the FinnTwin16 samples and the Health2000 sample of young adults with substance use 
and/or psychiatric problems and their controls.   
 
5. In 2005, we have established collaboration with researchers in disability pension 
and sickness absence in Finland (Drs. Timo Klaukka and Antti Huunan Seppälä, from 
the The Social Insurance Institution of Finland and MSc Karoliina Harkonmäki, Local 
communities pensions fund). and with Professor Kristina Alexanderson (Karolinska 
Institute). The older twin cohort was linked to data on all pensions, with particular focus 
on disability pension. The data have been supplemented by information on diseases for 
which re-imbursement of medication expenses is provided and prescription drug infor-
mation. This greatly expands the phenotypic database of the older twin cohort. Thus for 
the 24043 twins of known zygosity resident in Finland in 1975, there are 4894 records 
of disability pension with at least one diagnosis by the end of 2004; in addition with 
10878 records of a right to reimbursed medication based on a medical certificate. 
The most common diagnostic categories are hypertension, diabetes, psychotic con-
ditions and CHD-related, including hyperlipidemia.   We have classified for example all 
diabetes cases into those with T1DM (162 cases), T2DM (2077), and other kinds (igt, 
gestational diabetes and secondary, 97 cases). Currently analyses are underway, with a 
focus on depression, and low back pain (a subproject led by Annina Ropponen, PhD, 
University of Kuopio). 
 
8.2.3. The main public health achievements 
 
Knowledge about nicotine dependence has been very limited in Finland until now. 
Our family data has yielded information about the utility of different measures of nico-
tine dependence, and confirmed that nicotine dependence is very common, probably the 
most common form of substance dependence in Finland. 
Our studies on the development of substance use and mental health in the younger 
twin cohorts have provided information about the importance of family and peer effects, 
particularly in the initiation of substance use, and that the genetic variance in substance 
use is moderated strongly by parenting practices, and by broad socio-economic indicators. 
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8.2.4. Funding for research and public health programs 
 
In addition to departmental funds, the twin studies at KTL are funded by the the 
Academy of Finland Centre of Excellence and the Addiction programme of the Acad-
emy of Finland. 
 
8.2.5. Personnel 
 
Current personnel paid by KTL include Jaakko Kaprio (35%), Ulla Broms, Antti 
Latvala, Ulla Kulmala-Gråhn and Kristiina Saanakorpi. Ulla Broms is completing her 
PhD thesis on nicotine dependence, while Antti Latvala is starting his PhD projects on 
neuropsychological correlates of alcohol and cannabis use.   
 
8.2.6. Collaboration 
 
In addition, the Finnish twin cohorts have been used for many other non-
psychiatric conditions, as evident from our publication list. These are primarily con-
ducted at the Department of Public Health, University of Helsinki. A major project in 
this context has been the large European collaboration, Genomeutwin, but also other 
EU-projects such as Euroclot, Eurohead, Diogenes; likewise we have active collabora-
tion with many Finnish scientists and research units. 
 
8.2.7. Proposal for future work and expected benefits 
 
We have planned for further follow-up of the twin cohorts with questionnaire stud-
ies of the older twin cohort, the FinnTwin12 and Finntwin16 cohorts. These would 
probably be undertaken in the next 2-3 years depending on funding. Register-follow-up 
will also continue. These continued longitudinal analyses will provide further informa-
tion on the evolving development of substance use and mental health from early adoles-
cence onwards into adulthood.  
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8.2.8. Main publications 
 
1. Ahveninen J, Jaaskelainen IP, Osipova D, Huttunen MO, Ilmoniemi RJ, Kaprio J, Lonnqvist J, 
Manninen M, Pakarinen S, Therman S, Naatanen R, Cannon TD. Inherited auditory-cortical dysfunction 
in twin pairs discordant for schizophrenia. Biol Psychiatry. 2006 Sep 15;60(6):612-20. Epub 2006 Jul 28.  
Department of Radiology, Harvard Medical School-Athinoula A. Martinos Center for Biomedical 
Imaging, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA. 
jyrki@nmr.mgh.harvard.edu 
BACKGROUND: Information on the inheritance of neurophysiological abnormalities might help 
elucidate the molecular genetic basis of schizophrenia. We used magnetoencephalography (MEG) and 
electroencephalography (EEG) to investigate the inheritance of auditory-cortical deficiencies in twin pairs 
discordant for schizophrenia. METHODS: Auditory EEG/MEG responses to frequent standard and occa-
sional deviant tones were measured in mono- and dizygotic (MZ and DZ) twin pairs discordant for 
schizophrenia and demographically matched healthy twin pairs, recruited from a total population cohort. 
The MEG/EEG results were regressed against the genetic resemblance to patients with schizophrenia 
across the patients' unaffected MZ/DZ co-twins and control subjects (with genetic correlations of 1, .5, 
and 0 to schizophrenia patients, respectively). RESULTS: The EEG responses P50, N100, and mismatch 
negativity (MMN), as well as the MEG response P50m, were reduced in the schizophrenic patients. P50 
and N100 were significantly decreased also in their unaffected co-twins, as compared with the control 
subjects. Importantly, the P50 and N100 decrease correlated with the unaffected subjects' genetic resem-
blance to schizophrenia patients. CONCLUSIONS: Our results suggest inherited abnormalities in cortical 
auditory processing in schizophrenia, reflected by the decreased P50/P50m and N100 amplitudes, 
whereas the MMN abnormalities might reflect predominantly state-dependent neurodegeneration. 
 
Publication Types: 
    Comparative Study  
    Research Support, N.I.H., Extramural  
    Research Support, Non-U.S. Gov't  
    Research Support, U.S. Gov't, Non-P.H.S.  
 
2. Keski-Rahkonen A, Sihvola E, Raevuori A, Kaukoranta J, Bulik CM, Hoek HW, Rissanen A, 
Kaprio J. Reliability of self-reported eating disorders: Optimizing population screening. Int J Eat Disord. 
2006 Dec;39(8):754-62.  
Department of Epidemiology, Columbia University, New York, New York 10032, USA. 
anna.keski-rahkonen@helsinki.fi 
OBJECTIVE: The objective of this study was to assess whether short self-report eating disorder 
screening questions are useful population screening methods. METHOD: We screened the female partici-
pants (N = 2881) from the 1975-1079 birth cohorts of Finnish twins for eating disorders, using several 
short screening questions and three Eating Disorder Inventory (EDI) subscales. Comparing these meas-
ures with clinician-conducted semi-structured diagnostic interviews (N =549) of Diagnostic and Statisti-
cal Manual of Mental Disorders-IV (DSM-IV) anorexia and bulimia, we calculated their sensitivities and 
specificities and drew receiver operating characteristic curves to further compare these items. RESULTS: 
For current and lifetime bulimia, best tradeoffs between sensitivity and specificity were reached by ad-
dressing purging behaviors. For current and lifetime anorexia, the questions "Have you ever had ano-
rexia" and "Has anybody ever suspected that you might have an eating disorder?" optimized tradeoffs 
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between sensitivity and specificity. These questions generally outperformed EDI subscales. 
CONCLUSION: Simple screening questions, although less than ideal, are at least as good as other avail-
able instruments for community screenings. 
Copyright 2006 by Wiley Periodicals, Inc. 
 
Publication Types: 
    Research Support, N.I.H., Extramural 
    Research Support, Non-U.S. Gov't 
    Twin Study 
 
3. Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M, Lonnqvist J, Kaprio J, 
Cannon TD, Hietala J. Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychia-
try. 2006 Oct;163(10):1747-53.  
Department of Psychiatry, University of Turku, Kunnallissairaalantie 20, Bldg. 9, 20700 Turku, 
Finland. 
OBJECTIVE: It has been suggested that deficits in higher-order cognitive functions serve as  
intermediate phenotypic indicators of genetic vulnerability to schizophrenia. The dopamine hy-
pothesis of schizophrenia postulates that insufficiency of dopamine transmission in the prefrontal cortex 
contributes to the cognitive deficits observed in patients with the disease, and there is robust empirical 
evidence for a central role of prefrontal cortex dopamine D(1) receptors in working memory functions. 
METHOD: The authors examined the genetic and nongenetic effects on D(1) receptor binding in schizo-
phrenia by studying monozygotic and dizygotic twin pairs discordant for schizophrenia as well as healthy 
comparison twins using positron emission tomography (PET) and the D(1) receptor antagonist ligand 
[(11)C]SCH 23390. Performance on neuropsychological tests sensitive to frontal lobe functioning was 
evaluated. RESULTS: High D(1) receptor density in the medial prefrontal cortex, superior temporal 
gyrus, and heteromodal association cortex (angular gyrus) was associated with increasing genetic risk for 
schizophrenia (comparison twins < unaffected dizygotic co-twins < unaffected monozygotic co-twins). 
Medicated schizophrenia patients demonstrated a widespread reduction in D(1) receptor binding when 
compared with the unaffected co-twin, and higher doses of antipsychotics were associated with lower 
D(1) receptor binding in the frontotemporal regions. CONCLUSIONS: This study demonstrated an asso-
ciation between genetic risk for schizophrenia and alterations in cortical D(1) receptor binding, an obser-
vation that has implications for future studies of the molecular genetics of schizophrenia. In addition, the 
data indicate a widespread reduction of D(1) receptor binding in medicated schizophrenia patients, sup-
porting a link between antipsychotic drug action and dopamine D(1) receptor down-regulation. 
 
Publication Types: 
    Research Support, N.I.H., Extramural 
    Research Support, Non-U.S. Gov't 
    Twin Study 
 
4. Broms U, Madden PA, Heath AC, Pergadia ML, Shiffman S, Kaprio J. The Nicotine Dependence 
Syndrome Scale in Finnish smokers. Drug Alcohol Depend. 2007 Jun 15;89(1):42-51. Epub 2006 Dec 13.  
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Department of Public Health, University of Helsinki, Mannerheimintie 172, P.O. Box 41, 00014 
Helsinki, Finland. ulla.broms@helsinki.fi 
The Nicotine Dependence Syndrome Scale (NDSS) is a new multidimensional measure of nicotine 
dependence. The study aim was to examine the structure and heritability of the NDSS and its associations 
with nicotine dependence defined by FTND and DSM-IV criteria among Finnish smokers participating in 
an ongoing twin-family study. Adult twin pairs concordant for smoking from the Finnish Twin Cohort 
Study, and their siblings and parents were interviewed. Among 1370 smokers, the sum score of the NDSS 
(a summary measure of dependence) correlated moderately highly with FTND score (r=0.62). Subjects in 
the highest NDSS sum score groups were more likely to be nicotine dependent according to DSM-IV 
criteria compared with those in the lowest quintile (odds ratio=36.7, 95% confidence interval 13.0-103). 
In exploratory factor analysis, we derived three factors, named drive/priority, stereotypy/continuity and 
tolerance. The drive/priority factor correlated best with FTND (r=0.54). Genetic modeling showed no 
differences in the genetic architecture of NDSS or FTND by gender; the overall heritability estimate for 
NDSS was 0.30 (95% CI 0.06-0.47), and for FTND 0.40 (95% CI 0.23-0.55). The sum score of the NDSS 
is moderately highly associated with DSM-IV nicotine dependence as well as FTND. These analyses 
indicate that the NDSS functions well in a Finnish family-based sample and provide additional validation 
of a new scale developed to capture complex behavioural features of nicotine dependence. 
Publication Types: 
    Comparative Study 
    Research Support, N.I.H., Extramural 
    Research Support, Non-U.S. Gov't 
    Twin Study 
 
5. Korhonen T, Broms U, Varjonen J, Romanov K, Koskenvuo M, Kinnunen T, Kaprio J. Smoking 
behaviour as a predictor of depression among Finnish men and women: a prospective cohort study of 
adult twins. Psychol Med. 2007 May;37(5):705-15. Epub 2006 Dec 21.  
Department of Public Health, University of Helsinki, Finland. tellervo.korhonen@helsinki.fi 
BACKGROUND: Depression is associated with smoking, but the causality of the relationship is 
debated. The authors examine smoking behaviour as a predictor of depression among the Finnish adult 
twin population. METHOD: Based on responses to surveys in 1975 and 1981, the authors characterized 
the subjects as never smokers, persistent former smokers, quitters, recurrent smokers and persistent 
smokers. The Beck Depression Inventory (BDI) was applied in 1990 to measure depression (BDI score 
>9). Although the population consisted of twins, the authors first considered the subjects as individuals. 
Logistic regression models were computed for 4164 men and 4934 women. In order to control for family 
and genetic background, conditional logistic regression analyses were conducted among twin pairs dis-
cordant for depression. Bivariate genetic modelling was used to examine genetic and environmental com-
ponents of the correlation between smoking and depression. RESULTS: Among the men, persistent 
smoking (OR 1 x 42,95% CI 1 x 07-1 x 89) and smoking in 1975 but quitting by 1981 (OR 1 x 68, 95% 
CI 1 x 17-2 x 42) was associated with a higher risk of depression, while amongthe women only the quit-
ters had an elevated risk (OR 1 x 38, 96% CI 1 x 01-1 x 87). The gender x smoking interaction showed 
persistent smoking to be a stronger risk for men. When family and genetic background were controlled, 
smoking remained a predictor of depression. Genetic modelling among the men suggested a modest cor-
relation (rg=0 x 25) between genetic components of smoking and depression. CONCLUSIONS: Smoking 
behaviour may be a gender-sensitive predictor of depression, the stronger association in men being partly 
accounted for by having underlying genes in common. 
Publication Types: 
    Research Support, Non-U.S. Gov't 
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    Twin Study 
 
6. Pietilainen KH, Sysi-Aho M, Rissanen A, Seppanen-Laakso T, Yki-Jarvinen H, Kaprio J, Oresic 
M. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic 
effects - a monozygotic twin study. PLoS ONE. 2007 Feb 14;2:e218.  
Obesity Research Unit, Department of Psychiatry, Helsinki University CentralHospital, Helsinki, 
Finland. 
Both genetic and environmental factors are involved in the etiology of obesity and the associated 
lipid disturbances. We determined whether acquired obesity is associated with changes in global serum 
lipid profiles independent of genetic factors in young adult monozygotic (MZ) twins. 14 healthy MZ pairs 
discordant for obesity (10 to 25 kg weight difference) and ten weight concordant control pairs aged 24-27 
years were identified from a large population-based study. Insulin sensitivity was assessed by the eugly-
cemic clamp technique, and body composition by DEXA (% body fat) and by MRI (subcutaneous and 
intra-abdominal fat). Global characterization of lipid molecular species in serum was performed by a 
lipidomics strategy using liquid chromatography coupled to mass spectrometry. Obesity, independent of 
genetic influences, was primarily related to increases in lysophosphatidylcholines, lipids found in proin-
flammatory and proatherogenic conditions and to decreases in ether phospholipids, which are known to 
have antioxidant properties. These lipid changes were associated with insulin resistance, a pathogonomic 
characteristic of acquired obesity in these young adult twins. Our results show that obesity, already in its 
early stages and independent of genetic influences, is associated with deleterious alterations in the lipid 
metabolism known to facilitate atherogenesis, inflammation and insulin resistance. 
 
7. Dick DM, Viken R, Purcell S, Kaprio J, Pulkkinen L, Rose RJ. Parental monitoring moderates the 
importance of genetic and environmental influences on adolescent smoking. J Abnorm Psychol. 2007 
Feb;116(1):213-8.  
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA. 
dickd@psychiatry.wustl.edu 
Although there is a substantial literature on the role of parenting in adolescent substance use, most 
parenting effects have been small in magnitude and studied outside the context of genetically informative 
designs, raising debate and controversy about the influence that parents have on their children (D. C. 
Rowe, 1994). Using a genetically informative twin-family design, the authors studied the role of parental 
monitoring on adolescent smoking at age 14. Although monitoring had only small main effects, consistent 
with the literature, there were dramatic moderation effects associated with parental monitoring: At high 
levels of parental monitoring, environmental influences were predominant in the etiology of adolescent 
smoking, but at low levels of parental monitoring, genetic influences assumed far greater importance. 
These analyses demonstrate that the etiology of adolescent smoking varies dramatically as a function of 
parenting. (c) 2007 APA, all rights reserved. 
Publication Types: 
    Research Support, N.I.H., Extramural 
    Research Support, Non-U.S. Gov't 
    Twin Study 
 
8. Saccone SF, Pergadia ML, Loukola A, Broms U, Montgomery GW, Wang JC, Agrawal A, Dick 
DM, Heath AC, Todorov AA, Maunu H, Heikkila K, Morley KI, Rice JP, Todd RD, Kaprio J, Peltonen L, 
Martin NG, Goate AM, Madden PA. Genetic linkage to chromosome 22q12 for a heavy-smoking quantita-
tive trait in two independent samples. Am J Hum Genet. 2007 May;80(5):856-66. Epub 2007 Mar 26.  
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Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA. 
saccones@msnotes.wustl.edu 
We conducted a genomewide linkage screen of a simple heavy-smoking quantitative trait, the 
maximum number of cigarettes smoked in a 24-h period, using two independent samples: 289 Australian 
and 155 Finnish nuclear multiplex families, all of which were of European ancestry and were targeted for 
DNA analysis by use of probands with a heavy-smoking phenotype. We analyzed the trait, using a regres-
sion of identity-by-descent allele sharing on the sum and difference of the trait values for relative pairs. 
Suggestive linkage was detected on chromosome 22 at 27-29 cM in each sample, with a LOD score of 
5.98 at 26.96 cM in the combined sample. After additional markers were used to localize the signal, the 
LOD score was 5.21 at 25.46 cM. To assess the statistical significance of the LOD score in the combined 
sample, 1,000 simulated genomewide screens were conducted, resulting in an empirical P value of .006 
for the LOD score of 5.21. This linkage signal is driven mainly by the microsatellite marker D22S315 
(22.59 cM), which had a single-point LOD score of 5.41 in the combined sample and an empirical P value 
<.001 from 1,000 simulated genomewide screens. This marker is located within an intron of the gene 
ADRBK2, encoding the beta-adrenergic receptor kinase 2. Fine mapping of this linkage region may re-
veal variants contributing to heaviness of smoking, which will lead to a better understanding of the ge-
netic mechanisms underlying nicotine dependence. 
Publication Types: 
    Research Support, N.I.H., Extramural 
    Research Support, Non-U.S. Gov't 
 
9. Viken RJ, Kaprio J, Rose RJ. Personality at ages 16 and 17 and drinking problems at ages 18 and 
25: genetic analyses of data from Finn Twin16-25. Twin Res Hum Genet. 2007 Feb;10(1):25-32.  
Department of Psychological and Brain Sciences, Indiana University, Bloomington 47405, USA. 
We enrolled more than 3500 same-sex twinsfrom 5 consecutive Finnish birth cohorts into a longitu-
dinal study as each cohort reached age 16. Twins completed the Psychopathic Deviate (Pd) Scale of the 
Minnesota Multiphasic Personality Inventory at baseline, Sensation Seeking Scale items as each cohort 
reached age 17, and later, at average ages 18.5 and 25, the Rutgers Alcohol Problem Index (RAPI). Using 
raw maximum likelihood estimation, we fit a Cholesky model to the 4 variables assessed at 4 ages across 
the 4 twin types; we estimated genetic and environmental influences on the stability of alcohol problems 
across development and the genetic and environmental contributions to predictive correlations between 
adolescent personality and later alcohol-related behavior problems. With one exception, the phenotypic, 
genetic, and environmental correlations were very similar for males and females. The exception was that 
the lagged associations of Pd and RAPI reflect a higher genetic correlation among males than females and 
a higher environmental correlation among females than males. Our analyses suggest that developmental 
changes underlying variation in alcohol problems from late adolescence to early adulthood differ for 
males and females. In males, the main change is decreased variation due to shared environmental effects; 
the magnitude of genetic effects is stable over time, and the high genetic correlation, .95, suggests that the 
same genetic influences are important at both ages. Among females, in contrast, genetic influences de-
cline in magnitude from age 18 to 25, and at least part of the genetic effect evident at age 25 differs from 
the genetic effect evident at age 18. 
Publication Types: 
    Comparative Study 
    Research Support, N.I.H., Extramural 
    Research Support, Non-U.S. Gov't 
    Twin Study 
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10. Loukola A, Broms U, Maunu H, Widen E, Heikkila K, Siivola M, Salo A, Pergadia ML, Nyman 
E, Sammalisto S, Perola M, Agrawal A, Heath AC, Martin NG, Madden PA, Peltonen L, Kaprio J. Link-
age of nicotine dependence and smoking behavior on 10q, 7q and 11p in twins with homogeneous genetic 
background. Pharmacogenomics J. 2007 Jun 5; [Epub ahead of print]  
[1] Department of Molecular Medicine, National Public Health Institute, Helsinki, Finland [2] Fin-
nish Genome Center, University of Helsinki, Helsinki, Finland. 
The significant worldwide health burden introduced by tobacco smoking highlights the importance 
of studying the genetic determinants of smoking behavior and the key factor sustaining compulsive smok-
ing, that is, nicotine dependence (ND). We have here addressed the genetic background of smoking in a 
special study sample of twins, harmonized for early life events and specifically ascertained for smoking 
from the nationwide twin cohort of the genetically unique population of Finland. The twins and their 
families were carefully examined for extensive phenotype profiles and a genome-wide scan was per-
formed to identify loci behind the smoking status, ND and the comorbid phenotype of ND and alcohol 
use in 505 individuals from 153 families. We replicated previous linkage findings on 10q (max logarithm 
of the odds (LOD) 3.12) for a smoker phenotype, and on 7q and 11p (max LOD 2.50, and 2.25, respec-
tively) for the ND phenotype. The loci linked for ND also showed evidence for linkage for the comorbid 
phenotype. Our study provides confirmatory evidence for the involvement of these genome regions in the 
genetic etiology of smoking behavior and ND and for the first time associates drinking and smoking to a 
shared locus on 10q.The Pharmacogenomics Journal advance online publication, 5 June 2007; 
doi:10.1038/sj.tpj.6500464. 
 
11. Keski-Rahkonen A, Hoek HW, Susser ES, Linna MS, Sihvola E, Raevuori A, Bulik CM, Kaprio 
J, Rissanen A. Epidemiology and course of anorexia nervosa in the community. Am J Psychiatry. 2007 
Aug;164(8):1259-65.  
Department of Public Health, PO Box 41, 00014 University of Helsinki, Finland. anna.keski-
rahkonen@helsinki.fi. 
OBJECTIVE: Most previous studies of the prevalence, incidence, and outcome of anorexia nervosa 
have been limited to cases detected through the health care system, which may bias our understanding of 
the disorder's incidence and natural course. The authors sought to describe the onset and outcomes of 
anorexia nervosa in the general population. METHOD: Lifetime prevalences, incidence rates, and 5-year 
recovery rates of anorexia nervosa were calculated on the basis of data from 2,881 women from the 1975-
1979 birth cohorts of Finnish twins. Women who screened positive for eating disorder symptoms 
(N=292), their screen-negative female co-twins (N=134), and 210 randomly selected screen-negative 
women were assessed for lifetime eating disorders by telephone by experienced clinicians. To assess 
outcomes after clinical recovery and to detect residua of illness, women who had recovered were com-
pared with their unaffected co-twins and healthy unrelated women on multiple outcome measures. 
RESULTS: The lifetime prevalence of DSM-IV anorexia nervosa was 2.2%, and half of the cases had not 
been detected in the health care system. The incidence of anorexia nervosa in women between 15 and 19 
years of age was 270 per 100,000 person-years. The 5-year clinical recovery rate was 66.8%. Outcomes 
did not differ between detected and undetected cases. After clinical recovery, the residua of illness stead-
ily receded. By 5 years after clinical recovery, most probands had reached complete or nearly complete 
psychological recovery and closely resembled their unaffected co-twins and healthy women in weight and 
most psychological and social measures. CONCLUSIONS: The authors found a substantially higher 
lifetime prevalence and incidence of anorexia nervosa than reported in previous studies, most of which 
were based on treated cases. Most women recovered clinically within 5 years, and thereafter usually pro-
gressed toward full recovery. 
 
172 
9. ADDICTION PREVENTION AND TREATMENT UNIT  
 
9.1. Background and goals 
 
Addiction Prevention and Treatment Unit (RHY) was established in 2006 and is a 
continuation of the clinical team of Alcohol Research Center at KTL-MAO. Currently 
this growing unit has five full time members.  Our mandate is not only to protect, main-
tain and improve the health of the Finnish people but also to prevent addiction related 
health problems and to evaluate and implement new treatments on substance abuse. As 
a clinical research unit, RHY plays an important role in this process in the areas of alco-
holism, drug dependence and mental health.  The strength of RHY comes largely from 
the unique ability to take a new treatments all the way from its beginnings in theory, 
through animal testing, to world-class double-blind placebo-controlled clinical trials, 
and then on to practical application.  RHY has this unique ability because of its history, 
its affiliations, associations, and networking. 
 
9.2. The Research, a far reaching impact and networking 
 
The research at RHY is widespread, from primary to tertiary prevention in many 
fields of substance abuse. The research is polarized in three dimensions, i) epidemiol-
ogical and preventive studies of hazardous alcohol drinking, ii) studies and implementa-
tion on new treatments on alcohol and opiate dependence, and iii) providing expert ser-
vices in the field of substance abuse.  The unit plays an active role in consulting Hel-
sinki University Hospital and hospitals in Finland and elsewhere, including strong net-
work with the Finnish Society of Addiction Medicine (president), the International So-
ciety for Addiction Medicine (vice president, ISAM) and providing expert consultations 
in preparation national and international Current Care Guidelines with Duodecim (team 
member) and the World Health Organization (advisor, WHO). Some of the organiza-
tions closely cooperating with RHY include:    
Järvenpää Social Hospital 
Unit on Substance Abuse Medicine, HY 
Department of General Medicine, TaY 
Helsinki University Student Health Service 
A-clinics and A-clinic Foundation 
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Duodecim 
Neurobehavioral Health Service (Sarasota) 
New Era Assisted Recovery (Miami) 
University of Kentucky College of Medicine 
National Anxiety Foundation (USA) 
WHO 
ISAM, ESBRA, ISBRA 
 
9.3. The research, achievements 
 
Hazardous Alcohol Consumption, detection, prevention and implementation 
Brief alcohol intervention has been proven to be effective in reducing heavy drink-
ing among primary health care patients. In recent years RHY and National Public 
Health Institute have been increasingly more active in promoting the use of brief inter-
vention in Finnish health care. This implementation activity has been based on high 
quality research leading to international publication and collaboration with national and 
international doers in action projects aiming at implementation of brief intervention. As 
an example of high quality research RHY-National Public Health Institute has been in-
volved with international collaboration leading to the first review article in the field 
(Nilsen et al. 2006). As part of practical implementation activity RHY has been in-
volved in National Brief Intervention Project (www.stm.fi/Resource.phx/hankk/ 
hankt/vamp/index.htx) as well with Primary Health Care European Project on Alcohol 
(www.gencat.cat/salut/phepa/units/phepa/html/en/Du9/index.html), funded by the Euro-
pean Commission. Both of these projects aim at wide-spread implementation of brief 
intervention activity. The wide-spread implementation of this activity will lead signifi-
cant public health improvement. The most important publications in this field of our 
research are: 
  
1.    Aalto M, Pekuri P, Seppä K. Use of laboratory markers and the AUDIT questionnaire by primary 
care physicians to detect alcohol abuse by patients. Alcohol Alcohol 2005; 40: 520-523. 
2.    Aalto M, Pekuri P, Seppä K. Implementation of brief alcohol intervention in primary health care: do 
nurses' and general practitioners' attitudes, skills and knowledge change? Drug Alcohol Rev 2005; 24: 
555-558. 
Department of Mental Health and Alcohol Research, National Public Health Institute, P.O. Box 33, 
FIN-00251 Helsinki, Finland. mauri.aalto@ktl.fi 
Brief alcohol intervention reduces heavy drinking, but its implementation has been challenging. The 
purpose was to evaluate self-reported changes in attitudes, skills and knowledge regarding brief interven-
tion among nurses and general practitioners (GPs) during an implementation project. A questionnaire 
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survey was used before and after the implementation to all nurses and GPs working at the time in the 
seven primary health-care centres of the city of Tampere, Finland. Several positive changes indicate an 
increased amount of knowledge regarding brief intervention among the professionals during the imple-
mentation. CONCLUSIONS: Brief intervention activity was found especially among the nurses. The 
success in increasing the knowledge can also be seen in a decrease of training needs. Instead, attitudes 
and skills among the professionals did not seem to develop positively. Increasing motivational skills es-
pecially seems to be the future challenge. 
3.    Aalto M, Hyvönen S, Seppä K. Do primary care physicians' own AUDIT scores predict their 
use of brief alcohol intervention? A cross-sectional survey. Drug Alcohol Depend 2006; 83:169-173. 
Department of Mental Health and Alcohol Research, National Public Health Institute, P.O. Box 33, 
FIN-00251 Helsinki, Finland. mauri.aalto@ktl.fi 
To define whether the Alcohol Use Disorders Identification Test (AUDIT) scores of primary care phy-
sicians themselves predict their willingness to use brief alcohol intervention. Cross-sectional self-
administered questionnaire survey to all 3193 physicians providing primary health care in Finland. The 
response rate was 1909 (59.8%). Odds ratios from multinomial regression analysis were calculated for self-
reported frequency (never, occasionally or regularly) of conducting brief interventions by physicians with 
AUDIT scores of 0-1, 2, 3, 4, 5-7 or >or=8. The prevalence of heavy drinkers based on AUDIT score 
(>or=8) was 14.5% among all physicians, 7.0% among females and 27.0% among males. Of the respondents 
9.4% reported doing brief intervention regularly and 50.0% occasionally. AUDIT scores did not signifi-
cantly predict either regular or occasional use of brief intervention. Instead, some other independent predic-
tors for more frequent use of brief intervention were found. These included having a specialist licence in 
general practice or occupational health care and the location of the practice, but not gender or age. 
CONCLUSIONS: The present results indicate that in general heavy drinking among primary care physicians 
do not explain the low frequency with which brief intervention is used in primary health care. 
4.    Sillanaukee P., Massot N., Jousilahti P., Vartiainen E., Poikolainen K., Olsson U. and Alho H.: 
Enhanced clinical utility of gamma-CDT in a general population.  Alcohol Clin Exp Res. 24(8)1202-
1206, 2000. 
Former employee of Department of Mental Health and Alcohol Research, National Public Health 
Institute, P.O. Box 33, FIN-00251 Helsinki, Finland.   
The use of a combination of markers to detect excessive alcohol consumption has been reported to 
provide better sensitivity in the diagnosis of alcohol abuse than single markers. However, the optimal 
combination of markers for the diagnosis of alcohol abuse has not yet been found. The aim of this study 
was to compare the diagnostic value of carbohydrate-deficient transferrin (CDT) and gamma-
glutamyltransferase (GGT) to discriminate among heavy drinkers (>280 g/week), moderate drinkers (105-
280 g/week), and light drinkers (<105 g/week). Their mathematical combination, named gamma-CDT, 
which has been found to be a strong marker of alcohol abuse in a former study, was also evaluated. The 
study was conducted in a group of 6962 subjects (3974 males and 2988 females), between the ages of 25 
and 74 years, who participated in a large cross-sectional risk factor survey carried out in five geographic 
areas in Finland. In each study area, an age- and gender-stratified random sample was drawn from the 
general population. Sensitivity, specificity, positive and negative predictive values, and receiver operating 
characteristic curves were used to evaluate the performance of CDT, GGT, and gamma-CDT. For both 
sexes, the combined marker had the highest specificity (95%) and sensitivity in detecting heavy drinkers. 
In all cases, gamma-CDT had the highest area under ROC plots. Our results also showed that GGT and 
CDT have similar, and rather low, sensitivity but high specificity in a general population. 
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CONCLUSIONS: Compared with single markers, a significant improvement of sensitivity was obtained 
when the combination of both markers was used, especially in females. 
5.    Sillanaukee P.,  Massot N., Jousilahti P.,  Vartiainen E.,  Sundvall J., Olsson U., Poikolainen K., 
Pönniö M.,  Allen J. P. and Alho H.: Dose response of laboratory markers to alcohol consumption in a 
general population. Am J Epidemiol. 152(8):747-751, 2000. 
Former employee of Department of Mental Health and Alcohol Research, National Public Health 
Institute, P.O. Box 33, FIN-00251 Helsinki, Finland.  
The dose response to alcohol use of carbohydrate-deficient transferrin (CDT), gamma-
glutamyltransferase (GGT), and their combination (gamma-CDT) was studied in an age- and gender-
stratified, random sample from Finland in 1997. A linear association with a threshold between alcohol 
consumption and the three markers was observed. Body mass index was negatively associated with CDT 
and positively with GGT Age was positively associated with GGT and gamma-CDT In conclusion, CDT 
appears to be an early phase marker of alcohol consumption. CONCLUSIONS: The combined marker, 
gamma-CDT, was less associated with factors such as body mass index but more strongly correlated with 
alcohol consumption than were the two markers separately. 
6.    Sillanaukee P., Strid N., Jousilahti P., Vartiainen E., Poikolainen K., Nikkari S., Allen J.P. and 
Alho H.: Association of self-reported diseases and health care use with commonly used laboratory mark-
ers for alcohol consumption. Alcohol Alcohol. 36(4):339-45, 2001. 
Former employee of Department of Mental Health and Alcohol Research, National Public Health 
Institute, P.O. Box 33, FIN-00251 Helsinki, Finland.  
The relationships of carbohydrate-deficient transferrin (CDT), gamma-glutamyltransferase (GGT) 
and their mathematical combination (gamma-CDT) with self-reported diseases were evaluated in a large 
cross-sectional risk factor survey. Significant gender effects were observed in associations of the markers 
with several medical conditions as well as with general health care utilization. In men, CDT was associ-
ated with rheumatoid arthritis. In both genders, GGT was positively associated with hypertension and 
diabetes. gamma-CDT was positively associated with hypertension in males and with asthma in females. 
CONCLUSIONS: This general population study demonstrates that these markers, although most com-
monly used to assess alcohol misuse, might also serve as health risk indicators. 
 
Treatment of alcohol and opiate addiction, from bench to practice 
An example of how RHY functions can be seen in the development, testing, and 
application of the treatment of alcohol dependence with the use of naltrexone and other 
opioid antagonists.  The basis for the treatment came from basic research showing first 
that alcohol drinking is a reinforced learned behavior (Sinclair, Nature, 1973, 1974) 
with the reinforcement involving the same neural system as morphine. This was fol-
lowed by a series of animal experiments showing that naltrexone, naloxone, and nalme-
fene could be used safely, without prior detoxification, to extinguish alcohol drinking 
and acquisition.  This resulted patents for the use of opiate antagonists in treatment of 
alcoholism (Sinclair, US, 1989; EU, 1995). 
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RHY put together a team and conducted a major double-blind placebo-controlled 
trial of naltrexone for treatment of alcohol dependence.  Following the lead from theory 
and animal studies, the RHY trial was the first to show that naltrexone was safe and 
effective without detoxification. This is a major improvement for the cost and patient 
acceptability of naltrexone treatment and has now been widely incorporated in protocols 
around the world. The trial also proved the conclusion from theory and animal studies 
(Fig. 1), that naltrexone is effective only when drinking accompanied the medication 
rather than abstinence, also applies to the treatment of human alcoholics (Fig. 2).  A 
database maintained by RHY, currently covering 68 clinical trials, clearly confirms 
those conclusions.  
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Figure 1.  In rats, the opioid antagonist nalmefene produced significant benefits 
over placebo when paired with drinking but not when given when no drinking 
was possible.  Shown is drinking on the 5th day (no medication) after 4 days of 
treatment. 
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Figure 2.  In human alcoholics, the opioid antagonist naltrexone produced 
significant benefits over placebo when paired with drinking but not when given 
when no drinking was possible.  Shown here are the percentages of patients 
never relapsing to heavy drinking (<4 drinks/day or < 4 drinking days/week). 
 
  
The findings were put into practice in clinics in Finland and abroad, with a manual writ-
ten describing the protocol for maximizing the benefits from this treatment.  The proce-
dures are constantly being improved on the basis of clinical experience in the field. 
 Many treatments, especially in the field of addiction medicine, are in clinical practice 
without proven efficacy and thus ethically and economically questionable.  Other areas 
of major achievements in our research include the detection of ineffectiveness of nitrous 
oxide in  the treatment of alcohol dependence and withdrawal symptoms, the superiority 
of disulfiram pharmacotherapy and safety of buprenorphine-naloxone combination in 
the treatment of opiate dependence. 
The most important publications in this field of our research are: 
7.    Heinälä P., Alho H., Kiianmaa K., Lönnqvist J., Kuoppasalmi K. and Sinclair D.: Targeted use 
of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind 
placebo-controlled trial. J Clin Psychopharm.  21(3): 287-292, 2001. 
National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, 
Finland, pekka.heinala@ktl.fi. 
Several studies have shown the opioid antagonist naltrexone to be effective when combined with 
psychosocial therapies for the treatment of patients who are dependent on alcohol with fixed medication 
and time (12 weeks). In this study, 121 nonabstinent outpatients with alcohol dependence (DSM-IV) were 
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treated with sessions of cognitive coping skills (N = 67) or supportive therapy (N = 54) and either naltrex-
one 50 mg/day (N = 63) or placebo (N = 58) daily for the first 12 weeks and thereafter for 20 weeks only 
when craving alcohol (i.e., targeted medication) in a prospective one-center, dual, double-blind, random-
ized clinical trial. The dropout rate for all subjects was 16.5% during the first 12-week period and ap-
proximately twice that level by the end of the study. There were no significant group differences in study 
completion and therapy participation rates. After the continuous medication (12 weeks), the cop-
ing/naltrexone group had the best outcome, and coping/placebo had the worst. This difference remained 
during the targeted medication period (the following 20 weeks). Naltrexone was not better than placebo in 
the supportive groups, but it had a significant effect in the coping groups: 27% of the coping/naltrexone 
patients had no relapses to heavy drinking throughout the 32 weeks, compared with only 3% of the cop-
ing/placebo patients. The authors' data confirm the original finding of the efficacy of naltrexone in con-
junction with coping skills therapy. In addition, their data show that detoxification is not required and that 
targeted medication taken only when craving occurs is effective in maintaining the reduction in heavy 
drinking. 
8.    Alho H., Methuen T.,  Paloheimo M., Seppä K., Strid N., Apter-Kaseva N., Tiainen J., 
Salaspuro M. and Roine R.: Nitrous oxide has no effect in the treatment of alcohol withdrawal syndrome: 
a double-blind placebo-controlled randomized trial. J Clin Psychpopharm. 23(2):211-4, 2003. 
9.    Alho H.,  Sinclair D., Vuori E., Holopainen A.: Abuse liability of buprenorphine-naloxone tab-
lets in untreated IV drug users. Drug Alcohol Depend 17;88(1):75-8. 2007. 
National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, 
Finland. hannu.alho@ktl.fi 
Buprenorphine (Subutex) is widely abused in Finland. A combination of buprenorphine plus 
naloxone (Suboxone) has been available since late 2004, permitting a comparison of the abuse of the two 
products among untreated intravenous (IV) users. A survey was distributed to attendees at a Helsinki 
needle exchange program over 2-weeks in April, 2005, At least 30% were returned anonymously. Survey 
variables included: years of prior IV opioid abuse, years of buprenorphine abuse, frequency, dosage, route 
of administration and reasons for use, concomitant IV abuse of other substances and amount paid on the 
street for both buprenorphine and buprenorphine+naloxone. Buprenorphine was the most frequently used 
IV drug for 73% of the respondents. More than 75% said they used IV buprenorphine to self-treat addic-
tion or withdrawal. Most (68%) had tried the buprenorphine+naloxone combination IV, but 80% said they 
had a "bad" experience. Its street price was less than half that of buprenorphine alone. CONCLUSIONS: 
Buprenorphine seems to be the most frequently used IV drug in metropolitan Helsinki area. The bupre-
norphine+naloxone combination appears to be a feasible tool, along with easier access to addiction treat-
ment, for decreasing IV abuse of buprenorphine. 
10.    E. Laaksonen; A. Koski-Jännes; M. Salaspuro; H Ahtinen and H. Alho. A randomized, multi-
centre, open-label, comparative trial of disulfiram, nalterexone and acamprosate in the treatment of alco-
hol dependence. Alc Alcohol, in press 2007. 
National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, 
Finland. esti.laaksonen@ktl.fi 
Acamprosate, naltrexone and disulfiram have been shown to reduce drinking and/or improve absti-
nence, but there are no randomized comparative studies on the effects of these three medication. This 
study compared the effect of brief manual-based cognitive behavioral intervention in conjunction with 
these three different pharmacotherapies. A randomized, open label, multicenter study in two phases; first, 
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12-week continuous supervised medication, followed by targeted medication up to 52 weeks in addition 
to a 67-week follow up period.  243 voluntary treatment-seeking alcohol-dependent adult outpatient were 
randomized to receive supervised naltrexone, acamprosate or disulfiram and brief manual-based cognitive 
behavioral intervention. The primary outcome measures were the time (days) to first heavy drinking day 
(HDD) and time during the first 3 months to the first drinking day after medication started. Secondary 
variables were abstinent days/week (0 drinks/day), average weekly alcohol intake, AUDIT (Alcohol Use 
Disorder Identification Test), SADD (Severity of Alcohol Dependence Data) and quality of life measures. 
All three study groups showed marked reduction in drinking from baseline to the end of the study. Disul-
firam was twice more effective in reducing HDD and time to first drink, and more effective in reducing 
abstinence days and average weekly alcohol consumption, during the continuous and targeted medication 
periods. Disulfiram patients had a quarter of the alcohol intake during first 12 weeks compared with the 
others.  There were no differences between the naltrexone and acamprosate groups in either phase of the 
study of drinking outcomes. However, naltrexone was better than acamprosate in reducing the severity of 
alcohol dependence indicator SADD scores. Conclusions: This randomized study indicates that acam-
prosate, naltrexone and disulfiram combined with brief manual-based cognitive behavioral intervention 
significantly reduces alcohol consumption and improves the quality of life. Supervised disulfiram was 
superior, especially during the continuous medication period, to naltrexone and acamprosate. 
 
 
Fig 3. Time to first heavy drink (days) during the continuous medication period (1-12 weeks). Sig-
nificant difference between DIS (p = 0.001) and others. 
 
9.4. Funding for research and public health programs 
 
The external funding for the research at RHY has been creditable. Approximately 
40-50 % of the research budget has been funded by external sources; those are Y. Jahns-
son Foundation, Alkoholitutkimussäätiö, Ahokaan Säätiö, Kordelinin Säätiö and HUS-
EVO from Finland. The unit has been taking part Finrisk 1997, 2002 and 2007 national 
public health surveys and Terveys 2000 studies with several external funding sources. 
RHY has been taking part to National Brief Intervention Project funded by Social and 
Health Ministry of Finland, and to Primary Health Care European Project on Alcohol 
funded by the European Commission. 
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9.5. Future Challenges 
 
Because the growing uptrend and demands of RHY it has many challenges in the 
field of maintaining top class experts in the team and marketing the research for external 
funding. So far the external funding has assured funding for five full time postgraduate 
students and is growing. Because Finland has limited resourses in experts working in 
the addiction field, the personnel challenges may be more difficult to archive. However, 
we believe that the interesting and academic-type challenging research also attracts ex-
perts into our team in the future. 
In the field of research much effort at RHY will be placed on the dissemination of 
the information about how to use brief intervention and effective medications on alcohol 
related problems effectively, with presentations at scientific conferences, interviews and 
websites, lectures, and publications. The development at RHY of a potential new treat-
ment of alcohol comorbid depression and panic disorders is following a similar path. 
